Final Programme - The British Society for Rheumatology
Final Programme - The British Society for Rheumatology
Final Programme - The British Society for Rheumatology
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Welcome to Glasgow . . .<br />
<strong>Final</strong> <strong>Programme</strong><br />
BSR and BHPR<br />
Annual Meetings 2009<br />
and 25 th Anniversary Celebrations<br />
28 April - 01 May 2009<br />
SECC, Glasgow<br />
www.bsrconference.org.uk<br />
<strong>Programme</strong> production kindly supported by: Chugai/Roche
Acknowledgements<br />
<strong>The</strong> <strong>British</strong> <strong>Society</strong> <strong>for</strong> <strong>Rheumatology</strong> would like to thank the following<br />
companies <strong>for</strong> their contribution to the success of <strong>Rheumatology</strong> ’09,<br />
in particular <strong>for</strong> support in the areas listed below:<br />
Abbott <strong>for</strong> their support of the BSR Innovation in <strong>Rheumatology</strong> Awards.<br />
Pfizer <strong>for</strong> their support of the BSR Medical Student Bursaries and sponsorship<br />
of the speaker preview room.<br />
Chugai Roche <strong>for</strong> supporting the production of the event announcements and the<br />
final programme as well as their sponsorship of the signage.<br />
Schering Plough <strong>for</strong> their support of the BSR Young Investigator Awards as well as<br />
their sponsorship of delegate registration and the pocket programme.<br />
Merck, Sharpe and Dohme <strong>for</strong> providing notepads and pens <strong>for</strong> the delegate bags.<br />
Wyeth <strong>for</strong> their sponsorship of the delegate bags.<br />
Abbott, Chugai Roche, Schering Plough, UCB and Wyeth <strong>for</strong> supporting the<br />
provision of educational satellite symposia <strong>for</strong> delegates.<br />
We would also like to thank our exhibitors <strong>for</strong> their attendance at <strong>Rheumatology</strong> ’09.<br />
<strong>The</strong> exhibition adds an exciting and interactive element to the conference and is much<br />
valued by delegates and so we thank all our exhibitors <strong>for</strong> their continued support.<br />
BSR, Bride House, 18-20 Bride Lane, London EC4Y 8EE<br />
Telephone: +44 (0) 20 7842 0900 Fax: +44 (0) 20 7842 0901<br />
Email: conferences@rheumatology.org.uk<br />
Website: www.rheumatology.org.uk www.bsrconference.org.uk<br />
A Company limited by guarantee with charitable status VAT No. 404 5637 66<br />
Company Reg. No. 3470316 Charity Reg. No. 1067124<br />
BSR <strong>Final</strong> <strong>Programme</strong> has been printed on: 9lives uncoated 100% recycled
Contents<br />
General In<strong>for</strong>mation 2<br />
BSR Prizes and Awards 4<br />
Venue Layout Diagram 5<br />
Meeting at a glance 7<br />
Registration and Exhibition Opening Hours 10<br />
BSR Annual Meeting | 28 April - 01 May 2009<br />
Scientific <strong>Programme</strong> Tuesday 11<br />
Scientific <strong>Programme</strong> Wednesday 21<br />
Scientific <strong>Programme</strong> Thursday 27<br />
Scientific <strong>Programme</strong> Friday 41<br />
Poster Viewing One Wednesday 47<br />
Poster Viewing Two Thursday 67<br />
Poster Viewing Three Friday 89<br />
Exhibition Floor Plan 109<br />
Exhibitors Details 110<br />
Abstract Reviewers 116<br />
1
General In<strong>for</strong>mation <strong>for</strong> Delegates:<br />
Welcome to Glasgow and thank you <strong>for</strong> attending <strong>Rheumatology</strong> ’09. We hope the conference proves<br />
to be an exciting and worthwhile experience <strong>for</strong> all attendees.<br />
Delegate Code of Conduct<br />
We strive to ensure that our event is a positive<br />
experience <strong>for</strong> all and ask that delegates abide by<br />
the following code of conduct:<br />
• <strong>The</strong> BSR cannot guarantee capacity in any<br />
particular session. Although we will do our best<br />
to avoid disappointment, there may be occasions<br />
when a room is full. Legally we are not allowed<br />
to let you into a room in this circumstance and<br />
neither BSR nor venue staff will tolerate verbal<br />
abuse.<br />
• Badges must be worn, in plain sight, at all times.<br />
If your badge is lost, immediately report to the<br />
registration desk <strong>for</strong> a replacement.<br />
• Delegates are responsible <strong>for</strong> all their property.<br />
Neither the BSR nor the venue accepts liability<br />
<strong>for</strong> loss of or damage to personal items.<br />
• Bags and packages must be in your possession at<br />
all times. <strong>The</strong> safety and security of delegates is<br />
paramount and unattended items may cause<br />
security alerts.<br />
<strong>The</strong> BSR reserves the right to remove any persons<br />
from the event if they are deemed to be acting<br />
inappropriately. No refund will be due in this instance.<br />
Name Badges<br />
Your name badge permits you access to all scientific<br />
sessions on the days <strong>for</strong> which you have registered.<br />
Exceptions apply only where previously specified<br />
(i.e. Primary Care Workshops) or where the session<br />
room has reached its capacity. You are also permitted<br />
access to the Exhibition Hall during open hours.<br />
<strong>The</strong> electronic badging system has been put in place<br />
<strong>for</strong> your safety and to ensure spaces in sessions are<br />
only taken by people who are entitled to be there.<br />
It is essential that you visibly display your badge at all<br />
times as BSR personnel will not allow persons without<br />
badges to access sessions or exhibition areas.<br />
Event personnel will be stationed around the venue to<br />
scan your badge periodically. We do this <strong>for</strong> the dual<br />
purpose of maintaining security and to record your<br />
presence at the conference to adhere to our CPD<br />
responsibilities. We do not track which sessions you<br />
attend nor give this in<strong>for</strong>mation to any third parties.<br />
To ensure that you presence at the conference is<br />
recorded <strong>for</strong> CPD, please make sure your badge is<br />
scanned <strong>for</strong> each day of the conference that you<br />
attend.<br />
Important Fire Safety In<strong>for</strong>mation<br />
Seating capacity in all sessions is set according to<br />
Fire Safety regulations and cannot be exceeded.<br />
Standing in the aisles or against walls is not<br />
permitted in any circumstances and will result in<br />
you being asked to leave the session room.<br />
To assist in the smooth and prompt running of all<br />
sessions we ask that delegates do the following:<br />
• Seat yourself as far <strong>for</strong>ward as possible and start<br />
seating in the centre of the row.<br />
• Fill all seats from the centre, ensuring that spare<br />
seats are on the outside of rows and there<strong>for</strong>e<br />
obvious and easy to access <strong>for</strong> late comers.<br />
• If you are not permitted entry to a full session,<br />
please step back from the door and <strong>for</strong>m a queue.<br />
You will only be admitted entry if others leave.<br />
Abstract Supplement<br />
As usual, all accepted abstracts have been published<br />
as a supplement the journal <strong>Rheumatology</strong>.<br />
A complimentary copy of this supplement has been<br />
provided <strong>for</strong> all delegates on arrival at the event, and<br />
will already be in your delegate pack given to you at<br />
the registration desk. Subscribers to the journal will<br />
also be able to access this in advance of the<br />
meeting, at http://rheumatology.ox<strong>for</strong>djournals.org.<br />
2
Catering<br />
Your registration fee <strong>for</strong> the conference includes lunch,<br />
tea and coffee <strong>for</strong> each day that you are registered.<br />
All catering will be served within the main exhibition in<br />
Hall 5. Please refer to the “Meeting at a Glance”<br />
section <strong>for</strong> timings.<br />
CPD<br />
We have been in<strong>for</strong>med by the CPD office of the Royal<br />
College of Physicians that we are limited to 6 credits<br />
per day. <strong>The</strong>re<strong>for</strong>e, the annual meeting will earn you<br />
the following:<br />
Tuesday 28 April 2009 6<br />
Wednesday 29 April 2009 6<br />
Thursday 30 April 2009 6<br />
Friday 01 May 2009 6<br />
A certificate of attendance is included in your<br />
delegate bag.<br />
Speaker Preview<br />
Check-in is expected of all speakers<br />
<strong>The</strong> speaker preview room is located in the Gala Room<br />
of the Clyde Building. Please check-in to the speaker<br />
preview room to upload and check your presentation<br />
on arrival at the SECC and no later than two hours<br />
prior to your session start time.<br />
Disclaimer<br />
Please note that the BSR accepts no responsibility<br />
<strong>for</strong> views expressed by speakers at the event.<br />
Accommodation Agents Contact Details<br />
If you have booked through our appointed<br />
accommodation agents, Virtuoso, you can<br />
contact them with queries directly on:<br />
Tel: 00 44 (0) 845 310 3333<br />
Fax: 00 44 (0) 1462 437 876<br />
Email: hotels@virtuosoltd.com<br />
Prayer space<br />
A quiet, non-denominational room will be available to<br />
anyone requiring space and privacy <strong>for</strong> prayer during<br />
the meeting. This is located in the Katrine Room, in<br />
the Seminar Suite.<br />
Under 16s<br />
Un<strong>for</strong>tunately it is not permissible <strong>for</strong> children under<br />
the age of 16 to have access to the meeting because<br />
we do not have sufficient liability insurance to cover a<br />
minor should it be required.<br />
No Smoking<br />
<strong>The</strong> SECC is a non smoking venue.<br />
First Aid<br />
Trained first-aiders will be on duty throughout the<br />
conference opening hours; please contact one of the<br />
organisers or the SECC staff. <strong>The</strong> First Aid Suite is<br />
situated at the east end of the SECC concourse and<br />
staffed by qualified first aid staff.<br />
Business Centre<br />
BSR Annual Meeting | 28 April - 01 May 2009<br />
On-site Contacts<br />
If you have a query on-site regarding <strong>Rheumatology</strong><br />
’09, please contact a member of the organising<br />
secretariat via the registration desk.<br />
Louis Bellintani – BSR Events Officer<br />
Stephanie Tame – BSR Senior Events Officer<br />
Hannah Gardner – BSR Senior Events Officer<br />
James Glavin – BSR Head of Education,<br />
Events and Journal<br />
Local In<strong>for</strong>mation<br />
If your query relates to the SECC or the local area,<br />
please visit the SECC In<strong>for</strong>mation Desk, located at<br />
the east end of the main concourse at entrance 5A<br />
of the exhibition hall (Hall 5)<br />
3<br />
<strong>The</strong> SECC provide complimentary wireless internet<br />
access to all delegates. Please ask at the registration<br />
desk <strong>for</strong> the code.<br />
Fax, photocopying and other business services are<br />
available via the SECC Business Centre / In<strong>for</strong>mation<br />
Desk. This unit is located on the concourse along<br />
from the east entrance to the SECC.<br />
Charges will apply.<br />
Presentation Relay Room<br />
In instances where rooms become overcapacity we<br />
have set up a presentation relay room in the Gala<br />
Room of the Clyde building. Should you be prevented<br />
from entering a session room please check with SECC<br />
or BSR staff if the session is being simultaneously<br />
streamed into this room.
BSR Prizes and Awards<br />
Prize Giving Ceremony<br />
<strong>The</strong> Prize Giving ceremony will be held on<br />
Wednesday 29 April 16.00 - 16.30,<br />
in the Clyde Auditorium.<br />
Innovation in <strong>Rheumatology</strong> Awards<br />
supported by Abbott Laboratories<br />
A representative from Abbott will be present.<br />
Innovation in Practice (Category 1)<br />
Dr Clive Kelly<br />
Title: How to reduce and mortality from chest infections<br />
in patients with rheumatoid arthritis<br />
Innovation in Development (Category 2)<br />
Dr Fraser Birrell<br />
Title: Inflammatory arthritis group clinics: a feasible<br />
model <strong>for</strong> an annual clinic<br />
Dr Edward Vital (210)<br />
Title: How to manage non-response to rituximab?<br />
Predictors and outcome of retreatment provide a<br />
treatment algorithm<br />
Ms Natalia Wegner (OP4)<br />
Title: Endogenously citrullinated proteins from<br />
Porphyromonas gingivalis as a candidate source of<br />
priming autoantigens in rheumatoid arthritis<br />
Michael Mason Prize<br />
Dr Karim Raza<br />
Title: Early rheumatoid arthritis: the window narrows<br />
Garrod Prize<br />
Dr Elizabeth Jury<br />
Title: <strong>The</strong> role of lipid rafts in lupus T cell pathology<br />
Young Investigator Award<br />
supported by Schering Plough<br />
A representative from Schering Plough will be present.<br />
Dr Isma Atchia (OP14)<br />
Title: Musculoskeletal ultrasound predicts response<br />
to corticosteroid injection in moderate-severe hip<br />
osteoarthritis<br />
Dr Michele Bombardieri (OP19)<br />
Title: IL-23 Overexpression as immunological<br />
signature of subclinical intestinal inflammation in<br />
ankylosing spondylitis<br />
Dr Emma Derrett-Smith (PO1)<br />
Title: Vasculopathy in a TGF-β; dependent<br />
mouse model of systemic sclerosis<br />
Dr Sahena Haque (OP39)<br />
Title: Impaired endothelial progenitor cell function<br />
and early atherosclerosis in systemic lupus<br />
eeythematosus (SLE)<br />
Medical Student Bursaries supported by Pfizer<br />
Ms Jasmine Ehsanullah (OP74)<br />
Title: <strong>The</strong> importance of anti-thrombin antibodies<br />
in the antiphospholipid syndrome<br />
Ms Emma Maclaren (171)<br />
Title: Parenteral methotrexate: is it worth it?<br />
Miss Joanne Anderson (176)<br />
Title: An investigation of the media coverage of<br />
tocilizumab<br />
Miss Carly Turner (6)<br />
Title: Expression of the peroxiredoxin-based antioxidant<br />
system in peripheral blood lymphocytes in rheumatoid<br />
arthritis<br />
Ms Emma Johnstone (159)<br />
Title: Acro-Osteolysis in systemic sclerosis: relationship<br />
to degree of digital ischaemia and to calcinosis<br />
Mr Alexander Oldroyd (245)<br />
Title: Does depo-provera decrease bone mineral<br />
density in the lumbar spine and femoral neck<br />
4
5<br />
BSR Annual Meeting | 28 April - 01 May 2009
Meeting at a Glance<br />
28 April - 01 May 2009<br />
Meeting at a Glance<br />
28 April - 01 May 2009
Additional Meetings<br />
Tuesday 28 April 2009<br />
Open Meetings<br />
12.30-14.00 BSR Standards Guidelines and Audit Working Group – lunch provided Carron Room<br />
12.30-14.00 Arthritis and Musculoskeletal Alliance – lunch provided Seminar Suite<br />
Wednesday 29 April 2009<br />
Open Meetings<br />
12.00-13.30 <strong>British</strong> <strong>Society</strong> <strong>for</strong> <strong>Rheumatology</strong> Biologics Register – lunch provided Hall 1<br />
12.00-13.30 Rheumatologists At Training – lunch provided Dochart Room<br />
Meeting at a glance | 28 April - 01 May 2009<br />
Closed Meetings<br />
09.30-10.30 AS guideline Ness Room<br />
12.00-13.30 <strong>Rheumatology</strong> Editorial Board Meeting Leven Room<br />
12.00-13.30 BHPR Research Group Morar Room<br />
12.00-13.30 Sjögrens Board Meeting Ness Room<br />
13.30-15.30 CAC Regional Chairs Meeting Ness Room<br />
18.40-19.40 Pharmacists Meeting Leven Room<br />
Thursday 30 April 2009<br />
Open Meetings<br />
07.30-08.30 CMF Breakfast Carron Room B<br />
Closed Meetings<br />
07.00-09.00 NRAS Medical Advisors Ness Room<br />
08.00-09.00 ERAN AGM Morar Room<br />
12.30-14.30 Physiotherapist Meeting Ness Room<br />
14.30-16.30 Website Editorial Board Meeting Ness Room<br />
As usual, all rooms are in high demand throughout <strong>Rheumatology</strong> ’09 and the turnaround time between<br />
sessions is very tight. It is essential that all meetings/sessions commence and conclude on time. Any over-run<br />
will have a severe impact on the remainder of a scientific programme.<br />
If you are attending any of the above meetings please ensure that you arrive promptly in order to<br />
avoid a late start and any resultant over-run.<br />
7
Meeting at a Glance - Tuesday 28 April 2009 Meeting at a Glance - Wednesday 29 April 2009<br />
07.30 Registration opens<br />
08.30 Poster Viewing including Tea/Coffee Hall 5<br />
09.00 Primary Care: Management of the foot and ankle Lomond Auditorium<br />
09.30 Science: A biology of lupus Hall 1<br />
10.00 BSR: Anti-phospholipid BSR: Predicting prognosis BHPR: Droitwich Lecture<br />
syndrome (10.00-12.00) and treatment response Clyde Auditorium<br />
Lomond Auditorium in OA (10.00-12.00) Hall 1<br />
10.00 Exhibition opens Tea/Coffee Hall 5<br />
10.30 Primary Care: Management Science: A biology of BSR: <strong>The</strong> liver and<br />
of the foot and ankle lupus Hall 1 rheumatic disease<br />
Lomond Auditorium Forth Room<br />
11.00 arc/BSR: Research and your career Dochart Room<br />
11.00 BHPR: Pursuing a clinical research BHPR: RA clinical issues Clyde Room<br />
career Forth Room<br />
12.00 Lunch Hall 5 BHPR: <strong>The</strong> NRAS/EPP CIC RA<br />
• BSR BR open meeting Hall 1 self-management programme<br />
• RATs meeting Dochart Room Lomond Auditorium<br />
12.30 Lunch Hall 5<br />
• ARMA Seminar Suite<br />
• SGAWG Carron Room<br />
13.30 BSR & BHPR: Plenary Oral Presentation of Abstracts Clyde Auditorium<br />
15.30 Tea/Coffee Hall 5<br />
14.00 Primary Care: Primary Care: Science: A biology BSR: Advances in BSR: Managing<br />
Musculoskeletal Management of the of lupus Hall 1 joint replacement back pain<br />
problems in childhood foot and ankle surgery Clyde<br />
Alsh Room Boisdale Room (Pre-booked workshop attendees only) Forth Room Auditorium<br />
16.00 Tea/Coffee Hall 5<br />
16.30 Primary Care: Primary Care: Science: BSR: Concurrent oral presentation<br />
Management Recognising A biology of of abstracts<br />
of the foot ankylosing lupus Hall 1 • Spondyloarthritis Clyde Auditorium<br />
and ankle spondylitis • Paediatric and adolescent<br />
Boisdale Room Alsh Room rheumatology Forth Room<br />
(Pre-booked workshop • Osteoarthritis Carron Room<br />
attendees only)<br />
• Novel autoantigens Dochart Room<br />
• Aetiopathogenesis Seminar Suite<br />
16.00 Prize Giving and Heberden Oration: Prof Stuart Ralston Clyde Auditorium<br />
17.40 RATs training workshop BSR: Special interest groups<br />
Lomond Auditorium • Scleroderma Alsh Room A<br />
• Osteoarthritis Alsh Room B<br />
• Interstitial lung disease Boisdale Room A<br />
• Cardiovascular co-morbidity in RA Boisdale Room B<br />
• Vasculitis Carron Room<br />
• Heritible disorders of connective tissue Dochart Room A<br />
• Osteoporosis Dochart Room B<br />
• Systemic lupus erythematosus Morar/Ness Room<br />
19.10 Satellite Symposia:<br />
• Abbott Forth Room<br />
• Wyeth Hall 1<br />
18.00 Welcome Buffet Reception and Now and <strong>The</strong>n Exhibit Hall 5<br />
19.30 Satellite Symposia<br />
• Chugai Roche Forth Room<br />
• Schering Plough Hall 1
Meeting at a Glance - Thursday 30 April 2009 Meeting at a Glance - Friday 01 May 2009<br />
08.30 Poster Viewing Hall 5 BHPR special interest groups:<br />
• Rheumatoid Arthritis Boisdale Room A<br />
• CTD Boisdale Room B<br />
• Osteoporosis Carron Room A<br />
08.30 Poster Viewing Hall 5<br />
10.00 State of the Art Lecture: BHPR: Research issues and Prize Giving<br />
Prof Richard Jones Clyde Auditorium Lomond Auditorium<br />
(09.30) BHPR AGM Dochart Room<br />
11.00 Tea/Coffee Hall 5<br />
10.00 Tea/Coffee Hall 5<br />
10.30 BSR: BSR and BSR: BSR: BHPR: Psycho- BHPR:<br />
Vasculitis BHPR: Health Genetics of Biomedical social issues Partnerships<br />
Clyde and work common research from in foot<br />
Auditorium Lomond rheumatic networks – childhood healthcare<br />
Auditorium disease the Canadian through Forth Room<br />
Hall 1 experience adult life<br />
Dochart Room Boisdale Room<br />
12.30 Lunch Hall 5 • BSR AGM Alsh Room BHPR: Writing <strong>for</strong><br />
publication (12.45-14.15)<br />
Hall 1<br />
14.30 BSR: Oral Presentation of Abstracts BHPR: Oral Presentation of Abstracts Hall 1<br />
• Rheumatoid arthritis Clyde Auditorium<br />
• Pain and fatigue Forth Room<br />
• Case reports Lomond Auditorium<br />
• Vascular biology and vasculitis Alsh Room<br />
• Connective tissue disease Boisdale Room<br />
• Education research Dochart Room<br />
11.30 Political Slot: BSR: BSR: New BHPR: BHPR: Clinical<br />
NICE and the Management of immunosup- Qualitative update on<br />
BSR Hall 1 unusual bone pressants studies of self- spondylodisease<br />
Lomond management in arthropathies<br />
Forth Room Auditorium osteoarthritis Boisdale Room<br />
Alsh Room<br />
13.00 Lunch Hall 5 BSR: Special interest groups<br />
• Musculoskeletal health <strong>for</strong> the multi ethnic minority<br />
Carron Room A<br />
• Polymyalgia rheumatica and giant cell arteritis Carron Room B<br />
• Sjögrens syndrome Dochart Room A<br />
• Paediatric and adolescent rheumatology Dochart Room B<br />
• Sport and exercise medicine Leven Room<br />
• Musculoskeletal ultrasound Morar/Ness Room<br />
14.00 Exhibition closes BHPR: Designing solutions not problems<br />
Forth Room<br />
15.00 BSR: Setting up a fracture liaison service BSR: Psoriasis and the scoring systems<br />
Lomond Auditorium Forth Room<br />
16.30 Tea/Coffee Hall 5<br />
17.00 Meeting closes<br />
17.00 Heberden Round: Prof Patricia Woo Clyde Auditorium<br />
18.00 Satellite Symposium<br />
• UCB Forth Room<br />
19.35 Coaches to BSR social event<br />
20.00 BSR social event - 25th Anniversary celebrations, Kelvingrove (Welcome drinks from 19.30, carriages 00.30)
Registration and Exhibition Opening Hours<br />
Registration Desk Opening Hours<br />
Tuesday 28 April 2009 07.30 – 19.30<br />
Wednesday 29 April 2009 08.00 – 19.15<br />
Thursday 30 April 2009 08.00 – 18.00<br />
Friday 01 May 2009 08.00 – 15.00<br />
Exhibition Opening Hours<br />
Tuesday 28 April 2009 10.00 – 19.30<br />
Wednesday 29 April 2009 08.30 – 17.00<br />
Thursday 30 April 2009 08.30 – 17.00<br />
Friday 01 May 2009 08.00 – 14.00<br />
Please note that exhibitors are only asked to be present in the exhibition hall<br />
during catering breaks and special Hall 5 events such as the Welcome Reception<br />
and Poster Viewing.<br />
BSR is 25!<br />
We are celebrating our 25th anniversary with an exhibition devoted to BSR, past and present.<br />
Visit the BSR stand and see the history of rheumatology spanning back to 1768. See how<br />
rheumatology has changed over the last 25 years with memories from past presidents and<br />
BSR members. Come and celebrate with us at our annual social event with a five-piece band<br />
and four course dinner! Tickets are available from the registration desk at £25 <strong>for</strong> members<br />
and £55 <strong>for</strong> non members.<br />
10
Scientific <strong>Programme</strong><br />
Tue 28 April 2009<br />
Scientific <strong>Programme</strong><br />
Tuesday 28 April 2009
BSR Scientific <strong>Programme</strong> 2009<br />
Tuesday 28 April 2009<br />
09.00-10.00 Primary Care: Management of the foot and ankle Lomond Auditorium<br />
Dr Simon Bowman, Dr Shrish Dubey, Dr Elspeth Wise and Dr Phillip Helliwell<br />
• Introduction and background – Dr Shirish Dubey and Dr Simon Bowman<br />
• Anatomy – Dr Tony Redmond and Dr Philip Helliwell<br />
10.00-10.30 Exhibition opens Hall 5<br />
Tea/Coffee<br />
10.30-12.30 Primary Care: Management of the foot and ankle Lomond Auditorium<br />
Dr Simon Bowman, Dr Shrish Dubey, Dr Elspeth Wise and Dr Phillip Helliwell<br />
• Soft tissue disorders and their treatment – Dr Deborah Turner, Dr Philip Helliwell,<br />
Dr Wendy Smith, Ms Heidi Siddle, Dr Anne-Maree Keenan and Dr Ruth Semple<br />
• Video of examination Dr Elspeth Wise<br />
Scientific <strong>Programme</strong> | Tuesday 28 April 2009<br />
Science: A biology of lupus Hall 1<br />
Prof David Isenberg<br />
• Genetics: how to study the genome and identify the really bad genes in lupus –<br />
Prof Tim Wise<br />
Multiple genes contribute to the risk of developing SLE. <strong>The</strong> advent of genome-wide genetic<br />
association analysis has dramatically increased our understanding of the genetic basis of<br />
SLE and is shedding light on the pathogenesis of this disease.<br />
• Apoptosis: defects and deficiencies – Prof Martin Herrman<br />
<strong>The</strong> impaired removal of apoptotoc cells and either low phagocytic activities or the<br />
production of inflammatory cytokines are key elements in SLE pathogenesis. This talk<br />
explores these events in more detail.<br />
• <strong>The</strong> role of complement in lupus – Prof Marina Botto<br />
<strong>The</strong> lecture will illustrate how complement contributes to modulate the innate and<br />
adaptive immune response in SLE.<br />
• Is interferon alpha the key cytokine in lupus? – Prof Lars Ronnblom<br />
Patients with SLE have an increased expression of type I interferon (IFN) regulated genes<br />
due to a continuous production of IFN-alpha. What are the reasons behind the IFN-alpha<br />
production and is it important in the etiopathogenesis of the disease?<br />
This topic will be discussed during the session, as well as possible clinical consequences<br />
of this knowledge.<br />
BSR: <strong>The</strong> liver and rheumatic disease Forth Room<br />
Prof Chris Denton<br />
• Viral hepatitis – Dr Martin Prince<br />
Demographic and social changes mean that the prevalence of chronic viral hepatitis is<br />
increasing with implications <strong>for</strong> all specialties. Viral hepatitis and its treatment may lead<br />
directly to rheumatological complications or complicate choice of immunosuppressive<br />
therapy.<br />
11
• Hepatic complications of anti-rheumatic therapies – Dr Ian Bruce<br />
This talk will focus on non-infection related hepatic complications of anti-rheumatic drugs<br />
especially DMARDs and anti-TNF agents. It will consider prescribing issues associated with<br />
relevant co-morbid conditions and the potential of genetics and additional biomarkers <strong>for</strong><br />
more personalised prescribing of these agents.<br />
• Liver complications of connective tissue disease – Prof Andy Burroughs<br />
Hepatic abnormalities in association with rheumatic disease are due to drugs and less<br />
frequently due to specific hepatic disease associations. Minor abnormalities of LFTs are<br />
frequent and often normalize with control of active rheumatic disease. Arthralgia is common<br />
in many chronic liver diseases, due to different mechanisms and rarely due to specific<br />
rheumatological disease.<br />
11.00-13.00 Research and your career – your questions answered Dochart Room<br />
A joint arc/BSR initiative<br />
Prof Alan Silman, Prof David Scott, Dr D Bax<br />
Tired of doing the same job? Stuck in a rut and looking <strong>for</strong> something to put a spring<br />
in your step?<br />
<strong>The</strong>re are opportunities <strong>for</strong> research at any stage in your career, so come along and find out more<br />
from current researchers, hear about their experiences, discover how to approach research<br />
whatever the stage or type of career you are undertaking. Get the chance to meet and talk with<br />
others, learn about the opportunities <strong>for</strong> funding from arc and others and how to choose<br />
projects and find supervisors.<br />
• Undertaking a career in clinical research Dr Mohini Gray<br />
• Continuing research as an established clinician<br />
• Establishing a research career as an AHP Dr Deborah Turner<br />
• Establishing independence as a scientist Dr Carl Goodyear<br />
• Research funding opportunities Dr Liz Waterman, arc<br />
12.30-14.00 Lunch Hall 5<br />
Arthritis and Musculoskeletal Alliance open meeting Seminar Suite<br />
What has ARMA been up to in the last year? Ros Meek Director of ARMA will provide an overview<br />
of ongoing activity. Ailsa Bosworth Co Chair of the <strong>Rheumatology</strong> Futures Group will present the<br />
findings of the report by the health think tank <strong>The</strong> Kings Fund, on the perceptions of patients and<br />
professionals of rheumatoid arthritis care which was launched earlier this year. This will be<br />
followed by an update and mini debate on the contribution of primary care to musculoskeletal<br />
health which will be led by Dr Alan Nye. Alan is a GP and Chief Executive of Pennine MSK<br />
Partnership. He is also clinical lead on the 18 weeks team at the DH.<br />
BSR Standards Guidelines and Audit Working Group open meeting Carron Room<br />
<strong>The</strong> Draft BSR RA Biologics Guidelines – introduced by Dr Chris Deighton, this is an opportunity to<br />
get a copy of and discuss the draft guidelines<br />
<strong>The</strong> results of the first BSR national audit – this is the chance to hear the first results of the audit<br />
on time <strong>for</strong> diagnosis to 1st DMARDS, which many of you took part in at the end of last year.<br />
12
14.00-16.00 Primary Care: Management of the foot and ankle - limited spaces available<br />
Boisdale Room<br />
Dr Simon Bowman, Dr Shrish Dubey, Dr Elspeth Wise and Dr Phillip Helliwell<br />
• Examination practical – Dr John Dickson, Dr Deborah Turner, Dr Wendy Smith,<br />
Ms Heidi Siddle, Dr Anne-Maree Keenan, Dr Ruth Semple, Dr Philip Helliwell,<br />
Dr Simon Bowman,<br />
Dr Shirish Dubey, Dr Tony Redmond, Dr Elspeth Wise, Mr Michael Backhouse<br />
• Quiz - Dr Philip Helliwell and Dr Elspeth Wise<br />
Primary Care: Musculoskeletal problems in childhood Alsh Room<br />
Dr Clive Ryder<br />
A practical approach to the assessment and early management of children’s<br />
musculoskeletal problems.<br />
Science: A biology of lupus Hall 1<br />
Prof David Isenberg<br />
B cell abnormalities<br />
• Lessons from experimental models – Prof Rizgar Mageed<br />
This presentation will summarise progress in understanding mechanisms of autoimmunity in<br />
murine lupus. Key findings will be discussed in the context of relevance to human systemic<br />
lupus erythematosus.<br />
• B regs: the facts! – Dr Claudia Mauri<br />
We have recently identified the existence of regulatory B cells in the peripheral blood of<br />
healthy individuals and demonstrate that they strongly suppress Th1 differentiation. In<br />
patients with active SLE, Bregs produce less IL-10, and lack the functional suppressive<br />
capacity of their healthy counterparts. In addition we will discuss our recent findings on the<br />
effect of rituximab therapy on the function of repopulating B regs.<br />
• B cell activating factors: block and benefit? – Dr Claudia Penarossi<br />
• B cells in SLE: a suitable case <strong>for</strong> treatment? – Prof David Isenberg<br />
<strong>The</strong> notion that B lymphocyte abnormalities are integral to the development of SLE is<br />
supported by open clinical trial data that their removal is invariably beneficial. However,<br />
problems remain about optimal dosing, the rate of return of the B cells and how this<br />
links to clinical flare.<br />
Scientific <strong>Programme</strong> | Tuesday 28 April 2009<br />
BSR: Advances in joint replacement surgery Forth Room<br />
Dr Paul Bowness<br />
• How to run a combined orthopaedic/rheumatology service – Dr Paul Bowness<br />
<strong>The</strong> benefits and practicalities of setting up a multidisciplinary rheumatology/orthopaedic<br />
service in the biologic era will be discussed, together with the description of individual cases.<br />
• Rheumatoid surgery of the shoulder and elbow – Prof Andrew Carr<br />
<strong>The</strong> role of arthroscopic debridement, synovectomy, osteotomy and joint replacement<br />
surgery. Advantages of assessing outcome using patient reported outcome measures<br />
(PROs). Influence of implant design, diagnosis and stage of disease on outcome.<br />
Complications of arthroplasty and their management.<br />
• When to operate on the rheumatoid neck – Miss Jennifer Brown<br />
A brief review of therapeutic and prophylactic indications <strong>for</strong> surgery on the rheumatoid<br />
cervical spine.<br />
• Lower limb surgery in RA – Mr Roger Gundle<br />
A discussion current indications <strong>for</strong> surgical procedures to the hip and knee, with comments<br />
on hip resurfacing and unicompartmental knee replacement, focussing on the particular<br />
needs of patients with RA.<br />
13
BSR: Managing back pain: where do we go from here? An epidemiological and<br />
intervention perspective Clyde Auditorium<br />
Prof Alan Silman<br />
• Back pain: an epidemiological update on risk factors <strong>for</strong> onset and outcome –<br />
Prof Gary McFarlane<br />
• Management: what works and what doesn’t – Dr Danielle Van der Windt<br />
Most randomised trials on the effectiveness of interventions <strong>for</strong> back pain show large and<br />
significant improvements of pain and function within intervention groups, but very little<br />
difference between different types of treatment. <strong>The</strong> question is to what extent this response<br />
is specific to the intervention itself, or is determined by characteristics of the patient, the<br />
care provider, or the setting in which the intervention is given. Some new developments in<br />
back pain research will be presented that focus on optimising treatment effects, and<br />
address these non-specific elements in the management of back pain.<br />
• Challenges in improving outcome <strong>for</strong> patients – Prof Peter Croft<br />
<strong>The</strong> talk will consider whether we can make back pain care more effective in primary care. It<br />
will discuss the extent to which we are getting research evidence into practice, the need <strong>for</strong><br />
new models of primary care in order to deliver effective treatment, and whether the real<br />
challenge is to deliver public health interventions in primary care to deliver long-term<br />
reductions in chronic pain and disability in the whole population.<br />
16.00-16.30 Tea/Coffee Hall 5<br />
16.30-18.00 Primary Care: Management of the foot and ankle - limited spaces available<br />
Boisdale Room<br />
Dr Simon Bowman, Dr Shrish Dubey, Dr Elspeth Wise and Dr Phillip Helliwell<br />
• Taping/insoles/injections (workshops) – Dr Ann-Maree Keenan, Ms Heidi Siddle,<br />
Dr Philip Helliwell, Dr Tony Redmond, Dr Deborah Turner, Mr Michael Backhouse,<br />
Dr Wendy Smith, Dr Ruth Semple, Dr Simon Bowman<br />
• Summary and close – Dr Simon Bowman and Dr Shirish Dubey<br />
Primary Care: Recognising ankylosing spondylitis Alsh Room<br />
Dr Andrew Keat and Mrs Claire Harris, Specialist Physiotherapist<br />
Ankylosing spondylitis, spotting it in the community, assessing it and why it is important to do.<br />
Science: A biology of lupus Hall 1<br />
Prof David Isenberg<br />
T cell Abnormalities<br />
• T cell abnormalities and the role of tregs – Prof Michael Ehrenstein<br />
Regulatory T cells play a key role in controlling autoimmunity. In SLE both effector and<br />
regulatory T cells are malfunctioning. Understanding these defects are key to identifying<br />
new avenues of therapy.<br />
• Responses to T cell peptides: towards a new therapeutic approach – Prof Sylvianne Muller<br />
14
16.30-18.00 Concurrent Oral Presentations of Abstracts<br />
Novel autoantigens Dochart Room<br />
OP1<br />
OP2<br />
CITRULLINATED α-ENOLASE - A MAJOR AUTOANTIGEN LINKING SMOKING AND HLA-DRB1<br />
SHARED EPITOPE TO RHEUMATOID ARTHRITIS<br />
Karin Lundberg 1 , Hiba Mahdi 2 , Benjamin Fisher 1 , Henrik Kallberg 3 , Darren Plant 4 , Johan<br />
Ronnelid 5 , Peter Charles 1 , Bo Ding 3 , Deborah Symmons 4 , Patrick J. Venables 1 , Lars Klareskog 2 ;<br />
1<br />
Kennedy Institute of <strong>Rheumatology</strong>, Imperial College London, London, United Kingdom;<br />
2<br />
<strong>Rheumatology</strong> Unit, Karolinska Institutet, Stockholm, Sweden; 3 Institute <strong>for</strong> Environmental<br />
Medicine, Karolinska Institutet, Stockholm, Sweden; 4 Arthritis Research Campaign Epidemiology<br />
Unit, University of Manchester, Manchester, United Kingdom; 5 Unit of Clinical Immunology,<br />
Uppsala University, Uppsala, Sweden<br />
IDENTIFICATION BY PROTEOMIC ANALYSIS OF CHAPERONES AND CITRULLINATED<br />
GLYCOLYTIC ENZYMES AS CANDIDATE AUTOANTIGENS IN EARLY RHEUMATOID ARTHRITIS<br />
Vincent Goeb 1 , Marlene Thomas-L’Otellier 2 , Romain Daveau 2 , Roland Charlionet 2 ,<br />
Patrice Fardellone 3 , Xavier Le Loet 1 , Francois Tron 2 , Daniele Gilbert 2 , Olivier Vittecoq 1 ;<br />
1<br />
<strong>Rheumatology</strong> and Inserm U905, University Hospital, Rouen, France; 2 Immunology and Inserm<br />
U905, University Hospital, Rouen, France; 3 <strong>Rheumatology</strong>, University Hospital, Amiens, France<br />
Scientific <strong>Programme</strong> | Tuesday 28 April 2009<br />
OP3<br />
OP4<br />
T CELL RESPONSES TO CITRULLINATED AGGRECAN PEPTIDE IN RHEUMATOID ARTHRITIS<br />
Alexei von Delwig, James Locke, John H. Robinson, Wan-Fai Ng;<br />
Musculoskeletal Research Group, Institute of Cellular Medicine, Newcastle University,<br />
Newcastle upon Tyne, United Kingdom<br />
YOUNG INVESTIGATOR AWARD WINNER<br />
ENDOGENOUSLY CITRULLINATED PROTEINS FROM PORPHYROMONAS GINGIVALIS<br />
AS A CANDIDATE SOURCE OF PRIMING AUTOANTIGENS IN RHEUMATOID ARTHRITIS<br />
Natalia Wegner 1 , Sigrun Eick 2 , Aneta Sroka 3 , Ky-Anh Nguyen 4 , Jan Potempa 3,5 , Patrick Venables 1 ;<br />
1<br />
Kennedy Institute of <strong>Rheumatology</strong>, Imperial College London, London, United Kingdom;<br />
2<br />
Department of Medical Microbiology, University Hospital Jena, Jena, Germany; 3 Department<br />
of Microbiology, Jagiellonian University, Krakow, Poland; 4 Institute of Dental Research,<br />
Westmead Centre <strong>for</strong> Oral Health, Sydney, NSW, Australia; 5 Department of Biochemistry,<br />
University of Georgia, Athens, GA<br />
OP5<br />
INFLAMMATORY POLYARTHRITIS PATIENTS WITH ANTI-CYCLIC CITRULLINATED PEPTIDE<br />
(ANTI-CCP) ANTIBODIES DO NOT BENEFIT FROM EARLY TREATMENT IN TERMS OF<br />
LONG-TERM FUNCTIONAL DISABILITY AS WELL AS THOSE WITHOUT ANTI-CCP ANTIBODIES<br />
Tracey Farragher 1 , Mark Lunt 1 , Diane Bunn 2 , Deborah Symmons 1 ;<br />
1<br />
arc Epidemiology Unit, <strong>The</strong> University of Manchester, Manchester, United Kingdom;<br />
2<br />
Norfolk Arthritis Register, Norfolk and Norwich University Hospital, Norfolk, United Kingdom<br />
OP6<br />
OXIDATIVE MODIFICATIONS TO C1Q INCREASE THE SENSITIVITY OF AN ANTI-C1Q ELISA IN<br />
THE DIAGNOSIS OF SYSTEMIC LUPUS ERYTHEMATOSUS<br />
Brent Ryan 1 , Paul G. Winyard 1 , Nick Viner 1 , Richard Haigh 1 , Miriam Haas 1 , Ahuva Nissim 2 ,<br />
David Isenberg 3 , Paul Eggleton 1 ;<br />
1<br />
Institute of Biomedical and Clinical Sciences, Peninsula Medical School, Exeter, United<br />
Kingdom; 2 Barts and <strong>The</strong> London Medical School, London, United Kingdom; 3 Centre <strong>for</strong><br />
<strong>Rheumatology</strong>, University College London, London, United Kingdom.<br />
15
Paediatric and adolescent rheumatology Forth Room<br />
OP7<br />
OP8<br />
OP9<br />
SENSITIVITY OF MUSCULOSKELETAL HISTORY IN CHILDREN IS POOR - THE NEED TO SCREEN<br />
ALL JOINTS<br />
Iain Goff 1 , Amy Rowan 2 , Belinda J. Bateman 5 , Mark Friswell 4,6 , Andrea Myers 3,6 , Helen E. Foster 6,4 ;<br />
1<br />
Education Department, Northumbria Healthcare NHS Foundation Trust, North Shields, United<br />
Kingdom; 2 School of Medicine, University of Newcastle upon Tyne, Newcastle, United Kingdom;<br />
3<br />
Department of <strong>Rheumatology</strong>, Northumbria Healthcare NHS Foundation Trust, North Shields,<br />
United Kingdom; 4 Department of <strong>Rheumatology</strong>, Newcastle upon Tyne Hospitals NHS Foundation<br />
Trust, Newcastle, United Kingdom; 5 Department of Paediatrics, Northumbria Healthcare NHS<br />
Foundation Trust, North Shields, United Kingdom; 6 Newcastle Musculoskeletal Research Group,<br />
University of Newcastle upon Tyne, Newcastle, United Kingdom<br />
THE PREVALENCE OF HYPERMOBILITY IN UK SCHOOL CHILDREN: WHERE SHOULD THE LINE<br />
BE DRAWN?<br />
Jacqui Clinch 1,2 , Rita Doerner 2 , Emma Clark 2 , Shea Palmer 3 , Jon Tobias 2 ;<br />
1<br />
Paediatric <strong>Rheumatology</strong>, Bristol Royal Hospital <strong>for</strong> Children, Bristol, United Kingdom; 2 Academic<br />
<strong>Rheumatology</strong> Unit, University of Bristol, Bristol, United Kingdom; 3 University of West of England,<br />
Bristol, United Kingdom<br />
ACZ885 (CANAKINUMAB), A NEW IL-1 BETA BLOCKING MONOCLONAL ANTIBODY HAS A<br />
BENEFICIAL EFFECT IN CHILDREN WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA)<br />
Nicolino Ruperto 1 , Pierre Quartier 2 , Nico Wulffraat 3 , Anna Loy 1 , Richard Mouy 2 , Pat Woo 4 , Berent<br />
Prakken 3 , Brigitte Bader-Meunier 2 , Emanuele Noseda 5 , Christiane Rordorf 5 , Alberto Martini 1 ;<br />
1<br />
Pediatria II - PRINTO, IRCCS G. Gaslini, Largo Gaslini, Genova, Italy; 2 Unit’e d’Immunologie,<br />
Hospital Necker Enfants Malades,Hematologie et Rhumatologie Pediatrique, Paris, France; 3 Dept<br />
Pediatric Immunology, University Medical Center Utrecht, Utrecht, Netherlands; 4 Centre<br />
of Paediatric and Adolescent <strong>Rheumatology</strong>, <strong>The</strong> Windeyer Institute, London, United Kingdom;<br />
5<br />
Novartis Pharma AG, Basel, Switzerland<br />
OP10<br />
OP11<br />
OP12<br />
PUTATIVE AUTOIMMUNE SUSCEPTIBILITY LOCI; TENR-IL2-IL21, IL7R, CTLA4 AND LAF4,<br />
ARE ASSOCIATED WITH JUVENILE IDIOPATHIC ARTHRITIS<br />
Anne Hinks 1 , Steve Eyre 1 , Anne Barton 1 , Paul Martin 1 , Edward Flynn 1 , Xiayi Ke 1 , Jon Packham 2 ,<br />
Jane Worthington 1 , Wendy Thomson 1 ;<br />
1<br />
arc epidemiology unit, University of Manchester, Manchester, United Kingdom; 2 Haywood Hospital,<br />
University Hospital of North Staf<strong>for</strong>dshire, Stoke-on-Trent, United Kingdom<br />
GENERATION OF NOVEL PHARMACOGENOMIC CANDIDATES IN THE RESPONSE TO<br />
MTX IN JUVENILE IDIOPATHIC ARTHRITIS (JIA): CORRELATION BETWEEN GENE EXPRESSION<br />
AND GENOTYPE<br />
Halima Moncrieffe 1 , Simona Ursu 1 , Nipurna Jina 2 , Anne M. Hinks 3 , Paul Martin 3 , Wendy Thomson 3 ,<br />
Lucy R. Wedderburn 1 ;<br />
1<br />
<strong>Rheumatology</strong> Unit, UCL Institute of Child Health, London, United Kingdom; 2 Molecular<br />
Haematology and Cancer Biology Unit, UCL Institute of Child Health, London, United Kingdom;<br />
3<br />
Arthritis Research Campaign (arc)-Epidemiology Unit, University of Manchester, Manchester,<br />
United Kingdom<br />
INCIDENCE OF CHILDHOOD SCLERODERMA IN THE UK AND IRELAND<br />
Ariane L. Herrick 1,2 , Holly Ennis 1 , Alan Silman 1 , Eileen M. Baildam 3 ;<br />
1<br />
arc Epidemiology Unit, University of Manchester, Manchester, United Kingdom; 2 Sal<strong>for</strong>d Royal<br />
NHS Foundation Trust, Sal<strong>for</strong>d, United Kingdom; 3 Alder Hey Children’s NHS Foundation Trust,<br />
Liverpool, United Kingdom<br />
16
Osteoarthritis Carron Room<br />
OP13<br />
OP14<br />
A COMMUNITY-BASED INTEGRATED REHABILITATION PROGRAMME FOR<br />
CHRONIC KNEE PAIN<br />
Mike Hurley 1 , Sally Jessop 2 , Nicki Walsh 3 , Julie Ratcliffe 4 ;<br />
1<br />
Academic Physiotherapy, King’s College London, London, United Kingdom; 2 Physiotherapy<br />
Department, West Kent Primary Care Trust, Sevenoaks, United Kingdom; 3 Faculty of Health and<br />
Life Sciences, University of the West of England, Bristol, United Kingdom; 4 Division of Health<br />
Sciences, University of South Australia, Brisbane, United Kingdom<br />
YOUNG INVESTIGATOR AWARD WINNER<br />
MUSCULOSKELETAL ULTRASOUND PREDICTS RESPONSE TO CORTICOSTEROID INJECTION IN<br />
MODERATE-SEVERE HIP OSTEOARTHRITIS<br />
Ismaël Atchia 1,2 , David Kane 2 , Mike R. Reed 1 , John Isaacs 2 , Fraser Birrell 1,2 ;<br />
1<br />
Northumbria Healthcare NHS Foundation Trust, Northumberland, United Kingdom;<br />
2<br />
Musculoskeletal Research Group, Institute of Cellular Medicine, Newcastle University, Newcastle<br />
Upon Tyne, United Kingdom<br />
Scientific <strong>Programme</strong> | Tuesday 28 April 2009<br />
OP15<br />
OP16<br />
EPIDEMIOLOGICAL AND MOLECULAR EVIDENCE FOR THE CHONDROPROTECTIVE EFFECT OF<br />
GARLIC IN OSTEOARTHRITIS<br />
Frances Williams 1 , Rose Davidson 2 , Jane Skinner 2 , Kirsty Culley 2 , Yongping Bao 2 , Aedin Cassidy 2 ,<br />
Ian Clark 2 , Alex MacGregor 1,2 ;<br />
1<br />
Department of Twin Research and Genetic Epidemiology, Kings College, London, United<br />
Kingdom; 2 University of East Anglia, Norwich, United Kingdom<br />
CORRELATION OF SYNOVITIS WITH PROTEASE-ACTIVATED RECEPTOR-2 EXPRESSION<br />
IN OSTEOARTHRITIS<br />
Elizabeth B. Kelso 1 , William R. Ferrell 1 , John C. Lockhart 2 , David A. Walsh 3 , J. Alastair Gracie 1 ,<br />
Iain B. McInnes 1 ;<br />
1<br />
Centre <strong>for</strong> Rheumatic Diseases, University of Glasgow, Glasgow, United Kingdom;<br />
2<br />
Science and Engineering, University of the West of Scotland, Paisley, United Kingdom;<br />
3<br />
<strong>Rheumatology</strong>, University of Nottingham, Nottingham, United Kingdom<br />
OP17<br />
OP18<br />
SHAPE OF THE FEMORAL HEAD AND NECK CORRELATES WITH CLINICAL FEATURES OF<br />
OA AND CAN PREDICT PROGRESSION TO TOTAL HIP REPLACEMENT<br />
Jennifer S. Gregory 1 , Rebecca J. Barr 1 , Kanako Yoshida 1 , David M. Reid 1 , Richard M. Aspden 1 ,<br />
Alan J. Silman 5 , Gillian Hosie 4 , Salvatore Alesci 2 , Gary J. Macfarlane 3 ;<br />
1<br />
Division of Applied Medicine, University of Aberdeen, Aberdeen, United Kingdom; 2 Discovery<br />
Translational Medicine, Wyeth Research, Collegeville, PA; 3 Division of Applied Health Science,<br />
University of Aberdeen, Aberdeen, United Kingdom; 4 Primary Care <strong>Rheumatology</strong> <strong>Society</strong>,<br />
Northallerton, United Kingdom; 5 Department of <strong>Rheumatology</strong>, University of Manchester,<br />
Manchester, United Kingdom<br />
RESTRICTED SELF-CARE AND LOOKING AFTER THE HOME IN ADULTS 50 YEARS AND<br />
OLDER WITH HAND OSTEOARTHRITIS; PREVALENCE AND LINKS WITH JOINT SPECIFIC<br />
CHARACTERISTICS<br />
Yeliz Greenhill, Ross Wilkie, Elaine Nicholls, Helen Myers, Michelle Marshall, Susan Hill,<br />
Krysia Dziedzic;<br />
Arthritis Research Campaign National Primary Care Centre, Keele University,<br />
Newcastle-under-Lyme, United Kingdom<br />
17
Spondyloarthritis Clyde Auditorium<br />
OP19<br />
OP20<br />
OP21<br />
OP22<br />
IL-23 OVEREXPRESSION AS IMMUNOLOGICAL SIGNATURE OF SUBCLINICAL<br />
INTESTINAL INFLAMMATION IN ANKYLOSING SPONDYLITIS<br />
Michele Bombardieri 1 , Francesco Ciccia 2 , Alfonso Principato 2 , Claudio Tripodo 2 , Sergio Peralta 2 ,<br />
Giovanni Triolo 2 , Costantino Pitzalis 1 ;<br />
1<br />
Experimental Medicine and <strong>Rheumatology</strong>, William Harvey Research Institute, Barts and <strong>The</strong><br />
London School of Medicine, London, United Kingdom; 2 University of Palermo, Palermo, Italy<br />
IL-12 AND IL-23 SECRETION BY DENDRITIC CELLS IN SPONDYLOARTHROPATHY<br />
Claudia Prevosto, Jane C. Goodall, Hill J. Gaston;<br />
Medicine, University of Cambridge, Cambridge, United Kingdom<br />
EFFECTIVE TREATMENT FOR JOINT AND SKIN SYMPTOMS WITH ADALIMUMAB IN<br />
COMBINATION WITH VARIOUS DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (DMARDS) IN<br />
PATIENTS WITH PSORIATIC ARTHRITIS (PSA): RESULTS OF THE STEREO TRIAL<br />
Neil McHugh 2 , Filip van den Bosch 1 , Erik Røedevand 3 , Palle Holck 4 , Martina Kron 5 , Sonja Kary 5 ,<br />
Hartmut Kupper 5 ;<br />
1<br />
University Hospital, Ghent, Belgium; 2 Royal National Hospital, Bath, United Kingdom; 3 St Olavs<br />
Hospital, Trondheim, Norway; 4 Regionshospitalet Silkeborg, Silkeborg, Denmark; 5 Abbott GmbH<br />
& Co KG, Ludwigshafen, Germany<br />
GOLIMUMAB ADMINISTERED SUBCUTANEOUSLY EVERY FOUR WEEKS IN PSORIATIC<br />
ARTHRITIS: 52-WEEK EFFICACY AND SAFETY RESULTS OF THE GO-REVEAL STUDY<br />
Iain McInnes 1 , Philip Mease 3 , Gerald Krueger 4 , Dafna Gladman 5 , Juan Gomez-Reino 6 , Kim Papp 7 ,<br />
Frederick Murphy 8 , Michael Mack 9 , Julie Zrubek 9 , Arthur Kavanaugh 2 ;<br />
1<br />
University of Glasgow, Glasgow, United Kingdom; 2 University of Cali<strong>for</strong>nia San Diego, La Jolla, CA;<br />
3<br />
Swedish Medical Center and Seattle <strong>Rheumatology</strong> Associates, Seattle, WA; 4 University of Utah,<br />
Salt Lake City, UT; 5 University of Toronto, Toronto, ON, Canada; 6 Hospital Clinico University,<br />
Santiago, Spain; 7 Probity Medical Research, Waterloo, ON, Canada; 8 Altoona Center <strong>for</strong> Clinical<br />
Research, Duncansville, PA; 9Centocor Research and Development, Inc., Malvern, PA<br />
OP23<br />
OP24<br />
EVALUATING ANKYLOSING SPONDYLITIS QUALITY OF LIFE (EASI-QOL): RELIABILITY AND<br />
VALIDITY OF A NEW PATIENT REPORTED OUTCOME MEASURE<br />
Kirstie L. Haywood 1,4 , Andrew M. Garratt 2 , Emma L. Healey 3,4 , Kelvin P. Jordan 4 ,<br />
Jon C. Packham 3,4 ; 1 Royal College of Nursing Research Institute, School of Health and Social<br />
Studies, University of Warwick, Coventry, CV4 7AL, United Kingdom; 2 National Resource Centre<br />
<strong>for</strong> Rehabilitation in <strong>Rheumatology</strong>, Diakonhjemmet Hospital, Oslo, Norway; 3 Staf<strong>for</strong>dshire<br />
<strong>Rheumatology</strong> Centre, Haywood Hospital, Stoke-on-Trent, Staf<strong>for</strong>dshire, United Kingdom; 4 Arthritis<br />
Research Campaign National Primary Care Centre, Keele University, Staf<strong>for</strong>dshire, ST5 5BG,<br />
United Kingdom<br />
THE EFFECT OF SOCIAL DEPRIVATION IN ANKYLOSING SPONDYLITIS<br />
Emma L. Healey 1,2 , Kirstie L. Haywood 3,1 , Kelvin P. Jordan 1 , Andrew M. Garratt 4 , Jon C. Packham 2,1 ;<br />
1<br />
Arthritis Research Campaign National Primary Care Centre, Keele University,<br />
Newcastle-under-Lyme, United Kingdom; 2 Staf<strong>for</strong>dshire <strong>Rheumatology</strong> Centre, Haywood Hospital,<br />
Stoke-on-Trent, United Kingdom; 3 RCN Research Institute, School of Health & Social Studies,<br />
Warwick University, Coventry, United Kingdom; 4 National Resource Centre <strong>for</strong> Rehabilitation in<br />
<strong>Rheumatology</strong>, Diakonhjemmet Hospital, Oslo, Norway<br />
18
Aetiopathogenesis of rheumatic disease Seminar Suite<br />
OP25<br />
OP26<br />
OP27<br />
FUNCTIONAL ROLE OF DR3 IN INFLAMMATORY ARTHRITIS: A NOVEL TARGET FOR THERAPY?<br />
Anwen S. Williams 1 , Melanie J. Bull 2 , Zarabeth Mecklenburgh 2 , Claudia J. Calder 2 , Jason P.<br />
Twohig 2 , Carole El<strong>for</strong>d 3 , Bronwen Evans 3 , Aymen Al-Shamkhani 4 , Eddie Wang 2 ; 1 <strong>Rheumatology</strong>,<br />
Cardiff University, Cardiff, United Kingdom; 2 Medical Biochemistry and Immunology, Cardiff<br />
University, Cardiff, United Kingdom; 3 Child Health, Cardiff University, Cardiff, United Kingdom;<br />
4<br />
Cancer Science Division, University of Southampton, Southampton, United Kingdom<br />
DOES LIGHT PLAY A ROLE IN THE PATHOGENESIS OF INFLAMMATORY JOINT DESTRUCTION?<br />
Catherine Swales, David Mahoney, Paul Wordsworth, Nick Athanasou, Afsie Sabokbar;<br />
Nuffield Department of Orthopaedic Surgery, Botnar Research Centre, University of Ox<strong>for</strong>d,<br />
Ox<strong>for</strong>d, United Kingdom<br />
LOCALLY GENERATED GLUCOCORTICOIDS, RATHER THAN PRO-INFLAMMATORY CYTOKINES,<br />
DIRECTLY REGULATE SYNOVIAL DKK-1 EXPRESSION IN INFLAMMATORY ARTHRITIS<br />
Rowan S. Hardy 1 , Mohammad Ahasan 1 , Pushpa Patel 1 , Elizabeth Rabbitt 1 , Andrew Filer 2 ,<br />
Karim Raza 2 , Paul Stewart 1 , Chris Buckley 2 , Mark S. Cooper 1 ;<br />
1<br />
School of Clinical and Experimental Medicine, <strong>The</strong> University of Birmingham, Birmingham, United<br />
Kingdom; 2 Immunity and Infection, <strong>The</strong> University of Birmingham, Birmingham, United Kingdom<br />
Scientific <strong>Programme</strong> | Tuesday 28 April 2009<br />
OP28<br />
OP29<br />
OP30<br />
INTRACELLULAR SIGNALLING IN RESPONSE TO WOUNDING OF CONNECTIVE TISSUES<br />
Fiona Watt, Athanasios Didangelos, Matthew Peirce, Robin Wait, Jeremy Saklatvala;<br />
Kennedy Institute of <strong>Rheumatology</strong>, Imperial College London, London, United Kingdom<br />
ANALYSIS OF DISEASED POSTERIOR TIBIALIS TENDON SPECIMENS REVEALS COMMON<br />
MOLECULAR PATHOGENESIS OF TENDINOPATHY AT DIFFERENT ANATOMICAL SITES<br />
Graham Riley 1,4 , Anthony Corps 4 , Nicholas Avery 3 , Valerie Curry 4 , Andrew Robinson 2 ,<br />
Rebecca Harrall 4 , Brian Hazleman 4 ;<br />
1<br />
School of Biological Sciences, University of East Anglia, Norwich, United Kingdom; 2 Department<br />
of Trauma and Orthopaedics, Addenbrooke’s Hospital, Cambridge, United Kingdom; 3 Matrix<br />
Biology Research Group, University of Bristol, Bristol, United Kingdom; 4 <strong>Rheumatology</strong> Research<br />
Unit, Addenbrooke’s Hospital, Cambridge, United Kingdom<br />
THE SERUM RESPONSE PROGRAMME LEADS TO CONVERGENCE OF TRANSCRIPTIONAL<br />
PROFILES IN RHEUMATOID ARTHRITIS AND OSTEOARTHRITIS SYNOVIAL FIBROBLASTS<br />
Andrew Filer 1 , Philipp Antczak 2 , Greg Parsonage 1 , Steve Kissane 1 , Holly Legault 3 , Margot O’Toole 3 ,<br />
Karim Raza 1 , Dagmar Scheel-Toellner 1 , Christopher D. Buckley 1 , Francesco Falciani 2 ;<br />
1<br />
<strong>Rheumatology</strong> Research Group, University of Birmingham, Birmingham, United Kingdom;<br />
2<br />
School of Biosciences, University of Birmingham, Birmingham, United Kingdom;<br />
3<br />
Wyeth Research, Cambridge, MA<br />
18.00-19.30 Welcome Reception Hall 5<br />
Now and <strong>The</strong>n Exhibition and Address<br />
19
19.30-21.00 Satellite Symposia<br />
Chugai/Roche Forth Room<br />
Introduction – future pathways in RA care – Prof Paul Emery<br />
Making policy work in practice – Dr Anthony Redmond<br />
Future pathways – a clinical review – Prof John Isaacs<br />
Cytokine inhibition and the IL-6 pathway – Dr Ernest Choy<br />
IL-6 receptor inhibition in practice – Prof Paul Emery<br />
Question & answer session – Prof Paul Emery/All<br />
Summary and close<br />
Schering Plough Hall 1<br />
Milestones in rheumatology<br />
Nicky Campbell, investigative journalist, asks tough questions about the past,<br />
present and future of RA management.<br />
<strong>The</strong> journey so far – Prof Peter Taylor<br />
At the crossroads – Dr Mark Quinn<br />
<strong>The</strong> road ahead – Prof Iain McInnes<br />
Panel discussion – led by Nicky Campbell<br />
20
Scientific <strong>Programme</strong><br />
Wed 29 April 2009<br />
Scientific <strong>Programme</strong><br />
Wednesday 29 April 2009
BSR Scientific <strong>Programme</strong> 2009<br />
Wednesday 29 April 2009<br />
08.30-10.00 Poster Viewing Hall 5<br />
10.00-12.00 BSR: Antiphospholipid syndrome Lomond Auditorium<br />
Dr Ian Giles and Dr David D’Cruz<br />
• An overview of recent developments in the pathogenesis and treatment of APS – Dr Ian Giles<br />
This introductory session will provide an overview of the most important recent scientific<br />
and clinical developments in the field of antiphospholipid syndrome related research.<br />
• Mechanisms of thrombosis – Prof Anisur Rahman<br />
This talk will summarise the ways in which antiphospholipid antibodies are believed to act<br />
upon endothelial cells, monocytes, platelets and the clotting cascade to promote thrombosis<br />
in the antiphospholipid syndrome.<br />
• Mechanisms of pregnancy morbidity – Prof Lesley Regan<br />
Antiphospholipid antibody syndrome is now recognised to be the most important treatable<br />
cause of recurrent miscarriage. <strong>The</strong> mechanisms of pregnancy failure are primarily defective<br />
embryonic implantation and thrombosis of the placental vascular tree.<br />
• New targeted therapies – Prof Silvia Pierangeli<br />
<strong>The</strong> talk will cover current therapies and the associated problems and limitations of such<br />
treatments in antiphospholipid syndrome (APS). Based on new knowledge on<br />
pathophysiology of the disease and molecular targets recognised by antiphospholipid<br />
antibodies, new emerging therapies will be thoroughly discussed.<br />
• Controversies in current management – Dr Munther Khamashta<br />
Evidence based treatment recommendations <strong>for</strong> selected patients with aPL associated<br />
thromboembolism can now be made based on published literature. However, numerous<br />
questions remain unanswered. <strong>The</strong>se questions include the optimal management of patients<br />
with arterial thrombosis in the setting of persistently positive aPL, optimal management of<br />
patients who suffer recurrent thrombosis despite therapeutic anticoagulation and<br />
refinement of current diagnostic tests to allow more confident assignment of patients with<br />
suspected APS.<br />
Scientific <strong>Programme</strong> | Wednesday 29 April 2009<br />
BSR: Predicting prognosis and treatment response in OA Hall 1<br />
Dr Nigel Arden<br />
• Epidemiology of progression in osteoarthritis – Dr Fraser Birrell<br />
• Animal models of progressions – Dr Wim Van den Berg<br />
This talk will summarise animal models of OA, illustrate progression of OA joint pathology<br />
and show ways of target identification and validation.<br />
• Progression in clinical trials – Prof Tim Spector<br />
• Response to therapy – Prof Mike Doherty<br />
10.00-10.50 Droitwich Lecture Clyde Auditorium<br />
Chair: Mrs Diana Finney<br />
Prof Jim Woodurn<br />
What is hidden in the shoes? How to find your RA patients’ real clinical CV.<br />
Hidden away in shoes, the feet of our RA patients are often overlooked and poorly understood.<br />
Giving this year’s Droitwich Lecture, Prof Jim Woodburn will attempt to arm delegates with the<br />
knowledge and understanding to challenge this day-to-day clinical problem.<br />
21
11.00-12.00 BHPR: Pursuing a clinical research career Forth Room<br />
Mr Douglas Lauchlin<br />
• Attractions of a clinical research career and how to get started – Dr Candy McCabe<br />
This workshop will discuss how to get started in clinical research, the opportunities <strong>for</strong><br />
progression from a lone researcher to leading your own research team, how to fund research<br />
along the way and to combine clinical practice and academic study. <strong>The</strong> speakers will bring a<br />
range of perspectives from the novice researcher to the highly experienced and all will focus on<br />
the very practical aspects of this most rewarding career pathway.<br />
• Is there life outside work? Undertaking a higher degree while in clinical practice –<br />
Ms Julie Taylor<br />
<strong>The</strong> seminar follows a personal journey of a nurse specialist studying <strong>for</strong> a masters degree<br />
whilst juggling clinical workload, studying and family life. It focuses on advice that was given,<br />
that which was taken and that which was ignored - analysing in hindsight if the correct path<br />
was followed.<br />
• Developing your clinical research career: fellowships and other routes –<br />
Prof Jim Woodburn<br />
This presentation will summarise the available fellowship options <strong>for</strong> early-senior career<br />
researchers in the field via the research councils, medical charities, NHS and other<br />
organisations. <strong>The</strong> author will share his experiences on how to develop successful fellowships<br />
based on the cornerstone principles of the ‘Person, Place and Project’.<br />
• Creating a team and a programme of clinical research – Prof Sarah Hewlett<br />
This presentation will look at the transition from lone researcher to leading a research team,<br />
including building a portfolio of research, team building, and the highs and lows of fitting in<br />
clinical and teaching commitments.<br />
11.00-12.00 BHPR: RA clinical issues Clyde Auditorium<br />
Mrs Diana Finney and Dr Stewart Glaspole<br />
• Joint aspiration and injection – Dr Andy Hassell<br />
This talk will cover: the indications <strong>for</strong> joint aspiration and <strong>for</strong> <strong>for</strong> intra-articular steroid injection;<br />
possible side-effects; general procedural aspects; and the technical aspects <strong>for</strong> aspirating and<br />
injecting common target joints.<br />
• NICE RA management guidelines – Dr Chris Deighton<br />
<strong>The</strong> NICE RA Management Guidelines were published in February 2009, and give the<br />
opportunity to raise the quality of care <strong>for</strong> our patients. <strong>The</strong> key recommendations will be<br />
reviewed and justified, and resource implications <strong>for</strong> the multidisciplinary team considered.<br />
12.00-13.30 Lunch Hall 5<br />
BSR BR open meeting Hall 1<br />
Introduction – Professor David Isenberg<br />
Update on the register – Professor Deborah Symmons and Dr Kimme Hyrich<br />
Looking to the future<br />
Ankylosing spondylitis – Dr Andrew Keat<br />
TNF alpha drug switching – where are we now? – Debbie Smith<br />
Where are we going with the register? – Professor David Isenberg<br />
RATs Meeting Dochart Room<br />
22
12.15-13.30 BHPR: <strong>The</strong> NRAS/EPP CIC RA self-management programme - health<br />
professionals and patients working together Lomond Auditorium<br />
Mrs Trish Cornell<br />
• What is the rationale and evidence behind self-care and self-management? – Ms Sue Oliver<br />
Healthcare professionals refer to terms such as self-care, patient education,<br />
self-management and in recent years patient empowerment yet what do these terms mean<br />
to the patient? How do we support the patient in these principles and how do we ensure<br />
support <strong>for</strong> such approaches in the current healthcare system?<br />
• Why a disease specific self-management programme <strong>for</strong> RA and experiences of running a<br />
trial programme – Ms Alisa Bosworth and Ms Maggie Carr<br />
This presentation will focus on background to this collaboration, progress of the programme<br />
to date and results of initial pilots, experience of working in equal partnership with a person<br />
with RA to deliver the RA self-management programme, and value of healthcare<br />
professional tutor in RA.<br />
• Patient experience of being involved in the trial programme – Ms Susan Winder<br />
How the NRAS Trial programme has helped me and how it could be a real support<br />
to others with RA.<br />
Scientific <strong>Programme</strong> | Wednesday 29 April 2009<br />
13.30-15.30 BSR & BHPR shared session<br />
Plenary Oral Presentation of Abstracts Clyde Auditorium<br />
Dr Deborah Bax and Mrs Diana Finney<br />
PO1<br />
PO2<br />
PO3<br />
YOUNG INVESTIGATOR AWARD WINNER<br />
VASCULOPATHY IN A TGF-β DEPENDENT MOUSE MODEL OF SYSTEMIC SCLEROSIS<br />
Emma C. Derrett-Smith, Audrey Dooley, Korsa Khan, Xu Shi-Wen, Patricia De Winter,<br />
David Abraham, Christopher P Denton;<br />
Centre <strong>for</strong> <strong>Rheumatology</strong>, UCL (Royal Free Campus), London, United Kingdom<br />
COMBINED EFFECTS OF THREE INDEPENDENT SNPS INCREASE THE RISK ESTIMATE FOR<br />
RA AT 6Q23<br />
Gisela Orozco, Anne Hinks, Steve Eyre, Xiayi Ke, Laura J. Gibbons, John Bowes, Year<br />
Consortium, Ukrag Consortium, Wendy Thomson, Anne Barton, Jane Worthington;<br />
ARC Epidemiology Unit, <strong>The</strong> University of Manchester, Manchester, United Kingdom<br />
A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY ON ADDITION OF 6-MONTH<br />
INDUCTION THERAPY WITH INFLIXIMAB TO TRIPLE DMARD PLUS PREDNISOLONE THERAPY<br />
IN PATIENTS WITH EARLY ACTIVE RHEUMATOID ARTHRITIS: HIGH REMISSION RATES AND<br />
NO JOINT DESTRUCTION DURING FIRST 2 YEARS. THE NEO-RACO STUDY<br />
Marjatta Leirisalo-Repo 1 , Hannu Kautiainen 2 , Leena Laasonen 3 , Timo Möttönen 4 ,<br />
Pekka Hannonen 5,8 , Markku Korpela 6 , Markku Kauppi 7 , Oili Kaipiainen-Seppänen 8 ,<br />
Riitta Luosujärvi 1 , Harri Blåfield 9 , Eeva Moilanen 10 ;<br />
1<br />
<strong>Rheumatology</strong>, Helsinki University Central Hospital, Helsinki, Finland; 2 <strong>Rheumatology</strong>,<br />
Rheumatism Foundation Hospital, Heinola, Finland; 3 Radiology, Helsinki University Central<br />
Hospital, Helsinki, Finland; 4 Medicine, Turku University Central Hospital, Turku, Finland;<br />
5<br />
Medicine, Jyväskylä Central Hospital, Jyväskylä, Finland; 6 <strong>Rheumatology</strong>, Tampere University<br />
Hospital, Tampere, Finland; 7 <strong>Rheumatology</strong>, Rheumatism Foundation Hospital, Heinola, Finland;<br />
8<br />
Medicine, Kuopio University Hospital, Kuopio, Finland; 9 Medicine, Seinäjoki Central Hospital,<br />
Seinäjoki, Finland; 10 <strong>The</strong> Immunopharmacology Research Group, Medical School, University of<br />
Tampere, Tampere, Finland<br />
23
PO4<br />
PO5<br />
NOVEL ANALYSIS OF MARGOLIS PAIN DIAGRAM ALLOWS IDENTIFICATION OF UNDERLYING<br />
VERTEBRAL FRACTURE<br />
Emma Clark 1 , Alison Hutchinson 1 , Eugene McCloskey 2 , Mike Stone 3 , James Martin 4 ,<br />
Ashok Bhalla 5 , Jon Tobias 1 ;<br />
1<br />
University of Bristol, Bristol, United Kingdom; 2 University of Sheffield, Sheffield, United<br />
Kingdom; 3 Bone Research Unit, Llandough Hospital, Penarth, United Kingdom; 4 Royal Glamorgan<br />
Hospital, Llantrisant, United Kingdom; 5 Royal National Hospital <strong>for</strong> Rheumatic Diseases, Bath,<br />
United Kingdom<br />
DEVELOPMENT AND INITIAL VALIDATION OF THE BRISTOL RA FATIGUE MULTI-DIMENSIONAL<br />
QUESTIONNAIRE (BRAF-MDQ)<br />
Joanna K. Nicklin 1 , John Kirwan 2 , Fiona Cramp 1 , Marie Urban 1 , Sarah Hewlett 1 ;<br />
1<br />
Faculty of Health and Life Sciences, University of West of England, Bristol, United Kingdom;<br />
2<br />
Academic <strong>Rheumatology</strong>, University of Bristol, Bristol, United Kingdom<br />
PO6<br />
LAY SYMPTOM ATTRIBUTIONS FOR KNEE PAIN AND HAND PAIN: A CROSS-SECTIONAL STUDY<br />
George Peat, June Handy, Christian Mallen, Sue Hill, Krysia Dziedzic;<br />
Arthritis Research Campaign National Primary Care Centre, Keele University, Keele,<br />
United Kingdom<br />
15.30-16.00 Tea/Coffee Hall 5<br />
16.00-17.30 Prize Giving and<br />
Heberden Oration Clyde Auditorium<br />
Chair: Dr Deborah Bax<br />
Prof Stuart Ralston<br />
Thirty years’ progress in bone disease<br />
Prof Ralston will review advances in our understanding the causes of bone disease over the past<br />
three decades and how this has impacted on diagnosis and management.<br />
17.40-19.10 BSR: Special interest groups<br />
Heritable disorders of connective tissue and musculoskeletal pain Dochart Room A<br />
Convenors: Rodney Grahame; Anthony Jones<br />
Recent advances in the understanding of pain as it might relate to the chronic pain in EDS<br />
Prof Praveen Anand<br />
Fibromyalgia, dysautonomia, hypermobility and positional myelopathy<br />
Dr Andrew Holman<br />
Discussion introduced by Prof Peter Beighton, Emeritus Professor of Genetics,<br />
University of Cape Town<br />
Interstitial lung disease in RA and CTD Boisdale Room A<br />
Convenor: Clive Kelly<br />
Update on clinical management of RA-ILD – Clive Kelly<br />
Multi centre study of RA-ILD – progress and development – Judy Dawson<br />
Coordinating data collection and storage <strong>for</strong> multi centre study – Will Dixon<br />
24
Osteoarthritis Alsh Room B<br />
Convenor: Fraser Birrell<br />
Introduction and overview: goals of meeting – Fraser Birrell<br />
UK multicentre osteoarthritis audit – Mike Pieri<br />
Meaningful patient involvement – Cheryl Koehn/Jo Cumming<br />
Clinical studies group <strong>for</strong> OA and related disorders update: challenges and solutions –<br />
Philip Conaghan/Paul Dieppe<br />
Cardiovascular co-morbidity in rheumatoid arthritis Boisdale Room B<br />
Convenor: George Kitas<br />
Cardiovascular disease and inflammation – Prof Gordon Lowe<br />
Trial in rheumatoid arthritis of lisinopril (TRALIS) – Dr Frances Hall<br />
<strong>The</strong> effects of rosuvastatin in rheumatoid arthritis – Dr Pradeep Kumar<br />
Trial of atorvastatin <strong>for</strong> the primary prevention of cardiovascular events in rheumatoid arthritis<br />
(TRACE RA): Progress to date – Prof George Kitas, Professor Jill Belch,<br />
Prof Deborah Symmons<br />
Systemic lupus erythematosus Morar/Ness Room<br />
Convenor: Ian Bruce<br />
Rituximab in neuropsychiatric lupus: initial experience and trial proposal – M Zandi<br />
What we have learned so far from SLE trials? – Prof C Gordon<br />
A UK lupus biologics prospective cohort study – Dr I Bruce<br />
Open <strong>for</strong>um <strong>for</strong> potential collaborative studies<br />
Scientific <strong>Programme</strong> | Wednesday 29 April 2009<br />
Osteoporosis Dochart Room B<br />
Convenor: Emma Clarke<br />
Incorporation of FRAX into routine DXA reporting – Prof Juliet Compston<br />
Use of MXA / IVA in clinical practice – Dr Nicky Peel<br />
Bisphosphonates, osteoporosis and PPIs – Prof Cyrus Cooper<br />
Scleroderma Alsh Room A<br />
Convenor: Chris Denton<br />
Bullet or bomb: the future of scleroderma treatment – Prof Chris Denton<br />
Tyrosine kinase inhibitors <strong>for</strong> treatment of systemic sclerosis – imatinib and beyond –<br />
Dr Oliver Distler<br />
High intensity immunosuppression <strong>for</strong> dcSSc – Prof Jaap van Laar<br />
When to treat SSc lung fibrosis – applying a data-driven algorithm – Prof Athol Wells<br />
What matters to patients – results of the second Raynaud’s and Scleroderma Association<br />
questionnaire – Mrs Anne Mawdsley<br />
Vasculitis Carron Room<br />
Convenor: Raashid Luqmani<br />
EUVAS trials update – David Jayne/Raashid Luqmani<br />
New proposals <strong>for</strong> diagnostic criteria study – Richard Watts/Raashid Luqmani<br />
Impact of vasculitis guidelines: what shall we do with them? – David Carruthers<br />
Classification and diagnostic criteria in vasculitis project – Neil Basu<br />
Assessment of children with vasculitis – Nick Wilkinson/Raashid Luqmani<br />
OMERACT update of disease assessment in systemic vasculitis: where are we now? –<br />
Raashid Luqmani<br />
25
RATs training workshop Lomond Auditorium<br />
Trainee dilemmas - can a mentoring scheme help?<br />
Mentorship refers to a developmental relationship in which a more experienced person helps a<br />
less experienced person. It is intended to do something different from educational or clinical<br />
supervision. A mentor should provide an impartial sounding board that may be useful at many<br />
stages in your career.<br />
<strong>Programme</strong><br />
Introduction to mentoring and how the scheme is rolling out in the north west deanery –<br />
Dr Neil Snowden, Consultant Rheumatologist, North Manchester General Hospital<br />
Case studies of trainee dilemmas. Expert panel and group discussion<br />
Round-up and discussion about possible implementation<br />
19.10-20.40 Satellite Symposia<br />
Abbott Forth Room<br />
Time to act: evidence, commissioning and politics in inflammatory arthritis<br />
(RA, PsA and AS) – Dr Duncan Porter<br />
Early disease intervention: what are we looking <strong>for</strong>? – Dr Duncan Porter<br />
Excellence as rheumatologists: evidence the route to optimum outcomes? – Dr Mark Quinn<br />
Beyond joints and pain: cardiovascular disease a comorbidity model in rheumatoid<br />
arthritis – Dr Ian Bruce and Prof Naveed Sattar<br />
Commissioning <strong>for</strong> better outcomes: getting your PCT onside – Andrew Riley, Stoke PCT<br />
Are your patients working? Employment, retention and the importance of managing<br />
inflammatory arthritis (RA, AS and PsA) – John Robertson, MP Glasgow<br />
Question time - Panel, led by chair<br />
Wyeth Hall 1<br />
Changing practice in rheumatoid arthritis<br />
Prof Chris Buckley<br />
Chairman’s welcome and agenda overview<br />
How do we get greater access to anti-TNF agents <strong>for</strong> RA? – Dr Chris Deighton<br />
Are biologic guidelines evidence based? – Prof Paul Emery<br />
10 years experience of treating to target – Prof Piet Van Riel<br />
Discussion<br />
Chairman’s summary and close<br />
26
Scientific <strong>Programme</strong><br />
Thu 30 April 2009<br />
Scientific <strong>Programme</strong><br />
Thursday 30 April 2009
BSR Scientific <strong>Programme</strong> 2009<br />
Thursday 30 April 2009<br />
08.30-10.00 Poster Viewing Hall 5<br />
08.30-09.30 BHPR SIGs<br />
Rheumatoid arthritis Boisdale Room A<br />
Convenor: Janet Cushnaghan<br />
Fatigue: predictors of fatigue and the evidence <strong>for</strong> intervention –<br />
Sarah Hewlett and Louise Pollard<br />
Self-assessment of joint counts as indicators of disease severity in RA –<br />
Chandra Chattopadhyay and Caroline Tierney<br />
Scientific <strong>Programme</strong> | Thursday 30 April 2009<br />
Connective tissue disease Boisdale Room B<br />
Convenor: Sue Brown<br />
Scleroderma: managing a multi-system disease<br />
Managing Raynaud’s, calcinosis and ulcers – Sue Brown RNHRD<br />
Managing gastro-intestinal complications of scleroderma – Dr Geraldine Brough<br />
Managing cardio-pulmonary complications of scleroderma – Dr John Pauling<br />
Living with scleroderma – Naomi Reay<br />
Osteoporosis Carron Room A<br />
09.30-10.00 BHPR AGM Dochart Room<br />
10.00-10.30 Tea/Coffee Hall 5<br />
10.30-12.30 BSR: Vasculitis Clyde Auditorium<br />
Dr Richard Watts<br />
• Management of Behcet’s disease – Prof Hassan Yazici<br />
• Viral vasculitis – Prof Loic Guillevin<br />
Vasculitides are sometimes the consequence of virus infections. It is the case <strong>for</strong> HBV pol<br />
yarteritis nodosa and more frequently <strong>for</strong> HCV-associated cryoglobulinemia. Several other<br />
infections agents have been considered responsible <strong>for</strong> vasculitis. When present, treatment<br />
of vasculitis is based also on the treatment of viral infection, and not only on<br />
corticosteroids and immunosuppressants.<br />
• Takayasu’s arteritis – Dr Justin Mason<br />
Takayasu’s arteritis is a challenging condition <strong>for</strong> the rheumatologist, from difficulties in<br />
diagnosis to lack of an evidence base <strong>for</strong> treatment. However, advances in our<br />
understanding of disease pathogenesis, diagnostic imaging and treatment are being<br />
made, and will be reviewed in detail.<br />
27
• When is vasculitis not vasculitis? – Dr Raashid Luqmani<br />
<strong>The</strong> systemic vasculitides are a set of unusual diseases characterised by blood vessel<br />
inflammation leading to organ damage, failure or death if untreated, and an early<br />
diagnosis is important in order to initiate effective therapy often with potent<br />
immunosuppressive agents such as cyclophosphamide and glucocorticoid. However,<br />
the differential diagnosis is very wide, with patients presenting to a number of different<br />
specialists; it is important <strong>for</strong> the clinician to discriminate between active vasculitis and<br />
conditions which mimic vasculitis, such as sepsis, atherosclerosis or cancer.<br />
BSR and BHPR joint session: Health and work Lomond Auditorium<br />
Prof Alan Silman<br />
• Work and musculoskeletal health: challenges and opportunities – Dr Ross Wilkie<br />
Musculoskeletal disorders are the most frequently cited cause <strong>for</strong> the problems of ill<br />
health that threaten work ability in the United Kingdom. <strong>The</strong> challenge that this presents will<br />
be reviewed and the opportunities explored <strong>for</strong> all stakeholders involved in the management<br />
of musculoskeletal conditions.<br />
• Vocational rehabilitation: what works, <strong>for</strong> whom, and when? – Prof Gordon Waddell<br />
This talk will present the findings of a review of the scientific evidence on vocational<br />
rehabilitation: what works, <strong>for</strong> whom and when? and discuss the implications <strong>for</strong> clinical<br />
and workplace management.<br />
• Dame Carol Black’s review and response to parliament’s reaction – Dame Carol Black<br />
<strong>The</strong> lecture will cover the Government’s response to my review “Working <strong>for</strong> a Healthier<br />
Tomorrow”. It will discuss in greater depth some of the initiatives which are of importance to<br />
all of those interested in musculoskeletal disease.<br />
BSR: Genetics of common rheumatic disease Hall 1<br />
Prof Alex MacGregor<br />
• <strong>The</strong> rough guide to the RA genome – Prof Jane Worthington<br />
• New genes <strong>for</strong> old joints - the future of OA genetics – Prof John Loughlin<br />
• Genomewide Association studies - what to do after the party – Prof Matthew Brown<br />
• Personalised genomics – Prof Tim Spector<br />
This talk will cover the current state of personalised genomics, the use of do-it-yourself<br />
internet companies and the predictive value of genome-wide scans <strong>for</strong> an individual <strong>for</strong> a<br />
range of common diseases and traits.<br />
BHPR: Psychosocial issues from childhood through adult life Boisdale Room<br />
Ms Keri Hutchinson and Mrs Lindsay Hawley<br />
• JIA and family function: implications <strong>for</strong> transitional care – Dr Jenny Waite-Jones<br />
JIA can create a medicalised family life, through three identifiable phases of symptom onset,<br />
searching <strong>for</strong> an explanation and diagnosis/ post diagnosis experiences. During transition to<br />
adult care it is useful <strong>for</strong> staff to be aware of past family experiences, to avoid a potential<br />
fourth phase, as according to some families, this can “feel like starting all over again.”<br />
• Coping with rheumatoid arthritis – Dr Sarah Ryan<br />
This presentation will explore the impact of RA on mood and social support with practical<br />
advise regarding the role of the health professional. Studies where health professionals<br />
have impacted positively on coping will also be discussed.<br />
• Sore feet, sore face – Ms Vickie Cameron<br />
This presentation explores the psychosocial issues surrounding foot pain, and asks the<br />
question ‘who is at the end of the feet?’ <strong>The</strong> way that the foot is managed in podiatry<br />
rheumatology is challenged and considers if the podiatrist’s focus is too biomedical.<br />
28
• Sexual problems: the patient’s perspective – Dr Jackie Hill<br />
Rheumatic diseases have the potential to affect all areas of a patient’s life, including their<br />
sexual life. <strong>The</strong> problems that patients with RA, OA and fibromyalgia encounter will be<br />
discussed in this talk.<br />
• <strong>The</strong> impact of psychosocial influences on quality of life in osteoarthritis –<br />
Dr Anne-Marie Keenan<br />
<strong>The</strong> focus of this presentation is to report the findings of a study (n=248) which<br />
investigated the impact of physical and psychosocial aspects of quality of life and found<br />
that the single most important factor in predicting quality of life was anxiety, which has<br />
received little attention in assessment and treatment of OA. While function and age also<br />
contributed to QoL, pain only had an indirect impact, either through decreased function<br />
or increased anxiety. This study highlights the importance of psychological factors in<br />
determining quality of life in those with osteoarthritis.<br />
• <strong>The</strong> impact of ankylosing spondylitis on work in the UK – Dr Jon Packham<br />
<strong>The</strong> impact of ankylosing spondylitis on effectiveness at work (presenteeism), time off<br />
work (absenteeism) and unemployment in a large cohort of patients from across the UK.<br />
Scientific <strong>Programme</strong> | Thursday 30 April 2009<br />
BSR: Biomedical research networks – the Canadian experience Dochart Room<br />
Dr Fraser Birrell<br />
• Introduction and welcome<br />
• Brief history, goals, structure of CAN – Prof John Esdaile<br />
• Consumer involvement in CAN and the networks – Prof Cheryl Kohen<br />
• CAN’s clinical research teams – Prof John Esdaile<br />
• CAN’s basic science teams – Prof Robin A. Poole<br />
• Current State of Musculoskeletal Network Research in the UK – Dr Deborah Symmons<br />
• Open <strong>for</strong>um: are there lessons from Canada?<br />
BHPR: Partnerships in foot healthcare Forth Room<br />
Ms Andrea Graham and Dr Jill Firth<br />
• Medical and non medical management of foot problems in patients with psoriatic<br />
arthritis – Prof Iain McInnes and Ms Elaine Hyslop<br />
This lecture will discuss the common conditions that arise in patients with psoriatic<br />
arthritis in the foot and ankle area. <strong>The</strong> overarching approach to diagnosis will be<br />
discussed, after which the key investigation, including optimal imaging modalities will be<br />
considered. Medical and surgical therapeutics will be reviewed and the expected clinical<br />
outcome <strong>for</strong> patients defined.<br />
• Medical and non medical management of foot problems in patients with juvenile<br />
idiopathic arthritis – Dr Janet Gardner Medwin and Mr Gordon Hendry<br />
• Foot and ankle triage service – how the barriers were broken –<br />
Mr Sethil Kumar and Dr Colin Thomson<br />
This session will discuss how a multidisciplinary team approach to orthopaedic foot and<br />
ankle services leads to a reduction in waiting times and improved patient satisfaction.<br />
Future development of the service will also be discussed.<br />
• A multidisciplinary ultrasound guided joint injection clinic – Dr Debbie Turner and<br />
Mrs Mhairi Brandon<br />
An allied health profession lead ultrasound guided joint injection clinic has been running<br />
in Glasgow <strong>for</strong> five years and has provided a mechanism to improve patient care and an<br />
infrastructure to support training in both injection therapy and diagnostic ultrasound<br />
imaging. This presentation will provide a reflective summary on the development, day<br />
to day practical issues and outcomes from running a musculoskeletal ultrasound joint<br />
injection clinic.<br />
29
12.30-14.30 Lunch Hall 5<br />
BSR AGM Alsh Room<br />
(Lunch will be available at the meeting)<br />
12.45-14.15 BHPR: Writing <strong>for</strong> publication Hall 1<br />
Ms Emma Healey<br />
• How to get an article published: the editor’s perspective – Dr Sarah Ryan<br />
This presentation will focus on the five ‘rights’ of publishing including the ‘right’ topic in the<br />
‘right’ journal at the ‘right’ time. Barriers and solutions to publishing <strong>for</strong> health<br />
professionals will also be discussed.<br />
• How to write a qualitative article – Ms Liz Hale<br />
How to construct a qualitative article, with examples of layout style. Perils, pitfalls, and<br />
points to remember. How to manage reviewer, editorial and reader expectations.<br />
• How to get quantitative research published – Dr Alison Hammond<br />
This presentation will address: the structure of quantitative papers; what to ensure you<br />
include; the CONSORT statement <strong>for</strong> non-pharmacolgical studies; and pitfalls and errors<br />
to (try to) avoid.<br />
• How to write a conference abstract – Prof Sarah Hewlett<br />
This presentation will explore the benefits of writing abstracts, how to get started, how<br />
to get it into just 250-300 words, how to upload it, and then tips <strong>for</strong> presentation<br />
(and pitfalls!).<br />
14.30-16.30 Concurrent Oral Presentation of Abstracts<br />
Pain and fatigue Forth Room<br />
OP31<br />
IDENTIFICATION OF MODIFIABLE PERSONAL FACTORS THAT PREDICT LOW BACK PAIN<br />
IN NURSING STUDENTS: A PROSPECTIVE STUDY<br />
Tim Mitchell 1 , Peter O’Sullivan 1 , Angus Burnett 2 , Leon Straker 1 , Jenny Thornton 1 , Anne Smith 1 ;<br />
1<br />
Curtin University, Perth, WA, Australia; 2 Edith Cowan University, Perth, WA, Australia<br />
OP32<br />
THE EFFECT OF MILNACIPRAN ON EVOKED PAIN IN FIBROMYALGIA:<br />
A PSYCHOPHYSICAL AND FUNCTIONAL MRI ANALYSIS<br />
Ernest Choy 1 , Serena Carville 1 , Steven Williams 1 , Karin Jensen 2 , Eva Kosek 2 , Martin Ingvar 2 ,<br />
Peter Fransson 3 , Hanke Marcus 3 , Frank Petzke 3 , Yves Mainguy 4 , Rick Gracely 5 ;<br />
1<br />
King’s College London, London, United Kingdom; 2 Karolinska Institutet, Stockholm, Sweden;<br />
3<br />
University Hospital of Cologne, Cologne, Germany; 4 Pierre Fabre Medicament, Laberge, France;<br />
5<br />
University of North Carolina, Chapel Hill, NC<br />
OP33<br />
EFFECTIVE MANAGEMENT OF FIBROMYALGIA WITH GRADED EXERCISE THERAPY<br />
Natasha E. McNeilly 1 , Suzanne Miles 1 , Rebecca Pollin 1 , Verity Appleyard 1 , Kate Carr 1 ,<br />
Karen O’Brenovic 3 , Karen M. Douglas 2 ;<br />
1<br />
<strong>Rheumatology</strong> Physiotherapy, Dudley Group of Hospitals NHS Trust, Dudley, United Kingdom;<br />
2<br />
Department of <strong>Rheumatology</strong>, Dudley Group of Hospitals NHS Trust, Dudley, United Kingdom;<br />
3<br />
Clinical Audit Department, Dudley Group of Hospitals NHS Trust, Dudley, United Kingdom<br />
OP34<br />
GRADED MOTOR IMAGERY PROGRAMMES IN COMPLEX REGIONAL PAIN SYNDROME:<br />
ONE SIZE DOESN’T FIT ALL?<br />
Jane Hall 1,2 , Catherina Mattheus 1 , Candida S. McCabe 1,2 ;<br />
1<br />
Bath Centre <strong>for</strong> Pain Services, Royal National Hospital <strong>for</strong> Rheumatic Diseases, Bath,<br />
United Kingdom; 2 School <strong>for</strong> Health, University of Bath, Bath, United Kingdom<br />
30
OP35<br />
OP36<br />
OP37<br />
GENETIC VARIATION IN THE SEROTONIN PATHWAY IS ASSOCIATED WITH CHRONIC<br />
WIDESPREAD PAIN: RESULTS FROM THE EPIFUND STUDY<br />
Barbara I. Nicholl 1 , Kate L. Limer 1 , Gary J. Macfarlane 2 , Wendy Thomson 1 , Kelly A. Davies 1 ,<br />
John McBeth 1 ;<br />
1<br />
arc Epidemiology Unit, University of Manchester, Manchester, United Kingdom;<br />
2<br />
Aberdeen Pain Research Collaboration (Epidemiology Group), University of Aberdeen,<br />
Aberdeen, United Kingdom<br />
GENETIC VARIATION IN THE HYPOTHALAMIC-PITUITARY-ADRENAL AXIS GENES MAY<br />
INFLUENCE SUSCEPTIBILTY TO MUSCULOSKELETAL PAIN: RESULTS FROM THE<br />
EPIFUND STUDY<br />
Kate L. Limer 1 , Barbara I. Nicholl 1 , Gary J. Macfarlane 2 , Wendy Thomson 1 , Kelly A. Davies 1 ,<br />
John McBeth 1 ;<br />
1<br />
ARC Epidemiology Unit, University of Manchester, Manchester, United Kingdom;<br />
2<br />
University of Aberdeen, Aberdeen, United Kingdom<br />
RHEUMATOID ARTHRITIS PATIENTS’ INTERPRETATION OF THE DAS PATIENT GLOBAL<br />
USED AT BRISTOL ROYAL INFIRMARY<br />
Tessa Sanderson 1 , Michael Calnan 2 , Marianne Morris 3 , Pam Richards 4 , Sarah Hewlett 1 ;<br />
1<br />
Academic <strong>Rheumatology</strong>, University of the West of England, Bristol, United Kingdom;<br />
2<br />
Centre <strong>for</strong> Health Services Studies, University of Kent, Canterbury, United Kingdom;<br />
3<br />
Centre <strong>for</strong> Appearance Research, University of the West of England, Bristol, United Kingdom;<br />
4<br />
Academic <strong>Rheumatology</strong>, University of Bristol, Bristol, United Kingdom<br />
Scientific <strong>Programme</strong> | Thursday 30 April 2009<br />
OP38<br />
DEVELOPMENT AND INITIAL VALIDATION OF SHORT SCALES TO MEASURE SEVERITY,<br />
EFFECT AND ABILITY TO COPE WITH FATIGUE IN RA<br />
Joanna K. Nicklin 1 , John Kirwan 2 , Fiona Cramp 1 , Sarah Hewlett 1 ;<br />
1<br />
Faculty of Health and Life Sciences, University of West of England, Bristol, United Kingdom;<br />
2<br />
Academic <strong>Rheumatology</strong>, University of Bristol, Bristol, United Kingdom<br />
Vascular biology and vasculitis Alsh Room<br />
OP39<br />
OP40<br />
YOUNG INVESTIGATOR AWARD WINNER<br />
IMPAIRED ENDOTHELIAL PROGENITOR CELL FUNCTION AND EARLY ATHEROSCLEROSIS<br />
IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)<br />
Sahena Haque 1 , Chadi Rakieh 2 , Michael C. Jackson 3 , M. Y. Alexander 4 , Ian N. Bruce 1 ;<br />
1<br />
arc Epidemiology Unit, University of Manchester, Manchester, United Kingdom; 2 Translational<br />
Medicine, University of Manchester, Manchester, United Kingdom; 3 Faculty of Life Sciences,<br />
University of Manchester, Manchester, United Kingdom; 4 Cardiovascular Medicine, University<br />
of Manchester, Manchester, United Kingdom<br />
COMPLEMENT DYSREGULATION LINKS ACCELERATED ATHEROSCLEROSIS AND<br />
GLOMERULONEPHRITIS IN SLE<br />
Myles J. Lewis 1 , Talat H. Malik 1 , Liliane M. Fossati-Jimack 1 , Daniele Carassiti 1 ,<br />
Terence H. Cook 2 , Dorian O. Haskard 3 , Marina Botto 1 ;<br />
1<br />
Molecular Genetics & <strong>Rheumatology</strong> Section, Imperial College, London, United Kingdom;<br />
2<br />
Histopathology Dept, Imperial College, London, United Kingdom; 3 BHF Cardiovascular<br />
Medicine Unit, Imperial College, London, United Kingdom<br />
31
OP41<br />
THE EFFECTS OF A REDUCTION IN DISEASE ACTIVITY ON MICROVASCULAR FUNCTION,<br />
MACROVASCULAR FUNCTION AND ARTERIAL STIFFNESS IN PATIENTS WITH<br />
RHEUMATOID ARTHRITIS<br />
Aamer Sandoo 2,1 , Jet Veldhuijzen van Zanten 2,1 , Jacqueline P. Smith 1 , George S. Metsios 1,3 ,<br />
Antonios Stavropoulos-Kalinoglou 1,3 , Douglas Carroll 2 , George D. Kitas 1 ;<br />
1<br />
Department of <strong>Rheumatology</strong>, Dudley Group of Hospitals NHS Trust, Dudley, United Kingdom;<br />
2<br />
School of Sport and Exercise Sciences, University of Birmingham, Birmingham, United<br />
Kingdom; 3 School of Sport, Per<strong>for</strong>ming Arts & Leisure, Wolverhampton University,<br />
Wolverhampton, United Kingdom<br />
OP42<br />
BIMODAL MORTALITY RISK IN WEGENER’S GRANULOMATOSIS<br />
Raashid A. Luqmani 1 , Christopher Edwards 2 , David Culli<strong>for</strong>d 3 , Joe Maskell 4 , David Jayne 5 ,<br />
Nigel Arden 2 ;<br />
1<br />
<strong>Rheumatology</strong> Department, Botnar Research Centre, University of Ox<strong>for</strong>d, Ox<strong>for</strong>d, United<br />
Kingdom; 2 <strong>Rheumatology</strong> Department, Southampton General Hospital, Southampton, United<br />
Kingdom; 3 Research & Development Support Unit, University of Southampton, Southampton,<br />
United Kingdom; 4 PHSMS, University of Southampton, Southampton, United Kingdom;<br />
5<br />
Nephrology Department, Addenbrooke’s Hospital, Cambridge, United Kingdom<br />
OP43<br />
OP44<br />
IS THERE SPATIAL CLUSTERING OF ANCA-ASSOCIATED VASCULITIS IN THE UK?<br />
Richard Watts 1 , Divya Nelson 1 , Janice Mooney 1 , Alex MacGregor 1 , David Scott 2 ;<br />
1<br />
Health and Social Sciences Research Institute, University of East Anglia, Norwich,<br />
United Kingdom; 2 Department of <strong>Rheumatology</strong>, Norfolk and Norwich University Foundation<br />
NHS Trust, Norwich, United Kingdom<br />
USING THE BIRMINGHAM VASCULITIS ACTIVITY SCORE (VERSION 3) FOR<br />
DIAGNOSING VASCULITIS<br />
Chetan Mukhtyar 1 , Denise Brown 1 , Catherine Hall 2 , John McLaren 2 , Raashid Luqmani 1 ;<br />
1<br />
University of Ox<strong>for</strong>d, Ox<strong>for</strong>d, United Kingdom; 2 University of Edinburgh, Edinburgh,<br />
United Kingdom<br />
OP45<br />
DISEASE ACTIVITY, QUALITY OF LIFE AND ADVERSE EVENTS IN THE FIRST TWO YEARS<br />
OF POLYMYALGIA RHEUMATICA<br />
B. Dasgupta 1 , A. Hutchings 2 , J. Hollywood 1 , D. Lamping 2 , N. Gendi 3 , K. Chakravarty 9 ,<br />
D. G. Scott 5 , B. Bourke 6 , E. Choy 7 , B. Silverman 4 , C. Pease 8 ;<br />
1<br />
Southend University Hospital, Westcliff, United Kingdom; 2 London School of Hygiene & Tropical<br />
Medicine, Westcliff, United Kingdom; 3 Basildon & Thurrock Hospital, Basildon, United Kingdom;<br />
4<br />
Addenbrookes Hospital, Cambridge, United Kingdom; 5 Norfolk & Norwich Hospital, Norwich,<br />
United Kingdom; 6 St Georges Hospital, Tooting, United Kingdom; 7 Kings College Hospital,<br />
London, United Kingdom; 8 Leeds General Infirmary, Leeds, United Kingdom;<br />
9<br />
Queens Hospital, Rom<strong>for</strong>d, United Kingdom<br />
OP46<br />
FACTORS AT DIAGNOSIS PREDICTING THE OUTCOME OF POLYMYALGIA RHEUMATICA:<br />
DURATION OF STEROID THERAPY, OCCURRENCE OF RELAPSES, AND LATE DEVELOPMENT<br />
OF GIANT CELL ARTERITIS<br />
Sarah L. Mackie 1 , Elizabeth M. Hensor 1 , Bipin Bhakta 2 , Colin T. Pease 2 ;<br />
1<br />
University of Leeds, Leeds, United Kingdom; 2 Leeds Teaching Hospitals NHS Trust,<br />
Leeds, United Kingdom<br />
32
Rheumatoid arthritis Clyde Auditorium<br />
OP47<br />
OP48<br />
LONG-TERM SAFETY OF RITUXIMAB: 6-YEAR FOLLOW-UP OF THE RA CLINICAL TRIALS<br />
AND RE-TREATMENT POPULATION<br />
Ronald F. van Vollenhoven 1 , Paul Emery 2 , Clifton O. Bingham III 3 , Edward Keystone 4 ,<br />
Roy Fleischmann 5 , Karen A. Rowe 6 , Marianne Sweetser 7 , Ope Osikoya 6 , Ariella Kelman 8 ,<br />
Ravi M. Rao 6 ;<br />
1<br />
Karolinska University Hospital, Stockholm, Sweden; 2 Leeds General Infirmary, Leeds, United<br />
Kingdom; 3 Johns Hopkins University, Baltimore, MD; 4 University of Toronto, Toronto, ON,<br />
Canada; 5 University of Texas Southwestern Medical Center at Dallas, Dallas, TX; 6 Roche<br />
Products Ltd, Welwyn Garden City, United Kingdom; 7 Biogen Idec Inc, Cambridge, MA;<br />
8Genentech, Inc., South San Francisco, CA<br />
GOLIMUMAB, A HUMANTNF-ALPHA ONOCLONAL ANTIBODY, IN RHEUMATOID ARTHRITIS<br />
PATIENTS PREVIOUSLY TREATED WITH ANTI-TNF-ALPHA AGENTS (GO-AFTER STUDY)<br />
Paul Wordsworth 1 , Josef Smolen 2 , Jonathan Kay 3 , Mittie K. Doyle 4 , Robert Landewe 5 ,<br />
Eric L. Matteson 6 , Y. Zhou 7 , E. C. Hsia 4 , M. U. Rahman 4 , <strong>for</strong> the GO-AFTER Study<br />
Investigators 7 ;<br />
1<br />
Nuffield Orthopaedic Centre, Ox<strong>for</strong>d, United Kingdom; 2 Medical University of Vienna/Hietzing<br />
Hospital, Vienna, Austria; 3 Massachusetts General Hospital/Harvard Medical School, Boston,<br />
MA; 4 Centocor R&D, Inc./U Penn Med School, Philadelphia, PA; 5 University Hospital<br />
Maastricht, Maastricht, Netherlands; 6 Mayo Clinic, Rochester, MN; 7 Centocor Research<br />
and Development, Inc., Malvern, PA<br />
Scientific <strong>Programme</strong> | Thursday 30 April 2009<br />
OP49<br />
RAPID INHIBITION OF PROGRESSION OF STRUCTURAL DAMAGE WITH CERTOLIZUMAB<br />
PEGOL, A NOVEL SC PEGYLATED, FC-FREE ANTI-TNF<br />
Desiree van der Heijde 1 , Michael Weinblatt 2 , Robert Landewé 3 , Niti Goel 4 , Roy Fleischmann 5 ;<br />
1<br />
Leiden University Medical Center, Leiden, Netherlands; 2 Brigham and Women’s Hospital,<br />
Boston, MA; 3 University Hospital Maastricht, Maastricht, Netherlands; 4 UCB, Smyrna, GA;<br />
5<br />
University of Texas Southwestern Medical Center, Dallas, TX<br />
OP50<br />
ADALIMUMAB AND METHOTREXATE COMBINATION THERAPY IN PATIENTS WITH EARLY<br />
RA SUSTAINS CLINICAL REMISSON AND RESPONSE THROUGH 5 YEARS OF<br />
ADALIMUMAB TREATMENT<br />
Aileen L. Pangan 5 , Ferdinand C. Breedveld 1 , Arthur Kavanaugh 2 , Piet van Riel 3 , Kaushik Patra 4 ,<br />
John L. Perez 4 ;<br />
1<br />
University Medical Center, Leiden, Netherlands; 2 UCSD Center <strong>for</strong> Innovative <strong>The</strong>rapy, La Jolla,<br />
CA; 3 University Medical Centre, Nijmegen, Netherlands; 4 Abbott Laboratories, Parsippany, NJ;<br />
5<br />
Abbott Laboratories, Abbott Park, IL<br />
OP51<br />
TOCILIZUMAB SIGNIFICANTLY IMPROVES PATIENT OUTCOMES REGARDLESS OF PRIOR<br />
INADEQUATE RESPONSE TO TUMOUR NECROSIS FACTOR ANTAGONISTS IN<br />
RHEUMATOID ARTHRITIS<br />
P. Emery 1 , E. Keystone 2 , H. P. Tony 3 , A. Law 4 , T. Woodworth 4 , J. Kremer 5 ;<br />
1<br />
Leeds Teaching Hospitals Trust, University of Leeds, Leeds, United Kingdom; 2 Mount Sinai<br />
Hospital, Toronto, ON, Canada; 3 Medizinische Klinik II, Würzburg, Germany; 4 Roche, Welwyn,<br />
United Kingdom; 5 University of Leeds, Leeds, NY<br />
33
OP52<br />
OP53<br />
OP54<br />
MATRIX RISK MODEL FOR PREDICTION OF RAPID RADIOGRAPHIC PROGRESSION IN<br />
RHEUMATOID ARTHRITIS<br />
Nathan Vastesaeger 1 , Stephen Xu 2 , Daniel Aletaha 3 , E.William St. Clair 4 , Josef Smolen 3 ;<br />
1<br />
Centocor BV, Leiden, Netherlands; 2 Centocor R&D, Malvern, PA; 3 Medical University of Vienna,<br />
Vienna, Austria; 4 Duke University Medical Center, Durham, NC<br />
METHOTREXATE THERAPY ASOCIATES WITH REDUCED PREVALENCE OF THE METABOLIC<br />
SYNDROME IN RHEUMATOID ARTHRITIS: MORE THAN JUST AN ANTI-INFLAMMATORY EFFECT<br />
Tracey E. Toms, Vasileios F. Panoulas, Karen M. Douglas, George D. Kitas;<br />
<strong>Rheumatology</strong>, Dudley Group of Hospitals NHS Trust, Dudley, United Kingdom<br />
FACTORS ASSOCIATED WITH WORK DISABILITY IN RHEUMATOID ARTHRITIS PATIENTS:<br />
RESULTS FROM THE BSR BIOLOGICS REGISTER (BSRBR)<br />
Suzanne. M.M. Verstappen, Kath D. Watson, Katie McGrother, Deborah P.M. Symmons, Kimme<br />
L. Hyrich, On behalf of the BSR Biologics Register;<br />
arc Epidemiology, the University of Manchester, Manchester, United Kingdom<br />
Case reports Lomond Auditorium<br />
OP55<br />
OP56<br />
OP57<br />
OP58<br />
RITUXIMAB IS EFFECTIVE IN REFRACTORY INFLAMMATORY EYE DISEASE ASSOCIATED WITH<br />
RHEUMATOID ARTHRITIS<br />
Sadra I. Razzaq 2 , Kathryn E. Moss 2 , Ahmed Kamal 3 , C. Estrach 1 , R. N. Thompson 1 ,<br />
S. Chauhan 4 , Robert J. Moots 1 ;<br />
1<br />
<strong>Rheumatology</strong>, University Hospital Aintree, Liverpool, United Kingdom; 2 Medicine, University<br />
of Liverpool, Liverpool, United Kingdom; 3 Opthalmology, University Hospital Aintree, Liverpool,<br />
United Kingdom; 4 General Medicine, Government Medical College & Hospital Chandigarh,<br />
Chandigarh, India<br />
SPONTANEOUS PNEUMOMEDIASTINUM SECONDARY TO REFRACTORY<br />
DERMATOMYOSITIS SUCCESSFULLY TREATED WITH RITUXIMAB: A CASE REPORT<br />
AND REVIEW OF THE LITERATURE<br />
Martin A. Lee, David G. Hutchinson;<br />
<strong>Rheumatology</strong>, Royal Cornwall Hospital, Truro, United Kingdom<br />
RITUXIMAB AS PRIMARY THERAPY FOR PULMONARY HAEMORRHAGE IN SYSTEMIC<br />
LUPUS ERYTHEMATOSUS<br />
Chetan B. Narshi, Seema Haider, Charlotte M. Ford, David A. Isenberg, Ian P. Giles;<br />
Centre <strong>for</strong> <strong>Rheumatology</strong> Research, University College Hospital, London, United Kingdom<br />
RASBURICASE IN TREATMENT FAILURE GOUT<br />
Derek R. Baxter 1 , Martin E. Perry 1 , Roger D. Sturrock 1 , Laura Johnstone 2 ;<br />
1<br />
Centre <strong>for</strong> Rheumatic Diseases, Glasgow Royal Infirmary, Glasgow, United Kingdom;<br />
2<br />
Area Medicines In<strong>for</strong>mation Centre, Glasgow Royal Infirmary, Glasgow, United Kingdom<br />
OP59<br />
THE VITAMIN D AND CALCIUM CHALLENGE TEST<br />
Adrian Peall 1 , Gwennan Hughes 2 , James Martin 2 ;<br />
1<br />
<strong>Rheumatology</strong>, University Hospital Wales, Cardiff, United Kingdom;<br />
2<br />
<strong>Rheumatology</strong>, Royal Glamorgan Hospital, Llantrisant, United Kingdom<br />
34
OP60<br />
OP61<br />
OP62<br />
SLE WITH C1Q DEFICIENCY TREATED WITH FRESH FROZEN PLASMA (FFP):<br />
A TEN YEAR EXPERIENCE<br />
P. Mehta1, P. J. Norsworthy 1 , M. J. Walport 2 , M. Botto 1 , M. C. Pickering 1 ;<br />
1<br />
Molecular Genetics & <strong>Rheumatology</strong> Section, Hammersmith Hospital, London,<br />
United Kingdom; 2 <strong>The</strong> Wellcome Trust, London, United Kingdom<br />
A CASE OF SJÖGREN’S SYNDROME WITH RENAL TUBULAR ACIDOSIS AND CENTRAL<br />
PONTINE MYELINOLYSIS<br />
Kathryn Watson, Sureshni de Fonseka, Damodharan Suresh;<br />
University College London Hospital Trust, London, United Kingdom<br />
PERSISTANT PAIN AT THE 1ST CMC JOINT MISDIAGNOSED FOR YEARS<br />
Ahmad Al-Shami 1 , James Taylor 2 ;<br />
1<br />
<strong>Rheumatology</strong>, University Hospitals of Leicester NHS Trust, Leicester Royal Infirmary,<br />
Leicester, United Kingdom; 2 <strong>Rheumatology</strong>, Northampton General Hospital NHS Trust,<br />
Northampton, United Kingdom.<br />
Scientific <strong>Programme</strong> | Thursday 30 April 2009<br />
Education research Dochart Room<br />
OP63<br />
OP64<br />
OP65<br />
USE OF ‘GALS’ IN CLINICAL PRACTICE. WHY ARE WE STILL FAILING?<br />
K. Chakravarty, Mathura Selvarajah, Hamida Begum, Jasmin Sajna;<br />
<strong>Rheumatology</strong> Deprtment, Queens Hospital, Rom<strong>for</strong>d, United Kingdom<br />
AN EVIDENCE AND PRACTICE BASED REGIONAL MUSCULOSKELETAL EXAMINATION FOR<br />
SCHOOL AGED CHILDREN - PREMS<br />
Tim Rapley 1,2 , Ben Heaven 1 , Carl May 1,2 , Lesley Kay 2,1 , Helen Foster 2,1 ;<br />
1<br />
Institute of Health & <strong>Society</strong>, Newcastle University, Newcastle, United Kingdom; 2 Institute of<br />
Cellular Medicine, Newcastle University, Newcastle, United Kingdom<br />
PEER-ASSISTED LEARNING BY MEDICAL STUDENTS IMPROVES MUSCULOSKELETAL<br />
SYSTEM EXAMINATION SKILLS<br />
Martin E. Perry 1 , Joanne Burke 2 , Lorraine Friel 1 , Max Field 1 ;<br />
1<br />
Centre <strong>for</strong> Rheumatic Disease, Glasgow Royal Infirmary, Glasgow, United Kingdom;<br />
2<br />
Department of Medical Education, <strong>The</strong> University of Glasgow, Glasgow, United Kingdom<br />
OP66<br />
OP67<br />
BECOMING ESTABLISHED: LEARNING ABOUT ANKYLOSING SPONDYLITIS (AS) FROM THE<br />
PATIENT’S PERSPECTIVE<br />
Ben Thompson 1 , Tim J. Rapley 2 , Wendy Broderick 3 , Carl R. May 2 , Lesley J. Kay 1 ;<br />
1<br />
Newcastle Musculoskeletal Research Group, Newcastle University, Newcastle-upon-Tyne,<br />
United Kingdom; 2 Institute of Health and <strong>Society</strong>, Newcastle University, Newcastle-upon-Tyne,<br />
United Kingdom; 3 National Ankylosing Spondylitis <strong>Society</strong> (NASS), Tyne and Wear Branch,<br />
United Kingdom<br />
VALIDATION OF THE EDUCATIONAL NEEDS ASSESSMENT TOOL IN 6 RHEUMATIC<br />
DISEASES<br />
Mwidimi Ndosi 1 , Jackie Hill 1 , Alan Tennant 2 , Claire Hale 3 , Ade Adebajo 4 ;<br />
1<br />
Academic & Clinical Unit <strong>for</strong> Musculoskeletal Nursing, University of Leeds, Leeds, United<br />
Kingdom; 2 Academic Department of Rehabilitation Medicine, University of Leeds, Leeds,<br />
United Kingdom; 3 School of Healthcare, University of Leeds, Leeds, United Kingdom;<br />
4<br />
<strong>Rheumatology</strong> Department, Barnsley Hospital NHS Foundation Trust, Barnsley, United<br />
Kingdom<br />
35
OP68<br />
OP69<br />
HOW READABLE ARE THE RHEUMATOLOGY INFORMATION LEAFLETS WE GIVE OUR PATIENTS?<br />
Wendy Holden 1 , Joseph Joseph 2 ;<br />
1<br />
<strong>Rheumatology</strong>, Basingstoke and North Hampshire NHS Foundation Trust, Basingstoke,<br />
United Kingdom; 2 <strong>Rheumatology</strong>, Aretaeion Private Hospital, Nicosia, Cyprus<br />
INTERPRETATION AND UTILISATION OF THE STANFORD HEALTH ASSESSMENT<br />
QUESTIONNAIRE DISABILITY INDEX (HAQ-DI) AMONGST RHEUMATOLOGISTS IN<br />
TRAINING IN THE UNITED KINGDOM<br />
John D. Pauling 1 , Raj Sengupta 1 , David R. Blake 1,2 ;<br />
1<br />
<strong>Rheumatology</strong>, Royal National Hospital <strong>for</strong> Rheumatic Diseases, Bath, United Kingdom;<br />
2<br />
School <strong>for</strong> health, University of Bath, Bath, United Kingdom<br />
OP70<br />
NEW EDUCATIONAL TECHNIQUES IN RHEUMATOLOGY: IMPLEMENTING A MULTI MEDIA<br />
VIRTUAL LEARNING ENVIRONMENT FOR RHEUMATOLOGY EDUCATION AND RESEARCH<br />
James Bateman 1,2 , David Davies 2 , Maggie E. Allen 1 ;<br />
1<br />
Department of <strong>Rheumatology</strong>, University Hospital Coventry and Warwickshire, Coventry,<br />
United Kingdom; 2 Warwick Medical School, University of Warwick, Warwick, United Kingdom<br />
Connective tissue disease Boisdale Room<br />
OP71<br />
OP72<br />
OP73<br />
IN ADULT IDIOPATHIC INFLAMMATORY MYOPATHIES (IIM), THE HLA-DRB1*03-ASSOCIATED<br />
INCREASED RISK FOR DEVELOPING ANTI-JO-1 ANTIBODIES IS EXACERBATED IN SMOKERS<br />
Suresh Adimulam 1 , Hector Chinoy 1 , Kathryn Edge 1 , Chester V. Oddis 3 , William.E R. Ollier 2 , Robert<br />
G. Cooper 1 ;<br />
1<br />
<strong>The</strong> University of Manchester Rheumatic Diseases Centre, Sal<strong>for</strong>d Royal NHS Foundation Trust,<br />
Manchester, United Kingdom; 2 Centre <strong>for</strong> Integrated Genomic Medical Research, University of<br />
Manchester, Manchester, United Kingdom; 3 Division of <strong>Rheumatology</strong>,<br />
University of Pittsburgh, pittsburgh, PA<br />
IN UK CAUCASIAN ADULT AND JUVENILE-ONSET DERMATOMYOSITIS (DM), THE VITAMIN D<br />
RECEPTOR GENE (VDR) IS ASSOCIATED WITH POSSESSION OF ANTI-155/140 ANTIBODIES<br />
Sabrina R. Kapoor 1 , Hector Chinoy 2,3 , Lucy R. Wedderburn 4 , Chester V. Oddis5, Neil J. McHugh6,<br />
William E. Ollier 2 , Robert G. Cooper 3 ;<br />
1<br />
<strong>Rheumatology</strong>, Russells Hall Hospital, Dudley, United Kingdom; 2 Centre <strong>for</strong> Integrated Genomic<br />
Medical Research,, University of Manchester, Manchester, United Kingdom;<br />
3<br />
<strong>The</strong> University of Manchester Rheumatic Diseases Centre, Sal<strong>for</strong>d Royal NHS Foundation Trust,<br />
Sal<strong>for</strong>d, United Kingdom; 4 <strong>Rheumatology</strong> Unit, Institute of Child Health, UCL, London, United<br />
Kingdom; 5 Division of <strong>Rheumatology</strong> & Clinical Immunology, University of Pittsburgh School of<br />
Medicine,, Pittsburgh,, PA; 6 <strong>Rheumatology</strong> Dept, Royal National Hospital <strong>for</strong> Rheumatic Diseases,<br />
Bath, United Kingdom<br />
SHOULD HEADACHE BE INCLUDED IN DISEASE ACTIVITY MEASURES OF NPSLE?<br />
Pamela L. Peterson 1,2 , Franklyn A. Howe 3 , Phil Rich 5 , A. Clifton 5 , Chris A. Clark 4 ,<br />
John S. Ax<strong>for</strong>d 2 ;<br />
1<br />
<strong>Rheumatology</strong>, Newcastle Foundation Trust, Newcastle Upon Tyne, United Kingdom; 2 Academic<br />
<strong>Rheumatology</strong>, St George’s University, London, London, United Kingdom;<br />
3<br />
Basic Medical Sciences, St George’s University, London, London, United Kingdom;<br />
4<br />
Dept Child Health, UCL, London, United Kingdom; 5 Neuroradiology, St George’s Hospital,<br />
London, United Kingdom<br />
36
OP74<br />
OP75<br />
OP76<br />
MEDICAL STUDENT BURSARY WINNER<br />
THE IMPORTANCE OF ANTI-THROMBIN ANTIBODIES IN THE ANTIPHOSPHOLIPID<br />
SYNDROME<br />
Jasmine Ehsanullah, Anisur Rahman, Ian Giles;<br />
Centre <strong>for</strong> <strong>Rheumatology</strong>, Department of Medicine, University College, London,<br />
United Kingdom<br />
OBSERVATIONAL STUDY OF TREATMENT OUTCOME IN EARLY DIFFUSE CUTANEOUS<br />
SYSTEMIC SCLEROSIS<br />
Ariane L. Herrick 1 , Mark Lunt 1 , Nina Whidby 1 , Holly Ennis 1 , Alan Silman 1 , Neil McHugh 2 ,<br />
Christopher P. Denton 3 ;<br />
1<br />
arc Epidemiology Unit, University of Manchester, Manchester, United Kingdom; 2 Royal National<br />
Hospital <strong>for</strong> Rheumatic Diseases, Bath, United Kingdom; 3 Royal Free Hospital, London,<br />
United Kingdom<br />
CLINICAL AND SEROLOGICAL HALLMARKS OF SYSTEMIC SCLEROSIS OVERLAP<br />
SYNDROMES<br />
Angela Pakozdi, Svetlana I. Nihtyanova, Geraldine M. Brough, Carol M. Black,<br />
Christopher P. Denton;<br />
Centre <strong>for</strong> <strong>Rheumatology</strong>, Royal Free Hospital, London, United Kingdom<br />
Scientific <strong>Programme</strong> | Thursday 30 April 2009<br />
OP77<br />
OP78<br />
TADALAFIL IS EFFECTIVE IN THE MANAGEMENT OF RESISTANT SECONDARY RAYNAUD’S<br />
PHENOMENON AND IMPROVES ENDOTHELIAL FUNCTION<br />
Padmanabha Shenoy 1 , Vikas Agarwal 1 , Sudeep Kumar 2 , Sunil Choudhary 2 , Lalan Jha 2 ,<br />
Uttam Singh 3 , Ramnath Misra 1 ;<br />
1<br />
Department of Immunology, Sanjay Gandhi Post Graduate Institute of Medical Sciences,<br />
Lucknow, India; 2 Department of Cardiology, Sanjay Gandhi Post Graduate Institute of Medical<br />
Sciences, Lucknow, United Kingdom; 3 Department of Biostatistics, Sanjay Gandhi Post<br />
Graduate Institute of Medical Sciences, Lucknow, United Kingdom<br />
STRESS SIGNAL TRANSDUCTION PATHWAYS ACTIVATED IN EPIDERMAL KERATINOCYTES<br />
IN SYSTEMIC SCLEROSIS<br />
Nima H. Aden, Anna Nuttall, Shiwen Xu, Chris Denton, Carol Black, David Abraham,<br />
Richard Stratton;<br />
Centre <strong>for</strong> <strong>Rheumatology</strong>, Royal Free Hospital and University College Medical School, London,<br />
United Kingdom<br />
BHPR Concurrent Oral Presentation of Abstracts Hall 1<br />
OP79<br />
GROUP CLINICS CAN DELIVER EFFECTIVE CARE FOR RHEUMATOID ARTHRITIS:<br />
A FEASIBLE MODEL FOR AN ANNUAL REVIEW CLINIC<br />
Fraser Birrell;<br />
1<br />
<strong>Rheumatology</strong>, Northumbria Healthcare NHS Foundation Trust, Newcastle, United Kingdom;<br />
2<br />
Newcastle University, Newcastle, United Kingdom<br />
OP80<br />
SELF-REPORTED HAND FUNCTION AND ADAPTATION BEHAVIOUR IN<br />
COMMUNITY-DWELLING OLDER ADULTS OVER AN 18-MONTH PERIOD<br />
Helen Myers 1 , Elaine Nicholls 1 , George Peat 1 , Danielle van der Windt 1,2 , Krysia Dziedzic 1 ;<br />
1<br />
Arthritis Research Campaign National Primary Care Centre, Keele University, Keele,<br />
United Kingdom; 2 EMGO Institute, VU University Medical Center, Amsterdam, Netherlands<br />
37
OP81<br />
OP82<br />
OP83<br />
A CONTROLLED STUDY OF PLANTAR FOOT PRESSURES IN PATIENTS WITH<br />
RHEUMATOID ARTHRITIS<br />
Ruth P. Allen 1 , James Beacroft 1 , Cathy J. Bowen 1 , Anita Gay 1 , Lindsey Hooper 1 ,<br />
Jane H. Burridge 1 , Christopher J. Edwards 2,3 , Nigel K. Arden 4,5 ;<br />
1<br />
School of Health Sciences, University of Southampton, Southampton, United Kingdom;<br />
2<br />
Department of <strong>Rheumatology</strong>, Southampton University Hospitals NHS Trust, Southampton,<br />
United Kingdom; 3 Wellcome Trust Clinical Research Facility, Southampton University Hospitals<br />
NHS Trust, Southampton, United Kingdom; 4 MRC Epidemiology Resource Centre, University of<br />
Southampton, Southampton, United Kingdom; 5 Musculoskeletal Biomedical Research Unit,<br />
University of Ox<strong>for</strong>d, Ox<strong>for</strong>d, United Kingdom<br />
IMPROVING SKILL-MIX IN RHEUMATOLOGY: HIGH QUALITY OF CARE FROM AN<br />
INDEPENDENTLY PRESCRIBING RHEUMATOLOGY PHARMACIST PRACTITIONER<br />
Richard Copeland 1,2 , Fraser Birrell 3,4 ;<br />
1<br />
Pharmacy, Northumbria Healthcare NHS Foundation Trust, Ashington, United Kingdom;<br />
2<br />
School of Pharmacy, University of Sunderland, Sunderland, United Kingdom; 3 <strong>Rheumatology</strong>,<br />
Northumbria Healthcare NHS Foundation Trust, Ashington, United Kingdom; 4 School of Clinical<br />
Medical Sciences, Newcastle University, Newcastle, United Kingdom<br />
MEASURING THE IMPACT OF FOOT DISEASE IN PATIENTS WITH RHEUMATOID ARTHRITIS<br />
COMMENCING ANTI TNF-BIOLOGIC THERAPY USING THE LEEDS FOOT IMPACT SCALE<br />
Heidi J. Siddle 1 , Domini J. Bryer 2 , Philip S. Helliwell 1 ;<br />
1<br />
Section of Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom;<br />
2<br />
<strong>Rheumatology</strong> Department, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom<br />
OP84<br />
AN AUDIT ON SERUM 25-HYDROXY VITAMIN D IN A RHEUMATOLOGY OUT-PATIENT CLINIC<br />
Kate M. Wilkinson 1 , John A. Reynolds 1 , Jacqueline L. Berry 2,1 , Ian N. Bruce 1 , Rachel Gorodkin 1 ,<br />
Kimme Hyrich 1 , Alan Silman 1 , Pauline Ho 1 ;<br />
1<br />
Kellgren Centre <strong>for</strong> <strong>Rheumatology</strong>, Manchester Royal Infirmary, Manchester, United Kingdom;<br />
2<br />
Vitamin D Research Group, Manchester Royal Infirmary, Manchester, United Kingdom<br />
OP85<br />
OP86<br />
THE EFFORT PROJECT: A QUALITATIVE EXPLORATION OF ORTHOSES AND FOOTWEAR<br />
PROVISION FOR PEOPLE WITH RHEUMATOID ARTHRITIS (RA)<br />
Maggie McArthur, Bryony Crompton;<br />
School of Aliied Health Professions, University of East Anglia, Norwich, United Kingdom<br />
A COMPARISON OF A COMPUTER GAME-BASED EXERCISE SYSTEM WITH CONVENTIONAL<br />
APPROACHES OF EXERCISE THERAPY IN RHEUMATOLOGY PATIENTS<br />
Kirsti McCormack 1 , Diarmaid Fitzgerald 1 , Oliver Fitzgerald 2 , Brian Caulfield 1 ;<br />
1<br />
School of Physiotherapy, University College Dublin, Belfield, Dublin 4, Ireland; 2 <strong>Rheumatology</strong><br />
Unit, Our Lady`s Hospice, Harold`s Cross, Dublin, Ireland<br />
16.30-17.00 Tea/Coffee Hall 5<br />
17.00-18.00 Heberden Round Clyde Auditorium<br />
Chair: Dr Deborah Bax<br />
Prof Patricia Woo<br />
More than meets the eye<br />
This lecture will explore the clinical heterogeneity and outcomes of conditions diagnosed as<br />
juvenile idiopathic arthritis. Cases will be presented to illustrate classical clinical observations<br />
can provide direction to laboratory investigations, results from which can in turn lead to choice<br />
of therapies.<br />
38
18.00-19.30 Satellite Symposia<br />
UCB Forth Room<br />
Steering an optimal course <strong>for</strong> patients with rheumatoid arthritis<br />
Welcome – Prof Peter C Taylor<br />
What does Alice want? – Alice Peterson<br />
Bound <strong>for</strong> a response to treatment?: managing and meeting patient expectations –<br />
Mrs Trish Cornell<br />
Mapping effective patient pathways: a rapid response as a predictor of a sustained response –<br />
Prof Peter C Taylor<br />
<strong>The</strong> productive patient, a new destination: patient-reported outcomes in clinical<br />
decision-making – Dr Chris Edwards<br />
Patient/rheumatology team partnership: working together to achieve optimum outcomes <strong>for</strong><br />
patients – Alice Peterson<br />
19.35 Coaches to BSR Social Event<br />
20.00-00.30 BSR social event<br />
25th Anniversary dinner dance<br />
Kelvingrove art gallery and museum<br />
(Welcome drinks from 19.30, concludes at 00.30)<br />
Scientific <strong>Programme</strong> | Thursday 30 April 2009<br />
39
Scientific <strong>Programme</strong><br />
Fri 01 May 2009<br />
Scientific <strong>Programme</strong><br />
Friday 01 May 2009
BSR Scientific <strong>Programme</strong> 2009<br />
Friday 01 May 2009<br />
08.30-10.00 Poster Viewing including Tea/Coffee Hall 5<br />
10.00-11.00 State of the Art Lecture Clyde Auditorium<br />
Nanotechnology in medicine<br />
Prof Richard Jones<br />
Nanotechnology refers to our developing capability to manipulate matter on the nanoscale.<br />
This is the length-scale of the fundamental processes of cell biology, so we should expect<br />
that medical interventions on this length-scale – nanomedicine – to grow in importance.<br />
<strong>The</strong> session will explore’ current and prospective applications of nanomedicine, particularly in<br />
targeted drug delivery and diagnostic devices, be<strong>for</strong>e discussing what might and might not be<br />
possible in the longer term.<br />
Scientific <strong>Programme</strong> | Friday 01 May 2009<br />
BHPR: Research issues and Prize Giving Lomond Auditorium<br />
Dr Ross Wilkie and Mrs Diana Finney<br />
• <strong>Rheumatology</strong> health professionals and their current practice - results from<br />
the BHPR/RCN survey – Dr Jackie Hill<br />
BHPR and the RCN <strong>Rheumatology</strong> Forum have conducted a joint survey to gain insight<br />
of the demographics and current rheumatology practice of the multidisciplinary team.<br />
<strong>The</strong> preliminary results will be presented in this paper<br />
• Funding opportunities – Mr Mike Patnick<br />
• Priority areas <strong>for</strong> UK clinical studies in osteoarthritis and crystal diseases – Dr George Peat<br />
• Prize Giving and NRAS presentation<br />
11.00-11.30 Tea/Coffee Hall 5<br />
11.30-13.00 Political Slot: NICE and the BSR Hall 1<br />
Dr Chris Deighton<br />
• <strong>The</strong> advantages of NICE rheumatology guidelines and technology appraisals –<br />
Prof David L Scott<br />
National standards enable patients with long-term conditions to access treatments in an<br />
era of limited healthcare budgets. NICE provides a framework to achieve equity between<br />
different patient groups, including patients with rheumatic diseases.<br />
• <strong>The</strong> disadvantages of NICE rheumatology guidelines and technology appraisals –<br />
Dr Chris Deighton<br />
<strong>Rheumatology</strong> technology appraisals have lead to a number of appeals, suggesting that<br />
stakeholders disagree with the results. This talk will consider the problems that lead to this<br />
dissatisfaction.<br />
• NICE technology appraisals methodology: working effectively with health care<br />
professionals – Prof David Barnett Chair of NICE Appraisal Committee<br />
NICE technology appraisal guidance to the NHS is developed on the basis of a robust<br />
review of the evidence available on both clinical and cost effectiveness. It is important<br />
that all stakeholders are fully consulted during the development of the guidance. <strong>The</strong> input<br />
from clinical professionals is especially relevant to ensure both consistency between<br />
appraisals and that the final guidance is implemented appropriately.<br />
• Discussion<br />
41
BSR: Management of unusual bone disease Forth Room<br />
Prof Paul Wordsworth<br />
• New insights in skeletal development – Prof William Horton<br />
Achondroplasia and related human chondrodysplasias are due to activating mutations of<br />
transmembrane receptor, FGFR3, a key negative regulator in linear bone growth. Evidence<br />
suggests that they act in part by interfering with the normal turnover of the activated<br />
receptor. Strategies to reduce stability of the mutant receptors are being developed to<br />
potentially stimulate bone growth in these conditions.<br />
• Matrix disorders in skeletal dysplasia – Dr Michael Briggs<br />
<strong>The</strong> skeletal dysplasias are a clinically and genetically heterogeneous group of diseases.<br />
Mutations in the genes encoding cartilage structural proteins can cause a distinct group of<br />
autosomal dominant phenotypes, the disease mechanisms of which will be discussed.<br />
• Running a skeletal dysplasia clinic – Prof Paul Wordsworth<br />
Input from many disciplines is required <strong>for</strong> optimal management of these rare and often<br />
complex disorders. This will be illustrated by the multidisciplinary approach of the Ox<strong>for</strong>d<br />
Skeletal Dysplasia Clinic in this presentation. A brief approach to the categorisation of these<br />
dysplasias will be presented, including useful websites and approaches to management.<br />
BHPR: Qualitative studies of self-management in osteoarthritis Alsh Room<br />
Prof Pauline Ong<br />
• Providing in<strong>for</strong>mation to support self-management of OA – Mrs Janet Grime<br />
This talk will examine the role and value of providing patients with in<strong>for</strong>mation on their<br />
chronic condition from a professional, lay and organisational perspective and report on<br />
a project which developed written material on OA to help support patient self-management.<br />
• Decision making by people with knee OA about self-management of their pain and<br />
disability – Dr Claire Jinks and Mr Andrew Morden<br />
This session will explore what factors shape people’s decision-making to self-manage knee<br />
OA and will discuss supported self-management in primary care.<br />
• Providing in<strong>for</strong>mation to support self-management of OA – Prof Pauline Ong<br />
This session will consider the contested nature of self-management and report on a project<br />
in which patients and health professionals developed written material on OA.<br />
BSR: New immunosuppressants Lomond Auditorium<br />
Prof Hill Gaston<br />
• Mycophenolate mofetil in the treatment of SLE – Dr Liz Lightstone<br />
Mycophenolate mofetil (MMF) has trans<strong>for</strong>med the treatment options <strong>for</strong> lupus nephritis.<br />
Establishing its role in induction therapy generated the largest randomised controlled trials<br />
in lupus nephritis ever undertaken. However, with the advent of newer treatment options<br />
such as Rituximab, has it had its day or will it reign supreme over cyclophosphamide?<br />
This session will review the evidence <strong>for</strong> the role of MMF in the treatment of lupus nephritis,<br />
the limitations to its effectiveness and new therapeutic strategies.<br />
• Leflunomide and deoxyspergualin in the treatment of vasculitis – Prof Wolfgang Gross<br />
• <strong>The</strong> role of methotrexate in the management of vasculitis – Dr Christian Pagnoux<br />
Methotrexate is used to treat various vasculitides: in GCA it is used as a steroid-sparing<br />
agent, in Wegener’s and MPA it can be as effective as azathioprine in maintaining remission,<br />
and it is an alternative to cyclophosphamide <strong>for</strong> induction therapy in localized Wegener’s.<br />
It has a relatively good safety profile, but should be used prudently when renal function<br />
is impaired.<br />
42
13.00-14.00 Lunch Hall 5<br />
BHPR: Clinical update on spondyloarthropathies Boisdale Room<br />
Dr Anthony Redmond<br />
• AS – Dr Lesley Kay<br />
• PsA – Ms Kate Gadsby<br />
This talk will provide an update on the assessment and treatments available <strong>for</strong> patients<br />
with psoriatic arthritis and incorporating NICE guidance into clinical practice.<br />
13.00-15.00 BSR Special interest groups<br />
Sport and exercise medicine Leven Room<br />
Convenor: Dr Jonathan Rees<br />
How to manage exercise induced lower leg pain<br />
Exercise induced lower leg pain – introduction, differential diagnosis and investigations –<br />
Dr Jonathan Rees<br />
Rehabilitation / assessment of exercise induced lower leg pain – Jayne McLenaghan<br />
Exercise induced lower leg pain – conservative management –<br />
Lt Col Jonathan Houghton MRCP, MFSEM<br />
Pressure study monitoring and surgical management of chronic exertional compartment<br />
syndrome – Squadron Leader Shreshth Datta<br />
Open <strong>for</strong>um question and answer session<br />
Scientific <strong>Programme</strong> | Friday 01 May 2009<br />
Musculoskeletal ultrasound Morar/Ness Room<br />
Convenor: Cristina Estrach<br />
Welcome and introduction – Cristina Estrach (Chair) and David Kane (Co-chair)<br />
Liverpool and Nottingham MUS surveys: where are we and where do we want to go? –<br />
Claire Dubois and Ira Pandya<br />
<strong>The</strong> EULAR courses guidelines. How should we run the BSR courses? – Richard Wakefield<br />
Practical training: the Belfast SpR training program. – Alistair Taggart<br />
MUS and rheumatology research: from simple projects to extraordinary advances –<br />
Peter Taylor<br />
General discussion<br />
Musculo-skeletal health <strong>for</strong> the multi ethnic minority Carron Room A<br />
Convenor: Kuntal Chakravarty and Ash Samanta<br />
Attitudes to arthritis: an Indian concept – Professor Paul Bacon and Dr Mahendranath<br />
Clinico-pathological conference: lupus in West India – Professor Peter Maddison (Chair),<br />
Professor K Chakravarty (Presenter) and Dr Clive Gratten<br />
Minor etchings in managing rheumatoid arthritis in the ethnic minority groups –<br />
Dr Ash Samanta (Presenter) and Dr Asad Zoma<br />
Future of the group and various research agendas<br />
Polymyalgia rheumatica/giant cell arteritis Carron Room B<br />
Convenor: Bhaskar Dasgupta<br />
HTA proposal – comparison of duplex ultrasonography to temporal artery biopsy in suspected<br />
giant cell arteritis – Raashid Luqmani<br />
National organisation <strong>for</strong> PMR and GCA – PMR-GCA.UK – scope and objectives – Jean Miller<br />
Proposal <strong>for</strong> an education booklet on GCA – Wendy Morrison/Frances Borg<br />
Midlands region audit of BSR guidelines on PMRGCA – Ash Samanta<br />
Proposal <strong>for</strong> an RCT- study of leflunomide in PMR and GCA – Frances Borg<br />
RCTs of biologics in PMRGCA – what is the right design? – Bhaskar Dasgupta<br />
43
Sjögren’s syndrome Dochart Room A<br />
Convenor: Dr Simon Bowman<br />
Collaborative research update: MRC UK Sjögren’s registry (goal - 500 UK patients with primary<br />
SS) (now recruiting) – Dr Fai Ng<br />
Collaborative research update: EULAR project on consensus disease activity and patient<br />
reported outcome tools (now recruiting) – Dr Simon Bowman<br />
Science update: immunology of Sjögren’s syndrome and factors involved in lymphoma risk –<br />
Dr Michele Bombardieri<br />
Clinical update: role of ultrasound in diagnosis and management of SS – Dr Iain Macleod<br />
Paediatric and adolescent rheumatology Dochart Room B<br />
Convenors: Dr Alison Jordan and Dr Liza McCann<br />
What are you doing locally to improve the experience of young people moving from paediatric to<br />
adult rheumatology care?<br />
A discussion of current practice and proposal <strong>for</strong> audit of services<br />
Research update – Michael Beres<strong>for</strong>d<br />
Training update – Janet McDonagh<br />
14.00-15.30 BHPR: Designing solutions not problems Forth Room<br />
Ms Vicki Cameron and Dr Helen Myers<br />
• I’m too young to have that in my house – Dr Lynne Goodacre<br />
People with rheumatic diseases are amongst the largest users of assistive technologies yet<br />
studies of non-use suggest that up to one third of the devices provided are not used.<br />
This presentation will explore the reasons <strong>for</strong> non-use with reference to the assessment,<br />
selection and design of products and explore ways in which non-use can be minimised.<br />
• Inclusive design: designing people in – Ms Julia Cassim<br />
• In other people’s shoes: exploring the social life of feet – Ms Fiona Candy<br />
This session will create a focus on the everyday practice of dressing in and wearing clothing,<br />
particularly on the many ways that people experience and understand the aesthetics and<br />
social meanings of footwear. <strong>The</strong> speaker will draw on recent qualitative research in the<br />
context of rheumatoid arthritis and the wardrobe, and on her experience as a designer<br />
within the fashion industry.<br />
15.00-16.30 BSR: Setting up a fracture liaison service Lomond Auditorium<br />
Dr Gavin Clunie<br />
• <strong>The</strong> case <strong>for</strong> a Fracture Liason Service – Dr Stephen Gallacher<br />
<strong>The</strong> incidence of low trauma fractures is <strong>for</strong>ecast to increase through the first half of the<br />
21st century. This problem will put an increasing load on health care services. A strategic<br />
framework needs to be developed to properly address this problem. One part of this<br />
strategy is the Fracture Liaison Service. This presentation will describe the background<br />
case that is made <strong>for</strong> fracture secondary prevention and put this in context of other<br />
intervention pathways.<br />
• A secondary care-based FLS in a single hospital – Dr Gavin Clunie<br />
We will discuss the interventions to consider, service implementation and pitfalls of an FLS<br />
in an NHS acute-care facility where NHS targets need to be achieved and services need to<br />
respond appropriately to Healthcare commissioners’ demands.<br />
• A primary care-based FLS – Dr Alun Cooper<br />
Alun is a GP in Crawley and a Trustee of the National Osteoporosis <strong>Society</strong>. Fragility<br />
fracture is not part of QOF in the GP contract – to help fill this gap Alun’s PCT has agreed<br />
to fund a Primary Care based Fracture Liaison Service to compliment the acute service.<br />
44
• Funding opportunities – Mr Paul Mitchell<br />
National audit of the organisation of services <strong>for</strong> falls and bone health suggests that<br />
roughly a quarter of hospitals operate a Fracture Liaison Service 1 . In 2009, the<br />
Department of Health is developing a commissioning framework on falls and fragility<br />
fractures which will provide opportunities <strong>for</strong> healthcare localities that are yet to implement<br />
an FLS to address the secondary fracture prevention care gap 2 .<br />
1<br />
National organisational audit of services <strong>for</strong> falls and bone health. Royal College of Physicians Clinical<br />
Evaluation and Assessment Unit, London. January 2006.<br />
Available <strong>for</strong> download from http://www.rcplondon.ac.uk/CLINICAL-STANDARDS/CEEU/CURRENT-<br />
WORK/FALLS/Pages/Audit.aspx<br />
2<br />
“Old age is the new middle age”. Secretary of State <strong>for</strong> Health. Press Release 21 May 2008.<br />
Available <strong>for</strong> down load from http://nds.coi.gov.uk/environment/fullDetail.asp?ReleaseID=<br />
368178&NewsAreaID=2&NavigatedFromDepartment=True<br />
BSR: Psoriasis and the scoring systems Forth Room<br />
Dr Chris Lovell<br />
• Lupus and the skin – Dr Simon Meggitt<br />
Cutaneous lupus is a diverse group of related conditions which are potentially scarring,<br />
poorly understood and require different therapeutic approaches to SLE. Diagnosis and<br />
management, including common pitfalls <strong>for</strong> non-dermatologists, will be discussed.<br />
• What’s new in localised scleroderma – Dr Lindsay Shaw<br />
Localised scleroderma is a potentially disfiguring and disabling condition which is difficult<br />
to predict and monitor. Some recent developments may help our understanding of the<br />
condition.<br />
• Recent developments in psoriasis – Prof Jonathan Barker<br />
Considerable progress has been made in understanding basic pathogenetic mechanisms<br />
in psoriasis resulting in the development of new and more specific immunotherapy <strong>for</strong> the<br />
disease. In addition it is becoming clear that several important key co-morbidities are<br />
observed in patients with moderate and severe disease, similar to that observed in<br />
rheumatoid arthritis. This talk will focus on key recent advances in psoriasis science and<br />
therapeutics.<br />
Scientific <strong>Programme</strong> | Friday 01 May 2009<br />
45
Poster Viewing One<br />
Wednesday 29 April 2009<br />
Poster Viewing One<br />
Wed 29 April 2009
Poster Viewing One<br />
Wednesday 29 April 2009, 08.30-10.00<br />
Biology of bone, cartilage and connective tissue disease<br />
Poster No. 1<br />
THE ROLE OF DR3/TL1A IN CARTILAGE DEPLETION CAUSED BY INFLAMMATORY ARTHRITIS<br />
ZaraBeth Newton 1 , Melanie J. Bull 1 , Eddie Wang 1 , Anwen S. Williams 2 ;<br />
1<br />
Medical Biochemistry and Immunology, Cardiff University, Cardiff, United Kingdom;<br />
2<br />
<strong>Rheumatology</strong>, Cardiff University, Cardiff, United Kingdom<br />
Matrix metalloproteinases and its inhibitors<br />
Poster Viewing One | Wednesday 29 April 2009<br />
Poster No. 2<br />
ASSOCIATION OF OSTEOCHONDRAL ANGIOGENESIS, CARTILAGE LESION AND<br />
BEHAVIOURAL PAIN IN A RAT MODEL OF OSTEOARTHRITIS<br />
David A. Walsh 1 , Paul I. Mapp 1 , Ruth Webster 2 , Jonathan J. Bowyer 2 , Rose A. Maciewicz 2 ;<br />
1<br />
Academic <strong>Rheumatology</strong>, University of Nottingham, Nottingham, United Kingdom;<br />
2<br />
AstraZeneca, Macclesfield, United Kingdom<br />
Poster No. 3<br />
THE TYPE III 8-10 REPEATS OF FIBRONECTIN INDUCE AGGRECANASE ACTIVITY VIA<br />
ALPHA5BETA1 INTEGRIN AND THE TYPE III 13-14 REPEATS ACT VIA TLR 4 RECEPTORS<br />
Nidhi Sofat, Linda Troeberg, Hideaki Nagase;<br />
Matrix Biology, <strong>The</strong> Kennedy Institute of <strong>Rheumatology</strong>, London, United Kingdom<br />
Cell receptor-ligand interaction, signaling, activation and apoptosis<br />
Poster No. 4<br />
SELECTIVE TARGETING OF THE CANONICAL OR ALTERNATIVE NF-κB PATHWAY REVEALS<br />
NEW INSIGHTS INTO MECHANISMS OF B-LYMPHOCYTE SURVIVAL AND SELECTION<br />
Ali S. Jawad 1 , T. E. Taher 2 , A. Rahim 2 , F. D’Acquisto 2 , D. Gould 2 , R. A. Mageed 2 ;<br />
1<br />
<strong>Rheumatology</strong>, <strong>The</strong> Royal London Hospital, London, United Kingdom; 2 <strong>The</strong> Bone and Joint<br />
Research Unit, Barts and the London Queen Mary School of Medicine and Dentistry,<br />
London, United Kingdom<br />
Poster No. 5<br />
ENRICHMENT OF LIPID SPECIFIC IMMUNEREGULATORY T LYMPHOCYTES WITH MAGNETIC<br />
CD1D-MICROBEADS<br />
Joseph P. Sanderson 1 , Martina Wilm 2 , Karen Parker 1 , Richard R. Schmidt 3 ,<br />
Stephan D. Gadola 4,1 ;<br />
1<br />
Division of Infection, Inflammation & Repair, School of Medicine, University of Southampton,<br />
Southampton, United Kingdom; 2 R&D Reagents, Bergisch-Gladbach, Germany; 3 Department<br />
of Chemistry, University of Konstanz, Konstanz, Germany; 4 Department of <strong>Rheumatology</strong>,<br />
Southampton University Hospitals NHS Trust, Southampton, United Kingdom<br />
47
Poster No. 6<br />
Poster No. 7<br />
Poster No. 8<br />
MEDICAL STUDENT BURSARY WINNER<br />
EXPRESSION OF THE PEROXIREDOXIN-BASED ANTIOXIDANT SYSTEM IN PERIPHERAL<br />
BLOOD LYMPHOCYTES IN RHEUMATOID ARTHRITIS<br />
Carly A. Turner 1 , Katalin E. Szabo 1 , Richard Haigh 2 , Joanna Tarr 1 , Jennifer A. Littlechild 3 ,<br />
Paul Eggleton 1 , Paul G. Winyard 1 ;<br />
1<br />
Peninsula Medical School, Exeter, United Kingdom; 2 Royal Devon and Exeter Health Care Trust,<br />
Exeter, United Kingdom; 3 School of Biosciences, University of Exeter, Exeter, United Kingdom<br />
IMBALANCE OF PRO AND ANTI APOPTOTIC FACTORS IN PATIENTS WITH JSLE COMPARED<br />
TO CONTROLS<br />
Angela J. Midgley, Michael W. Beres<strong>for</strong>d;<br />
Institute of Child Health, University of Liverpool, Liverpool, United Kingdom<br />
ALTERED MEMBRANE CD45 ISOFORM EXPRESSION AND INTRACELLULAR SIGNALLING<br />
DEFECTS IN B CELLS FROM PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS(SLE)<br />
R. A. Mageed 1 , S. Mletzko 1 , M. Varin 1 , J. Duchene 1 , T. Taher 1 , G. Warnes 1 , A. S. Jawad 2 ,<br />
D. A. Isenberg 3 ;<br />
1<br />
<strong>The</strong> Bone and Joint Research Unit, Barts and the London School of Medicine and Dentistry,<br />
London, United Kingdom; 2 <strong>Rheumatology</strong>, <strong>The</strong> Royal London Hospital, London, United Kingdom;<br />
3<br />
Medicine, UCL, London, United Kingdom<br />
Cytokines and inflammatory mediators<br />
Poster No. 9<br />
Poster No. 10<br />
Poster No. 11<br />
Poster No. 12<br />
Poster No. 13<br />
HYDROGEN SULFIDE (H2S) AS A NOVEL MEDIATOR OF CARTILAGE LOSS AND<br />
SYNOVIAL HYPERPLASIA IN RHEUMATOID ARTHRITIS<br />
Matthew Whiteman;<br />
Peninsula Medical School, Institute of Biomedical and Clinical Science, Exeter, United Kingdom<br />
CONCURRENT ROLES OF THE SENSORY NEUROPEPTIDES SUBSTANCE P AND CGRP IN<br />
ENDOTHELIAL CELL PROLIFERATION IN VIVO<br />
Paul I. Mapp, Daniel F. McWilliams, David A. Walsh;<br />
Department of Academic <strong>Rheumatology</strong>, University of Nottingham, Nottingham, United Kingdom<br />
GOUT: OLD DISEASE - NEW THERAPY<br />
Johann Gruber;<br />
Internal Medicine, Innsbruck Medical School, Innsbruck, Austria<br />
ER STRESS SIGNALS PLAY AN IMPORTANT ROLE IN MODULATING CYTOKINE EXPRESSION<br />
BY DENDRITIC CELLS<br />
Jane C. Goodall, Lou Ellis, Louise O’Brien, Hill Gaston;<br />
Medicine, University of Cambridge, Cambridge, United Kingdom<br />
SYNERGISTIC VASCULAR PROTECTION BY STATIN AND RAPAMYCIN IS HO-1, PKCα AND p38<br />
MAPK-DEPENDENT<br />
Shahir S. Hamdulay, Bufei Wang, Dorian Haskard, Justin Mason;<br />
Eric Bywaters Centre, Hammersmith Campus, Imperial College London, London,<br />
United Kingdom<br />
48
Poster No. 14<br />
Poster No. 15<br />
Poster No. 16<br />
CELECOXIB ENHANCES ENDOTHELIAL HO-1 EXPRESSION AND ACTIVITY: A NOVEL<br />
MECHANISM OF VASCULAR CYTOPROTECTION<br />
Shahir S. Hamdulay 1 , Bufei Wang 1 , Dorian 0. Haskard 1 , Caroline Wheeler-Jones 2 ,<br />
Justin Mason 1 ;<br />
1<br />
Eric Bywaters Centre, Hammersmith Campus, Imperial College London, London, United<br />
Kingdom; 2 Department of Veterinary Basic Sciences, Royal Veterinary College, University of<br />
London, London, United Kingdom<br />
PERSISTENT AND ACUTE INFLAMMATORY PAIN INDUCES DIFFERENTIAL EXPRESSION OF<br />
ILβ AND FRACTALKINE MRNA IN THE RAT BRAIN<br />
Helen S. Jerina, Vivienne R. Winrow, Clif<strong>for</strong>d R. Stevens;<br />
School <strong>for</strong> Health, University of Bath, Bath, United Kingdom<br />
INCREASED CD80 AND CD86 IN THE SERUM OF PATIENTS WITH JSLE COMPARED<br />
TO CONTROLS<br />
Angela J. Midgley, Michael W. Beres<strong>for</strong>d;<br />
Institute of Child Health, University of Liverpool, Liverpool, United Kingdom<br />
Poster Viewing One | Wednesday 29 April 2009<br />
Poster No. 17<br />
Poster No. 18<br />
Poster No. 19<br />
DISTINCT CYTOKINE/CHEMOKINE PROFILES IN RA SYNOVIAL FLUID BASED ON<br />
DIAGNOSIS, THERAPY AND RESPONSE<br />
Helen L. Wright 1 , Roger C. Bucknall 2 , Steven W. Edwards 1 ;<br />
1<br />
Biological Sciences, University of Liverpool, Liverpool, United Kingdom; 2 Rheumatic Diseases<br />
Unit, Royal Liverpool Hospital, Liverpool, United Kingdom<br />
EFFICACY AND SAFETY OF CANAKINUMAB (ACZ885), A FULLY HUMAN<br />
ANTI-INTERLEUKIN-1BETA ANTIBODY, IN CRYOPYRIN-ASSOCIATED PERIODIC FEVER<br />
SYNDROME: RESULTS OF A MULTICENTER, RANDOMIZED, DOUBLE-BLIND,<br />
PHASE III STUDY<br />
Helen Lachmann 1 , Isabelle Kone-Paut 2 , Jasmin Kuemmerle-Deschner 3 , Kieron Leslie 4 , Eric<br />
Hachulla 5 , Pierre Quartier 6 , Xavier Gitton 7 , Neha P. Patel 8 , Karine Lheritier 7 , Philip N. Hawkins 1 ;<br />
1<br />
Royal Free& University college Medical school, London, United Kingdom; 2 Hopital Kremlin<br />
Bicetre, Le Kremlin Bicetre, France; 3 Universitatsklinik, Tuebingen, Germany; 4 UCSF, San<br />
Fransisco, CA; 5 Hopital Claude Huriez, Lille Cedex, France; 6 Unit’e d’Immunologie, Hopital<br />
Necker-Enfants Malades,Hematologie et Rhumatologie Pediatrique, Paris, France; 7 Novartis,<br />
Basel, Switzerland; 8 Novartis, East Hanover, NJ<br />
RHEUMATOID FACTOR INTERFERENCE WITH BEAD-BASED MULTIPLEX<br />
IMMUNOASSAYS PRECLUDES ITS USE IN RHEUMATOID ARTHRITIS<br />
Sarah M. Churchman 1 , Elizabeth A. Horner 1 , Leigh D. Church 2 , Rekha Parmar 1 ,<br />
Frederique Ponchel 1 ;<br />
1<br />
Musculoskeletal Disease, Leeds Institute of Molecular Medicine, Leeds, United Kingdom;<br />
2<br />
Department of <strong>Rheumatology</strong>, Institute <strong>for</strong> Biomedical Research, University of Birmingham,<br />
United Kingdom<br />
49
Rheumatoid arthritis – aetiopathogenesis and animal models<br />
Poster No. 20<br />
ROLE OF APOPTOSIS IN THE PATHOGENESIS AND PROGRESSION OF RHEUMATOID<br />
ARTHRITIS AND NON-RESPONSE TO ANTI-TNF THERAPY<br />
Sinisa Savic 1 , Rebeccah Mathews 1 , Karen Henshaw 2 , Sarah Churchman 1 , Maya Buch 2 ,<br />
Domini Bryer 2 , Lydia Coulthard 1 , Paul Emery 2 , Michael F. McDermott 1 ;<br />
1<br />
Experimental <strong>Rheumatology</strong>, Leeds Institute of Molecular Medicine, Leeds, United Kingdom;<br />
2<br />
Academic Unit of Musculoskeletal Medicine, Chapel Allerton Hospital, Leeds, United Kingdom<br />
Poster No. 21<br />
Poster No. 22<br />
CD4+ T CELL RESPONSES TO AUTOANTIGENS IN PATIENTS WITH RHEUMATOID ARTHRITIS<br />
James Locke, Julie Diboll, Susan Tudhope, Alexei von Delwig, John D. Isaacs, Wan-Fai Ng;<br />
Musculoskeletal Research Group, Institute of Cellular Medicine, Newcastle University, Newcastle<br />
upon Tyne, United Kingdom<br />
ANTIBODIES TO MUTATED CITRULLINATED VIMENTIN (MCV) IN RHEUMATOID ARTHRITIS:<br />
CLINICAL AND GENETIC ASSOCIATIONS<br />
Peter J. Charles 1 , Hannah Poulsom 2 , Darren Plant 3 ;<br />
1<br />
Kennedy Institute of <strong>Rheumatology</strong>, Faculty of Medicine, Imperial College, London, United<br />
Kingdom; 2 Immunology Dept, Imperial College Healthcare NHS Trust, London, United Kingdom;<br />
3<br />
ARC Epidemiology Unit, Univ. Of Manchester, Manchester, United Kingdom<br />
Poster No. 23<br />
CD3+CD8+CD28- CELLS ARE INCREASED IN RHEUMATOID ARTHRITIS (RA) PATIENTS BUT<br />
HAVE DEFICIENT ACTIVITY AND UPREGULATION OF NEGATIVE COSTIMULATORY MOLECULES<br />
Sabrina Ceeraz 1 , Jo Spencer 2 , Ernest H. Choy 1 , Valerie M. Corrigall 1 ;<br />
1<br />
Academic Department of <strong>Rheumatology</strong>, Kings College London, London, United Kingdom;<br />
2<br />
Department of Immunobiology, Kings College London, London, United Kingdom<br />
Poster No. 24<br />
Poster No. 25<br />
PROTEASE-ACTIVATED RECEPTOR-2 EXPRESSION IN PERIPHERAL BLOOD<br />
MONONUCLEAR CELLS FROM PATIENTS WITH RHEUMATOID ARTHRITIS<br />
Elizabeth Burns 1 , Mohammad B. Nickdel 1 , John C. Lockhart 1 , Martin E. Perry 2 ,<br />
Peter W. Ferrell 3 , Derek Baxter 2 , J. Alastair Gracie 4 , William R. Ferrell 5 , Iain B. McInnes 4 ;<br />
1<br />
School of Engineering and Science, University of the West of Scotland, Paisley, United<br />
Kingdom; 2 Centre <strong>for</strong> Rheumatic Diseases, Royal Infirmary, Glasgow, United Kingdom;<br />
3<br />
Orthopaedic Surgery, Ninewells Hospital, Dundee, United Kingdom; 4 Division of Immunology,<br />
Infection & Inflammation, University of Glasgow, Glasgow, United Kingdom; 5 Integrative &<br />
Systems Biology, University of Glasgow, Glasgow, United Kingdom<br />
CHARACTERISATION OF JOINT PATHOLOGY IN IL-7 TRANSGENIC MICE: PILOT DATA<br />
Elizabeth A. Horner 1,2 , Xeubin B. Yang 2 , Frederique Ponchel 1 ;<br />
1<br />
Musculoskeletal Disease, Leeds Univeristy, Leeds, United Kingdom;<br />
2<br />
Oral Biology, Leeds Univeristy, Leeds, United Kingdom<br />
Poster No. 26<br />
Poster No. 27<br />
LONG-TERM REMISSION AFTER TNF-BLOCKADE IN EARLY RHEUMATOID ARTHRITIS<br />
IS ASSOCIATED WITH A NORMALISATION OF IMMUNOLOGICAL STATUS<br />
Rekha Parmar, Vincent Goeb, Benazir Saleem, Mark Quinn, Philip G. Conaghan,<br />
Frederique Ponchel, Paul Emery;<br />
LIMM, Section MSK, LMBRU, University of Leeds, Leeds, United Kingdom<br />
CITRULLINATED ALPHA ENOLASE: A MAJOR AUTOANTIGEN IN RA<br />
Andrew J. Kinloch, Robin Wait, Patrick J. Vensbles;<br />
Kennedy Institute, Imperial College London, London, United Kingdom<br />
50
Poster No. 28<br />
Poster No. 29<br />
TURNOVER OF MHC CLASS II MOLECULES MEASURED BY HEAVY WATER LABELLING:<br />
EFFECTS OF ARTHRITIS-ASSOCIATED POLYMORPHISM AND APC ACTIVATION<br />
Robert Busch 1 , Alessandra De Riva 1 , Mike Deery 2 , Sarah McDonald 1 , Daniel G. Lewis 1 ,<br />
Sarah Jackson 3 , Anne Cooke 4 , Les Bluck 3 , Kathryn Lilley 2 ;<br />
1<br />
Dept of Medicine, University of Cambridge, Cambridge, United Kingdom; 2 Cambridge Centre<br />
<strong>for</strong> Proteomics, University of Cambridge, Cambridge, United Kingdom; 3 Stable Isotope<br />
Laboratory, MRC-HNR Widdowson Labs, Cambridge, United Kingdom; 4 Dept of Pathology,<br />
University of Cambridge, Cambridge, United Kingdom<br />
INHIBITION OF MURINE CHRONIC ARTHRITIS BY A MONOCLONAL ANTIBODY AGAINST<br />
PROTEASE-ACTIVATED RECEPTOR-2<br />
Lynette Dunning 1 , John C. Lockhart 1 , William R. Ferrell 4 , Robin J. Plevin 3 , J. Alastair Gracie 2 ,<br />
Iain B. McInnes 2 , Gary W. Boyd 1 ;<br />
1<br />
School of Engineering & Science, University of the West of Scotland, Paisley, United<br />
Kingdom; 2 Division of Immunology, Infection & Inflammation, University of Glasgow, Glasgow,<br />
United Kingdom; 3 Pharmacology & Physiology, University of Strathclyde, Glasgow, United<br />
Kingdom; 4 Integrative & Systems Biology, University of Glasgow, Glasgow, United Kingdom<br />
Poster Viewing One | Wednesday 29 April 2009<br />
Poster No. 30<br />
Poster No. 31<br />
Poster No. 32<br />
Poster No. 33<br />
REPLICATION STUDY OF NEWLY CONFIRMED RHEUMATOID ARTHRITIS<br />
SUSCEPTIBILITY LOCI<br />
Gisela Orozco, Anne Hinks, Steve Eyre, Xiayi Ke, Laura J. Gibbons, Ukrag Consortium,<br />
Wendy Thomson, Anne Barton, Jane Worthington;<br />
ARC Epidemiology Unit, <strong>The</strong> University of Manchester, Manchester, United Kingdom<br />
ELEVATED SYNOVIAL FLUID LEVELS OF HYDROGEN SULFIDE (H2S) IN<br />
RHEUMATOID ARTHRITIS: CORRELATION WITH DISEASE ACTIVITY AND OTHER<br />
CLINICAL INFLAMMATORY INDICES<br />
Matthew Whiteman1, Joanna Tarr1, Philip K. Moore3, Richard Haigh2, Paul G. Winyard1;<br />
1Peninsula Medical School, Institute of Biomedical and Clinical Sciences, Exeter, United<br />
Kingdom; 2<strong>Rheumatology</strong>, Royal Devon and Exeter Hospital Trust, Exeter, United Kingdom;<br />
3Pharmaceutical Science, King’s College, London, United Kingdom<br />
TNF-ALPHA MODULATES TISSUE-SPECIFIC VASCULAR DETERMINANTS<br />
RECOGNIZED IN VIVO BY A PHAGE CLONE DISPLAYING A SYNOVIAL-HOMING<br />
PEPTIDE IN THE HUMAN /SCID MOUSE TRANSPLANTATION MODEL<br />
Toby Garrood, Lewis Lee, Mark Blades, Panagiotis Kamperidis, Costantino Pitzalis;<br />
William Harvey Research Institute, Barts and the London School of Medicine, London,<br />
United Kingdom<br />
PADI4 GENOTYPE IS NOT ASSOCIATED WITH RHEUMATOID ARTHRITIS IN A LARGE UK<br />
CAUCASIAN POPULATION<br />
Marian L. Burr 1 , Haris Naseem 1 , Laura Gibbons 1 , John Bowes 1 , U. Krag 2 , Anne Barton 1 ;<br />
1<br />
arc-Epidemiology Unit, University of Manchester, Manchester, United Kingdom;<br />
2<br />
UK Rheumatoid Arthritis Genetics Consortium, UKRAG, United Kingdom<br />
Poster No. 34<br />
VARIATION IN THE CD226 GENE PREDICTS RESPONSE TO ANTI-TNF THERAPY<br />
IN RHEUMATOID ARTHRITIS<br />
Rachael Tan 1 , Laura J. Gibbons 1 , Catherine Potter 4 , Kimme Hyrich 1 , Ann W. Morgan 2 ,<br />
Anthony G. Wilson 3 , John D. Isaacs 4 , Anne Barton 1 ;<br />
1<br />
arc Epidemiology Unit, University of Manchester, Manchester, United Kingdom; 2 University of<br />
Leeds, Leeds, United Kingdom; 3 University of Sheffield, Sheffield, United Kingdom; 4 Newcastle<br />
University, Newcastle, United Kingdom<br />
51
Poster No. 35<br />
Poster No. 36<br />
MICROANATOMICAL STUDIES TO DEFINE FACTORS THAT MAY PREDICT THE<br />
TOPOGRAPHY OF PERIARTICULAR EROSION FORMATION IN ARTHRITIS<br />
Ai Lyn Tan 1 , Michael Benjamin 2 , Uffe M. Døhn 3 , Mikkel Østergaard 3 , Dennis McGonagle 1 ;<br />
1<br />
Academic Unit of Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom;<br />
2<br />
School of Biosciences, Cardiff University, Cardiff, United Kingdom; 3 Departments of<br />
<strong>Rheumatology</strong> and Diagnostic Radiology, Copenhagen University Hospitals,<br />
Copenhagen, Denmark<br />
NOVEL SMALL MOLECULE INHIBITORS OF TNF- AND RANKL-SIGNALING PREVENT<br />
COLLAGEN INDUCED ARTHRITIS<br />
Ejaz Pathan 1 , Emmanuel Coste 2 , Lorraine Rose 2 , Aymen I. Idris 2 , Anna Daroszewska 2,1 ,<br />
Iain R. Greig 3 , Mohini Gray 2,1 , Stuart H. Ralston 2,1 , Rob J. van ‘t Hof 2 ;<br />
1<br />
<strong>Rheumatology</strong>, Western General Hospital, Edinburgh, United Kingdom; 2 <strong>Rheumatology</strong>,<br />
University of Edinburgh, Edinburgh, United Kingdom; 3 Medicine and <strong>The</strong>rapeutics, University<br />
of Aberdeen, Edinburgh, United Kingdom<br />
Functional genomics<br />
Poster No. 37<br />
THE PTPN22 C1858T POLYMORPHISM IS NOT ASSOCIATED WITH SYSTEMIC<br />
RHEUMATIC DISEASES IN BLACK SOUTH AFRICANS<br />
Mohammed Tikly 1,2 , Nimmisha Govind 1,2 , Jacqueline Frost 3,2 , Michele Ramsay 3,2 ;<br />
1<br />
<strong>Rheumatology</strong>, Chris Hani Baragwanath Hospital, Johannesburg, South Africa; 2 University of<br />
the Witwatersrand, Johannesburg, South Africa; 3 Human Genetics, National Health Laboratory<br />
Services, Johannesburg, South Africa<br />
Stem cells and tissue engineering<br />
Poster No. 38<br />
Poster No. 39<br />
THE EFFECTS OF INFLAMMATORY CYTOKINES FROM ARTHRITIC SYNOVIUM ON SKELETAL<br />
STEM CELL FUNCTION-IMPLICATIONS FOR REPARATIVE STRATEGIES<br />
Emma L. Williams 1,2 , Helmtrud I. Roach 2 , Cyrus Cooper 3,1 , Richard O. Oreffo 2 ,<br />
Christopher J. Edwards 1 ;<br />
1<br />
<strong>Rheumatology</strong> Department, Southampton University Hospitals NHS Trust, Southampton,<br />
United Kingdom; 2 Bone and Joint Group, University of Southampton, Southampton, United<br />
Kingdom; 3 MRC Epidemiology Resource Centre, University of Southampton, Southampton,<br />
United Kingdom<br />
EFFICACY, LONG-TERM EFFECTS AND COMPLICATIONS OF AUTOLOGOUS T CELL DEPLETED<br />
HAEMATOPOIETIC STEM CELL TRANSPLANTATION FOR CHILDREN WITH SEVERE JUVENILE<br />
IDIOPATHIC ARTHRITIS<br />
Mario Abinun 1 , Paul Veys 2 , Joyce Davidson 3 , Eileen Baildam 4 , Taunton Southwood 5 ,<br />
Polly Livermore 6 , Mark Friswell 1 , Amy Rowan 7 , Helen Foster 7 , Lucy Wedderburn 6 ;<br />
1<br />
Newcastle upon Tyne NHS Foundation Trust, Newcastle upon Tyne, United Kingdom; 2 Great<br />
Ormond Street Hospital NHS Trust, London, United Kingdom; 3 Royal Hospital <strong>for</strong> Sick Children,<br />
Yorkhill, Glasgow, United Kingdom; 4 Royal Liverpool Children’s Hospital, Liverpool, United<br />
Kingdom; 5 Birmingham Children’s Hospital NHS Foundation Trust, Birmingham, United Kingdom;<br />
6<br />
Institute of Child Health, University College, London, United Kingdom; 7 Newcastle University,<br />
Newcastle upon Tyne, United Kingdom.<br />
52
Vasculitis<br />
Poster No. 40<br />
Poster No. 41<br />
Poster No. 42<br />
ATYPICAL GIANT CELL ARTERITIS<br />
Sayam R. Dubash, Rob Callaghan;<br />
<strong>Rheumatology</strong>, Nevill Hall Hospital, Gwent NHS Trust, Abergavenny, United Kingdom<br />
CLINICAL PROFILE OF CRYOGLOBULINEMIA IN RHEUMATIC DISEASE<br />
Subha Arthanari, Mohamed Nisar;<br />
Dept of <strong>Rheumatology</strong>, Queen’s Hospital, Burton on Trent, United Kingdom<br />
ARE WE MEETING THE STANDARDS FOR TEMPORAL ARTERY BIOPSY IN<br />
GIANT CELL ARTERITIS?<br />
Anushka Soni 1 , Samantha Cragg 3 , Simon Fung 2 , Brendan McDonald 3 ,<br />
Raashid Luqmani 1 ;<br />
1<br />
<strong>Rheumatology</strong>, Nuffield Orthopaedic Centre, Ox<strong>for</strong>d, United Kingdom; 2 Ophthalmology,<br />
Ox<strong>for</strong>d Eye Hospital, Ox<strong>for</strong>d, United Kingdom; 3 Neuropathology, John Radcliffe Hospital,<br />
Ox<strong>for</strong>d, United Kingdom<br />
Poster Viewing One | Wednesday 29 April 2009<br />
Poster No. 43<br />
WEGENER’S GRANULOMATOSIS PRESENTING AS INTERMENSTRUAL BLEEDING<br />
Sandeep Mukherjee 1 , Wessam Al-Utayem 2 , Lindsey Bergin 2 , John R. Bevan 3 , Richard Hull 1 ;<br />
1<br />
<strong>Rheumatology</strong> Department, Queen Alexandra Hospital, Portsmouth, United Kingdom;<br />
2<br />
Histopathology Department, Queen Alexandra Hospital, Portsmouth, United Kingdom;<br />
3<br />
Gynaecology Department, Queen Alexandra Hospital, Portsmouth, United Kingdom<br />
Poster No. 44<br />
Poster No. 45<br />
Poster No. 46<br />
Poster No. 47<br />
Poster No. 48<br />
WHAT ARE THE EDUCATIONAL NEEDS OF PATIENTS WITH PRIMARY<br />
SYSTEMIC VASCULITIS?<br />
Janice Mooney 1 , Richard Watts 1 , Fiona Poland 1 , Nicola Spalding 1 , David Scott 2 ;<br />
1<br />
School of Social Sciences, University of East Anglia, Norwich, United Kingdom; 2 Department<br />
of <strong>Rheumatology</strong>, Norfolk & Norwich University Hospital, Norwich, United Kingdom<br />
EFFICACY AND TOLERABILITY OF LEFLUNOMIDE IN DIFFICULT-TO-TREAT<br />
POLYMYALGIA RHEUMATICA AND GIANT CELL ARTERITIS: A CASE SERIES<br />
C. Dharmapalaiah, F. Borg, B. Dasgupta;<br />
<strong>Rheumatology</strong>, Southend University Hospital, Westcliff, United Kingdom<br />
GIANT CELL ARTERITIS: AN AUDIT OF EARLY RECOGNITION AND MANAGEMENT<br />
F. Borg, A. Ezeonyegi, W. M. Wong, I. Riaz, T. Gordon, B. Dasgupta;<br />
Southend University Hospital, Westcliff, United Kingdom<br />
TOLERABILITY OF REMISSION-MAINTENANCE AGENTS AFTER INDUCTION THERAPY<br />
IN ANCA ASSOCIATED SYSTEMIC VASCULITIS (AASV)<br />
Maria AL-Deiri 1 , Peter Lanyon 1 , Ellie Sproson 2 , Nick Jones 2 ;<br />
1<br />
<strong>Rheumatology</strong>, Nottingham University Hospitals, Queens Medical Centre Campus,<br />
Nottingham, United Kingdom; 2 Otolaryngology, Nottingham University Hospitals,<br />
Queens Medical Centre Campus, Nottingham, United Kingdom<br />
LONG TERM OUTCOMES OF B CELL DEPLETION IN REFRACTORY VASCULITIS AND<br />
TIMING OF RE-TREATMENT<br />
Ramin Yazdani 1 , Anshul Sama 2 , Nick Jones 2 , Ian Gaywood 1 , Peter Lanyon 1 ;<br />
1<br />
<strong>Rheumatology</strong> Department, Nottingham University Hospitals, Nottingham, United Kingdom;<br />
2<br />
Otololaryngology Department, Nottingham University Hospitals, Nottingham, United Kingdom<br />
53
Poster No. 49<br />
A REGIONAL RETROSPECTIVE AUDIT OF TEMPORAL ARTERY BIOPSIES IN PATIENTS WITH<br />
A CLINICAL DIAGNOSIS OF GIANT CELL ARTERITIS<br />
Tazeen J. Ahmed 1 , Sara Burton 2 , William R. Tucker 2 , Kay M. Garmston 2 ,<br />
Alastair L. Hepburn 3 , Raad M. Makadsi 4 , Sian M. Griffith 4 , Patrick D. Kiely 1 , Mark Lloyd 2 ; 1 St<br />
George’s Hospital, London, United Kingdom; 2 Frimley Park Hospital, Frimley, United Kingdom;<br />
3<br />
Worthing Hospital, Worthing, United Kingdom; 4 East Surrey Hospital, Redhill, United Kingdom<br />
SLE and antiphospholipid syndrome<br />
Poster No. 50<br />
Poster No. 51<br />
AN AUDIT OF CARDIOVASCULAR RISK RECORDING AND REDUCTION IN PATIENTS WITH<br />
SYSTEMIC LUPUS ERYTHEMATOSUS<br />
Frances C. Hall 1 , Christopher See 1 , David Chapireau 1 , Ei Phyu Htut 1 , Lapraik Chloe 2 ,<br />
Diana Chin 1 , Mark Lillicrap 3,1 , Kuntal Chakravarty 4 , Nicholas J. Sheehan 5 , Malcolm Stodell 2 ,<br />
Adam Young 6 ;<br />
1<br />
Department of Clinical Medicine, University of Cambridge, Cambridge, United Kingdom;<br />
2<br />
Department of <strong>Rheumatology</strong>, Luton and Dunstable Hospital, Luton, United Kingdom;<br />
3<br />
Department of <strong>Rheumatology</strong>, Hinchingbrooke Hospital, Huntingdon, United Kingdom;<br />
4<br />
Department of <strong>Rheumatology</strong>, Queen’s Hospital, Rom<strong>for</strong>d, United Kingdom; 5 Department of<br />
<strong>Rheumatology</strong>, Edith Cavell Hospital, Peterborough, United Kingdom; 6 Department of<br />
<strong>Rheumatology</strong>, St Alban’s Hemel NHS Trust, St Alban’s, United Kingdom<br />
ACCULTURATION INDEX AND ITS USE ON PATIENTS’ KNOWLEDGE IN LUPUS DISEASE<br />
Euthalia Roussou 1,2 , Madura Appanna 2 , Khalid Ahmed 3 ;<br />
1<br />
<strong>Rheumatology</strong> & Rehabilitation, King George Hospital, London, United Kingdom;<br />
2<br />
Barts and the London, School of Medicine and Dentistry, London, United Kingdom;<br />
3<br />
<strong>Rheumatology</strong>, Princess Alexandra Hospital, Harlow, United Kingdom<br />
Poster No. 52<br />
Poster No. 53<br />
SYSTEMATIC REVIEW AND META-ANALYSIS OF PREGNANCY OUTCOMES<br />
IN LUPUS NEPHRITIS<br />
Charlotte Ford, Cordelia Coltart, David Williams, Ian Giles;<br />
<strong>Rheumatology</strong>, University College London and Institute <strong>for</strong> Women’s Health,<br />
London, United Kingdom<br />
PREMATURE ATHEROSCLEROSIS IN THROMBOTIC PRIMARY ANTIPHOSPHOLIPID<br />
SYNDROME<br />
Paul R. Ames 1 , Iole Antinolfi 2 , Giovanna Scenna 2 , Giovanni Gaeta 2 , Annamaria Margarita 2 ,<br />
Maurizio Margaglione 3 ;<br />
1<br />
Royal Preston Hospital, Preston, United Kingdom; 2 Cardarelli Hospital, Naples, Italy;<br />
3<br />
Foggia University, Foggia, Italy<br />
Poster No. 54<br />
AN ANALYSIS OF THE CAUSES AND OUTCOME OF PATIENTS WITH LUPUS<br />
REQUIRING TOTAL JOINT REPLACEMENT<br />
Ana F. Mourão 1,2 , Marta Amaral 1,3 , David Isenberg 1 ;<br />
1<br />
<strong>Rheumatology</strong>, Centre For <strong>Rheumatology</strong>, Department of Medicine, University College of<br />
London Hospital, London, United Kingdom., London, United Kingdom; 2 <strong>Rheumatology</strong>,<br />
<strong>Rheumatology</strong> Department, Centro Hospitalar de Lisboa Ocidental, Hospital Egas Moniz, EPE,<br />
Lisbon, Portugal., Lisbon, Portugal; 3 Internal Medicine, Autoimmune Diseases Unit, Internal<br />
Medicine Department, Hospital de Curry Cabral, Lisbon, Portugal, Lisbon, Portugal<br />
54
Poster No. 55<br />
Poster No. 56<br />
SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS WITH HYPERMOBILITY SYNDROME<br />
EXPERIENCE HIGHER LEVELS OF CHRONIC PAIN THAN THOSE WITHOUT JOINT<br />
HYPERMOBILITY<br />
Helen E. Harris 1 , Jane Gibson 1 , Adele Osborne 1 , David Chinn 2 , Hazem Youssef 3 ;<br />
1<br />
<strong>Rheumatology</strong>, NHS Fife, Kirkaldy, United Kingdom; 2 Research and Development, NHS Fife,<br />
Kirkaldy, United Kingdom; 3 <strong>Rheumatology</strong>, University of Aberdeen, Aberdeen, United Kingdom<br />
DELAY TO DIAGNOSIS IN JUVENILE SLE (JSLE) PATIENTS: PRELIMINARY DATA<br />
FROM THE UK JSLE COHORT STUDY<br />
Clare Pain 2 , Janet Gardner-Medwin 3 , Janet McDonagh 4 , Clarissa Pilkington 5 ,<br />
Rangaraj Satyapal 6 , Jane Tizard 8 , Nick Wilkinson 7 , Michael W. Beres<strong>for</strong>d 1 ;<br />
1<br />
Institute of Child Health, University of Liverpool, Liverpool, United Kingdom; 2 Department of<br />
<strong>Rheumatology</strong>, Alder Hey Children’s NHS Foundation Trust, Liverpool, United Kingdom;<br />
3<br />
Department of <strong>Rheumatology</strong>, Royal Hospital <strong>for</strong> Sick Children, Glasgow, United Kingdom;<br />
4<br />
Department of <strong>Rheumatology</strong>, Birmingham Children’s Hospital, Birmingham, United<br />
Kingdom; 5 Department of <strong>Rheumatology</strong>, Great Ormond Street Hospital, London, United<br />
Kingdom; 6 Department of <strong>Rheumatology</strong>, Queen’s Medical Centre, Nottingham, United<br />
Kingdom; 7 Department of <strong>Rheumatology</strong>, Nuffield Orthopaedic Centre, Ox<strong>for</strong>d, United<br />
Kingdom; 8 Department of Nephrology, Bristol Royal Hospital <strong>for</strong> Children, Bristol, United<br />
Kingdom<br />
Poster Viewing One | Wednesday 29 April 2009<br />
Poster No. 57<br />
Poster No. 58<br />
Poster No. 59<br />
Poster No. 60<br />
SYSTEMIC LUPUS ERYTHEMATOSUS: CONCORDANCE AND ACCURACY OF<br />
PATIENT AND PHYSICIAN EXPECTATIONS OF PHYSICAL FUNCTIONING<br />
Sophie Cleanthous 1 , Debbie Cooke 1 , Shashi Hirani 1 , Adrienne Kirk 1 , David Isenberg 2 ,<br />
Stanton Newman 1 ;<br />
1<br />
Unit of Behavioural Medicine, Division of Research Strategy, University College London,<br />
London, United Kingdom; 2 Centre <strong>for</strong> <strong>Rheumatology</strong> Research, Division of Medicine,<br />
University College London, London, United Kingdom<br />
FUNCTIONAL ABNORMALITIES OF MYELOID DENDRITIC CELLS IN SYSTEMIC<br />
LUPUS ERYTHEMATOSUS<br />
Chak S. Lau 1,2 , Ou Jin 2 , Sushma Kavikondala 2 , Mo Y. Mok 2 , Albert Chan 2 , Joseph Yeung 2 ;<br />
1<br />
Medicine, University of Dundee, Dundee, United Kingdom; 2 Medicine, University of Hong<br />
Kong, Hong Kong, China<br />
CLINICAL EXPERIENCE WITH ETANERCEPT IN SYSTEMIC LUPUS ERYTHEMATOSUS<br />
PATIENTS<br />
Inmaculada de la Torre Ortega, Francisco Javier López-Longo, Indalecio Monteagudo,<br />
Carlos Manuel González, Luis Carreño;<br />
<strong>Rheumatology</strong>, Gregorio Marañón Hospital, Madrid, Spain<br />
DYSLIPIDAEMIA IN SLE IS COMMON AND PARTICULARLY PRONOUNCED IN<br />
THE QUIESCENT PHASE OF DISEASE<br />
Sahena Haque 1 , Yasmeen Ahmad 2 , Valentine Charlton-Menys 3 , Paul N. Durrington 3 ,<br />
Bruce N. Ian 1 ;<br />
1<br />
arc Epidemiology Unit, University of Manchester, Manchester, United Kingdom; 2 Department<br />
of <strong>Rheumatology</strong>, Llandudno General Hospital, Llandudno, United Kingdom; 3 Cardiovascular<br />
Medicine, University of Manchester, Manchester, United Kingdom<br />
55
Poster No. 61<br />
Poster No. 62<br />
THE PODOCYTE IN LUPUS NEPHRITIS - HOW DO PATHOGENIC AUTOANTIBODIES EXERT<br />
THEIR EFFECT?<br />
Jessica J. Manson 1 , Elizabeth Jury 1 , Kevin Mills 2 , David A. Isenberg 1 , Anisur Rahman 1 ; 1 Centre<br />
<strong>for</strong> <strong>Rheumatology</strong> Research, University College London, London, United Kingdom; 2 Clinical<br />
and Molecular Genetics, Institute of Child Health, University College London, London,<br />
United Kingdom<br />
DIFFERENCES IN APOPTOSIS GENE EXPRESSION IN LYMPHOCYTES FROM SYSTEMIC<br />
LUPUS ERYTHEMATOSUS (SLE) AND RHEUMATOID ARTHRITIS (RA) PATIENTS<br />
Paul Eggleton 1 , Richard Haigh 2 , Nick Viner 3 , Suzanne Donnelly 4 , Lorna W. Harries 1 ,<br />
Giada Alberigo 1 , Paul G. Winyard 1 ;<br />
1<br />
Biomedical and Clinical Science, Peninsula College of Medicine and Dentistry, Exeter, United<br />
Kingdom; 2 <strong>Rheumatology</strong>, Royal Devon and Exeter Foundation Trust, Exeter, United Kingdom;<br />
3<br />
<strong>Rheumatology</strong>, Torbay Hospital, Torquay, United Kingdom; 4 <strong>Rheumatology</strong>, Mater Misericordiae<br />
Hospital, Dublin, Ireland<br />
Poster No. 63<br />
STATINS AND HYDROXYCHLOROQUINE CAN PREVENT THE PROCOAGULANT/<br />
THROMBOGENIC PROPERTIES OF ANTIPHOSPHOLIPID ANTIBODIES IN MONOCYTES<br />
Anastasia Lambrianides 1 , Silvia Pierangeli 2 , David Latchman 1 , David Isenberg 1 ,<br />
Anisur Rahman 1 , Ian Giles 1 ;<br />
1<br />
University College London, London, United Kingdom; 2 University of Texas, Galveston, TX<br />
Poster No. 64<br />
Poster No. 65<br />
RITUXIMAB IN CUTANEOUS LUPUS: RESPONSIVENESS DEPENDS ON PATTERN<br />
OF SKIN INVOLVEMENT<br />
Edward M. Vital 1 , Shouvik Dass 1 , Olabambo Ogunbambi 1 , Mark Goodfield 2 , Paul Emery 1 ;<br />
1<br />
Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine,University of Leeds,<br />
Leeds, United Kingdom; 2 Department of Dermatology, Leeds Teaching Hospitals NHS Trust,<br />
Leeds, United Kingdom<br />
RITUXIMAB IN SLE: HIGHLY SENSITIVE FLOW CYTOMETRY ALLOWS EARLY PREDICTION OF<br />
NON-RESPONSE AND RELAPSE<br />
Edward M. Vital 1 , Shouvik Dass 1 , Michael F. Martin 1 , Colin T. Pease 1 , Andrew C. Rawstron 2 ,<br />
Paul Emery 1 ;<br />
1<br />
Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine,University of Leeds,<br />
Leeds, United Kingdom; 2 Haematological Malignancy Diagnostic Service, Leeds Teaching<br />
Hospitals NHS Trust, Leeds, United Kingdom<br />
Poster No. 66<br />
PLASMACYTOID DENDRITIC CELLS IN SYSTEMIC LUPUS ERYTHEMATOSUS<br />
Chak S. Lau 1,2 , Ou Jin 2 , Sushma Kavikondala 2 , Mo Y. Mok 2 , Albert W. Chan 2 , Joseph Yeung 2 ;<br />
1<br />
Medicine, University of Dundee, Dundee, United Kingdom; 2 Medicine, University of Hong Kong,<br />
Hong Kong, China<br />
Spondylarthropathies (including psoriatic arthritis)<br />
Poster No. 67<br />
THE BENEFITS OF INTENSIVE EXERCISE AND EDUCATION FOR ANKYLOSING SPONDYLITIS:<br />
A QUANTITATIVE AND QUALITATIVE ANALYSIS<br />
Emma Carroll 1 , Tara Cusack 1 , Rose Galvin 2 , Breon White 3 , Anne-Marie Keown 3 ;<br />
1<br />
UCD School of Physiotherapy and Per<strong>for</strong>mance Science, University College Dublin, Dublin,<br />
Ireland; 2 School of Physiotherapy, Trinity College Dublin, Dublin, Ireland; 3 Department of<br />
Physiotherapy, Mater Misericordiae University Hospital, Dublin, Ireland<br />
56
Poster No. 68<br />
Poster No. 69<br />
Poster No. 70<br />
PARADOXICAL ADVERSE EVENTS OF ANTI-TUMOR NECROSIS FACTOR<br />
THERAPIES DURING SPONDYLARTHROPATHIES<br />
Vincent Goeb 1 , Damien Fouache 2 , Nathalie Massy-Guillemant 2 , Gilles Avenel 1 ,<br />
Macha Kozyreff-Meurice 1 , Alain Daragon 1 , Xavier Le Loet 1 , Jean-Francois Menard 1 ,<br />
Catherine Tharasse 2 , Olivier Vittecoq 1 ;<br />
1<br />
<strong>Rheumatology</strong>, University Hospital, Rouen, France; 2 Pharmacy, University Hospital,<br />
Rouen, France<br />
PROTOTYPE FINGER COIL FOR THE STUDY OF NAIL UNIT IN PSORIATIC ARTHRITIS<br />
PATIENTS USING A LOW FIELD MRI<br />
Ernesto Soscia 4 , Mariangela Atteno 1 , Luisa Costa 1 , Rosario Peluso 1 , Salvatore Iervolino 1 ,<br />
Francesco Caso 1 , Luigi Satragno 3 , Marco A. Cimmino 2 , A. Del Puente 1 , Raffaele Scarpa 1 ;<br />
1<br />
Dpt of Clinical and Experimental Medicine, University Federico II, Naples, Italy;<br />
2<br />
<strong>Rheumatology</strong> Unit, University of Genoa, Genoa, Italy; 3 ESAOTE, Genoa, Italy;<br />
4<br />
Radiology Unit, University Federico II, Naples, Italy<br />
ANTIBIOTICS TREATMENT OF REACTIVE ARTHRITIS: A SYSTEMATIC REVIEW OF<br />
THE LITERATURE<br />
Helen Linklater, Ernest Choy;<br />
Department of <strong>Rheumatology</strong>, Kings College Hospital, Denmark Hill, London, United Kingdom<br />
Poster Viewing One | Wednesday 29 April 2009<br />
Poster No. 71<br />
Poster No. 72<br />
Poster No. 73<br />
Poster No. 74<br />
FREQUENCY AND PREDICTORS OF MINIMAL DISEASE ACTIVITY IN AN OBSERVATIONAL<br />
PSA COHORT<br />
Laura C. Coates 1 , Catherine T. Schentag 2 , Ker-Ai Lee 3 , Vinod Chandran 2 , Richard J. Cook 3 ,<br />
Dafna D. Gladman 2 ;<br />
1<br />
Academic Section of MSK Disease, University of Leeds, Leeds, United Kingdom; 2 Toronto<br />
Western Hospital, University Health Network, Toronto, ON, Canada; 3 University of Waterloo,<br />
Waterloo, ON, Canada<br />
AN EXPLORATORY STUDY OF FATIGUE IN ANKYLOSING SPONDYLITIS PATIENTS<br />
Julie Barlow 1 , Lorraine McFarland 1 , Jaya Ravindaran 2 , Philip Perkins 2 ;<br />
1<br />
Self-management <strong>Programme</strong>, Coventry University, Coventry, United Kingdom;<br />
2<br />
<strong>Rheumatology</strong> Department, University Hospitals Coventry & Warwickshire, Coventry,<br />
United Kingdom<br />
PHYSICAL THERAPY IN ANKYLOSING SPONDYLITIS<br />
Shirish Dubey 1 , Jane Leeder 2 , Alison Gibb 2 , Karl Gaffney 2 ;<br />
1<br />
Heart of England NHS Trust, Solihull, United Kingdom; 2 Norfolk and Norwich University<br />
Hospital, Norwich, United Kingdom<br />
A RANDOMISED, CONTROLLED TRIAL OF INTRA-ARTICULAR STEROID INJECTIONS<br />
FOR SACROILIAC JOINT (SIJ) PAIN IN SPONDYLOARTHRITIS PATIENTS<br />
Sreekanth Vasireddy 2 , Chandini Rao 3 , Hazel Miller 1 , C. Chattopadhyay 1 ;<br />
1<br />
Dept of <strong>Rheumatology</strong>, Wrightington Hospital, Wigan, United Kingdom;<br />
2<br />
Dept of <strong>Rheumatology</strong>, Bolton PCT, Bolton, United Kingdom; 3 Dept of <strong>Rheumatology</strong>,<br />
Blackpool Victoria Hospital, Blackpool, United Kingdom<br />
57
Poster No. 75<br />
Poster No. 76<br />
Poster No. 77<br />
Poster No. 78<br />
Poster No. 79<br />
Poster No. 80<br />
Poster No. 81<br />
EDUCATION FOR PEOPLE WITH ANKYLOSING SPONDYLITIS: CURRENT PRACTICE IN THE UK<br />
Ben Thompson 1 , Tim J. Rapley 2 , Wendy Broderick 3 , Carl R. May 2 , Lesley J. Kay 1 ;<br />
1<br />
Newcastle Musculoskeletal Research Group, Newcastle University, Newcastle-upon-Tyne,<br />
United Kingdom; 2 Institute of Health and <strong>Society</strong>, Newcastle University, Newcastle-upon-Tyne,<br />
United Kingdom; 3 National Ankylosing Spondylitis <strong>Society</strong> (NASS), Tyne and Wear Branch,<br />
United Kingdom<br />
ACHIEVING MINIMAL DISEASE ACTIVITY (MDA) CRITERIA DECREASES PROGRESSION OF<br />
JOINT DAMAGE IN PSORIATIC ARTHRITIS<br />
Laura C. Coates 1 , Catherine T. Schentag 2 , Ker-Ai Lee 3 , Vinod Chandran 2 , Richard J. Cook 3 ,<br />
Dafna D. Gladman 2 ;<br />
1<br />
Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds,<br />
Leeds, United Kingdom; 2 Centre <strong>for</strong> Prognosis Studies in the Rheumatic Diseases, Toronto<br />
Western Hospital, Toronto, ON, Canada; 3 Statistics and Actuarial Science, University of<br />
Waterloo, Waterloo, ON, Canada<br />
A REGIONAL AUDIT OF COMPLIANCE WITH NICE TA 104 AND 125 IN PSORIATIC ARTHRITIS<br />
Maria Juarez 1 , William Tillett 3 , Robert Marshall 2 , Sandra Green 3 , Elizabeth Price 1 ,<br />
Lyn Williamson 1 , David Collins 1 ;<br />
1<br />
<strong>Rheumatology</strong>, Great Western Hospital, Swindon, United Kingdom; 2 <strong>Rheumatology</strong>, University<br />
Hospitals Bristol, Bristol, United Kingdom; 3 <strong>Rheumatology</strong>, Weston General Hospital, Weston<br />
super Mare, United Kingdom<br />
REFINING THE GENETIC ASSOCIATION BETWEEN ANKYLOSING SPODYLITIS AND ERAP1<br />
David Harvey 1 , Jennifer J. Pointon 1 , Claire Farrar 1 , Louise A. Appleton 1 , Udo Oppermann 2 ,<br />
Matthew A. Brown 1,3 , Bryan P. Wordsworth 1 ;<br />
1<br />
Botnar Research Centre, Ox<strong>for</strong>d, United Kingdom; 2 Structural Genomics Consortium, Ox<strong>for</strong>d,<br />
United Kingdom; 3 Diamantina Institute of Cancer, Brisbane, QLD, Australia<br />
TH17 T CELLS IN ANKYLOSING SPONDYLITIS ARE POLYFUNCTIONAL AND EXPRESS HIGH<br />
LEVELS OF THE CHEMOKINE RECEPTOR CCR6<br />
Paul Bowness 1,2 , Jacqueline Shaw 1 , Kirsty McHugh 1 , Joanna Giles 1 , Simon Kollnberger 1 ;<br />
1<br />
MRC Human Immunology Unit, Weatherall Institute <strong>for</strong> Molecular Medicine, John Radcliffe<br />
Hospital, Ox<strong>for</strong>d, United Kingdom; 2 Dept. <strong>Rheumatology</strong>, Nuffield Orthopaedic Centre NHS Trust,<br />
Ox<strong>for</strong>d, United Kingdom<br />
INTIMA MEDIA WALL THICKNESS (a-IMT) IS INCREASED IN PATIENTS WITH PSORIATIC<br />
ARTHRITIS<br />
Rosario Peluso, Luisa Costa, Francesco Caso, Mariangela Atteno, Salvatore Iervolino,<br />
Antonio Del Puente, Raffaele Scarpa;<br />
Clinical and Experimental Medicine - <strong>Rheumatology</strong> Unit, University Federico II, Naples, Italy<br />
CANDIDATE GENES FOR ANKYLOSING SPONDYLITIS<br />
Jennifer J. Pointon 1 , Tugce Karaderi 1 , Louise H. Appleton 1 , David Harvey 1 , Claire Farrar 1 ,<br />
Wellcome Trust Case Control Consortium 2 , Matthew A. Brown 3 , Bryan P. Wordsworth 1 ;<br />
1<br />
Nuffield Department of Orthopaedic Surgery, Ox<strong>for</strong>d University, Ox<strong>for</strong>d, United Kingdom;<br />
2<br />
Wellcome Trust Case Control Consortium, Hinxton, Cambridge, United Kingdom;<br />
3<br />
Diamantina Institute of Cancer, Immunology and Metabolic Medicine, University of Queensland,<br />
Brisbane, QLD, Australia<br />
58
Poster No. 82<br />
Poster No. 83<br />
Poster No. 84<br />
A REGION ON CHROMOSOME 16 ASSOCIATED WITH ANKYLOSING SPONDYLITIS<br />
Jennifer J. Pointon 1 , David Harvey 1 , Tugce Karaderi 1 , Louise H. Appleton 1 , Claire Farrar 1 ,<br />
Wellcome Trust Case Control Consortium 2 , Matthew A. Brown 3 , Bryan P. Wordsworth 1 ;<br />
1<br />
Nuffield Department of Orthopaedic Surgery, Ox<strong>for</strong>d University, Ox<strong>for</strong>d, United Kingdom;<br />
2<br />
Wellcome Trust Case Control Consortium, Hinxton, Cambridge, United Kingdom; 3 Diamantina<br />
Institute <strong>for</strong> Cancer, Immunology and Metabolic Medicine, University of Queensland,<br />
Brisbane, QLD, Australia<br />
PATELLAR TENDON PROPERTIES AND LOWER LIMB FUNCTION IN RHEUMATOID ARTHRITIS<br />
AND ANKYLOSING SPONDYLITIS<br />
Verena Matschke 1,2 , Andrew B. Lemmey 1 , Jeremy G. Jones 1,2 , Peter J. Maddison 1,2 ,<br />
Jeanette M. Thom 1 ;<br />
1<br />
School of Sport, Health and Exercise Sciences, University of Bangor, Bangor, United<br />
Kingdom; 2 Department of <strong>Rheumatology</strong>, Gwynedd Hospital, North West Wales NHS Trust,<br />
Bangor, United Kingdom<br />
MORTALITY IN PSORIATIC ARTHRITIS - A UK PERSPECTIVE<br />
Caitriona Buckley 1 , Charlotte Cavill 1 , Gordon Taylor 2 , Hazel Kay 2 , Nicola Waldron 1 ,<br />
Eleanor Korendowych 1 , Neil McHugh 1 ;<br />
1<br />
<strong>Rheumatology</strong> Department, Royal National Hospital <strong>for</strong> Rheumatic Diseases, Bath,<br />
United Kingdom; 2 Research and Development Support Unit, University of Bath, Bath,<br />
United Kingdom<br />
Poster Viewing One | Wednesday 29 April 2009<br />
Poster No. 85<br />
ASSESSMENT OF CLINICAL EFFICACY IN A RANDOMIZED, DOUBLE-BLIND STUDY OF<br />
ETANERCEPT AND SULPHASALAZINE IN PATIENTS WITH ANKYLOSING SPONDYLITIS<br />
Irene E. van der Horst-Bruinsma 1 , Jurgen Braun 2 , Feng Huang 3 , Ruben Burgos-Vargas 4 ,<br />
Bruce Freundlich 5 , Bonnie Vlahos 5 , Andrew S. Koenig 5 ;<br />
1<br />
Department of <strong>Rheumatology</strong>, VU University Medical Center, Amsterdam, Netherlands;<br />
2<br />
<strong>Rheumatology</strong> Medical Center, Ruhrgebeit, Herne, Ruhr-University, Bochum, Germany;<br />
3<br />
Department of <strong>Rheumatology</strong>, Chinese Liberation Army General Hospital, Beijing, China;<br />
4<br />
Hospital General de México and, Universidad Nacional Autónoma de México, Mexico City,<br />
Mexico; 5Global Medical Affairs, Wyeth Research, Collegeville, PA<br />
Poster No. 86<br />
“PITFALLS FOR THE DETECTION OF SACROILIITIS BY MR IMAGING IN A DGH SETTING”.<br />
(RESULTS FROM AN AUDIT)<br />
Euthalia Roussou 1 , Anne Grethe Jurik 3 , Reuben Obaro 2 ;<br />
1<br />
<strong>Rheumatology</strong> and Rehabilitation, King George Hospital Barking Havering and Redbridge<br />
NHS Trust, London, United Kingdom; 2 Radiology, King George Hospital Barking Havering and<br />
Redbridge NHS Trust, London, United Kingdom; 3 Department of <strong>Rheumatology</strong>, Aarchus<br />
University Hospital, Aarchus, Denmark<br />
Poster No. 87<br />
TREATMENT OF DMARD RESISTANT KNEE MONOARTHRITIS WITH REPEATED COURSES<br />
OF INTRA-ARTICULAR INFLIXIMAB: AN OBSERVATIONAL STUDY WITH CLINICAL AND<br />
ULTRASOUND MEASURES<br />
Sarah J. Levy 1 , Oliver Wignall 2 , Christine Heron 2 , James Pilcher 2 , Patrick D. Kiely 1 ;<br />
1<br />
<strong>Rheumatology</strong>, St Georges Healthcare NHS Trust, London, United Kingdom;<br />
2<br />
Radiology, St Georges Healthcare NHS Trust, London, United Kingdom<br />
59
Poster No. 88<br />
HIGHLY EFFECTIVE TREATMENT WITH ADALIMUMAB IN PATIENTS WITH ANKYLOSING<br />
SPONDYLITIS (AS) WITH ADVANCED SPINAL FUSION<br />
Millicent Stone 2 , Martin Rudwaleit 1 , Juan Carlos Torre-Alonso 3 , Wolfgang Spieler 4 , Robert Wong 5 ,<br />
Martina Kron 6 , Sonja Kary 6 , Hartmut Kupper 6 ;<br />
1<br />
Campus Benjamin Franklin, Charité-University Medicine Berlin, Berlin, Germany; 2 Bath Institute<br />
<strong>for</strong> Rheumatic Diseases, Bath, United Kingdom; 3 Hospital Monte Naranco, Oviedo, Spain;<br />
4<br />
Rheumatologische Schwerpunktpraxis, Zerbst, Germany; 5 Abbott Laboratories, Parsippany, NJ;<br />
6<br />
Abbott GmbH & Co KG, Ludwigshafen, Germany<br />
Poster No. 89<br />
PATIENTS WITH PSORIATIC ARTHRITIS (PsA) TREATED WITH ADALIMUMAB ACHIEVED CLINI-<br />
CAL REMISSION AND GOOD CLINICAL RESPONSES IN THE STEREO TRIAL<br />
Richard Reece 5 , Filip Van den Bosch 1 , Bernhard Manger 2 , Philippe Goupille 3 , Martina Kron 4 ,<br />
Sonja Kary 4 , Hartmut Kupper 4 ;<br />
1<br />
University Hospital, Ghent, Belgium; 2 Universität Erlangen/Nürnberg, Erlangen, Germany;<br />
3<br />
University Hospital, Tours, France; 4 Abbott GmbH & Co KG, Ludwigshafen, Germany;<br />
5<br />
Calderdale and Huddersfield NHS Foundation Trust, Leeds, United Kingdom<br />
Poster No. 90<br />
Poster No. 91<br />
Poster No. 92<br />
Poster No. 93<br />
CLINICAL RESPONSE AND PARTIAL REMISSION SUSTAINED THROUGH 3 YEARS OF<br />
ADALIMUMAB TREATMENT IN THE ATLAS TRIAL<br />
P. Wordsworth 6 , D. van der Heijde 1 , B. A. Dijkmans 2 , M. H. Schiff 3 , A. Kivitz 4 , K. de Vlam 5 ,<br />
S. Ballal 7 , H. Kupper 8 , R. L. Wong 7 , J. Sieper 9 ;<br />
1<br />
Leiden University Medical Center, Leiden, Netherlands; 2 VU Medical Centre and the Jan van<br />
Breeman Institute, Amsterdam, Netherlands; 3 University of Colorado, Denver, CO; 4 Altoona<br />
Center <strong>for</strong> Clinical Research, Duncansville, PA; 5 KU Leuven, Leuven, Belgium; 6 Nuffield<br />
Orthopaediatric Centre, Ox<strong>for</strong>d, United Kingdom; 7 Abbott Laboratories, Parsippany, NJ; 8 Abbott<br />
GmbH & Co KG, Ludwigshafen, Germany; 9 Charite Universitätsmedizin Berlin, Berlin, Germany<br />
IMPROVEMENT IN LONG-TERM SPINAL MOBILITY IN PATIENTS WITH ANKYLOSING<br />
SPONDYLITIS (AS) IS SUSTAINED DURING UP TO 3 YEARS OF ADALIMUMAB TREATMENT:<br />
3-YEAR ATLAS RESULTS<br />
D. G. Scott 9 , D. van der Heijde 1 , M. H. Schiff 2 , J. Sieper 3 , A. Kivitz 4 , B. A. Dijkmans 5 ,<br />
P. J. Mease 6 , H. Kupper 7 , S. Ballal 8 , R. L. Wong 8 ;<br />
1<br />
Leiden University Medical Center, Leiden, Netherlands; 2 University of Colorado, Denver, CO;<br />
3<br />
Charité Berlin, Berlin, Germany; 4 Altoona Center <strong>for</strong> Clinical Research, Duncansville, PA; 5 VU<br />
University Medical Center and the Jan van Breemen Institute, Amsterdam, Netherlands; 6 Seattle<br />
<strong>Rheumatology</strong> Associates, Seattle, WA; 7 Abbott GmbH & Co KG, Ludwigshafen, Germany;<br />
8<br />
Abbott Laboratories, Parsippany, NJ; 9 Norfolk and Norwich University Hospital, Norfolk,<br />
United Kingdom<br />
IN PATIENTS WITH PSORIATIC ARTHRITIS RECEIVING ADALIMUMAB, IMPROVEMENT IN<br />
PSORIASIS IS ASSOCIATED WITH LONG-TERM INHIBITION OF RADIOGRAPHIC<br />
PROGRESSION<br />
E. Choy 1 , D. Gladman 2 , P. J. Mease 3 , C. Ritchlin 4 , M. Olds 5 , R. L. Wong 6 , S. Wang 5 , J. Medich 6 ;<br />
1<br />
King’s College, London, United Kingdom; 2 University of Toronto, Toronto, ON, Canada; 3 Seattle<br />
<strong>Rheumatology</strong>, Seattle, WA; 4 University of Rochester, Rochester, NY; 5 Abbott Laboratories,<br />
Abbott Park, IL; 6 Abbott Laboratories, Parsippany, NJ<br />
DEVELOPMENT OF A COMPOSITE DISEASE ACTIVITY SCORE IN PSORIATIC ARTHRITIS<br />
Aizad Mumtaz 1 , Phil Gallagher 1 , Brian Kirby 2 , Laura C Coates 3 , Robin Waxman 3 , Philip Helliwell 3 ,<br />
Oliver FitzGerald 1 ;<br />
1<br />
<strong>Rheumatology</strong>, St Vincents University Hospital, Dublin, Ireland; 2 Dermatology, St Vincents<br />
University Hospital, Dublin, Ireland; 3 <strong>Rheumatology</strong>, University Of Leeds, Leeds, United Kingdom<br />
60
Poster No. 94<br />
Poster No. 95<br />
GOLIMUMAB, A NEW, HUMAN, TNFα ANTIBODY, IN ANKYLOSING SPONDYLITIS<br />
(AS): 24-WEEK EFFICACY AND SAFETY RESULTS OF THE GO-RAISE STUDY<br />
Jurgen Braun 1 , John Davis 2 , Desiree van der Heijde 3 , Atul Deodhar 4 , Laura Diekman 5 ,<br />
Joachim Sieper 6 , Sung Il Kim 7 , John Han 8 , B. Hsu 8 , Robert Inman 9 , <strong>for</strong> the GO-RAISE<br />
Study Investigators 8 ;<br />
1<br />
Rheumazentrum Ruhrgebiet, Herne, Germany; 2 University of Cali<strong>for</strong>nia, San Francisco, CA;<br />
3<br />
Leiden University Medical Center, Leiden, Netherlands; 4 Oregon Health and Science<br />
University, Portland, OR; 5 University of Texas-Houston, Houston, TX; 6 Charite Hospital, Berlin,<br />
Germany; 7 Pusan National University Hospital, Busan, Korea, South; 8 Centocor Research and<br />
Development, Inc, Malvern, PA; 9 University of Toronto, Toronto, ON, Canada<br />
REVIEW OF PSORIATIC ARTHRITIS IN THE WEST MIDLANDS: ELIGIBILITY FOR<br />
ANTI-TUMOUR NECROSIS FACTOR THERAPY UNDER THE NICE GUIDELINES<br />
James Bateman 1 , Caroline M. Cardy 2 , Sophia Y. Khan 3 , Ajit Menon 4 , Karen Obrenovic 5 ,<br />
Ian F. Rowe 6 , Nicola Erb 3 ;<br />
1<br />
Department of <strong>Rheumatology</strong>, University Hospital Coventry and Warwickshire, Coventry,<br />
United Kingdom; 2 Department of <strong>Rheumatology</strong>, Here<strong>for</strong>d Hospital NHS Trust, Here<strong>for</strong>d,<br />
United Kingdom; 3 Department of <strong>Rheumatology</strong>, Dudley Group of Hospitals NHS Trust,<br />
Birmingham, United Kingdom; 4 Department of <strong>Rheumatology</strong>, University Hospital of North<br />
Staf<strong>for</strong>dshire NHS Trust, Birmingham, United Kingdom; 5 Department of Clinical Audit, Dudley<br />
Group of Hospitals NHS Trust, Worcester, United Kingdom; 6 Department of <strong>Rheumatology</strong>,<br />
Worcestershire Royal Hospital NHS Trust, Worcester, United Kingdom<br />
Poster Viewing One | Wednesday 29 April 2009<br />
Poster No. 96<br />
IN PATIENTS WITH ANKYLOSING SPONDYLITIS (AS), ADALIMUMAB IMPROVES<br />
INFLAMMATORY BOWEL DISEASE (IBD) AND PSORIASIS (Ps) AND PREVENTS<br />
ANTERIOR UVEITIS (AU) FLARES<br />
Paul Wordsworth 4 , Martin Rudwaleit 1 , Pascal Claudepierre 2 , Eduardo Loza 3 ,<br />
Ignazio Olivieri 5 , Robert L. Wong 6 , Uemit Oezer 7 , Sonja Kary 7 , Hartmut Kupper 7 ;<br />
1<br />
Charité Universitätsmedizin Berlin, Berlin, Germany; 2 Hopital Universitaire Créteil-Paris XII,<br />
Créteil, France; 3 Hospital de Navarra, Pamplona, Spain; 4 Nuffield Orthopaedic Centre, Ox<strong>for</strong>d,<br />
United Kingdom; 5 Ospedale San Carlo di Potenza, Potenza, Italy; 6 Abbott, Parsippany, NJ;<br />
7<br />
Abbott GmbH & Co KG, Ludwigshafen, Germany<br />
Poster No. 97<br />
GOLIMUMAB ADMINISTERED EVERY FOUR WEEKS AS A SUBCUTANEOUS INJECTION IN<br />
PSORIATIC ARTHRITIS: NAIL, ENTHESITIS, AND DACTYLITIS RESPONSE IN THE<br />
RANDOMIZED, PLACEBO-CONTROLLED, GO-REVEAL STUDY<br />
Iain McInnes 1 , Dafna Gladman 2 , Arthur Kavanaugh 3 , Philip Mease 4 , Juan Gomez-Reino 5 ,<br />
Kim Papp 6 , Julie Zrubek 7 , Surekha Mudivarthy 7 , Anna Beutler 7 , Gerald Krueger 8 ;<br />
1<br />
University of Glasgow, Glasgow, United Kingdom; 2 University of Toronto, Toronto, ON, Canada;<br />
3<br />
University of Cali<strong>for</strong>nia, San Diego, CA; 4 Swedish Medical Center and Seattle <strong>Rheumatology</strong><br />
Associates, Seattle, WA; 5 Hospital Clinico Universitaire, Santiago, Spain; 6 Probity Medical<br />
Research, Waterloo, ON, Canada; 7 Centocor Research and Development, Inc., Malvern, PA;<br />
8<br />
University of Utah, Salt Lake City, UT<br />
Rheumatoid arthritis - treatment<br />
Poster No. 98<br />
WHY IS BIOLOGIC THERAPY NOT PRESCRIBED IN PATIENTS WITH RHEUMATOID<br />
ARTHRITIS AND A HIGH DISEASE ACTIVITY SCORE?: EXPLORATION OF REASONS FROM<br />
A 5 YEAR PROSPECTIVE STUDY (MASCOT)<br />
Rosie Hampson, Lucy Wait, Ann Tierney, Rajan Madhok, Hilary Capell;<br />
Centre <strong>for</strong> Rheumatic Diseases, Royal Infirmary, Glasgow, United Kingdom<br />
61
Poster No. 99<br />
Poster No. 100<br />
Poster No. 101<br />
SUBCUTANEOUS METHOTREXATE IS SUPERIOR TO ORAL METHOTREXATE IN<br />
THE TREATMENT OF RHEUMATOID ARTHRITIS<br />
Beena Hameed, Kate Hunt, Hugh Jones;<br />
<strong>Rheumatology</strong>, Kingston Hospital, Kingston Upon Thames, United Kingdom<br />
CAN STANDARD 5 OF THE 2005 BSR GUIDANCE ON RA CARE BE ACHIEVED<br />
WITH A SINGLE 12 MONTHLY REVIEW?<br />
Jo Reed, Ruth Slack, David O’Reilly;<br />
<strong>Rheumatology</strong>, West Suffolk Hospital, Bury St Edmunds, United Kingdom<br />
AN AUDIT OF CARDIOVASCULAR RISK RECORDING AND REDUCTION IN<br />
PATIENTS WITH RHEUMATOID ARTHRITIS<br />
Frances C. Hall 1 , David Chapireau 1 , Christopher See 1 , Chloe Lapraik 2 , Anne Meadows 3 ,<br />
Gillian Pountain 4 , Kuntal Chakravarty 5 , Nicholas J. Sheehan 3 , Adam Young 6 , Richard Watts 8 ,<br />
David O’Reilly 7 ;<br />
1<br />
Department of Clinical Medicine, University of Cambridge, Cambridge, United Kingdom;<br />
2<br />
Department of <strong>Rheumatology</strong>, Luton and Dunstable Hospital, Luton, United Kingdom;<br />
3<br />
Department of <strong>Rheumatology</strong>, <strong>The</strong> Edith Cavell Hospital, Peterborough, United Kingdom;<br />
4<br />
Department of <strong>Rheumatology</strong>, Hinchingbrooke Hospital, Huntingdon, United Kingdom;<br />
5<br />
Department of <strong>Rheumatology</strong>, Queen’s Hospital, Rom<strong>for</strong>d, United Kingdom; 6 Department of<br />
<strong>Rheumatology</strong>, St Alban’s Hemel NHS Trust, St Alban’s, United Kingdom; 7 Department of<br />
<strong>Rheumatology</strong>, West Suffolk Hospital, Bury-St-Edmunds, United Kingdom; 8 Department of<br />
<strong>Rheumatology</strong>, Ipswich Hospital, Ipswich, United Kingdom<br />
Poster No. 102<br />
AUDIT OF NATIONAL PATIENT SAFETY AGENCY PATIENT-HELD METHOTREXATE<br />
MONITORING BOOKLETS<br />
C. Bracewell 1 , Neil Gammack 2 , Jacqui Binding 1 , Clive Kelly 1 , Jennifer Hamilton 1 ;<br />
1<br />
<strong>Rheumatology</strong> Department, Queen Elizabeth Hospital, Gateshead, United Kingdom;<br />
2<br />
Pharmacy Department, Queen Elizabeth Hospital, Gateshead, United Kingdom<br />
Poster No. 103<br />
Poster No. 104<br />
Poster No. 105<br />
Poster No. 106<br />
EARLY RHEUMATOID ARTHRITIS-ARE WE FOLLOWING THE GUIDELINES?<br />
Su-Yin Tan, Smita Bhat, Thomas Pullar;<br />
Rheumatic Diseases Unit, Ninewells Hospital and Medical School, Dundee, United Kingdom<br />
EVOLVING PATTERNS OF BIOLOGIC USE FROM 2001 TO 2008- A DGH EXPERIENCE<br />
Alice Groves, Adele Howe, Shouma Dutta, Stuart M. Linton;<br />
<strong>Rheumatology</strong>, Nevill Hall Hospital, Gwent, United Kingdom<br />
IS A SINGLE DOSE INTRAMUSCULAR (IM) TRIAMCINOLONE ACETONIDE INJECTION MORE<br />
EFFECTIVE IN TREATING SYMPTOMATIC FLARE IN ESTABLISHED RHEUMATOID ARTHRITIS<br />
THAN EQUIVALENT DOSE OF ORAL PREDNISOLONE?<br />
Yoke-Mei McLoughlin, Gillian Scott, Nancy Mills, Penny Storrs, Frank McKenna;<br />
<strong>Rheumatology</strong> Dept, Traf<strong>for</strong>d General Hospital, Manchester, United Kingdom<br />
AN AUDIT OF METHOTREXATE MONITORING IN PRIMARY CARE AS PART OF A SHARED CARE<br />
AGREEMENT<br />
Lois A. Lloyd 1 , Anne Breslin 2 , Jeremy Jones 2 ;<br />
1<br />
Dept of Pharmacy, North West Wales NHS Trust, Bangor, United Kingdom;<br />
2<br />
Dept of <strong>Rheumatology</strong>, North West Wales NHS Trust, Bangor, United Kingdom<br />
62
Poster No. 107<br />
Poster No. 108<br />
Poster No. 109<br />
Poster No. 110<br />
ESTABLISHING THE IMPLICATIONS OF CHRONIC KIDNEY DISEASE (CKD), PARTICULARLY<br />
CKD3, ON CVD RISK IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA)<br />
Anita Weerakoon 1 , Robert C. Nightingale 2 , Gavin P. Clunie 1 ;<br />
1<br />
<strong>Rheumatology</strong>, <strong>The</strong> Ipswich Hospital NHS Trust, Ipswich, United Kingdom;<br />
2<br />
Radiology, <strong>The</strong> Ipswich Hospital NHS Trust, Ipswich, United Kingdom<br />
LEUCOPENIA IN RHEUMATOID ARTHRITIS PATIENTS PRESCRIBED METHOTREXATE<br />
AS COMBINATION OR MONOTHERAPY<br />
Neal D. Reynolds, Mark H. Edwards, Richard G. Hull, Joanna M. Ledingham;<br />
<strong>Rheumatology</strong>, Queen Alexander Hospital, Portsmouth, United Kingdom<br />
Withdrawn<br />
A STUDY OF ANTI-TNF THERAPY USE FOR RHEUMATOID ARTHRITIS PATIENTS IN WALES<br />
Shouma Dutta;<br />
<strong>Rheumatology</strong>, Ysbyty Gywnedd, Bangor, United Kingdom<br />
Poster Viewing One | Wednesday 29 April 2009<br />
Poster No. 111<br />
PREDICTING REMISSION IN TRIAL OF INTENSIVE THERAPY IN EARLY RA: HAQ AND<br />
GENDER ARE KEY FACTORS<br />
Margaret H. Ma 1 , David Walker 2 , Andrew Hassell 3 , Ernest H. Choy 1 , David L. Scott 1 ;<br />
1<br />
<strong>Rheumatology</strong>, King’s College Hospital, London, United Kingdom; 2 <strong>Rheumatology</strong>, Freeman<br />
Hospital, Newcastle, United Kingdom; 3 <strong>Rheumatology</strong>, Hayward Hospital,<br />
Stoke On Trent, United Kingdom<br />
Poster No. 112<br />
IS SWITCHING TO A SECOND ANTI-TNF ALPHA AGENT WORTHWHILE? THE TAYSIDE<br />
EXPERIENCE<br />
Smita Bhat 2 , Lyndsey Atterton 1 , Ken Morley 2 , Donna Daugherty 2 ;<br />
1<br />
University of Dundee Medical School, Dundee, United Kingdom; 2 Rheumatic Diseases Unit,<br />
Ninewells Hospital and Medical School, Dundee, United Kingdom<br />
Poster No. 113<br />
WHAT COMPONENT OF THE DAS28 IS MOST LIKELY TO CONTRIBUTE TO RA<br />
PATIENTS BEING CLASSIFIED AS “FAILURES” ON ANTI-TNF?<br />
Fionn Toolis, Sayqa Butt, Kate Gadsby, Chris Deighton;<br />
Department of <strong>Rheumatology</strong>, Derbyshire Royal Infirmary, Derby, United Kingdom<br />
Poster No. 114<br />
COMPARING OUTCOME FOR THE FIRST 12 MONTHS OF ANTI-TNF THERAPY IN<br />
RHEUMATOID ARTHRITIS (RA) IN STANDARD CLINICAL PRACTICE IN UK<br />
Mandy C. Greenwood, Alan J. Hakim, Simon P. Donnelly, Margaretta M. Rooney, Hasan Tahir;<br />
<strong>Rheumatology</strong>, Whipps Cross University Hospital, London, United Kingdom<br />
Poster No. 115<br />
THE IMPACT OF ANTI-TNF ON THE WEIGHT OF RHEUMATOID ARTHRITIS PATIENTS<br />
Nicola Alcorn 1 , Ann Tierney 1 , Olivia Wu 2 , Harper Gilmour 2 , Hillary Capell 1 , Rajan Madhok 1 ;<br />
1<br />
Centre Rheumatic Disease, Glasgow Royal Infirmary, Glasgow, United Kingdom;<br />
2<br />
Public Health Department, Glasgow University, Glasgow, United Kingdom<br />
Poster No. 116<br />
SYSTEMATIC REVIEW: COMPARATIVE EFFECTIVENESS OF BIOLOGIC DMARD<br />
THERAPIES VERSUS TRADITIONAL DMARD THERAPIES IN RA<br />
Richard C. Campbell, Gabrielle Kingsley, David Scott;<br />
<strong>Rheumatology</strong>, Kings College Hospital, London, United Kingdom<br />
63
Poster No. 117<br />
Poster No. 118<br />
Poster No. 119<br />
Poster No. 120<br />
Poster No. 121<br />
ACTIVE RHEUMATOID ARTHRITIS: A CASE STUDY APPROACH INVESTIGATING<br />
HYPNOTHERAPY AND IMAGERY WITHIN A BIOPSYCHOSOCIAL FRAMEWORK<br />
Bryan M. Bennett, Nichola Callow, Jeremy G. Jones;<br />
School of Sport, Health, & Exercise Sciences, Bangor University, Bangor, Gwynedd,<br />
United Kingdom<br />
POOR EFFICACY OF SULPHASALAZINE AS A SECOND DMARD IN PATIENTS WITH ACTIVE<br />
RHEUMATOID ARTHRITIS DESPITE METHOTREXATE TREATMENT<br />
Amjad A. Jilani, Margaret Callan;<br />
Department of <strong>Rheumatology</strong>, Chelsea and Westminster Foundation trust, London,<br />
United Kingdom<br />
FOUR YEAR OUTCOME DATA IN RHEUMATOID ARTHRITIS (RA) PATIENTS RECEIVING EITHER<br />
ETANERCEPT OR INFLIXIMAB IN STANDARD CLINICAL PRACTICE<br />
Mandy C. Greenwood, Simon P. Donnelly, Margaretta M. Rooney, Alan J. Hakim, Hasan Tahir;<br />
<strong>Rheumatology</strong>, Whipps Cross University Hospital, London, United Kingdom<br />
AN AUDIT OF GUIDELINES FOR THE EARLY MANAGEMENT OF RHEUMATOID ARTHRITIS IN<br />
A DISTRICT GENERAL HOSPITAL SETTING<br />
Simon Roughneen, Sarah Dunn, Shirley Rigby;<br />
Department of <strong>Rheumatology</strong>, South Warwickshire General Hospitals NHS Trust, Warwick,<br />
United Kingdom<br />
EVALUATION OF JOINT DAMAGE IN RA PATIENTS TREATED WITH RITUXIMAB: COMPARISON<br />
OF GENANT- AND VAN DER HEIJDE-MODIFIED SHARP RADIOGRAPHIC SCORING<br />
Mark Genovese 1 , Charles Peterfy 2 , Paul Emery 3 , Edward Keystone 4 , Paul-Peter Tak 5 , Stanley B.<br />
Cohen 6 , Julie DiCarlo 2 , David Hagerty 7 , Mathew Cravets 7 , Tim Shaw 8 ;<br />
1<br />
Stan<strong>for</strong>d University, Stan<strong>for</strong>d, CA; 2 Synarc, San Francisco, CA; 3 Leeds General Infirmary, Leeds,<br />
United Kingdom; 4 University of Toronto, Toronto, ON, Canada; 5 Academic Medical Centre,<br />
University of Amsterdam, Amsterdam, Netherlands; 6 Metroplex, Dallas, TX; 7 Biogen Idec,<br />
San Diego, CA; 8 Roche Products Ltd, Welwyn Garden City, United Kingdom<br />
Poster No. 122<br />
LOW DOSE TIMED RELEASE PREDNISONE REDUCES IL-6 IN RA<br />
Lynsey L. Clarke 1 , David S. Jessop 1 , Linda P. Hunt 1 , Rainer H. Straub 2 , Mark G. Perry 1 ,<br />
John R. Kirwan 1 ;<br />
1<br />
University of Bristol, Bristol, United Kingdom; 2 University Hospital Regensburg,<br />
Regensburg, Germany<br />
Poster No. 123<br />
EFFICACY AND SAFETY OF REPEAT TREATMENT COURSES OF RITUXIMAB IN RA PATIENTS<br />
(PTS) WITH INADEQUATE RESPONSE (IR) TO TUMOUR NECROSIS FACTOR (TNF) INHIBITORS:<br />
LONG-TERM EXPERIENCE FROM THE REFLEX STUDY<br />
Edward C. Keystone 1 , Roy M. Fleischmann 2 , Paul Emery 3 , Andrew Chubick 4 ,<br />
Maxime R. Dougados 5 , Andrew R. Baldassare 6 , Joan M. Bathon 7 , Eva W. Hessey 8 ,<br />
David Hagerty 9 , Simon Safa-Leathers 8 ;<br />
1<br />
Mount Sinai Hospital, Toronto, ON, Canada; 2 University of Texas Southwestern Medical Center,<br />
Dallas, TX; 3 Leeds University, Leeds, United Kingdom; 4 Arthritis Centers of Texas, Dallas, TX;<br />
5<br />
Rene Descartes University, Paris, France; 6 Arthritis Consultants Inc., St Louis, MO; 7 <strong>The</strong> Johns<br />
Hopkins Arthritis Center, Baltimore, MD; 8 Roche Products Ltd, Welwyn Garden City, United<br />
Kingdom; 9 Biogen Idec, San Diego, CA<br />
64
Poster No. 124<br />
Poster No. 125<br />
Poster No. 126<br />
Poster No. 127<br />
SULFASALAZINE DESENSITISATION KIT IS EFFECTIVE AND WORTHWHILE IN<br />
INFLAMMATORY ARTHRITIS - AUDIT OF PRACTICE<br />
Maciej Brzeski;<br />
<strong>Rheumatology</strong>, Falkirk & District Royal Infirmary, Falkirk, United Kingdom<br />
POTENTIAL COSTS TO THE NATIONAL HEALTH SERVICE FOR THE TREATMENT OF SERIOUS<br />
LOWER RESPIRATORY TRACT INFECTIONS IN RA PATIENTS TREATED WITH DIFFERENT<br />
TNF-α INHIBITORS IN THE UNITED KINGDOM: A PROSPECTIVE 5 YEAR MODEL<br />
James Warburton, Rohit Batta, Maximilian Lebmeier, Volker Koscielny, Manjinder Bains;<br />
Wyeth Pharmaceuticals, Taplow, United Kingdom<br />
PATIENTS FAILING TO RESPOND ON ANTI-TNF TREATMENT - WILL SUBCUTANEOUS<br />
METHOTREXATE HELP?<br />
Thiraupathy Marianayagam, Shilpa Selvan, Ruth Slack, David O’Reilly, Vivek Rajagopal;<br />
<strong>Rheumatology</strong>, West Suffolk Hospital, Bury St Edmunds, United Kingdom<br />
THE STEROID SPARING EFFECT OF ANTI-TNF TREATMENT IN PATIENTS WITH<br />
RHEUMATOID ARTHRITIS<br />
Laura-Jane Smith, Helen C. Reade, Nicholas J. Sheehan, Sandeep Dahiya;<br />
Department of <strong>Rheumatology</strong>, Peterborough and Stam<strong>for</strong>d Hospitals NHS Foundation Trust,<br />
Peterborough, United Kingdom<br />
Poster Viewing One | Wednesday 29 April 2009<br />
Poster No. 128<br />
Poster No. 129<br />
Poster No. 130<br />
Poster No. 131<br />
Poster No. 132<br />
FAILURE OF METHOTREXATE THERAPY IN APTIENTS WITH EARLY PERSISTENT<br />
INFLAMMATORY ARTHRITIS: TO SWITCH, TO ADD ANOTHER DMARD, OR TO GO<br />
FOR BIOLOGIC THERAPY?<br />
Yasser El Miedany 1 , Deborah Palmer 1 , Maha El Gaafary 2 , Annie N. Mehanna 3 ;<br />
1<br />
<strong>Rheumatology</strong>, Darent Valley Hospital, Dart<strong>for</strong>d, United Kingdom; 2 Community, Environmental<br />
and Occupational Medicine, Ain Shams University, Cairo, Egypt; 3 Radiology, Ain Shams<br />
University, Cairo, Egypt<br />
NEUTROPENIA IN PATIENTS TREATED WITH TNF-ALPHA ANTAGONISTS<br />
Jasroop K. Chana, Ishita Patel, Nicola Kennedy, Matthew Adler, Francesca Demetriadi,<br />
Alan Steuer;<br />
<strong>Rheumatology</strong>, Wexham Park Hospital, Slough, United Kingdom<br />
WITHDRAWAL OF DMARDS IN PATIENTS WITH RHEUMATOID ARTHRITIS: A SYSTEMATIC<br />
REVIEW AND META-ANALYSIS<br />
Rachel O’Mahony 1 , Alison Richards 1 , Chris Deighton 2 , David Scott 3 ;<br />
1<br />
National Collaborating Centre <strong>for</strong> Chronic Conditions (NCC-CC), Royal College of Physicians,<br />
London, United Kingdom; 2 Department of <strong>Rheumatology</strong>, Derbyshire Royal Infirmary, Derby,<br />
United Kingdom; 3 Academic and <strong>Rheumatology</strong> Department, King’s College London, London,<br />
United Kingdom<br />
PARENTERAL METHOTREXATE - WHICH PATIENTS BENEFIT MOST?<br />
Hayley Mainman, Emma Maclaren, Kirstin Scott, Vadivelu Saravanan, Jennifer Hamilton,<br />
Carol Heycock, Clive Kelly;<br />
<strong>Rheumatology</strong>, Queen Elizabeth Hospital, Gateshead, United Kingdom<br />
INTENSIVE MONITORING MAY ALLOW THE REDUCTION OF THE BIOLOGICS<br />
DOSE IN PATIENTS WITH RHEUMATOID ARTHRITIS<br />
Anurag Bharadwaj, Natasha Jegganathan, Mike Batley, Anthony Hammond;<br />
<strong>Rheumatology</strong>, Maidstone Hospital, Maidstone, United Kingdom<br />
65
Poster No. 133<br />
Poster No. 134<br />
Poster No. 135<br />
Poster No. 136<br />
NEUTROPENIA WITH ANTI-TNF THERAPY FOR RHEUMATOID ARTHRITIS<br />
Anna E. Litwic 1 , Maxine Tann 2 , Joanna M. Ledingham 2 ;<br />
1<br />
Renal Department, Queen Alexandra Hospital, Portsmouth, United Kingdom; 2 <strong>Rheumatology</strong><br />
Department, Queen Alexandra Hospital, Portsmouth, United Kingdom<br />
COMBINATION DMARDS FOR RHEUMATOID ARTHRITIS: A COST-EFFECTIVENESS ANALYSIS<br />
Jonathan Tosh, Allan Wailoo;<br />
Health Economics and Decision Science. School of Health and Related Research, University of<br />
Sheffield, Sheffield, United Kingdom<br />
BASELINE IMMUNOLOGICAL STATUS OF EARLY RHEUMATOID ARTHRITIS PATIENTS PREDICT<br />
RESPONSE TO TREATMENT<br />
Frederique Ponchel, Rekha Parmar, Vincent Goeb, Benazir Saleem, Philip Conaghan,<br />
Paul Emery;<br />
LIMM, Section MSK, LMBRU, University of Leeds, Leeds, United Kingdom<br />
A COMPARISON OF DRUG SURVIVAL TIMES FOR INFLIXIMAB, ADALIMUMAB AND<br />
ETANERCEPT<br />
Joanna M. Pocock 1 , Samir Albreshni 2 , Ruth Slack 2 , Varvara Polydoropoulou 3 , David O’Reilly 2 ,<br />
Andrew J. Östör 1 ;<br />
1<br />
Department of <strong>Rheumatology</strong>, Addenbrooke’s Hospital, Cambridge, United Kingdom;<br />
2<br />
Department of <strong>Rheumatology</strong>, West Suffolk Hospital, Bury St Edmunds, United Kingdom;<br />
3<br />
Centre <strong>for</strong> Applied Medical Statistics, University of Cambridge, Cambridge, United Kingdom<br />
Poster No. 137<br />
Poster No. 138<br />
DOES TEMPORARY DISCONTINUATION OF ANTI TNF-α AGENT ETANERCEPT AFFECT THE<br />
THERAPEUTIC RESPONSE AT SIX MONTH<br />
A. Abhishek, S. Butt, K. Gadsby, C. M. Deighton;<br />
Department of <strong>Rheumatology</strong>, Derbyshire Royal Infirmary, Derby, United Kingdom<br />
GOAL DIRECTED THERAPY FOR RHEUMATOID ARTHRTIS IN ROUTINE PRACTICE IMPROVES<br />
CONTROL OF DISEASE ACTIVITY AND PREVENTS DETERIORATION IN HAQ<br />
Nicola J. Gullick 1,2 , Stephen P. Oakley 1 , Tim Jones 1 , Alan Mistlin 1 , Jonathan D. Rees 1 ,<br />
Gabriel S. Panayi 1,2 , Bruce W. Kirkham 1 ;<br />
1<br />
RA Centre, Guy’s & St Thomas’ NHS Foundation Trust, London, United Kingdom;<br />
2<br />
<strong>Rheumatology</strong>, King’s College, London, United Kingdom<br />
Poster No. 139<br />
Poster No. 140<br />
Poster No. 141<br />
QUANTIFERON GOLD SCREENING FOR LATENT TUBERCULOSIS - COST COMPARISON WITH<br />
MANTOUX TESTING<br />
Natasha Jordan, Patricia Kavanagh, Patricia Dooley, Suzanne Donnelly, Geraldine McCarthy,<br />
Conor McCarthy;<br />
<strong>Rheumatology</strong>, Mater Misericordiae University Hospital, Dublin 7, Ireland<br />
PREDICTION MODEL FOR THERAPEUTIC OUTCOME ASSESSMENT IN PATIENTS WITH EARLY<br />
PERSISTENT INFLAMMATORY ARTHRITIS<br />
Yasser El Miedany 1 , Deborah Palmer 1 , Maha El Gaafary 2 ;<br />
1<br />
<strong>Rheumatology</strong>, Darent Valley Hospital, Dart<strong>for</strong>d, United Kingdom; 2 Community, Environmental<br />
and Occupational Medicine, Ain Shams University, Cairo, Egypt<br />
HOW WELL DOES IMPROVEMENT IN THE HAQ CORRELATE WITH THE DAS28<br />
IN RA PATIENTS ON ANTI-TNF?<br />
Fionn Toolis, Butt Sayqa, Kate Gadsby, Chris Deighton;<br />
Department of <strong>Rheumatology</strong>, Derbyshire Royal Infirmary, Derby, United Kingdom<br />
66
Poster Viewing Two<br />
Thursday 30 April 2009<br />
Poster Viewing Two<br />
Thu 30 April 2009
Poster Viewing Two<br />
Thursday 30 April 2009, 08.30-10.00<br />
Sjögren’s syndrome and other connective tissue disorders<br />
Poster No. 142<br />
Poster No. 143<br />
EVALUATION OF PRIMARY AND SECONDARY SJÖGREN’S SYNDROME IN IRAQI PATIENTS<br />
Mohammed H. Munshed 1 , Ziad s. Alrawi 2 ;<br />
1<br />
medicine, baghdad, Iraq; 2 medicine, baghdad, Iraq<br />
A LONGITUDINAL STUDY OF NAILFOLD CAPILLARY ABNORMALITIES IN PATIENTS WITH<br />
IDIOPATHIC INFLAMMATORY MYOPATHIES<br />
Louise K. Mercer 1 , Tonia L. Moore 2 , Hector Chinoy 2 , Andrea K. Murray 2 , Andrew Vail 2 ,<br />
Robert G. Cooper 2 , Ariane L. Herrick 2 ;<br />
1<br />
ARC Epidemiology Unit, <strong>The</strong> University of Manchester, Manchester, United Kingdom; 2 <strong>The</strong><br />
University of Manchester, Sal<strong>for</strong>d Royal NHS Foundation Trust, Sal<strong>for</strong>d, United Kingdom<br />
Poster Viewing Two | Thursday 30 April 2009<br />
Poster No. 144<br />
CARDIOVASCULAR RISK FACTORS AND OUTCOMES IN PATIENTS WITH IDIOPATHIC<br />
IMMUNE MYOSITIS<br />
Bryan R. Whelan 1 , Shabina Sultan 2 , David A. Isenberg 1 ;<br />
1<br />
<strong>Rheumatology</strong>, University College London, London, United Kingdom; 2 <strong>Rheumatology</strong>,<br />
Brad<strong>for</strong>d Royal Infirmary, Brad<strong>for</strong>d, United Kingdom<br />
Poster No. 145<br />
PATIENT-REPORTED OUTCOMES IN PRIMARY SJÖGREN’S SYNDROME: THE LONG AND<br />
SHORT VERSIONS OF THE PROFILE OF FATIGUE AND DISCOMFORT - SICCA SYMPTOMS<br />
INVENTORY<br />
Simon J. Bowman 1 , John Hamburger 2 , Andrea Richards 2 , Robert J. Barry 3 , Saaeha Rauz 3 ;<br />
1<br />
<strong>Rheumatology</strong>, University Hospital Birmingham NHS Foundation Trust, Birmingham, United<br />
Kingdom; 2 Oral Medicine, Birmingham Dental Hospital & School, Birmingham, United<br />
Kingdom; 3 Academic Unit of Ophthalmology, University of Birmingham, Birmingham,<br />
United Kingdom<br />
Poster No. 146<br />
Poster No. 147<br />
Poster No. 148<br />
THE SJÖGREN’S SYNDROME DAMAGE INDEX - OUTCOME OVER 10 YEARS<br />
Lada Krylova, David A. Isenberg;<br />
<strong>Rheumatology</strong>, University College London Hospitals, London, United Kingdom<br />
KILLER-CELL IMMUNOGLOBULIN-LIKE RECEPTOR GENE POLYMORPHISMS<br />
AND PRIMARY SJÖGREN’S SYNDROME<br />
David P. Lowe 1 , Mark A. Cook 2 , Simon J. Bowman 3 , David C. Briggs 1 , United Kingdom<br />
Sjögren’s Interest Group 4 ;<br />
1<br />
Histocompatibility & Immunogenetics, NHS Blood Transfusion Service, Birmingham, United<br />
Kingdom; 2 Haematology, University Hospital Birmingham NHS Foundation Trust, Birmingham,<br />
United Kingdom; 3 <strong>Rheumatology</strong>, University Hospital Birmingham NHS Foundation Trust,<br />
Birmingham, United Kingdom; 4 UK Sjögren’s Interest Group, UK, United Kingdom<br />
DAMAGE ACCRUAL IN PATIENTS WITH ADULT ONSET IDIOPATHIC IMMUNE MYOSITIS<br />
Bryan R. Whelan 1 , Shabina Sultan 2 , David A. Isenberg 1 ;<br />
1<br />
<strong>Rheumatology</strong>, University College London, London, United Kingdom;<br />
2<br />
<strong>Rheumatology</strong>, Brad<strong>for</strong>d Royal Infirmary, Brad<strong>for</strong>d, United Kingdom<br />
67
Poster No. 149<br />
CLASSIFICATION CRITERIA FOR IDIOPATHIC INFLAMMATORY MYOSITIS: COMPARISON OF<br />
THE PERFORMANCE OF ACCEPTED CRITERIA<br />
Helen Linklater 1 , Nicolo’ Pipitone 2 , Michael R. Rose 3 , Fiona Norwood 3 , David L. Scott 1 ,<br />
Patrick A. Gordon 1 ;<br />
1<br />
Department of <strong>Rheumatology</strong>, Kings College Hospital, Denmark Hill, London, United Kingdom;<br />
2<br />
<strong>Rheumatology</strong> Unit, Arcispedale Santa Maria Nuova, Reggio Emilia, Italy; 3 Department of<br />
Neurology, Kings College Hospital, Denmark Hill, London, United Kingdom<br />
Scleroderma and related disorders<br />
Poster No. 150<br />
Poster No. 151<br />
AN 8-YEAR RETROSPECTIVE STUDY ON THE PROFILE OF CLINICALLY DIAGNOSED PATIENTS<br />
WITH SCLERODERMA (SYSTEMIC SCLEROSIS) IN UNIVERSITY OF THE PHILIPPINES-<br />
PHILIPPINE GENERAL HOSPITAL (UP-PGH) MEDICAL CENTER: A REVIEW OF 27 CASES<br />
Tom Edward N. Lo, Ester G. Penserga;<br />
Medicine, University of the Philippines, Manila, Philippines<br />
THUMB INVOLVEMENT IN RAYNAUD’S PHENOMENON AS AN INDICATOR<br />
OF UNDERLYING CONNECTIVE TISSUE DISEASE<br />
Batsi Chikura 1,2 , Tonia Moore 2 , Joanne Manning 2 , Andy Vail 3 , Ariane L. Herrick 2 ;<br />
1<br />
<strong>Rheumatology</strong>, Royal Liverpool University Hospital, Liverpool, United Kingdom; 2 Rheumatic<br />
Diseases Centre, Sal<strong>for</strong>d Royal NHS Foundation Trust, Manchester, United Kingdom;<br />
3<br />
Biostatistics Group, University of Manchester, Manchester, United Kingdom<br />
Poster No. 152<br />
FUNCTIONAL REGULATION OF FIBROSIS BY CUTL1 ISOFORMS<br />
Tetsurou Ikeda 1,2 , Gisela Lindahl 1 , Maria Fragiadaki 2 , Xu Shi-wen 1 , Markella Ponticos 1 , Patricia<br />
Garcia 1 , Christopher Denton 1 , George Bou-Gharios 2 , David Abraham 1 ;<br />
1<br />
<strong>Rheumatology</strong>, Medical School, University College of London, London, United Kingdom;<br />
2<br />
Renal Medicine, Imperial College, London, United Kingdom<br />
Poster No. 153<br />
Poster No. 154<br />
Poster No. 155<br />
Poster No. 156<br />
TREATMENT OF SKIN DISEASE IN SYSTEMIC SCLEROSIS (SSc): RESPONSE<br />
TO A TARGETED TREATMENT REGIMEN WITH IV CYCLOPHOSPHAMIDE (CYC)<br />
Lesley Ottewell, Karen Walker, Bridget Griffiths;<br />
Department of <strong>Rheumatology</strong>, Freeman Hospital, Newcastle Upon Tyne, United Kingdom<br />
MULTI-SITE PHOTOPLETHYSMOGRAPHY VASCULAR ASSESSMENT OF AUTONOMIC<br />
FUNCTION IN PATIENTS WITH SYSTEMIC SCLEROSIS<br />
Neil D. McKay 1 , Stephen Hedley 2 , Bridget Griffiths 1 , John Allen 2 ;<br />
1<br />
Dept of <strong>Rheumatology</strong>, Freeman Hospital, Newcastle Upon Tyne, United Kingdom;<br />
2<br />
Microvascular Diagnostics, Regional Medical Physics Department, Newcastle Upon Tyne,<br />
United Kingdom<br />
RELATIONSHIP OF RESPIRATORY MUSCLES STRENGTH WITH DISEASE DURATION,<br />
PULMONARY FUNCTION, SKIN SCORE AND AGE OF PATIENTS WITH SYSTEMIC SCLEROSIS<br />
Lilia V. Shvets, Mykola A. Stanislavchuk;<br />
<strong>Rheumatology</strong>, Vinnytsya National Medical University, Vinnytsya, Ukraine<br />
LONG-TERM OUTCOME OF A TARGETED TREATMENT REGIMEN WITH IV<br />
CYCLOPHOSPHAMIDE (CYC) IN PATIENTS WITH SYSTEMIC SCLEROSIS (SSC)<br />
AND INTERSTITIAL LUNG DISEASE (ILD)<br />
Lesley Ottewell, Karen Walker, Bridget Griffiths;<br />
Department of <strong>Rheumatology</strong>, Freeman Hospital, Newcastle Upon Tyne, United Kingdom<br />
68
Poster No. 157<br />
Poster No. 158<br />
Poster No. 159<br />
DOES ANTI-RNA-POLYMERASE ANTIBODY LEVEL PREDICT ORGAN INVOLVEMENT<br />
OR DISEASE OUTCOME IN PATIENTS WITH SYSTEMIC SCLEROSIS?<br />
Svetlana I. Nihtyanova 1 , Jennifer C. Parker 2 , Carol M. Black 1 , Christopher C. Bunn 2 ,<br />
Christopher P. Denton 1 ;<br />
1<br />
Centre <strong>for</strong> <strong>Rheumatology</strong> and Connective Tissue Diseases, Royal Free Hospital,<br />
London, United Kingdom; 2 Clinical Immunology Department, Royal Free Hospital, London,<br />
United Kingdom<br />
PATIENTS WITH SYSTEMIC SCLEROSIS HAVE AN INCREASED PREVALENCE OF<br />
NON-RESTORATIVE SLEEP AS MEASURED BY THE EPWORTH SCORE<br />
Neil D. McKay 1 , Bridget Griffiths 1 , John Allen 2 ;<br />
1<br />
Dept of <strong>Rheumatology</strong>, Freeman Hospital, Newcastle Upon Tyne, United Kingdom;<br />
2<br />
Microvascular Diagnostics, Regional Medical Physics Department, Newcastle Upon Tyne,<br />
United Kingdom<br />
MEDICAL STUDENT BURSARY WINNER<br />
ACRO-OSTEOLYSIS IN SYSTEMIC SCLEROSIS - RELATIONSHIP TO DEGREE OF DIGITAL<br />
ISCHAEMIA AND TO CALCINOSIS<br />
Emma M. Johnstone, Charles Hutchinson, Ariane L. Herrick;<br />
University of Manchester, Sal<strong>for</strong>d Royal NHS Foundation Trust, Sal<strong>for</strong>d, United Kingdom<br />
Poster Viewing Two | Thursday 30 April 2009<br />
Poster No. 160<br />
Poster No. 161<br />
TGF-BETA INDUCTION OF THE MYOFIBROBLAST PHENOTYPE REQUIRES TAK-1<br />
Xu Shiwen 1 , Sunil Parapuram 2 , Daphne Pala 2 , David Carter 2 , Mark Eastwood 3 ,<br />
Christopher Denton 1 , Carol Black 1 , Andrew Leask 2 , David Abraham 1 ;<br />
1<br />
<strong>Rheumatology</strong>, University College London (Royal Free Campus), London, United Kingdom;<br />
2<br />
University of Western Ontario, London, ON, Canada; 3 University of Westminster, London,<br />
United Kingdom<br />
CONSTITUTIVE NUCLEAR ACCUMULATION OF CBF IN SYSTEMIC SCLEROSIS PULMONARY<br />
FIBROBLASTS: A PUTATIVE TRANSCRIPTIONAL MECHANISM UNDERLYING THE FIBROTIC<br />
PHENOTYPE<br />
Gisela Lindahl 1 , Patricia Leoni 1 , Markella Ponticos 1 , Xu Shi-wen 1 , Elisabetta Renzoni 2 , Alan<br />
Holmes 1 , Carol M. Black 1 , Christopher P. Denton 1 , David J. Abraham 1 ;<br />
1<br />
<strong>Rheumatology</strong>, UCL Medical School (Royal Free), London, United Kingdom;<br />
2<br />
National Heart and Lung Institute, Imperial College, London, United Kingdom<br />
Poster No. 162<br />
Poster No. 163<br />
NAILFOLD CAPILLARY ABNORMALITIES ARE ASSOCIATED WITH SEVERITY OF<br />
DIGITAL ISCHAEMIA AND ANTICENTROMERE ANTIBODY IN SYSTEMIC SCLEROSIS<br />
Ariane L. Herrick 1 , Moore Tonia 1 , Andrea K. Murray 1 , Whidby Nina 1 , Joanne Manning 1 ,<br />
Andrew Vail 2 ;<br />
1<br />
Rheumatic Diseases Centre, University of Manchester, Sal<strong>for</strong>d Royal NHS Foundation Trust,<br />
Sal<strong>for</strong>d, United Kingdom; 2 Biostatistics Group, University of Manchester, Sal<strong>for</strong>d Royal NHS<br />
Foundation Trust, Sal<strong>for</strong>d, United Kingdom<br />
EFFECT OF 8 WEEKS’ ATORVASTATIN ON ENDOTHELIAL FUNCTION IN PATIENTS WITH<br />
SYSTEMIC SCLEROSIS<br />
Hala Y. Sadik 1,2 , Tonia Moore 1 , Andy Vail 1,3 , Andrea Murray 1 , Marina Anderson 4 ,<br />
Blann Andrew 5 , Ariane L. Herrick 1 ;<br />
1<br />
Rheumatic Diseases Centre, University of Manchester, Sal<strong>for</strong>d Royal NHS Foundation Trust,<br />
Sal<strong>for</strong>d, United Kingdom; 2 Department of <strong>Rheumatology</strong>, Wirral University Teaching Hospital<br />
NHS Foundation Trust, Wirral, United Kingdom; 3 Health Methodology Research Group,<br />
University of Manchester, Manchester, United Kingdom; 4 Department of <strong>Rheumatology</strong>,<br />
University Hospital Aintree, Liverpool, United Kingdom; 5 City Hospital, Birmingham,<br />
United Kingdom<br />
69
Poster No. 164<br />
Poster No. 165<br />
Poster No. 166<br />
CONTEMPORARY OUTCOME IN SYSTEMIC SCLEROSIS: IMPROVED SURVIVAL<br />
WITH EARLIER RECOGNITION OF ORGAN-BASED COMPLICATIONS<br />
Edward C. Tang, Svetlana I. Nihtyanova, Christopher P. Denton;<br />
Centre <strong>for</strong> <strong>Rheumatology</strong> and Connective Tissue Diseases, Royal Free Hospital, London,<br />
United Kingdom<br />
MODULATION OF TYPE I COLLAGEN SYNTHESIS AND FIBROBLAST FUNCTION IN SYSTEMIC<br />
SCLEROSIS BY THE GREEN TEA ANTIOXIDANT (-)-EPIGALLOCATECHIN-3-GALLATE<br />
Audrey Dooley 1 , Xu Shiwen 1 , Nima Aden 1 , Thomas Tranah 2 , Nirupa Desai 2 ,<br />
Christopher P. Denton 1 , Carol M. Black 1 , David J. Abraham 1 , Richard Bruckdorfer 2 ;<br />
1<br />
Centre <strong>for</strong> <strong>Rheumatology</strong>, University College London Medical School (Royal Free Campus),<br />
London, United Kingdom; 2 Department of Biochemistry, University College London Medical<br />
School (Royal Free Campus), London, United Kingdom<br />
THE ROLE OF FIBROCYTES IN SYSTEMIC SCLEROSIS<br />
Thomas Hügle 1 , Christiaan Huigens 1 , Lesley Ottewell 2 , Alan Tyndall 3 , Bridget Griffiths 2 ,<br />
Jacob M. van Laar 1 ;<br />
1<br />
Musculoskeletal Research Group, Newcastle University, Newcastle upon Tyne, United Kingdom;<br />
2<br />
Department of <strong>Rheumatology</strong>, Freeman Hospital, Newcastle upon Tyne, United Kingdom;<br />
3<br />
Department of <strong>Rheumatology</strong>, University Hospital Basel, Basel, Switzerland<br />
Poster No. 167<br />
Poster No. 168<br />
ASTIS TRIAL<br />
Jacob M. van Laar 1 , Dominique Farge 2 , Alan Tyndall 3 , ASTIS Trial Investigators 4 ;<br />
1<br />
Musculoskeletal Research Group, Newcastle University, Newcastle upon Tyne, United Kingdom;<br />
2<br />
Service Medicine Interne, Hopital St Louis, Paris, France; 3 <strong>Rheumatology</strong>, University Hospital<br />
Basel, Basel, Switzerland; 4 Study Administration Office, <strong>The</strong> James Cook University Hospital,<br />
Middlesbrough, United Kingdom<br />
DISRUPTION OF TGFBETA SIGNALLING IN DERMAL FIBROBLASTS DELAYS SKIN WOUND<br />
HEALING AND REDUCES FIBROCYTE RECRUITMENT<br />
Korsa Khan, Rachel Hoyles, Xu Shiwen, David Abraham, Christopher P. Denton;<br />
Centre <strong>for</strong> <strong>Rheumatology</strong> and connective tissue diseases, Royal Free and University College<br />
Medical School, London, United Kingdom<br />
Rheumatoid arthritis – treatment<br />
Poster No. 169<br />
Poster No. 170<br />
SOCIO-ECONOMIC STATUS INFLUENCES THE TIMING OF RESPONSE IN<br />
A PROSPECTIVE STUDY OF PATIENTS WITH RHEUMATOID ARTHRITIS<br />
Ann Tierney 1 , Lucy Wait 1 , Rosie Hampson 1 , Alex McConnachie 2 , Claudia-Martina Messow 2 ,<br />
Hilary Capell 1 , Rajan Madhok 1 ;<br />
1<br />
Centre <strong>for</strong> Rheumatic Diseases, Royal Infirmary, Glasgow, United Kingdom; 2 Robertson Centre<br />
<strong>for</strong> Biostatistics, University of Glasgow, Glasgow, United Kingdom<br />
DOES MAGNITUDE OF FATIGUE DIFFER BETWEEN ANTI-RHEUMATIC THERAPIES IN 553 RA<br />
PATIENTS TREATED AT MAIDSTONE HOSPITAL?<br />
Richard C. Campbell 2,1 , Michael Batley 1 , Anthony Hammond 1 , Anarag Bharadwaj 1 ,<br />
Gabrielle Kingsley 2 , David Scott 2 ;<br />
1<br />
<strong>Rheumatology</strong>, Maidstone General Hospital, Maidstone, United Kingdom; 2 <strong>Rheumatology</strong>,<br />
King’s College Hospital, London, United Kingdom<br />
70
Poster No. 171<br />
Poster No. 172<br />
Poster No. 173<br />
MEDICAL STUDENT BURSARY WINNER<br />
PARENTERAL METHOTREXATE - IS IT WORTH IT?<br />
Emma Maclaren, Hayley Mainman, Kirstin Scott, Carol Heycock, Vadivelu Saravanan,<br />
Jennifer Hamilton, Clive Kelly;<br />
<strong>Rheumatology</strong>, Queen Elizabeth Hospital, Gateshead, United Kingdom<br />
EFFECTS OF ANT-TNF THERAPY ON WHITE CELL SUBSETS<br />
Richard Hastings 1 , Tina Ding 1 , Sayqa Butt 1 , Kate Gadsby 1 , Weiya Zhang 2 , Rob Moots 3 ,<br />
Chris Deighton 1 ;<br />
1<br />
<strong>Rheumatology</strong>, Derbyshire Royal Infirmary, Derby, United Kingdom; 2 Academic<br />
<strong>Rheumatology</strong>, Nottingham City Hospital, Nottingham, United Kingdom; 3 Inflammation<br />
Research Unit, University of Liverpool, Liverpool, United Kingdom<br />
RHEUMATOID ARTHRITIS PATIENTS TREATED WITH TOCILIZUMAB SHOW IMPROVED<br />
HAEMOGLOBIN LEVELS AND FACIT-FATIGUE SCORES<br />
J. S. Smolen 1 , M. Chester Wasko 2 , C. R. Ramos-Remus 3 , E. F. Mysler 4 , B. M. Day 5 ,<br />
C. Wiese 6 , R. Alten 7 ;<br />
1<br />
Department of <strong>Rheumatology</strong>, Vienna Medical University, Vienna, Austria; 2 University of<br />
Pittsburgh Medical Center, Pittsburgh, PA; 3 Department of <strong>Rheumatology</strong>, Centro Médico<br />
Occidente, Guadalajara, Mexico; 4 Organización Medica en Investigacion, Buenos Aires,<br />
Argentina; 5 Roche, Nutley, NJ; 6 Roche, Basel, Switzerland; 7 Schlosspark Klinik, Department<br />
of Medicine, Berlin, Germany<br />
Poster Viewing Two | Thursday 30 April 2009<br />
Poster No. 174<br />
ANALYSIS OF NEUTROPHIL COUNTS AND BASELINE DATA IN PATIENTS WITH SERIOUS<br />
INFECTIONS IN RECENT TOCILIZUMAB CLINICAL TRIALS<br />
J. S. Smolen 1 , R. van Vollenhoven 2 , A. Rubbert-Roth 3 , H. Kellner 4 , C. Ramos-Remus 5 ,<br />
B. M. Day 6 , T. Woodworth 7 , M. C. Genovese 8 ;<br />
1<br />
Medical University of Vienna and Heitzing Hospital, Vienna, Austria; 2 <strong>Rheumatology</strong> Unit,<br />
Karolinska University Hospital, Stockholm, Sweden; 3 Medical Hospital of the University of<br />
Cologne, Cologne, Germany; 4 Department of <strong>Rheumatology</strong>, Medical Policlinic Ludwig<br />
Maximilians University, Munich, Germany; 5 Department of <strong>Rheumatology</strong>, Centro Médico<br />
Occidente, Guadalajara, Mexico; 6 Roche, Nutley, NJ; 7 Roche, Welwyn, United Kingdom;<br />
8<br />
Stan<strong>for</strong>d University School of Medicine, Palo Alto, CA<br />
Poster No. 175<br />
Poster No. 176<br />
Poster No. 177<br />
ANALYSIS OF LOW-DENSITY LIPOPROTEIN AND ADVERSE EVENTS IN RHEUMATOID<br />
ARTHRITIS PATIENTS TREATED WITH TOCILIZUMAB PLUS STATINS: DATA FROM FIVE<br />
PHASE III CLINICAL TRIALS<br />
M. C. Genovese 1 , J. S. Smolen 2 , P. Emery 3 , G. Jones 4 , J. S. Lee 5 , E. Alecock 6 , J. M. Kremer 7 ;<br />
1<br />
Stan<strong>for</strong>d University School of Medicine, Palo Alto, CA; 2 Division of <strong>Rheumatology</strong>,<br />
Internal Medicine III, Medical University of Vienna, Vienna, Austria; 3 Medical Molecular Unit,<br />
University of Leeds, Leeds, United Kingdom; 4 University of Tasmania, Tasmania, TAS,<br />
Australia; 5 Roche, Nutley, NJ; 6 Roche, Welwyn, United Kingdom; 7 Albany Medical College<br />
and <strong>The</strong> Center <strong>for</strong> <strong>Rheumatology</strong>, Albany, NY<br />
MEDICAL STUDENT BURSARY WINNER<br />
AN INVESTIGATION OF THE MEDIA COVERAGE OF TOCILIZUMAB<br />
Joanne F. Anderson;<br />
<strong>Rheumatology</strong>, Royal Cornwall Hospital, Truro, United Kingdom<br />
TOLEROGENIC DENDRITIC CELLS: A NOVEL THERAPY FOR RHEUMATOID ARTHRITIS<br />
John D. Isaacs, Amy E. Anderson, Jeroen N. Stoop, Rachel A. Harry, David J. Swan,<br />
John H. Robinson, Catharien M. Hilkens;<br />
Musculoskeletal Research Group, Institute of Cellular Medicine, Newcastle University,<br />
Newcastle upon Tyne, United Kingdom<br />
71
Poster No. 178<br />
Poster No. 179<br />
Poster No. 180<br />
Poster No. 181<br />
Poster No. 182<br />
Poster No. 183<br />
Poster No. 184<br />
RITUXIMAB: A SAFER AND LONGER-LASTING ALTERNATIVE TO SWITCHING TO A SECOND<br />
ANTI-TNF AGENT IN RHEUMATOID ARTHRITIS PATIENTS<br />
Inmaculada de la Torre Ortega, Francisco Javier López Longo, Carlos Manuel González,<br />
Indalecio Monteagudo, Irene Díez-Merchan, Enrique Calvo, Elena Becerra, Luis Carreño;<br />
<strong>Rheumatology</strong>, Gregorio Marañón Hospital, Madrid, Spain<br />
SMOKING DECREASES THE EFFICACY OF ETANERCEPT IN RHEUMATOID ARTHRITIS<br />
A. Abhishek 1 , S. Butt 1 , K. Gadsby 1 , W. Zhang 2 , C. M. Deighton 1 ;<br />
1<br />
Department of <strong>Rheumatology</strong>, Derbyshire Royal Infirmary, Derby, United Kingdom; 2 Academic<br />
<strong>Rheumatology</strong>, University of Nottingham, Nottingham, United Kingdom<br />
DOES TREATMENT WITH RITUXIMAB INDUCE APOPTOSIS IN T LYMPHOCYTES?<br />
Joanna M. Tarr 1 , Katalin Szabo 1 , Richard C. Haigh 1,2 , Nick J. Viner 1,3 , Paul Eggleton 1 ,<br />
Paul G. Winyard 1 ;<br />
1<br />
Peninsula Medical School, Exeter, United Kingdom; 2 Royal Devon and Exeter Hospital, Exeter,<br />
United Kingdom; 3 Torbay Hospital, Torquay, United Kingdom<br />
TREATING EARLY RHEUMATOID ARTHRITIS (RA) INTENSIVELY: UK RHEUMATOLOGISTS<br />
VIEWS AND USE OF COMBINATION DISEASE MODIFYING ANTI-RHEUMATIC DRUGS<br />
(DMARDS)<br />
Toby Garrood 1 , Warren Shattles 1 , David L. Scott 2 ;<br />
1<br />
Department of <strong>Rheumatology</strong>, East Surrey Hospital, Redhill, United Kingdom; 2 Academic<br />
Department of <strong>Rheumatology</strong>, Kings College London, London, United Kingdom<br />
GOLIMUMAB SIGNIFICANTLY IMPROVES SELF-REPORTED PRODUCTIVITY IN PATIENTS WITH<br />
RHEUMATOID ARTHRITIS<br />
Paul Wordsworth 5 , Jacqueline Buchanan 1 , Roy Fleischmann 2 , Mark Genovese 3 , Jonathan Kay 4 ,<br />
Elizabeth Hsia 6 , Mittie Doyle 6 , Mahboob Rahman 6 , Chenglong Han 1 , Shreekant Parasuraman 1 ;<br />
1<br />
Johnson and Johnson Pharmaceutical Services, LLC, Malvern, PA; 2 University of Texas SW<br />
Medical Center, Dallas, TX; 3 Stan<strong>for</strong>d University, Palo Alto, CA; 4 Massachusetts General<br />
Hospital/Harvard Medical School, Boston, MA; 5 Nuffield Orthopaedic Center, Ox<strong>for</strong>d, United<br />
Kingdom; 6 Centocor Research and Development, Inc/Univ of Pennsylvania Medical School,<br />
Malvern/Philadelphia, PA<br />
PREVALENCE OF RISK FACTORS FOR STATIN-INDUCED MYOPATHY IN RHEUMATOID<br />
ARTHRITIS PATIENTS: DOES THE SLCO1B1 GENE PLAY A ROLE?<br />
Tracey E. Toms, Jacqueline P. Smith, Vasileios F. Panoulas, Karen M. Douglas,<br />
Athanasios N. Saratzis, George D. Kitas;<br />
Rhuematology, Dudley Group of Hospitals NHS trust, Dudley, United Kingdom<br />
GOLIMUMAB SIGNIFICANTLY IMPROVES PHYSICAL FUNCTION, HEALTH-RELATED QUALITY<br />
OF LIFE, AND FATIGUE IN RA(GO-FORWARD STUDY)<br />
Andrea Rubbert 1 , Mark C. Genovese 2 , Ed Keystone 3 , E. C. Hsia 4 , J. Buchanan 5 , Lars Klareskog 6 ,<br />
F. Murphy 7 , Z. Wu 8 , S. Parasuraman 5 , M. U. Rahman 4 ;<br />
1<br />
Univ Hosp Cologne, Cologne, Germany; 2 Stan<strong>for</strong>d Univ, Palo Alto, CA; 3 U Toronto/Mt Sinai<br />
Hosp, Toronto, ON, Canada; 4 Centocor R&D/U Penn Med School, Malvern/Philadelphia, PA;<br />
5<br />
JJPS, LLC, Malvern, PA; 6 Karolinska Inst/Hosp, Stockholm, Sweden; 7 Altoona Ctr <strong>for</strong> Clin<br />
Research, Duncansville, PA; 8 Centocor R&D, Inc., Malvern, PA<br />
72
Poster No. 185<br />
Poster No. 186<br />
Poster No. 187<br />
EFFICACY OF TOCILIZUMAB RELATIVE TO OTHER BIOLOGIC AGENTS IN PATIENTS WITH<br />
RHEUMATOID ARTHRITIS AND AN INADEQUATE RESPONSE TO TRADITIONAL DMARDs:<br />
A META-ANALYSIS WITH MIXED-TREATMENT COMPARISONS<br />
Gert Bergman 1 , Maarten Boers 2 , Marc C. Hochberg 3 , Adrian Kielhorn 4 , Neil S. Wintfeld 5 ,<br />
Jeroen P. Jansen 6 ;<br />
1<br />
Mapi Values, Houten, Netherlands; 2 VU University Medical Center, Amsterdam, Netherlands;<br />
3<br />
University of Maryland School of Medicine, Baltimore, MD; 4 Roche, Basel, Switzerland;<br />
5<br />
Roche, Nutley, NJ; 6 Mapi Values, Boston, MA<br />
TWO YEARS OF ADALIMUMAB AND METHOTREXATE COMBINATION THERAPY<br />
ASSOCIATED WITH GREATER INHIBITION OF RADIOGRAPHIC PROGRESSION<br />
AFTER 5 YEARS IN PATIENTS WITH EARLY RA<br />
A. L. Pangan 4 , D. van der Heijde 1 , R. Landewe 1 , E. C. Keystone 2 , K. Patra 3 , J. L. Perez 3 ;<br />
1<br />
Leiden University Medical Center, Leiden, Netherlands; 2 University of Toronto, Toronto, ON,<br />
Canada; 3 Abbott Laboratories, Parsippany, NJ; 4 Abbott Laboratories, Abbott Park, IL<br />
IN PATIENTS WITH EARLY RA WHO HAD ACHIEVED A NORMAL CRP, ADALIMUMAB<br />
INHIBITED RADIOGRAPHIC PROGRESSION MORE EFFECTIVELY THAN METHOTREXATE<br />
Paul Emery 1 , Mark Genovese 2 , Ronald F. van Vollenhoven 3 , Eric H. Sasso 4 ;<br />
1<br />
Leeds General Infirmary, Leeds, United Kingdom; 2 Stan<strong>for</strong>d University Medical Center,<br />
Palo Alto, CA; 3 Karolinska Hospital, Stockholm, Sweden; 4 Abbott Laboratories,<br />
Abbott Park, IL<br />
Poster Viewing Two | Thursday 30 April 2009<br />
Poster No. 188<br />
Poster No. 189<br />
Poster No. 190<br />
Poster No. 191<br />
CERTOLIZUMAB PEGOL DEMONSTRATES SIGNIFICANT IMPROVEMENTS IN PAIN AND<br />
QUALITY OF LIFE IN PATIENTS WITH ACTIVE RA DESPITE METHOTREXATE TREATMENT<br />
Peter Taylor 3 , Vibeke Strand 1 , Geoffroy Coteur 2 ;<br />
1<br />
Stan<strong>for</strong>d University School of Medicine, Stan<strong>for</strong>d, CA; 2 Global Health Outcomes Research,<br />
UCB, Braine l’Alleud, Belgium; 3 Kennedy Institute of <strong>Rheumatology</strong>, London, United Kingdom<br />
SUSTAINED LONG-TERM EFFICACY OF CERTOLIZUMAB PEGOL PLUS METHOTREXATE<br />
IN THE TREATMENT OF RHEUMATOID ARTHRITIS: A 2-YEAR ANALYSIS OF THE RAPID<br />
1 STUDY<br />
Josef Smolen 6 , Ed Keystone 1 , Michael Schiff 2 , Philip Mease 3 , Ronald van Vollenhoven 4 ,<br />
Chintu Desai 5 ;<br />
1<br />
Mount Sinai Hospital, Toronto, ON, Canada; 2 University of Colorado School of Medicine,<br />
Denver, CO; 3 Seattle <strong>Rheumatology</strong> Associates, Seattle, WA; 4 Karolinska University<br />
Hospital, Stockholm, Sweden; 5 UCB, Slough, United Kingdom; 6Medical University of<br />
Vienna, Vienna, Austria<br />
RHEUMATOID ARTHRITIS OUTCOMES IMPROVE WITH TOCILIZUMAB MONOTHERAPY<br />
REGARDLESS OF DISEASE DURATION<br />
M. Genovese 1 , D. Siri 2 , M. Tomsic 3 , R. Blackburn 4 , T. Woodworth 4 , G. Jones 5 ;<br />
1<br />
Stan<strong>for</strong>d University Medical Center, Palo Alto, CA; 2 Instituto CAICI, Rosario, Peru; 3 University<br />
Medical Centre, Ljubljana, Slovenia; 4 Roche, Welwyn, United Kingdom; 5 University of<br />
Tasmania, Hobart, TAS, Australia<br />
EVALUATION OF HEPATIC AMINOTRANSFERASES AND BILIRUBIN LEVELS DURING<br />
TOCILIZUMAB TREATMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS<br />
J. M. Kremer 1 , Ani K. John 2 , R. Malamet 3 , E. C. Keystone 3 ;<br />
1<br />
Albany Medical College and <strong>The</strong> Center <strong>for</strong> <strong>Rheumatology</strong>, Albany, NY; 2 Roche, Nutley, NJ;<br />
3<br />
University of Toronto, Toronto, ON, Canada<br />
73
Poster No. 192<br />
AN INTERIM ANALYSIS OF LONG-TERM EXTENSION TRIALS OF TOCILIZUMAB IN PATIENTS<br />
WITH RHEUMATOID ARTHRITIS<br />
R. F. van Vollenhoven 1 , J. S. Smolen 2 , H. P. Tony 3 , C. Codding 4 , E. C. Keystone 5 , T. Woodworth 6 ,<br />
E. Alecock 6 , R. Alten 7 ;<br />
1<br />
<strong>Rheumatology</strong> Unit, Karolinska University Hospital, Stockholm, Sweden; 2 Division of<br />
<strong>Rheumatology</strong>, Internal Medicine III, Medical University of Vienna and 2nd Department<br />
of Medicine, Hietzing Hospital, Vienna,, Austria; 3 <strong>Rheumatology</strong> & Clinical Immunology,<br />
Medizinische Klinik II, Wuerzburg, Germany; 4 1211 N Shartel Ave Ste 700, Oklahoma City, OK;<br />
5<br />
University of Toronto, Toronto, ON, Canada; 6 Roche, Welwyn, United Kingdom; 7 Teaching hospital<br />
of Charite, University of Berlin, Berlin, Germany<br />
Poster No. 193<br />
Poster No. 194<br />
TOCILIZUMAB IS WELL TOLERATED IN PATIENTS WITH RHEUMATOID ARTHRITIS WITH A<br />
LOW RATE OF SERIOUS ADVERSE EVENTS<br />
J. S. Smolen 1 , A. D. Beaulieu 2 , A. Dikranian 3 , I. Fenton 4 , E. Fisheleva 5 , E. Alecock 5 , P. Emery 6 ;<br />
1<br />
Medical University of Vienna, Vienna, Austria; 2 Centre de Rhumatologie St Louis, Quebec, QC,<br />
Canada; 3 San Diego Arthritis Medical Clinic, San Diego, CA; 4 Deerbrook Medical Associates,<br />
Illinois, IL; 5 Roche, Welwyn, United Kingdom; 6 Medical Molecular Unit,St James’s University,<br />
Leeds, United Kingdom<br />
RELATION BETWEEN YEAR 1 DAS28 STATUS AND 2 YEAR DISEASE ACTIVITY, FUNCTION<br />
AND EMPLOYMENT IN DMARD TREATED RA PATIENTS IN THE EARLY RHEUMATOID<br />
ARTHRITIS NETWORK (ERAN)<br />
Patrick D. Kiely 1,2 , Keeranur Jayakumar 1,3 , Sam Norton 1,4 , Richard Williams 1,5 , David Walsh 1,6 ,<br />
Adam Young 1,3 , On behalf of ERAN centers 1 ;<br />
1<br />
Early Rheumatoid Arthritis Network, St Albans, United Kingdom; 2 <strong>Rheumatology</strong>, St Georges<br />
Healthcare NHS Trust, London, United Kingdom; 3 <strong>Rheumatology</strong>, St Albans City Hospital,<br />
St Albans, United Kingdom; 4 Research Design Services, University of Hert<strong>for</strong>dshire, Hatfield,<br />
United Kingdom; 5 <strong>Rheumatology</strong>, Here<strong>for</strong>d Hospitals NHS Trust, Here<strong>for</strong>d, United Kingdom;<br />
6<br />
<strong>Rheumatology</strong>, University of Nottingham and Sherwood Forest NHSFT, Nottingham,<br />
United Kingdom<br />
Poster No. 195<br />
Poster No. 196<br />
CONTINUED INHIBITION OF STRUCTURAL DAMAGE IN RHEUMATOID ARTHRITIS PATIENTS<br />
TREATED WITH RITUXIMAB AT 2 YEARS: REFLEX STUDY<br />
Stanley B. Cohen 1 , Edward C. Keystone 2 , Mark Genovese 3 , Paul Emery 4 , Charles Peterfy 5 ,<br />
Paul-Peter Tak 6 , Mathew W. Cravets 7 , Tim Shaw 8 , David Hagerty 7 ; 1 Metroplex Clinical Research<br />
Center, Dallas, TX; 2 University of Toronto, Toronto, ON, Canada; 3 Stan<strong>for</strong>d University, Stan<strong>for</strong>d,<br />
CA; 4 Leeds University, Leeds, United Kingdom; 5 Synarc Inc., San Francisco, CA; 6 Academic<br />
Medical Center/University of Amsterdam, Amsterdam, Netherlands; 7 Biogen Idec Inc.,<br />
San Diego, CA; 8 Roche Products Ltd, Welwyn Garden City, United Kingdom<br />
BENEFIT OF ANTI-TNF THERAPY IN RHEUMATOID ARTHRITIS PATIENTS WITH<br />
MODERATE DISEASE ACTIVITY: RESULTS FROM THE BSR BIOLOGICS REGISTER<br />
Kimme Hyrich 1 , Chris Deighton 2 , Kath Watson 1 , . BSRBR Control Centre Consortium 1 , Deborah<br />
Symmons 1 , Mark Lunt 1 , . on behalf of the BSRBR 1 ;<br />
1<br />
arc Epidemiology Unit, University of Manchester, Manchester, United Kingdom; 2 Dept of<br />
<strong>Rheumatology</strong>, Derbyshire Royal Infirmary, Derby, United Kingdom<br />
74
Poster No. 197<br />
Poster No. 198<br />
Poster No. 199<br />
RITUXIMAB IN COMBINATION WITH METHOTREXATE OR LEFLUNOMIDE IN RA: CLINICAL,<br />
IMAGING AND FLOW CYTOMETRIC OUTCOMES<br />
Edward M. Vital 1 , Jane E. Freeston 1 , Shouvik Dass 1 , Laszlo Szabo 1 , Frederique Ponchel 1 ,<br />
Andrew C. Rawstron 2 , Paul Emery 1 ;<br />
1<br />
Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine,University of<br />
Leeds, Leeds, United Kingdom; 2 Haematological Malignancy Diagnostic Service, Leeds<br />
Teaching Hospitals NHS Trust, Leeds, United Kingdom<br />
TOCILIZUMAB IMPROVES AND MAINTAINS HAQ-DI SCORES LONG TERM IN PATIENTS<br />
WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS: A POOLED ANALYSIS<br />
Pierre Ducournau 1 , Rieke Alten 2 , Ronald van Vollenhoven 3 , Claire Davies 4 ;<br />
1<br />
Roche, Basel, Switzerland; 2 University of Berlin, Berlin, Germany; 3 Karolinska<br />
University Hospital, Stockholm, Sweden; 4 Roche, Welwyn, United Kingdom<br />
CERTOLIZUMAB PEGOL DEMONSTRATES RESPONSE AS EARLY AS WEEK 1 IN<br />
MODERATE-SEVERE RA PATIENTS<br />
Vibeke Strand 3 , Geoffroy Coteur 1 , Lucian Ionescu 2 ;<br />
1<br />
Global Health Outcomes Research, UCB, Braine l’Alleud, Belgium; 2 Global Medical Affairs,<br />
UCB, Anderlecht, Belgium; 3 Stan<strong>for</strong>d University School of Medicine, Stan<strong>for</strong>d, CA<br />
Poster Viewing Two | Thursday 30 April 2009<br />
Poster No. 200<br />
Poster No. 201<br />
Poster No. 202<br />
RAPID AND SIGNIFICANT REDUCTION IN DISEASE ACTIVITY WITH TOCILIZUMAB IN<br />
COMBINATION WITH SIX DIFFERENT DMARDS IN RHEUMATOID ARTHRITIS PATIENTS<br />
WITH AN INADEQUATE RESPONSE TO DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS:<br />
THE TOWARD STUDY<br />
J. J. Gomez-Reino 1 , E. L. Nasonov 2 , J. D. McKay 3 , E. F. Mysler 4 , N. da Silva 5 , E. Alecock 6 ,<br />
T. Woodworth 6 , M. C. Genovese 7 ;<br />
1<br />
Clinical Hospital, Santiago de Compostela University, Santiago de Compostela, Spain;<br />
2<br />
Institute of <strong>Rheumatology</strong>, Moscow, Russia; 3 Oklahoma State University, Tulsa, OK;<br />
4<br />
Organization <strong>for</strong> Medical Investigations, Buenos Aires, Argentina; 5 Federal University of<br />
Goiás, Goiania, Brazil, Brazil; 6 Roche, Welwyn, United Kingdom; 7 Stan<strong>for</strong>d University,<br />
Palo Alto, CA<br />
RHEUMATOID ARTHRITIS PATIENTS ACHIEVED RAPID AND SUSTAINED DECREASE<br />
IN BONE AND CARTILAGE DEGRADATION WHEN TREATED WITH TOCILIZUMAB<br />
P. Garnero 1 , E. Mareau 2 , L. Thompson 3 , T. Woodworth 3 ;<br />
1<br />
Synarc, INSERM Research Unit 664, Lyon, France; 2 Synarc, Lyon, France; 3 Roche Products<br />
Ltd, Welwyn, United Kingdom<br />
RHEUMATOID ARTHRITIS PATIENTS WITH INADEQUATE REPONSE TO TUMOUR NECROSIS<br />
FACTOR ANTAGONISTS SHOW RAPID AND SIGNIFICANT IMPROVEMENTS IN CLINICAL<br />
OUTCOME WHEN TREATED WITH TOCILIZUMAB<br />
P. Emery 1 , E. Keystone 2 , H. P. Tony 3 , A. Cantagrel 4 , R. van Vollenhoven 5 , A. Sanchez 6 ,<br />
E. Alecock 7 , J. Lee 8 , J. Kremer 9 ;<br />
1<br />
University of Leeds, Leeds, United Kingdom; 2 Mount Sinai Hospital, Toronto, ON, Canada;<br />
3<br />
Medizinische Klinik II, Würzburg, Germany; 4 Hôpital Rangueil, Toulouse, United Kingdom;<br />
5<br />
Karolinska University Hospital, Stockholm, Sweden; 6 Hospital de Especialidades,<br />
Guadalajara, Mexico; 7 Roche, Welwyn, United Kingdom; 8 Roche, Nutley, NY; 9Albany<br />
Medical Center, Albany, NY<br />
75
Poster No. 203<br />
Poster No. 204<br />
LIPID AND INFLAMMATORY BIOMARKER PROFILES WERE EVALUATED IN FIVE<br />
TOCILIZUMAB PHASE III CLINICAL TRIALS CONDUCTED IN RHEUMATOID ARTHRITIS<br />
PATIENTS<br />
M. C. Genovese 1 , J. S. Smolen 2 , P. Emery 3 , G. Jones 4 , J. S. Lee 5 , E. Alecock 6 , J. M. Kremer 7 ;<br />
1<br />
Stan<strong>for</strong>d University School of Medicine, Palo Alto, CA; 2 Department of <strong>Rheumatology</strong> Internal<br />
Medicine III, Medical University of Vienna, Vienna, Austria; 3 Medical Molecular Unit, St James<br />
University, Leeds, United Kingdom; 4 University of Tasmania Menzies Research Institute, Hobart,<br />
TAS, Australia; 5 Roche, Nutley, NJ; 6 Roche, Welwyn, United Kingdom; 7 Albany Medical College<br />
and <strong>The</strong> Center <strong>for</strong> <strong>Rheumatology</strong>, Albany, NY<br />
SAFETY OF OTHER BIOLOGIC THERAPIES FOLLOWING RITUXIMAB TREATMENT IN<br />
RA PATIENTS<br />
Mark C. Genovese 1 , Ferdinand C. Breedveld 2 , Paul Emery 3 , Stanley B. Cohen 4 ,<br />
Edward Keystone 5 , Eric Matteson 6 , Yvette Baptiste 7 , Laura Burke 7 , William Reiss 8 ,<br />
Marianne Sweetser 9 , Tim Shaw 7 ;<br />
1<br />
Stan<strong>for</strong>d University, Stan<strong>for</strong>d, CA; 2 Leiden University Medical Centre, Leiden, Netherlands;<br />
3<br />
Leeds General Infirmary, Leeds, United Kingdom; 4 Metroplex Clinical Research Center,<br />
Dallas, TX; 5 University of Toronto, Toronto, ON, Canada; 6 Mayo Clinic, Rochester, MN;<br />
7<br />
Roche, Welwyn Garden City, United Kingdom; 8 Genentech, San Francisco, CA; 9 Biogen<br />
Idec Inc., Cambridge, MA<br />
Poster No. 205<br />
RAPID AND SIGNIFICANT REDUCTION OF DAS28 FOLLOWING TOCILIZUMAB TREATMENT<br />
IN PATIENTS WITH RHEUMATOID ARTHRITIS INADEQUATELY RESPONDING TO<br />
DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS<br />
J. S. Smolen 1 , E. F. Mysler 2 , A. Rubbert-Roth 3 , J. Gomez-Reino 4 , R. Alten 5 , A. Law 6 ,<br />
T. Woodworth 7 , M. Genovese 8 ;<br />
1<br />
Hietzing Hospital, Vienna, Austria; 2 Organization <strong>for</strong> Medical Investigations, Buenos Aires,<br />
Argentina; 3 University of Cologne, Cologne, Germany; 4 University of Santiago de Compostela,<br />
Santiago de Compostela, Spain; 5 Schlosspark Clinic, University Medicine, Berlin, Germany;<br />
6<br />
Roche, Nutley, NJ; 7 Roche, Welwyn, United Kingdom; 8 Stan<strong>for</strong>d University, Palo Alto, CA<br />
Poster No. 206<br />
CERTOLIZUMAB PEGOL DEMONSTRATES SIGNIFICANT IMPROVEMENTS IN THE<br />
PRODUCTIVITY OF PATIENTS WITH ACTIVE RA, PARTICULARLY IN THE HOME<br />
Paul Emery 4 , Josef Smolen 1 , Oana Purcaru 2 , Lance Richard 3 ;<br />
1<br />
University of Vienna, Vienna, Austria; 2 Global Health Outcomes Research, UCB, Inc,<br />
Brussels, Belgium; 3 Global Health Outcomes Research, UCB, Inc, Slough, United Kingdom;<br />
4<br />
Leeds General Infirmary, Leeds, United Kingdom<br />
Poster No. 207<br />
TOCILIZUMAB DEMONSTRATES SUPERIORITY TO METHOTREXATE MONOTHERAPY<br />
IN PATIENTS WITH RHEUMATOID ARTHRITIS: THE AMBITION STUDY<br />
G. Jones 1 , J. R. Gu 2 , M. Lowenstein 3 , A. Calvo 4 , J. J. Gomez-Reino 5 , D. Siri 6 , M. Tomsic 7 , R.<br />
Blackburn 8 , T. Woodworth 8 , A. Sebba 9 , M. Genovese 10 ;<br />
1<br />
University of Tasmania, Hobart, TAS, Australia; 2 Hospital of Sun Yat-sen University, Guangzhou,<br />
China; 3 Arthritis Center, Palm Harbor, FL; 4 Universidad Peruana, San Felipe Clinic, Peru;<br />
5<br />
University of Santiago de Compostela, Santiago de Compostela, Spain; 6 Instituto CAICI,<br />
Rosario, Argentina; 7 University Medical Centre, Ljubljana, Slovenia; 8 Roche, Welwyn, United<br />
Kingdom; 9 Arthritis Research of Florida, Palm Harbor, FL; 10 Stan<strong>for</strong>d University Medical Center,<br />
Palo Alto, CA<br />
76
Poster No. 208<br />
Poster No. 209<br />
Poster No. 210<br />
DIFFERING DISTRIBUTION OF CERTOLIZUMAB PEGOL, ADALIMUMAB AND INFLIXIMAB IN<br />
THE INFLAMED PAWS OF MICE WITH COLLAGEN-INDUCED ARTHRITIS COMPARED WITH<br />
NORMAL MICE<br />
Andrew Nesbitt, Roger Palframan, Alexander Vugler, Roly Foulkes, Neil Gozzard; Inflammation<br />
Discovery, UCB, Slough, United Kingdom<br />
GOLIMUMAB ADMINISTERED SUBCUTANEOUSLY EVERY 4WEEKS IN ACTIVE<br />
RHEUMATOID ARTHRITIS DESPITE METHOTREXATE: WEEK 24 RESULTS OF<br />
GO-FORWARD STUDY<br />
Andrea Rubbert 1 , Ed Keystone 2 , Mark Genovese 3 , Lars Klareskog 4 , E. C. Hsia 5 , J. Zrubek 6 , Z.<br />
Wu 6 , M. U. Rahman 5 , <strong>for</strong> the GO-FORWARD Study Investigators 6 ;<br />
1<br />
University Hospital College, Cologne, Germany; 2 University of Toronto/Mount Sinai Hospital,<br />
Toronto, ON, Canada; 3 Stan<strong>for</strong>d University, Palo Alto, CA; 4 Karolinska Institute & Hospital,<br />
Stockholm, Sweden; 5 Centocor Research and Development, Inc/University of Pennsylvania,<br />
Malvern/Philadelphia, PA; 6 Centocor Research and Development, Inc, Malvern, PA<br />
YOUNG INVESTIGATOR AWARD WINNER<br />
HOW TO MANAGE NON-RESPONSE TO RITUXIMAB? PREDICTORS AND OUTCOME OF<br />
RETREATMENT PROVIDE A TREATMENT ALGORITHM<br />
Edward M. Vital 1 , Shouvik Dass 1 , Elizabeth A. Horner 1 , Vincent Goeb 1 , Andrew Rawstron 2 ,<br />
Frederique Ponchel 1 , Paul Emery 1 ;<br />
1<br />
Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine,University of<br />
Leeds, Leeds, United Kingdom; 2 Haematological Malignancy Diagnostic Service, Leeds<br />
Teaching Hospitals NHS Trust, Leeds, United Kingdom<br />
Poster Viewing Two | Thursday 30 April 2009<br />
Poster No. 211<br />
GOLIMUMAB, A NEW HUMAN ANTI-TNF-ALPHA MONOCLONAL ANTIBODY, IN<br />
METHOTREXATE-NAÏVE ACTIVE RHEUMATOID ARTHRITIS (GO-BEFORE STUDY)<br />
Paul Emery 1 , Roy M. Fleischmann 2 , Larry W. Moreland 3 , E. C. Hsia 4 , W. Xu 5 , M. U. Rahman 4 ,<br />
<strong>for</strong> GO-BEFORE Study Investigators 5 ;<br />
1<br />
University of Leeds, Leeds, United Kingdom; 2 University of Texas/SW Medical Center, Dallas,<br />
TX; 3 University of Pittsburgh, Pittsburgh, PA; 4 Centocor Research and Development,<br />
Inc./University of Pennsylvania, Malvern/Philadelphia, PA; 5 Centocor Research and<br />
Development, Inc., Malvern, PA<br />
Poster No. 212<br />
THE LITHE STUDY DEMONSTRATES THAT TOCILIZUMAB INHIBITS STRUCTURAL JOINT<br />
DAMAGE IN RHEUMATOID ARTHRITIS PATIENTS WITH AN INADEQUATE RESPONSE TO<br />
METHOTREXATE<br />
J. M. Kremer 1 , R. M. Fleischmann 2 , A. M. Halland 3 , J. Brzezcki 4 , T. Woodworth 5 ,<br />
E. Fisheleva 5 , E. Alecock 5 , R. Burgos-Vargas 6 ;<br />
1<br />
Albany Medical College and <strong>The</strong> Center <strong>for</strong> <strong>Rheumatology</strong>, Albany, NY; 2 Metroplex Clinical<br />
Research Center, Dallas, TX; 3 Arthritis Research Center,Panorama Hospital, Cape Town,<br />
South Africa; 4 Oddzial Reumatologiczny, Elblag, Poland; 5 Roche, Welwyn,<br />
United Kingdom; 6 Hospital General de México, Mexico City, Mexico<br />
Paediatric and adolescent rheumatology<br />
Poster No. 213<br />
“TO FIND THE RIGHT ANSWERS, YOU NEED TO ASK THE RIGHT QUESTIONS.”<br />
CONSUMER INVOLVEMENT IN SETTING OUR RESEARCH AGENDA<br />
Helen Hill 1 , Jane Kelly 1 , Sue Kemp 1 , Eileen Baildam 1 , Gavin Cleary 1 , Liza McCann 1 ,<br />
Beres<strong>for</strong>d Michael 2,1 ;<br />
1<br />
Department of <strong>Rheumatology</strong>, Alder Hey Children’s NHS Foundation Trust, Liverpool, United<br />
Kingdom; 2 Institute of Child Health, University of Liverpool, Liverpool, United Kingdom<br />
77
Poster No. 214<br />
ACCEPTABILITY AND PRACTICALITY OF MUSCULOSKELETAL EXAMINATION (pGALS)<br />
IN ACUTE PAEDIATRIC ASSESSMENT<br />
Iain Goff 1 , Belinda J. Bateman 2 , Andrea Myers 3,4 , Helen E. Foster 4,5 ;<br />
1<br />
Education Department, Northumbria Healthcare NHS Foundation Trust, North Shields, United<br />
Kingdom; 2 Department of Paediatrics, Northumbria Healthcare NHS Foundation Trust, North<br />
Shields, United Kingdom; 3 Department of <strong>Rheumatology</strong>, Northumbria Healthcare NHS<br />
Foundation Trust, North Shields, United Kingdom; 4 Newcastle Musculoskeletal Research Group,<br />
University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom; 5 Department of<br />
<strong>Rheumatology</strong>, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne,<br />
United Kingdom<br />
Soft tissue and regional musculoskeletal disease, fibromyalgia<br />
Poster No. 215<br />
Poster No. 216<br />
Poster No. 217<br />
RECURRENT GREATER TROCHANTERIC BURSITIS: AN ATYPICAL PRESENTATION<br />
OF DISC PROLAPE/ NERVE ROOT IRRITATION AT L4/5<br />
Yasser El Miedany 1 , Maha El Gaafary 2 , Sally Youssef 1 , Annie N. Mehanna 3 ;<br />
1<br />
<strong>Rheumatology</strong> and Rehabilitation, Ain Shams University, Cairo, Egypt; 2 Community,<br />
Environmental and Occupational Medicine, Ain Shams University, Cairo, Egypt; 3 Radiology,<br />
Ain Shams University, Cairo, Egypt<br />
OUTCOME OF CARDIOVASCULAR AUTONOMIC TESTING IN SYMPTOMATIC<br />
PATIENTS WITH BENIGN JOINT HYPERMOBILITY SYNDROME<br />
Alan J. Hakim 1 , Chris Mathias 2 , Rodney Grahame 1 ;<br />
1<br />
Department of <strong>Rheumatology</strong>, University College Hospital, London, United Kingdom; 2 <strong>The</strong><br />
Autonomic Unit, National Hospital <strong>for</strong> Neurology and Neurosurgery, London, United Kingdom<br />
JOINT HYPERMOBILITY & FUNCTIONAL GASTROINTESTINAL DISORDERS - IS CONNECTIVE<br />
TISSUE THE MISSING LINK?<br />
Adam D. Farmer 1 , Natalia Zarate-Lopez 1 , Sahar Mohammed 1 , S Mark Scott 1 ,<br />
Charles H. Knowles 1 , Rodney Grahame 2 , Qasim Aziz 1 ;<br />
1<br />
Wingate Institute of Neurogastroenterology, Barts and the London School of Medicine and<br />
Dentistry, London, United Kingdom; 2 Centre <strong>for</strong> <strong>Rheumatology</strong>, University College London<br />
Hospital, London, United Kingdom<br />
Poster No. 218 CLINICAL EVIDENCE OF PARIETAL LOBE DYSFUNCTION IN PATIENTS WITH CRPS TYPE 1<br />
Helen E. Cohen 1,2 , Candy S. McCabe 1,2 , Nigel Harris 1,2 , David R. Blake 1,2 ;<br />
1<br />
Royal National Hospital <strong>for</strong> Rheumatic Diseases, Bath, United Kingdom; 2 School <strong>for</strong> Health,<br />
University of Bath, Bath, United Kingdom<br />
Poster No. 219<br />
PERSONAL SOCIAL SUPPORT NETWORKS ARE ASSOCIATED WITH THE<br />
ONSET OF CHRONIC WIDESPREAD PAIN<br />
Lis Cordingley 1 , Barbara Nicholl 2 , John McBeth 2 ;<br />
1<br />
Translational Medicine, University of Manchester, Manchester, United Kingdom;<br />
2<br />
arc Epidemiology Unit, University of Manchester, Manchester, United Kingdom<br />
Poster No. 220<br />
MASSAGE IN CARPAL TUNNEL SYNDROME: A RATIONAL APPROACH<br />
Yasser El Miedany 1 , Maha El Gaafary 2 , Ihab Ahmed 4 , Annie Mehanna 3 , Sally Youssef 1 ;<br />
1<br />
<strong>Rheumatology</strong> and Rehabilitation, Ain Shams University, Cairo, Egypt; 2 Community,<br />
Environmental and Occupational Medicine, Ain Shams University, Cairo, Egypt; 3 Radiology<br />
Department, Ain Shams University, Cairo, Egypt; 4 Internal Medicine Department, Cairo<br />
University, Cairo, Egypt<br />
78
Poster No. 221<br />
Poster No. 222<br />
IS THERE A WINDOW OF OPPORTUNITY FOR PHYSIOTHERAPY AFTER STEROID<br />
INJECTIONS FOR SHOULDER PAIN? RESULTS FROM A LARGE RANDOMISED TRIAL<br />
Dickon P. Crawshaw 1,2 , Philip Helliwell 1 , Elizabeth M. Hensor 1 , Elaine M. Hay 3 ,<br />
Simon J. Aldous 4 , Philip G. Conaghan 1 ;<br />
1<br />
Section of Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom;<br />
2<br />
Leeds Musculoskeletal and Rehabilitation Service, NHS Leeds, Leeds, United Kingdom;<br />
3<br />
Primary Care Musculoskeletal Research Centre, Keele University, Keele, United Kingdom;<br />
4<br />
Physiotherapy Department, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom<br />
EXPERIENCES OF ADDENBROOKE’S HOSPITAL COMPLEX REGIONAL PAIN SYNDROME<br />
CLINIC<br />
Maliha F. Shaikh, Nicholas G. Shenker;<br />
<strong>Rheumatology</strong> Research Unit, Addenbrooke’s Hospital, Cambridge University Hospitals NHS<br />
Foundation Trust, Cambridge, United Kingdom<br />
Psychology, measurement and management of pain<br />
Poster Viewing Two | Thursday 30 April 2009<br />
Poster No. 223<br />
NECK, SHOULDER AND UPPER ARM PAIN. IS IT ALL IN THE MIND?<br />
Gemma C. Gillings 1 , Emma Wall 1 , Helen Smith 2 , Karen Walker-Bone 1 ;<br />
1<br />
<strong>Rheumatology</strong>, Brighton and Sussex Medical School, Brighton, United Kingdom;<br />
2<br />
Division of Primary Care, Brighton & Sussex Medical School, Brighton, United Kingdom<br />
Poster No. 224<br />
Poster No. 225<br />
EXPERIMENTAL MODIFICATION OF EXPECTATIONS AND BELIEFS ABOUT PAIN<br />
IN PATIENTS WITH FIBROMYALGIA AND HEALTHY CONTROLS<br />
Christopher Brown, Anthony Jones;<br />
Clinical Neurosciences Research Group, University of Manchester, Manchester,<br />
United Kingdom<br />
THE REPRODUCIBILITY OF PLACEBO ANALGESIA<br />
Debbie Morton 1 , Alison Watson 1 , Wael El-Deredy 2 , Anthony Jones 1 ;<br />
1<br />
Sal<strong>for</strong>d Royal Hospital, Sal<strong>for</strong>d, United Kingdom; 2 Psychology, Manchester University,<br />
Manchester, United Kingdom<br />
Osteoarthritis<br />
Poster No. 226<br />
Poster No. 227<br />
RADIOGRAPHIC OA IN THE 1ST CMC JOINT AND THE THUMB AS A WHOLE:<br />
ASSOCIATIONS WITH PAIN, CLINICAL FEATURES AND TEST RESULTS<br />
Michelle Marshall 1 , Danielle A. van der Windt 1,2 , Helen Myers 1 , Elaine E. Nicholls 1 ,<br />
Krysia S. Dziedzic 1 ;<br />
1<br />
Arthritis Research Campaign National Primary Care Centre, Keele University, Keele,<br />
United Kingdom; 2 Department of General Practice and EMGO Institute, VU University<br />
medical centre, Amsterdam, Netherlands<br />
THE IMPACT OF CONSTANT AND INTERMITTENT PAIN IN PEOPLE WITH HAND<br />
OSTEOARTHRITIS<br />
Krysia Dziedzic 1 , George Peat 1 , Elaine Nicholls 1 , Helen Myers 1 , Susan Hill 1 ,<br />
Michelle Marshall 1 , Danielle van der Windt 1,2 ;<br />
1<br />
Arthritis Research Campaign National Primary Care Centre, Keele University, Keele,<br />
United Kingdom; 2 EMGO Institute, VU University Medical Centre, Amsterdam, Netherlands<br />
79
Poster No. 228<br />
Poster No. 229<br />
Poster No. 230<br />
A MULTICENTRE AUDIT OF THE MANAGEMENT OF OSTEOARTHRITIS IN THE UNITED<br />
KINGDOM<br />
Michael Pieri 1 , Ramin Yazdani 2 , Nicholas Shenker 3 , Michael Doherty 2 , Fraser Birrell 1,4 ;<br />
1<br />
Northumbria Healthcare NHS Trust, Newcastle Upon Tyne, United Kingdom; 2 City Hospital,<br />
Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; 3 Addenbrooke’s<br />
Hospital, Cambridge University Hospitals NHS Trust, Cambridge, United Kingdom; 4 Newcastle<br />
University, Newcastle Upon Tyne, United Kingdom<br />
KNEE ALIGNMENT IN THE GENERAL POPULATION: IS THERE AN ASSOCIATION WITH<br />
TIBIOFEMORAL AND PATELLOFEMORAL OSTEOARTHRITIS?<br />
Alexandra N. Colebatch 1 , Kelsey M. Jordan 2 , Lyndsey M. Goulston 1 , Elaine M. Dennison 1 ,<br />
Cyrus Cooper 1 , Nigel K. Arden 1,3 ;<br />
1<br />
MRC Epidemiology Resource Centre, Southampton General Hospital, Southampton, United<br />
Kingdom; 2 Hayward’s Heath Hospital, Hayward’s Heath, United Kingdom; 3 Biomedical Research<br />
Unit, University of Ox<strong>for</strong>d, Ox<strong>for</strong>d, United Kingdom<br />
OSTEOCHONDRAL ANGIOGENESIS DESPITE INCREASED PROTEASE INHIBITOR<br />
EXPRESSION IN OA<br />
David A. Walsh 1,2 , Rebecca E. Franses 1 , Daniel F. McWilliams 1 ;<br />
1<br />
Academic <strong>Rheumatology</strong>, University of Nottingham, Nottingham, United Kingdom;<br />
2<br />
<strong>Rheumatology</strong>, Sherwood Forest NHS Foundation Trust, Mansfield, United Kingdom<br />
Poster No. 231<br />
NSAID USE BEFORE AND AFTER 28068 HIP AND 23634 KNEE ARTHROPLASTIES: RESULTS<br />
FROM THE UK GENERAL PRACTICE RESEARCH DATABASE<br />
Joe Maskell 1 , David Culli<strong>for</strong>d 2 , Mark Mullee 2 , Rafael Azagra 3 , Muhammad Javaid 4 ,<br />
Nigel Arden 3,4 ;<br />
1<br />
PHSMS, University of Southampton, Southampton, United Kingdom; 2 RDSU,<br />
University of Southampton, Southampton, United Kingdom; 3 MRC ERC, University of<br />
Southampton, Southampton, United Kingdom; 4 Botnar NIHR BRU, Nuff Dept Orthopaedics,<br />
University of Ox<strong>for</strong>d, Ox<strong>for</strong>d, United Kingdom<br />
Poster No. 232<br />
LINK BETWEEN THE SEVERITY OF OSTEOARTHRITIS AND THE SHAPE OF THE HIP JOINT<br />
USING DXA IMAGES<br />
Kanako Yoshida 1 , Rebecca J. Barr 1 , Jennifer S. Gregory 1 , Richard M. Aspden 1 , Salvatore Alesci 3 ,<br />
Gary J. Macfarlane 2 , David M. Reid 1 ;<br />
1<br />
Bone and Musculoskeletal <strong>Programme</strong>, School of Medicine & Dentistry, University of<br />
Aberdeen, Aberdeen, United Kingdom; 2 Epidemiology Research <strong>Programme</strong>, School of<br />
Medicine & Dentistry, University of Aberdeen, Aberdeen, United Kingdom; 3 Discovery<br />
Translational Medicine, Wyeth Research, Collegeville, PA<br />
Poster No. 233<br />
PREDICTORS OF KNEE PAIN AT 15 YEARS IN THE CHINGFORD STUDY - IS THERE AN<br />
INTERACTION BETWEEN BASELINE BODY WEIGHT AND RADIOGRAPHIC OSTEOARTHRITIS?<br />
Lyndsey M. Goulston 1 , Kassim Javaid 3 , Debbie J. Hart 2 , Tim D. Spector 2 , Nigel K. Arden 1,3 ;<br />
1<br />
MRC Epidemiology Resource Centre, University of Southampton, Southampton, United<br />
Kingdom; 2 Twin Research and Genetic Epidemiology Unit, St Thomas’ Hospital - King’s College<br />
London, London, United Kingdom; 3 Biomedical Research Unit, University of Ox<strong>for</strong>d, Ox<strong>for</strong>d,<br />
United Kingdom<br />
80
Poster No. 234<br />
Poster No. 235<br />
PREDICTING OSTEOARTHRITIS PROGRESSION TO TOTAL HIP REPLACEMENT: CAN<br />
WE DO BETTER THAN RISK FACTORS ALONE USING ACTIVE SHAPE MODELLING?<br />
Rebecca J. Barr 1 , Jennifer Gregory 1 , David M. Reid 1 , Richard Aspden 1 , Kanako Yoshida 1 ,<br />
Salvatore Alesci 2 , Gillian Hosie 3 , Alan Silman 4 , Gary J. Macfarlane 5 ;<br />
1<br />
Division of Applied Medicine, University of Aberdeen, Aberdeen, United Kingdom; 2 Discovery<br />
Translational Medicine, Wyeth Research, Collegeville, PA; 3Primary Care <strong>Rheumatology</strong><br />
<strong>Society</strong>, Northallerton, United Kingdom; 4 Department of <strong>Rheumatology</strong>, University of<br />
Manchester, Manchester, United Kingdom; 5 Division of Applied Health Science, University of<br />
Aberdeen, Aberdeen, United Kingdom<br />
INSIGHTS INTO THE PATHOGENESIS OF PROGRESSIVE FOOT AND ANKLE JOINT<br />
DESTRUCTION FROM A MAGNETIC RESONANCE IMAGING STUDY OF CHARCOT’S<br />
ARTHROPATHY AND OSTEOARTHRITIS<br />
Jill Halstead 1 , Diane Bergin 3 , Julie Madden 2 , Dennis McGonagle 1 ;<br />
1<br />
Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of<br />
Leeds, Leeds, United Kingdom; 2 Department of <strong>Rheumatology</strong>, Calderdale and Huddersfield<br />
NHS Trust, Halifax, United Kingdom; 3 Department of Radiology, Galway University Hospital,<br />
Galway, Ireland<br />
Poster Viewing Two | Thursday 30 April 2009<br />
Poster No. 236<br />
ANGIOGENESIS IN THE TRANSITION FROM RESOLVING TO PERSISTENT SYNOVITIS<br />
Sadaf Ashraf, Paul I. Mapp, David A. Walsh;<br />
Academic <strong>Rheumatology</strong>, University of Nottingham, Nottingham, United Kingdom<br />
Orthopaedics and rehabilitation<br />
Poster No. 237<br />
INTER-INSTRUMENT RELIABILITY OF TWO GONIOMETERS FOR THE MEASUREMENT OF<br />
HIP RANGE OF MOTION IN SYMPTOM-FREE SUBJECTS AND SUBJECTS WITH HIP OA<br />
Helen P. French, Mary Boyd;<br />
School of Physiotherapy, Royal College of Surgeons in Ireland, Dublin, Ireland<br />
Metabolic and crystal arthropathies<br />
Poster No. 238<br />
Poster No. 239<br />
AN AUDIT ON MANAGEMENT OF GOUT IN PRIMARY CARE: ARE GENERAL<br />
PRACTITIONERS ADHERING TO GUIDELINES<br />
Balaji Ramabhadran, Nada Hasan, Peter Merry, Karl Gaffney;<br />
Department of <strong>Rheumatology</strong>, Norfolk and Norwich University Hospital, Norwich,<br />
United Kingdom<br />
HOW IS ACUTE GOUT MANAGED IN PRIMARY CARE?<br />
Edward Roddy, Christian D. Mallen, Samantha L. Hider, Kelvin P. Jordan;<br />
Arthritis Research Campaign National Primary Care Centre, Keele University, Keele,<br />
United Kingdom<br />
81
Osteoporosis and metabolic bone disease<br />
Poster No. 240<br />
BONE MARROW OEDEMA SYNDROME (BMO)OF THE FOOT AND ANKLE AND RESPONSE<br />
TO PAMIDRONATE<br />
Gerard Hall 1 , Neerujah Balachandren 2 ;<br />
1<br />
<strong>Rheumatology</strong>, <strong>The</strong> Royal London Hospital, London, United Kingdom; 2 <strong>The</strong> Medical School,<br />
University College Hospital, London, United Kingdom<br />
Poster No. 241<br />
Poster No. 242<br />
SCREENING HIV-INFECTED MEN FOR LOW BONE MINERAL DENSITY: THE ROLE OF<br />
PERIPHERAL DEXA BONE DENSITOMETRY<br />
Charlotte-Eve S. Short 1 , Simon G. Shaw 1 , Yvonne C. Gilleece 1 , Martin Fisher 1 ,<br />
Karen Walker-Bone 2 ;<br />
1<br />
Department of HIV Medicine, Brighton and Sussex University NHS Hospitals Trust, Brighton<br />
and Hove, United Kingdom; 2 Department of <strong>Rheumatology</strong>, Brighton and Sussex University<br />
NHS Hospitals Trust, Brighton and Hove, United Kingdom<br />
INFLUENCE OF MARKERS OF BONE TURNOVER ON CALCANEAL QUANTITATIVE<br />
ULTRASOUND: RESULTS FROM THE EUROPEAN MALE AGEING STUDY (EMAS)<br />
Stephen R. Pye 1 , Terence W. O’Neill 1 , Herman Borghs 2 , Dirk Vanderschueren 2 ,<br />
Katrien Venken 2 , Judith E. Adams 3 , Kate A. Ward 3 , Joseph D. Finn 4 , Alan J. Silman 5 ,<br />
Frederick C. Wu 4 , Steven Boonen 2 ;<br />
1<br />
ARC Epidemiology Unit, <strong>The</strong> University of Manchester, Manchester, United Kingdom;<br />
2<br />
Katholieke Universiteit Leuven, Leuven, Belgium; 3 Department of Imaging Science and<br />
Biomedical Engineering, <strong>The</strong> University of Manchester, Manchester, United Kingdom;<br />
4<br />
Department of Endocrinology, <strong>The</strong> University of Manchester, Manchester, United Kingdom;<br />
5Arthritis Research Campaign, Chesterfield, United Kingdom<br />
Poster No. 243<br />
INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN-1 IS NEGATIVELY ASSOCIATED WITH<br />
CALCANEAL QUANTITATIVE ULTRASOUND (QUS) PARAMETERS: RESULTS FROM THE<br />
EUROPEAN MALE AGEING STUDY (EMAS)<br />
Stephen R. Pye 1 , Steven Boonen 2 , Herman Borghs 2 , Dirk Vanderschueren 2 , Katrien Venken 2 ,<br />
Judith E. Adams 3 , Kate A. Ward 3 , Joseph D. Finn 4 , Alan J. Silman 5 , Frederick C. Wu 4 ,<br />
Terence W. O’Neill 1 ;<br />
1<br />
ARC Epidemiology Unit, <strong>The</strong> University of Manchester, Manchester, United Kingdom;<br />
2<br />
Katholieke Universiteit Leuven, Leuven, Belgium; 3 Department of Imaging Science and<br />
Biomedical Engineering, <strong>The</strong> University of Manchester, Manchester, United Kingdom;<br />
4<br />
Department of Endocrinology, <strong>The</strong> University of Manchester, Manchester, United Kingdom;<br />
5<br />
Arthritis Research Campaign, Chesterfield, United Kingdom<br />
Poster No. 244<br />
A PROSPECTIVE EVALUATION MODELLING THE COST AND EFFECTIVENESS<br />
OF THE NOGG GUIDELINE IN PRIMARY CARE FRACTURE PREVENTION<br />
Janki Patel 1 , Wasim Baqir 1,2 , Fraser Birrell 3,4 , On behalf of the Northumbria Osteoporosis<br />
Strategy Group 3,4 ;<br />
1<br />
School of Pharmacy, University of Sunderland, Sunderland, United Kingdom; 2 Pharmacy,<br />
Northumbria Healthcare NHS Foundation Trust, Newcastle, United Kingdom; 3 <strong>Rheumatology</strong>,<br />
Northumbria Healthcare NHS Foundation Trust, Newcastle, United Kingdom; 4 <strong>Rheumatology</strong>,<br />
Newcastle University, Newcastle, United Kingdom<br />
82
Poster No. 245<br />
Poster No. 246<br />
Poster No. 247<br />
MEDICAL STUDENT BURSARY WINNER<br />
DOES DEPO-PROVERA DECREASE BONE MINERAL DENSITY IN THE LUMBAR SPINE AND<br />
FEMORAL NECK?<br />
Alexander Oldroyd 1 , Cathi Greenbank 2 , Bronwen Evans 2 , John Halsey 2 , Nicola Goodson 3 ,<br />
Marwan Bukhari 2,3 ;<br />
1<br />
University of Lancaster, Lancaster, United Kingdom; 2 <strong>Rheumatology</strong>, Royal Lancaster<br />
Infirmary, Lancaster, United Kingdom; 3 Clinical Sciences, University of Liverpool,<br />
Liverpool, United Kingdom<br />
FRACTURE RISK THRESHOLDS FOR INTERVENTION IMPLICIT WITHIN RCP,<br />
NICE TA87 AND NICE TA161 GUIDELINES FOR SECONDARY PREVENTION<br />
Margaret Callan, Ashlynne VanVuuren, Sarah Collis;<br />
Department of <strong>Rheumatology</strong>, Chelsea and Westminster NHS Foundation Trust,<br />
London, United Kingdom<br />
IS RESPIRATORY FUNCTION ASSOCIATED WITH BONE MASS? RESULTS FROM THE<br />
HERTFORDSHIRE COHORT STUDY<br />
Rafael Azagra 1 , Isabel Reading 1 , Avan Aihie Sayer 1 , Holly Syddall 1 , Seif Shaheen 2 ,<br />
Cyrus Cooper 1 , Elaine Dennison 1 ;<br />
1<br />
Southampton University, MRC Resource Centre, Southampton, United Kingdom;<br />
2<br />
Respiratory Epidemiology and Public Health Group, National Heart and Lung Group,<br />
Imperial College, London, United Kingdom<br />
Poster Viewing Two | Thursday 30 April 2009<br />
Poster No. 248<br />
Poster No. 249<br />
Poster No. 250<br />
Poster No. 251<br />
THE EFFECT OF PRIOR BISPHOSPHONATE THERAPY ON THE SUBSEQUENT BONE<br />
TURNOVER AND BMD RESPONSE TO STRONTIUM RANELATE<br />
Edward T. Middleton, Sue A. Steel, Mo Aye, Sheelagh M. Doherty;<br />
Centre <strong>for</strong> Metabolic Bone Disease, Hull Royal Infirmary, Hull, United Kingdom<br />
30 YEARS ON: HYPOVITAMINOSIS D IN HEPATOLOGY OUTPATIENTS<br />
Christopher J. Kelly 1 , Ken E. Poole 2,1 , Adrian J. Crisp 1 , David J. Halsall 3 , Bill Griffiths 4 ,<br />
Andrew J. Ostor 1 ;<br />
1<br />
Department of <strong>Rheumatology</strong>, Addenbrooke’s Hospital, Cambridge University, Cambridge,<br />
United Kingdom; 2 Department of Bone Research, Addenbrooke’s Hospital, Cambridge<br />
University, Cambridge, United Kingdom; 3 Department of Biochemistry, Addenbrooke’s<br />
Hospital, Cambridge University, Cambridge, United Kingdom; 4 Department of Hepatology,<br />
Addenbrooke’s Hospital, Cambridge University, Cambridge, United Kingdom<br />
ONCE-YEARLY ZOLEDRONIC ACID 5 MG INFUSION FOR TREATMENT OF<br />
POSTMENOPAUSAL OSTEOPOROSIS: EFFECTS ON FRACTURE INCIDENCE<br />
IN PATIENT SUBGROUPS FROM THE HORIZON-PFT STUDY<br />
Richard Eastell 1 , Dennis M. Black 2 , Steven Boonen 3 , Alastair R. McLellan 4 ,<br />
Steven R. Cummings 2 , Pierre D. Delmas 5 , Lisa Palermo 2 , Peter Mesenbrink 6 , Jane A. Cauley 7 ;<br />
1<br />
University of Sheffield, Sheffield, United Kingdom; 2 University of Cali<strong>for</strong>nia, San Francisco,<br />
CA; 3 Katholieke Universiteit Leuven, Leuven, Belgium; 4 Western Infirmary, Glasgow, United<br />
Kingdom; 5 INSERM Research Unit 831 and University of Lyon, Lyon, France; 6 Novartis<br />
Pharmaceuticals Corporation, East Hanover, NJ; 7 University of Pittsburgh, Pittsburgh, PA<br />
A CASE CONTROL STUDY TO DETERMINE WHETHER BONE IS LEACHED PREDOMINANTLY<br />
FROM THE LUMBAR VERTEBRAE OR THE HIP IN PATIENTS WITH HYPERPARATHYROIDISM<br />
Keith Green, Marwan Bukhari;<br />
<strong>Rheumatology</strong> Department, Royal Lancaster Infirmary, Lancaster, United Kingdom<br />
83
Poster No. 252<br />
Poster No. 253<br />
COMPARISON OF THE EFFICACY AND SAFETY OF A SINGLE INFUSION OF ZOLEDRONIC<br />
ACID 5 MG WITH DAILY ORAL RISEDRONATE 5 MG IN PATIENTS WITH<br />
GLUCOCORTICOID-INDUCED OSTEOPOROSIS: RESULTS FROM A 1-YEAR RANDOMISED,<br />
DOUBLE-BLIND TRIAL<br />
David M. Reid 1 , Jean-Pierre Devogelaer 2 , Kenneth Saag 3 , Richard Keen 4 , Christian Roux 5 ,<br />
Chak Sing Lau 6 , Jean-Yves Reginster 7 , Philemon Papanastasiou 8 , Taiwo Fashola 8 , Peter<br />
Mesenbrink 9 , Philip Sambrook 10 ;<br />
1<br />
University of Aberdeen, Aberdeen, United Kingdom; 2 Saint-Luc University Hospital, Brussels,<br />
Belgium; 3 University of Alabama at Birmingham, Birmingham, AL; 4 Royal National Orthopaedic<br />
Hospital, Stanmore, United Kingdom; 5 Cochin Hospital, Paris, France; 6 University of Dundee,<br />
Dundee, United Kingdom; 7 University of Liège, Liège, Belgium; 8 Novartis Pharma AG, Basel,<br />
Switzerland; 9 Novartis Pharmaceuticals Corporation, East Hanover, NJ; 10 University of Sydney,<br />
Sydney, NSW, Australia<br />
CHANGES IN THE TREATMENT OF RHEUMATIC DISEASE ACROSS THE WESSEX REGION:<br />
A 10 YEAR UPDATE<br />
Christopher R. Holroyd, Margaret Fletcher, Joanna M. Ledingham;<br />
<strong>Rheumatology</strong> Department, Queen Alexandra Hospital, Portsmouth, United Kingdom<br />
Health services research, economics and outcomes research<br />
Poster No. 254<br />
Poster No. 255<br />
Poster No. 256<br />
Poster No. 257<br />
THE COST-UTILITY OF ACUPUNCTURE AS AN ADJUNCT TO EXERCISE-BASED<br />
PHYSIOTHERAPY FOR OSTEOARTHRITIS OF THE KNEE<br />
David G. Whitehurst 1 , Stirling Bryan 2 , Elaine Thomas 1 , Elaine M. Hay 1 , Julie Young 1 ,<br />
Nadine E. Foster 1 ;<br />
1<br />
Arthritis Research Campaign National Primary Care Centre, Primary Care Sciences, Keele<br />
University, Keele, United Kingdom; 2 Centre <strong>for</strong> Clinical Epidemiology & Evaluation, Vancouver<br />
Coastal Health Research Institute, University of <strong>British</strong> Columbia, Vancouver, BC, Canada<br />
CAN CHOICES BETWEEN ALTERNATIVE HIP PROSTHESES BE EVIDENCE BASED?<br />
A REVIEW OF THE ECONOMIC EVALUATION LITERATURE<br />
Charlotte Davies 1 , Ian Shemilt 1 , Alexander Macgregor 1 , Miranda Mug<strong>for</strong>d 1 , Paula Lorgelly 2 ;<br />
1<br />
School of Medicine, UEA, Norwich, United Kingdom; 2 Section of Public Health and Health<br />
Policy, University of Glasgow, Glasgow, United Kingdom<br />
PERCEIVED BARRIERS TO INTEGRATED CARE IN RHEUMATOID ARTHRITIS (RA): VIEWS<br />
OF PROVIDERS AND RECIPIENTS OF PRIMARY AND SECONDARY CARE SERVICES<br />
Helen Graves 1 , Louise C. Pollard 1 , Heidi Lempp 1 , Gabrielle H. Kingsley 2 , David L. Scott 1 ;<br />
1<br />
Academic Department of <strong>Rheumatology</strong>, King’s College London, London, United Kingdom;<br />
2<br />
Department of <strong>Rheumatology</strong>, University Hospital Lewisham, London,<br />
United Kingdom<br />
MANAGING POLYPHARMACY IN RHEUMATOID ARTHRITIS: UNDERSTANDING HOW PATIENTS<br />
TAKE THEIR MEDICINES<br />
Rod Hughes 1 , Alison Carr 2 , Maggie Walsh 1 , Maggie Carr 1 ;<br />
1<br />
<strong>Rheumatology</strong>, Ash<strong>for</strong>d and St Peter’s NHS Trust, Chertsey, United Kingdom; 2 Academic<br />
<strong>Rheumatology</strong>, University of Nottingham, Nottingham, United Kingdom<br />
84
Poster No. 258<br />
Poster No. 259<br />
Poster No. 260<br />
COMPARISON OF LINEAR AND NONLINEAR UTILITY MAPPING BETWEEN HAQ AND<br />
EQ-5D USING POOLED DATA FROM THE TOCILIZUMAB TRIALS OPTION AND LITHE<br />
Pierre Ducournau 1 , Adrian Kielhorn 1 , Neil S. Wintfeld 2 ;<br />
1<br />
Roche, Basel, Switzerland; 2 Roche, Nutley, NJ<br />
HOW DO GENERAL PRACTITIONERS OBTAIN RHEUMATOLOGY ADVICE: A ROLE FOR A<br />
CONSULTANT-LED EMAIL ADVICE SERVICE?<br />
Emyr P. Humphreys 1 , Shireen Habboush 1 , Nia Owens 1 , Tom Lawson 1 , Stefan Siebert 1,2 ;<br />
1<br />
<strong>Rheumatology</strong>, Princess of Wales Hospital, Abertawe Bro Morgannwg University NHS Trust,<br />
Bridgend, United Kingdom; 2 Swansea University, Swansea, United Kingdom<br />
THE SAFETY AND EFFICACY OF INTRA-ARTICULAR AND INTRA-MUSCULAR STEROID<br />
INJECTIONS IN HIV POSITIVE INDIVIDUALS WITH MUSCULOSKELETAL DISORDERS.<br />
Authors: K.Glennon, K Walker-Bone<br />
Katie Glennon, Karen Walker-Bone;<br />
<strong>Rheumatology</strong>, Brighton & Sussex Medical School, Brighton, United Kingdom<br />
Poster Viewing Two | Thursday 30 April 2009<br />
Poster No. 261<br />
THE ECONOMIC BURDEN OF LOST PRODUCTIVITY IN A COHORT OF PATIENTS WITH<br />
EARLY RHEUMATOID ARTHRITIS (RA): Early Rheumatoid Arthritis Network (ERAN)<br />
Wei Zhang 1 , Nick Bansback 1 , Adam Young 2 , David Walsh 3,4 , Patrick Keily 5,2 , Aslam Anis 1 ;<br />
1<br />
Centre <strong>for</strong> Health Evaluation & Outcome Sciences, University of <strong>British</strong> Columbia,<br />
Vancouver, BC, Canada; 2 Early Rheumatoid Arthritis Network (ERAN), c/o St Albans City<br />
Hospital, St Albans, United Kingdom; 3 Academic <strong>Rheumatology</strong>, University of Nottingham,<br />
City Hospital, Nottingham, United Kingdom; 4 <strong>Rheumatology</strong>, Sherwood Forest Hospitals NHS<br />
Foundation Trust, Nottingham, United Kingdom; 5 <strong>Rheumatology</strong>, St George’s Hospital,<br />
London, United Kingdom<br />
Poster No. 262<br />
PRE-TREATMENT TMPT PHARMACOGENETIC TESTING AND RISK OF NEUTROPAENIA<br />
IN PATIENTS TREATED WITH AZATHIOPRINE: RESULTS FROM THE TPMT AZATHIOPRINE<br />
RESPONSE TO GENOTYPING AND ENZYME TESTING (TARGET) TRIAL<br />
William G. Newman 1,2 , Katherine Payne 2 , Karen Tricker 2 , Stephen A. Roberts 2,1 ,<br />
Emily A. Fargher 2 , Sudeep Pushpakom 1,2 , Jane Alder 2 , Kay Poulton 1 , Julie Andrews 2 ,<br />
Gary Sidwick 2 , J. Brian Houston 2 , Rachel Elliott, R. G. Elles, D. W. Ray, J. Shaffer, C. Griffiths,<br />
F. Qasim, I. N. Bruce, W. R. Ollier;<br />
1<br />
Central Manchester & Manchester Children’s University Hospitals, NHS Trust, Manchester,<br />
United Kingdom; 2 University of Manchester, Manchester, United Kingdom<br />
Poster No. 263<br />
VARIATION IN CASE MIX ACROSS WESSEX RHEUMATOLOGY UNITS OVER 10 YEARS<br />
Christopher R. Holroyd, Margaret J. Fletcher, Joanna M. Ledingham;<br />
<strong>Rheumatology</strong> Department, Queen Alexandra Hospital, Portsmouth, United Kingdom<br />
Poster No. 264<br />
IMPROVED WORK PRODUCTIVITY IN PATIENTS WITH ANKYLOSING SPONDYLITIS<br />
(AS) TREATED WITH ADALIMUMAB: RESULTS FROM THE RHAPSODY TRIAL<br />
Katherine L. Gooch 3 , Martin Rudwaleit 1 , Kyriaki Boki 2 , Mary A. Cifaldi 3 , Robert L. Wong 4 ,<br />
Naijun Chen 3 , Hartmut Kupper 5 ;<br />
1<br />
Charité Universitätsmedizin Berlin, Berlin, Germany; 2 <strong>Rheumatology</strong> Department,<br />
Sismanoglio Hospital, Athens, Greece; 3 Abbott Laboratories, Abbott Park, IL; 4 Abbott<br />
Laboratories, Parsippany, NJ; 5Abbott GmbH & Co KG, Ludwigshafen, Germany<br />
85
Poster No. 265<br />
Poster No. 266<br />
Poster No. 267<br />
Poster No. 268<br />
Poster No. 269<br />
Poster No. 270<br />
Poster No. 271<br />
Poster No. 272<br />
IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS ADALIMUMAB PLUS MTX<br />
COMBINATION THERAPY DECREASES RESOURCE USE<br />
Mary A. Cifaldi 2 , Ronald F. van Vollenhoven 1 , Saurabh Ray 2 , Chris Bojke 3 , Michael Weisman 4 ;<br />
1<br />
<strong>Rheumatology</strong>, Karolinska University Hospital, Stockholm, Sweden; 2 Abbott Laboratories,<br />
Abbott Park, IL; 3 Pharmerit International, York, United Kingdom; 4 Cedars-Sinai Medical Center,<br />
Los Angeles, CA<br />
IMPACT OF ADALIMUMAB TREATMENT IN THE WORKPLACE IN PATIENTS WITH RHEUMATOID<br />
ARTHRITIS<br />
Mary A. Cifaldi 4 , Howard Birnbaum 1 , Crystal Pike 1 , Rebecca Kaufman 1 , Matthew Schiller 1 ,<br />
Lizheng Shi 2 , Peter Sun 3 , Saurabh Ray 4 ;<br />
1<br />
Analysis Group, Boston, MA; 2 Tulane University, New Orleans, LA; 3 Kailo Research Group,<br />
Indianapolis, IN; 4 Abbott Laboratories, Abbott Park, IL<br />
SAME QUESTION, DIFFERENT ANSWER: A COMPARISON OF GLOBAL HEALTH<br />
ASSESSMENTS USING VAS SCALES<br />
Mark Harrison 1 , Annalies Boonen 2 , Peter Tugwell 3 , Deborah Symmons 1 ;<br />
1<br />
arc Epidemiology Unit, <strong>The</strong> University of Manchester, Manchester, United Kingdom; 2 Maastricht<br />
University Medical Centre, Maastricht, Netherlands; 3 Epidemiology & Community Medicine,<br />
University of Ottawa, Ottawa, ON, Canada<br />
COPYING CLINIC LETTERS TO PATIENTS - A PATIENT SURVEY<br />
Sharmistha K. Williams, Christopher R. Kelsey;<br />
<strong>Rheumatology</strong>, Queens Hospital, Rom<strong>for</strong>d, United Kingdom<br />
IMPACT OF RHEUMATOID ARTHRITIS ON WORKING PEOPLE<br />
Abhay Joshi, Elizabeth Price, Lyn Williamson, David Collins;<br />
<strong>Rheumatology</strong>, Great Western Hospital, Swindon, United Kingdom<br />
WORKING STATUS IN PATIENTS WITH ANKYLOSING SPONDYLITIS RECEIVING ANTI-TNF<br />
THERAPY<br />
Suzanne M.M. Verstappen, Kath D. Watson, Katie McGrother, Deborah P.M. Symmons,<br />
Kimme L. Hyrich, On behalf of the BSR Biologics Register;<br />
arc Epidemiology, the University of Manchester, Manchester, United Kingdom<br />
THE EFFECT OF RHEUMATOID ARTHRITIS (RA) ON JOB LOSS & WORK PRODUCTIVITY.<br />
RESULTS FROM AN INCEPTION COHORT WITH 10YR FOLLOW UP<br />
Adam Young, Peter Prouse, Peter Williams, Joe Devlin, Gouri Koduri, Dor Pattison,<br />
Sue Staf<strong>for</strong>d, Nigel Cox;<br />
ERAS, <strong>Rheumatology</strong>, City Hospital, St Albans, United Kingdom<br />
THE VALIDITY OF ESTIMATING EQ-5D SCORES FROM THE HAQ AND SF-36<br />
Mark Harrison 1 , Kath Watson 1 , Nick Bansback 2 , Suzanne Verstappen 1 , Deborah Symmons 1 ,<br />
on behalf of the BSRBR 1 ;<br />
1<br />
arc Epidemiology Unit, <strong>The</strong> University of Manchester, Manchester, United Kingdom;<br />
2<br />
St Paul’s Hospital, Vancouver, BC, Canada<br />
Poster No. 273<br />
IS RA CARE MEETING THE NEEDS OF PATIENTS IN ENGLAND? KEY FINDINGS<br />
FROM A PATIENT SURVEY<br />
Sophie J. Beale 1 , Tesha Cardow 1 , Paul Trueman 1 , Martin Land 2 ;<br />
1<br />
York Health Economics Consortium, University of York, York, United Kingdom; 2 <strong>The</strong> King’s Fund,<br />
London, United Kingdom<br />
86
Poster No. 274<br />
Poster No. 275<br />
ECONOMIC EVALUATION OF THERAPEUTIC APPROACHES FOR RHEUMATOID<br />
ARTHRITIS: THE CASE FOR SEQUENTIAL ANTI-TNF USE<br />
Mathew Taylor 1 , Carina Righetti 1 , Peter Conway 2 , Maximilian Lebmeier 3 ;<br />
1<br />
York Health Economics Consortium, University of York, York, United Kingdom; 2 Wyeth Europa,<br />
Maidenhead, United Kingdom; 3 Wyeth Pharmaceuticals, Taplow, United Kingdom<br />
THE HIDDEN WORK OF A RHEUMATOLOGY DEPARTMENT: SW THAMES, SURREY<br />
AND SUSSEX REGIONAL SURVEY OF IN-PATIENT RHEUMATOLOGY REFERRALS<br />
Patrick D. Kiely 1 , Piero P. Reynolds 1 , Kay M. Garmston 2 , Vinrod Ravindran 3 ,<br />
Alastair L. Hepburn 4 , Mike Chard 4 , Hugh Jones 5 , Rod Hughes 6 , Martin Ridley 7 ,<br />
Sanjeev Menon 7 , Mark Lloyd 2 ;<br />
1<br />
<strong>Rheumatology</strong>, St Georges Healthcare NHS Trust, London, United Kingdom; 2 <strong>Rheumatology</strong>,<br />
Frimley Park Hospital NHS Foundation Trust, Frimley, United Kingdom; 3 <strong>Rheumatology</strong>,<br />
St Helier University Hospital Trust, Carshalton, United Kingdom; 4 <strong>Rheumatology</strong>, Worthing and<br />
Southlands Hospital NHS Trust, Worthing, United Kingdom; 5 <strong>Rheumatology</strong>, Kingston Hospital<br />
NHS Trust, Kingston, United Kingdom; 6 <strong>Rheumatology</strong>, Ash<strong>for</strong>d and St Peter’s Hospitals NHS<br />
Trust, Kingston, United Kingdom; 7 <strong>Rheumatology</strong>, <strong>The</strong> Royal West Sussex NHS Trust,<br />
Chichester, United Kingdom<br />
Poster Viewing Two | Thursday 30 April 2009<br />
Miscellenaous rheumatic disease<br />
Poster No. 276<br />
Poster No. 277<br />
Poster No. 278<br />
Poster No. 279<br />
AN AUDIT OF TB PROPHYLAXIS IN ANTI-TNF TREATED PATIENTS IN SECONDARY CARE<br />
IN EAST LONDON - ARE WE IDENTIFYING THE RIGHT PATIENTS?<br />
Henry Penn, Mandy Greenwood, Margaretta Rooney, Alan J. Hakim, John Lanham,<br />
Simon P. Donnelly, Hasan Tahir;<br />
<strong>Rheumatology</strong>, Whipps Cross Hospital, London, United Kingdom<br />
CONSIDER HYPOADRENALISM IN PATIENTS WITH FATIGUE AND<br />
RHEUMATIC DISEASE<br />
Dimitra Methiniti, Jennifer Hamilton, Vadivelu Saravanan, Carol Heycock, Clive Kelly;<br />
<strong>Rheumatology</strong>, QEH, Gateshead, United Kingdom<br />
A ‘HOT JOINT PACK’ IMPROVES THE MANAGEMENT OF THE ACUTE HOT JOINT<br />
Brian F. Menezes, Richard P. Cooke, Cristina Estrach, Nicola J. Goodson,<br />
Robert N. Thompson;<br />
Aintree University Hospitals NHS Foundation Trust, Liverpool, United Kingdom<br />
THE TRANSITION FROM HOSPITAL TO HOME: A QUALITATIVE INVESTIGATION INTO THE<br />
ABILITY OF PATIENTS TO TRANSFER AND MAINTAIN SKILLS LEARNED ON A COMPLEX<br />
REGIONAL PAIN SYNDROME (CRPS) IN-PATIENT PROGRAMME<br />
Karen Rodham 1 , Megan Cockburn 1 , Candy McCabe 2 ;<br />
1<br />
Psychology, University of Bath, Bath, United Kingdom; 2 <strong>Rheumatology</strong>,<br />
Royal National Hospital <strong>for</strong> Rheumatic Diseases, Bath, United Kingdom<br />
87
Poster No. 280<br />
ORGAN-SPECIFIC AUTOANTIBODIES BUT NOT ANTI-CCP ARE A FEATURE OF AUTOIMMUNITY<br />
IN DOWN’S SYNDROME<br />
Benjamin A. Fisher 1 , Peter Charles 1 , Karin Lundberg 1 , Kathleen M. Gillespie 2 ,<br />
Richard W. Newton 3 , Patrick J. Venables 1 ;<br />
1<br />
Kennedy Institute of <strong>Rheumatology</strong>, Imperial College London, London, United Kingdom;<br />
2<br />
Diabetes and Metabolism Unit, University Of Bristol, Bristol, United Kingdom; 3 Department of<br />
Paediatric Neurology, Royal Manchester Children’s Hospital, Manchester, United Kingdom<br />
Poster No. 281<br />
Poster No. 282<br />
Poster No. 283<br />
Poster No. 284<br />
Poster No. 285<br />
TOLERABILITY OF COMBINING ANTI-TB PROPHYLAXIS WITH DIFFERENT DMARDS AND<br />
ANTI-TNF AGENTS<br />
Muhammad Haroon, Una Martin, Ciaron Duffy, Joe Devlin;<br />
Department of <strong>Rheumatology</strong>, Water<strong>for</strong>d Regional Hospital, Water<strong>for</strong>d, Ireland<br />
THE USE OF ANTI-TNF THERAPY IN THE TREATMENT OF NINE PATIENTS WITH BEHÇET’S<br />
SYNDROME IN A SINGLE RHEUMATOLOGY TERTIARY REFERRAL CENTRE<br />
Lynne M. Shand 1 , Dorian Haskard 2 ;<br />
1<br />
<strong>Rheumatology</strong>, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, United<br />
Kingdom; 2 Eric Bywaters Centre <strong>for</strong> Vascular Inflammation, Imperial College London, London,<br />
United Kingdom<br />
BILATERAL LIPOMA ARBORESCENS CO-EXISTING WITH PSORIATIC ARTHRITIS RELEASES<br />
TNF-ALPHA AND MATRIX METALLOPROTEINASE 3<br />
Martin E. Perry 1 , Alasdair R. Fraser 2 , Anne Crilly 2 , Jim Reilly 2 , Axel Hueber 2 , Iain B. McInnes 2 ;<br />
1<br />
Centre <strong>for</strong> Rheumatic Diseases, Glasgow Royal Infirmary, Glasgow, United Kingdom; 2 Division<br />
of Immunology, Infection and Inflammation, Faculty of Medicine, <strong>The</strong> University of Glasgow,<br />
Glasgow, United Kingdom<br />
Withdrawn<br />
TREATMENT OF CRYOPYRIN ASSOCIATED PERIODIC FEVER SYNDROME WITH A<br />
LONG-ACTING FULLY HUMAN ANTI-IL-1BETA MONOCLONAL ANTIBODY (ACZ885)<br />
Helen Lachmann 1 , Phil Lowe 2 , Mark Offer 1 , Christiane Rordorf 3 , Xavier Gitton 4 , Neha P. Patel 5 ,<br />
Philip N. Hawkins 1 ;<br />
1<br />
Department of Medicine, Royal Free and university College Medical School, London, United<br />
Kingdom; 2 Modelling and Simulation, Novartis, Basel, Switzerland; 3 Translational Medicine,<br />
Novartis, Basel, Switzerland; 4 Clinical Development, Novartis, Basel, Switzerland; 5 Clinical<br />
Development, Novartis, East Hanover, NJ<br />
88
Poster Viewing Three<br />
Friday 01 May 2009<br />
Poster Viewing Three<br />
Fri 01 May 2009
Poster Viewing Three<br />
Friday 01 May 2009, 08.30-10.00<br />
Case reports<br />
Poster No. 286<br />
Poster No. 287<br />
OSTEONECROSIS OF THE ELBOW FOLLOWING BISPHOSPHONATE TREATMENT<br />
Clare S. Bolton 1 , Neil D. McKay 2 , David Coady 2 , Terry Featherstone 3 ;<br />
1<br />
Medical School, Newcastle University, Newcastle, United Kingdom; 2 <strong>Rheumatology</strong>,<br />
Sunderland Royal Hospital, Sunderland, United Kingdom; 3 Radiology, Sunderland<br />
Royal Hospital, Sunderland, United Kingdom<br />
LANGERHANS CELL HISTIOCYTOSIS PRESENTING AS POLYMYALGIC ONSET OF ANTI-CCP<br />
POSITIVE RHEUMATOID ARTHRITIS<br />
Alison L. Endean 1,2 , Steven A. Young-Min 1 ;<br />
1<br />
<strong>Rheumatology</strong>, Queen Alexandra Hospital, Portsmouth, United Kingdom; 2 <strong>Rheumatology</strong>,<br />
Basingstoke and North Hampshire NHS Foundation Trust, Basingstoke, United Kingdom<br />
Poster Viewing Three | Friday 01 May 2009<br />
Poster No. 288<br />
Poster No. 289<br />
Poster No. 290<br />
HYDROXYUREA: A VASCULITIS MIMICK?<br />
Surabhi Wig, Mohammed Akil;<br />
<strong>Rheumatology</strong>, Royal Hallamshire hospital, Sheffield, United Kingdom<br />
A CASE OF CAT-SCRATCH DISEASE ARTHROPATHY<br />
John D. Pauling, Ellie Korendowych;<br />
<strong>Rheumatology</strong>, Royal National Hospital <strong>for</strong> Rheumatic Diseases, Bath, United Kingdom<br />
COMPLETE HEART BLOCK IN AN ADULT WITH ANTI-RO ANTIBODIES BUT NO CLINICAL<br />
FEATURES OF SJÖGREN’S SYNDROME<br />
Benjamin J. Wrigley 1 , Tracey E. Toms 2 , Dawn L. Adamson 1 ;<br />
1<br />
Department of Cardiology, University Hospital, Coventry, United Kingdom; 2 Department of<br />
<strong>Rheumatology</strong>, Russells Hall Hospital, Dudley, United Kingdom<br />
Poster No. 291<br />
Poster No. 292<br />
Poster No. 293<br />
POST SURGICAL WOUND INFLAMMATION - PYODERMA GANGRENOSUM OR<br />
NECROTISING FASCIITIS? A RHEUMATOLOGICAL SOLUTION<br />
Mytheen Jasminsajna, Kuntal Chakravarty;<br />
<strong>Rheumatology</strong>, Queen’s Hospital,Rom<strong>for</strong>d, Essex, United Kingdom<br />
NEISSERIA ELONGATA GLYCOLYTICA SEPTIC ARTHRITIS<br />
Amit k. Saha, Sangita Agarwal, Terence Gibson;<br />
Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom<br />
FISHY FINGER: MYCOBACTERIUM KANSASII, A RARE CAUSE OF TENOSYNOVITIS<br />
Judith S. Bubbear 1 , Lynne Shand 2 , Vanessa H. Morris 1 ;<br />
1<br />
<strong>Rheumatology</strong> Department, University College London Hospital, London, United Kingdom;<br />
2<br />
<strong>Rheumatology</strong> Department, Hammersmith Hospital, London, United Kingdom<br />
89
Poster No. 294<br />
Poster No. 295<br />
Poster No. 296<br />
Poster No. 297<br />
Poster No. 298<br />
Poster No. 299<br />
Poster No. 300<br />
Poster No. 301<br />
Poster No. 302<br />
A CASE OF POEMS SYNDROME<br />
Piero P. Reynolds, Rodney A. Hughes;<br />
<strong>Rheumatology</strong>, St. Peters Hospital, Chertsey, United Kingdom<br />
ESSENTIAL THROMBOCYTHAEMIA MIMICKING LARGE VESSEL VASCULITIS<br />
Catherine Gwynne 1 , Marguerite Hill 2 , Stefan Siebert 1 ;<br />
1<br />
<strong>Rheumatology</strong>, Princess of Wales Hospital, Bridgend, United Kingdom; 2 Neurology, Morriston<br />
Hospital, Swansea, United Kingdom<br />
RHABDOMYOLYSIS PRECIPITATED BY FUCIDIC ACID IN ASSOCIATION WITH LONG-TERM<br />
STATIN THERAPY<br />
Matthew Oates, James Dale, Margaret-Mary Gordon;<br />
<strong>Rheumatology</strong>, Gartnavel General Hospital, Glasgow, United Kingdom<br />
A KILLER MOCKING BIRD-CASE REPORT<br />
Sangeetha Baskar 1 , George D. Kitas 1 , Rainer Klocke 1 , Michael Cushley 2 , Sixto Batitang 4,<br />
Jeffrey Neilson 3 , Ruth Shave 5 , Karen Douglas 1 ;<br />
1<br />
<strong>Rheumatology</strong>, Dudley group of hospitals, Dudley, United Kingdom; 2 Respiratory<br />
medicine, Dudley group of hospitals, Dudley, United Kingdom; 3 Haematology, Dudley group of<br />
hospitals, Dudley, United Kingdom; 4 Histopathology, Dudley group of hospitals, Dudley, United<br />
Kingdom; 5 Radiology, Dudley group of hospitals, Dudley, United Kingdom<br />
CLINICAL AND RADIOGRAPHICAL CHARACTERISTICS OF MELORRHOESTOSIS<br />
Marian Chan, Paul B. Wordsworth, Yun Zhang;<br />
Nuffield Department of Orthopaedic Surgery, Botnar Research Centre-University of Ox<strong>for</strong>d,<br />
Ox<strong>for</strong>d, United Kingdom<br />
ADALIMUMAB ASSOCIATED PNEUMONITIS<br />
Gwenan Huws, James Martin, Rhodri Jones;<br />
<strong>Rheumatology</strong>, Royal Glamorgan Hospital, Llantrisant, United Kingdom<br />
SAFETY OF SEQUENTIAL MONOTHERAPY WITH LEFLUNOMIDE AND RITUXIMAB IN<br />
A TNF ALPHA BLOCKER NAÏVE RHEUMATOID ARTHRITIS PATIENT WITH PREVIOUS<br />
ANTI-RHEUMATIC DRUG INDUCED EPSTEIN BARR VIRUS ASSOCIATED B-CELL LYMPHOMA<br />
Anas Boulemden 1 , Neil McKay 1 , Mike Galloway 2 , Jamal Teir 1 , David Wright 1 ; 1 <strong>Rheumatology</strong>,<br />
Sunderland Royal Hospital, Sunderland, United Kingdom; 2 Haematology, Sunderland Royal<br />
Hospital, Sunderland, United Kingdom<br />
NECROTISING FASCIITIS - A LIFE-THREATENING COMPLICATION OF ANTI-TNF THERAPY?<br />
Anita Weerakoon 1 , David Rae 2 , Richard Watts1, Suzanne Lane 1 ;<br />
1<br />
<strong>Rheumatology</strong>, <strong>The</strong> Ipswich Hospital NHS Trust, Ipswich, United Kingdom; 2 Surgery, <strong>The</strong><br />
Ipswich Hospital NHS Trust, Ipswich, United Kingdom<br />
TACROLIMUS- A POTENTIAL THERAPY FOR POLYMYOSITIS?<br />
Lucy E. Waite, Rajan Madhok;<br />
Centre <strong>for</strong> Rheumatic Diseases, Glasgow Royal Infirmary, Glasgow, United Kingdom<br />
90
Poster No. 303<br />
Poster No. 304<br />
Poster No. 305<br />
IMMUNOTHERAPY-RESPONSIVE AUTOIMMUNE ENCEPHALOPTHY ASSOCIATED WITH<br />
BULLOUS PEMPHIGOID<br />
Anushka Soni 1 , Sarosh R. Irani 2 , Bethan Lang 2 , Robert Mann 3 , Angela Vincent 2 ,<br />
David Collins 1 ;<br />
1<br />
<strong>Rheumatology</strong>, Great Western Hospital, Swindon, United Kingdom; 2 <strong>The</strong> Neurosciences<br />
Group, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Ox<strong>for</strong>d, United<br />
Kingdom; 3 Dermatology, Great Western Hospital, Swindon, United Kingdom<br />
ACQUIRED HAEMOPHILIA A AND SYSTEMIC LUPUS ERYTHEMATOSUS- A CASE REPORT<br />
Madhura Castelino, Lee-Suan Teh;<br />
<strong>Rheumatology</strong>, Royal Blackburn Hospital, Blackburn, United Kingdom<br />
RESOLUTION OF SOMATOPARAPHRENIA IN CRPS OCCURS WITH CLINICAL<br />
IMPROVEMENT<br />
Maliha F. Shaikh, Nicholas G. Shenker;<br />
<strong>Rheumatology</strong> Research Unit, Addenbrooke’s, Cambridge University Hospitals, Cambridge,<br />
United Kingdom<br />
Poster Viewing Three | Friday 01 May 2009<br />
Poster No. 306<br />
Poster No. 307<br />
Poster No. 308<br />
Poster No. 309<br />
Poster No. 310<br />
HEARING IMPROVEMENT IN A FAMILY WITH MUCKLE WELLS SYNDROME TREATED WITH<br />
ANAKINRA<br />
Grainne Murphy 1 , Sinead Harney 1 , Fergus Shanahan 2 , Michael Molloy 1 ;<br />
1<br />
Dept of <strong>Rheumatology</strong>, Cork University Hospital, Cork, Ireland; 2 Dept of Medicine,<br />
Cork University Hospital, Cork, Ireland<br />
A CASE OF ISOLATED FOCAL ORBITAL MYOSITIS ASSOCIATED WITH NON OCCULAR<br />
DISTANT HERPES ZOSTER<br />
Ziad Estephan 2 , Deepwant Singh 1 , Susana Ramirez-Florez 2 , Sandeep Dahiya 1 ; 1 Department<br />
of <strong>Rheumatology</strong>, Peterborough and Stam<strong>for</strong>d Hospitals NHS<br />
Foundation Trust, Peterborough, United Kingdom; 2 Department of Ophthalmology,<br />
Peterborough and Stam<strong>for</strong>d Hospitals NHS Foundation Trust, Peterborough, United Kingdom<br />
CENTRAL NERVOUS SYSTEM ISCHAEMIA AS THE PRESENTING FEATURE OF<br />
CHURG-STRAUSS SYNDROME (CSS)<br />
Kaushik Sanyal 1 , Karen Walker-Bone 2 ;<br />
1<br />
<strong>Rheumatology</strong>, Princess Royal Hospital , Haywards Heath, RH16 4EX, Haywards Heath,<br />
United Kingdom; 2 <strong>Rheumatology</strong>, Brighton & Sussex Medical School, Brighton,<br />
United Kingdom<br />
RITUXIMAB INDUCED REMISSION OF ANCA-ASSOCIATED SCLERITIS: TWO CASE STUDIES<br />
Sarah C. Skeoch 1 , Deborah Symmons 2 , Fiona Carley 3 , Ian Bruce 1,2 ;<br />
1<br />
<strong>Rheumatology</strong>, Manchester Royal Infirmary, Manchester, United Kingdom; 2 ARC<br />
Epidemiology Unit, University of Manchester, Manchester, United Kingdom; 3 Ophthalmology,<br />
Manchester Royal Eye Hospital, Manchester, United Kingdom<br />
A TEN YEAR HISTORY OF MYCOBACTERIUM MALMOENSE SEPTIC ARTHRITIS OF<br />
THE WRIST<br />
C. Bracewell 1 , N. D. McKay 1 , C. Muwanga 2 , D. Wright 1 ;<br />
1<br />
<strong>Rheumatology</strong> Department, Sunderland Royal Hospital, Sunderland, United Kingdom;<br />
2<br />
Surgical Department, Sunderland Royal Hospital, Sunderland, United Kingdom<br />
91
Education research<br />
Poster No. 311<br />
I’M GLAD YOU KNOW WHAT THESE ‘VAGUE‘ SYMPTOMS ARE DOC - AN EXPLORATION OF<br />
THE JOURNEY FOR A DIAGNOSIS OF PRIMARY SYSTEMIC VASCULITIS<br />
Janice Mooney 1 , Richard Watts 1 , Fiona Poland 1 , Nicola Spalding 1 , David Scott 2 ;<br />
1<br />
School of Social Sciences, University of East Anglia, Norwich, United Kingdom;<br />
2<br />
Department of <strong>Rheumatology</strong>, Norfolk & Norwich University Hospital, Norwich, United Kingdom<br />
Poster No. 312<br />
CONCEPT MAPS: A TOOL FOR TEACHING AND ASSESSING MEDICAL STUDENTS<br />
RHEUMATOLOGY?<br />
William R. Tillett 1 , Abigail Samuels 2 , Shane Clarke 1 ;<br />
1<br />
Department of <strong>Rheumatology</strong>, Weston Area Health Trust, Weston-super-mare, United Kingdom;<br />
2<br />
Gloucestershire Academy, Gloucester Royal Hospital, Gloucester, United Kingdom<br />
Poster No. 313<br />
Poster No. 314<br />
Poster No. 315<br />
Poster No. 316<br />
Poster No. 317<br />
Poster No. 318<br />
A BEHAVIOURAL STUDY OF DISTRACTION AND ATTENTION TO A PAINFUL LASER STIMULUS<br />
IN FIBROMYALGIA, ARTHRITIS AND HEALTHY VOLUNTEERS<br />
Alison Watson, Shawn Morais, Deborah Bentley, Emma Boger, Yvonne Boyle, Bhavna Kulkarni,<br />
Anthony Jones;<br />
Human Pain Research Group, University of Manchester, Manchester, United Kingdom<br />
MUSCULOSKELETAL ULTRASOUND TRAINING SURVEY<br />
Claire Dubois, Sarang Chitale, Robert N. Thompson, Christina Estrach;<br />
<strong>Rheumatology</strong>, University Hospital Aintree, Liverpool, United Kingdom<br />
MSC IN CLINICAL RHEUMATOLOGY - STUDENT’S PERCEPTIONS OF INFLUENCE ON<br />
FURTHER CAREER<br />
Holly Ennis 1 , Neil Snowden 2 , Deborah Symmons 1 , Terence O’Neill 1 , I. N. Bruce 1 ,<br />
Antony Freemont 1 , Anne Barton 1 , Kimme Hyrich 1 , Ariane Herrick 1 ;<br />
1<br />
University of Manchester, Manchester, United Kingdom; 2 North Manchester General Hospital,<br />
Manchester, United Kingdom<br />
A ONE DAY EXERCISE PROGRAMME: COACHING FOR EXERCISE FOR ANKYLOSING<br />
SPONDYLITIS (COAX-AS)<br />
Lorraine A. McFarland 1 , Sheila Leddington Wright 2 , Jane Tooby 3 , Julie Barlow 1 ;<br />
1<br />
Faculty of Health & Life Sciences, Coventry University, Coventry, United Kingdom;<br />
2<br />
Physiotherapy Department, Coventry University, Coventry, United Kingdom; 3 Physiotherapy<br />
Department, University Hospital Coventry & Warwickshire NHS Trust, Coventry, United Kingdom<br />
Withdrawn<br />
ACCESS TO TRAINING IN MUSCULOSKELETAL ULTRASOUND: A SURVEY OF UK<br />
RHEUMATOLOGY TRAINEES<br />
Toby Garrood 1 , Philip Platt 2 ;<br />
1<br />
Department of <strong>Rheumatology</strong>, University Hospital Lewisham, London, United Kingdom;<br />
2<br />
Department of <strong>Rheumatology</strong>, Freeman Hospital, Newcastle-upon-Tyne, United Kingdom<br />
92
Epidemiology<br />
Poster No. 319<br />
Poster No. 320<br />
Poster No. 321<br />
OBESITY APPEARS TO BE ASSOCIATED WITH ANTI-CCP POSITIVE INFLAMMATORY<br />
POLYARTHRITIS: RESULTS FROM AN EARLY ARTHRITIS CLINIC<br />
Jenny Humphreys 2 , Sarang Chitale 2 , Cristina Estrach 2 , Nicola J. Goodson 1 ;<br />
1<br />
Academic <strong>Rheumatology</strong> dept, Liverpool University, Liverpool, United Kingdom;<br />
2<br />
<strong>Rheumatology</strong>, Aintree University Hospital, Liverpool, United Kingdom<br />
PREVALENCE OF GOUT IN CENTRAL GREECE<br />
Ioannis Alexiou 1 , Ioannis Anagnostopoulos 1 , Evangelos Davas 1 , Afrodite Papathanasiou 2 ,<br />
Athanasios Koutroumpas 1 , Georgia Barouta 1 , Lazaros I. Sakkas 1 ;<br />
1<br />
<strong>Rheumatology</strong>, University Hospital of Larissa, Larissa, Greece; 2 Biomathematics,<br />
University Hospital of Larissa, Larissa, Greece<br />
SEASON OF BIRTH AND THE DEVELOPMENT OF THE AUTOANTIBODIES RF AND ANA<br />
Sarah L. Westlake 1 , Karen Jameson 2 , Elaine M. Dennison 2 , Nigel K. Arden 2,3 , Cyrus Cooper 2,3 ,<br />
Christopher J. Edwards 1 ;<br />
1<br />
Department of <strong>Rheumatology</strong>, Southampton University Hospitals NHS Trust, Southampton,<br />
United Kingdom; 2 MRC Epidemiology Resource Centre, University of Southampton,<br />
Southampton, United Kingdom; 3 Musculoskeletal Biomedical Research Unit, University of<br />
Ox<strong>for</strong>d, Ox<strong>for</strong>d, United Kingdom<br />
Poster Viewing Three | Friday 01 May 2009<br />
Poster No. 322<br />
Poster No. 323<br />
Poster No. 324<br />
Poster No. 325<br />
THE OCCURRENCE AND PREDICTORS OF HEART FAILURE IN PATIENT WITH<br />
INFLAMMATORY POLYARTHRITIS<br />
Suet Ying Khong 1 , Tracey Farragher 1 , Jarrod Franklin 1 , Hoda Mirjafari 1 , Diane Bunn 2 ,<br />
Ian Bruce 1 , Deborah Symmons 1 ;<br />
1<br />
arc Epidemiology Unit, <strong>The</strong> University of Manchester, Manchester, United Kingdom; 2 Norfolk<br />
Arthritis Register, Norfolk and Norwich University Hospital, Norwich, United Kingdom<br />
PRELIMINARY RESULTS FROM THE SPARK SURVEY OF NORTH AMERICAN AND<br />
EUROPEAN CLINICAL PRACTICE: MORE RHEUMATOID ARTHRITIS (RA) OR MORE<br />
SPONDYLOARTHRITIS (SpA)?<br />
A. L. Pangan 5 , M. Dougados 1 , D. van der Hiejde 2 , J. Sieper 3 , P. J. Mease 4 ;<br />
1<br />
Hôpital Cochin and the University of Paris, Paris, France; 2 Leiden University Medical Center,<br />
Leiden, Netherlands; 3 Charité Universitätsmedizin, Berlin, Germany; 4 Swedish Medical Center<br />
and University of Washington, Seattle, WA; 5 Abbott Laboratories, Abbott Park, IL<br />
HYPONATRAEMIA INDEPENDENTLY OF OSTEOPOROSIS IS ASSOCIATED WITH VALIDATED<br />
FRACTURE OCCURRENCE AMONG FEMALE PATIENTS ATTENDING FOR BONE DENSITY<br />
MEASUREMENT<br />
Sinead M. Kinsella 1 , Miriam J. O Sullivan 2 , Michael G. Molloy 2 , Joseph A. Eustace 1 ;<br />
1<br />
Department of Renal Medicine, Cork University Hospital, Cork, Ireland; 2 Department of<br />
<strong>Rheumatology</strong>,Sports and Exercise Medicine, Cork University Hospital, Cork, Ireland<br />
ONSET AND PERSISTENCE OF DISABLING FOOT PAIN IN COMMUNITY-DWELLING OLDER<br />
ADULTS OVER A THREE-YEAR PERIOD<br />
Edward Roddy, Sara Mottram, Elaine Thomas;<br />
Arthritis Research Campaign National Primary Care Centre, Keele University, Keele,<br />
United Kingdom<br />
93
Poster No. 326<br />
THE PREVALENCE OF RHEUMATOID ARTHRITIS IN RURAL EGYPT:<br />
A WHO-ILAR-COPCORD STUDY<br />
Ahmed Abdel-Nasser 1 , Rawheya Abdel-Tawab 1 , Jehan Mahmoud 1 , Adel Sammy 2 ,<br />
Mahmoud Abdel-Fattah 3 ;<br />
1<br />
<strong>Rheumatology</strong>, Minia University, Minia, Egypt; 2 Radiology, Minia University, Minia, Egypt;<br />
3<br />
Epidemiology, Minia University, Minia, Egypt<br />
Poster No. 327<br />
Poster No. 328<br />
Poster No. 329<br />
Poster No. 330<br />
PATTERNS OF SELECTED PERIPHERAL JOINT PAINS IN COMMUNITY-DWELLING ADULTS<br />
AGED 50 YEARS AND OVER<br />
George Peat, Elaine Thomas, Krysia Dziedzic, Peter Croft;<br />
Arthritis Research Campaign National Primary Care Centre, Keele University, Keele,<br />
United Kingdom<br />
THE IMPACT OF MUSCULOSKELETAL PAIN ON SEXUAL FUNCTIONING IN MIDDLE AGED AND<br />
ELDERLY EUROPEAN MEN: RESULT FROM THE EUROPEAN MALE AGEING STUDY<br />
Abdelouahid Tajar 1 , Terence W. O’Neill 1 , György Bartfai 2 , Felipe F. Casanueva 3 , Gianni Forti 4 ,<br />
Aleksander Giwercman 5 , Krzysztof Kula 6 , Margus Punab 7 , Dirk Vanderschueren 8 ,<br />
Frederick C. Wu 9 , John McBeth 1 ;<br />
1<br />
ARC Epidemiology Unit, <strong>The</strong> University of Manchester, Manchester, United Kingdom;<br />
2<br />
Department of Obstetrics, Gynaecology and Andrology, Albert Szent-Göorgy Medical University,<br />
Szeged, Hungary; 3 Department of Medicine, Santiago de Compostela University, Complejo<br />
Hospitalario Universitario de Santiago (CHUS); CIBER de Fisiopatología Obesidad y Nutricion<br />
(CB06/03), Instituto Salud Carlos III, Santiago de Compostela, Spain; 4 Andrology Unit,<br />
Department of Clinical Physiopathology, University of Florence, Florence, Italy; 5 Scanian<br />
Andrology Centre, Department of Urology, Malmö University Hospital, University of Lund,<br />
Malmö, Sweden; 6 Department of Andrology and Reproductive Endocrinology, Medical University<br />
of Lodz, Lodz, Poland; 7 Andrology Unit, United Laboratories of Tartu University Clinics, Tartu,<br />
Estonia; 8 Department of Andrology and Endocrinology, Catholic University of Leuven, Leuven,<br />
Belgium; 9 Department of Endocrinology, Manchester Royal Infirmary, <strong>The</strong> University of<br />
Manchester, Manchester, United Kingdom<br />
HAND AND WRIST PROBLEMS IN GENERAL PRACTICE: WHAT IS THE VALUE OF<br />
DIAGNOSTIC INFORMATION FOR PATIENT OUTCOMES?<br />
Marinda N. Spies-Dorgelo 1 , Daniëlle A. van der Windt 2,1 , Pieter A. Prins 3 ,<br />
Bernard M. Uitdehaag 4 , Henriëtte E. van der Horst 1 ;<br />
1<br />
Departement of General Practice, VU university medical center/EMGO-institute, Amsterdam,<br />
Netherlands; 2 Primary Care Musculoskeletal Research Centre, Keele University, Keele, United<br />
Kingdom; 3 Jan van Breemen Institute <strong>for</strong> rheumatology, Amsterdam, Netherlands; 4 Department<br />
of Neurology, VU university medical center, Amsterdam, Netherlands<br />
PHYSICAL DISABILITY AND PAIN IN A PRIMARY CARE BASED COHORT OF OLDER PEOPLE<br />
WITH INFLAMMATORY AND NON-INFLAMMATORY MUSCULOSKELETAL CONDITIONS<br />
Jon C. Packham, Edward Roddy, Kelvin P. Jordan;<br />
Arthritis Research Campaign National Primary Care Centre, Keele University, Keele,<br />
United Kingdom<br />
94
Rheumatoid arthritis - clinical aspects<br />
Poster No. 331<br />
Poster No. 332<br />
ASSESSMENT OF FALLS RISK IN PATIENTS WITH RHEUMATOID ARTHRITIS IN<br />
THE STANDARD RHEUMATOLOGY PRACTICE: MISSION POSSIBLE<br />
Yasser El Miedany 1 , Deborah Palmer 1 , Mathias Toth 2 ;<br />
1<br />
<strong>Rheumatology</strong>, Darent Valley Hospital, Dart<strong>for</strong>d, United Kingdom; 2 Geriatrics Department,<br />
Darent Valley Hospital, Dart<strong>for</strong>d, United Kingdom<br />
GENDER DIFFERENCES IN DISEASE ACTIVITY IN EARLY RHEUMATOID ARTHRITIS<br />
R. Martin 1 , M. H. Ma 1 , A. B. Hassell 2 , P. Kiely 3 , D. Walker 4 , D. A. Walsh 5 , R. Williams 6 ,<br />
A. Young 7 , D. L. Scott 1 ;<br />
1<br />
Department of <strong>Rheumatology</strong>, King’s College School of Medicine, London, United Kingdom;<br />
2<br />
Department of <strong>Rheumatology</strong>, Hayward Hospital, Stoke-on-Trent, United Kingdom;<br />
3<br />
Department of <strong>Rheumatology</strong>, St Georges Hospital, London, United Kingdom; 4 Department<br />
of <strong>Rheumatology</strong>, Freeman Hospital, Newcastle upon Tyne, United Kingdom; 5 Academic<br />
<strong>Rheumatology</strong>, University of Nottingham, Nottingham, United Kingdom; 6 Department of<br />
<strong>Rheumatology</strong>, Here<strong>for</strong>d Hospital, Here<strong>for</strong>d, United Kingdom; 7 Department of <strong>Rheumatology</strong>,<br />
City Hospital, St Albans, United Kingdom<br />
Poster Viewing Three | Friday 01 May 2009<br />
Poster No. 333<br />
PLANTAR FOOT PRESSURES ARE NOT RELATED TO DISEASE ACTIVITY IN RHEUMATOID<br />
ARTHRITIS<br />
Anita L. Gay 1 , Catherine J. Bowen 1 , Lindsey Hooper 1 , Christopher J. Edwards 2,3 ,<br />
David Culli<strong>for</strong>d 4 , Nigel K. Arden 5,6 ;<br />
1<br />
School of Health Sciences, University of Southampton, Southampton, United Kingdom;<br />
2<br />
Department of <strong>Rheumatology</strong>, Southampton University Hospitals NHS Trust, Southampton,<br />
United Kingdom; 3 Wellcome Trust Clinical Research Facility, Southampton University<br />
Hospitals NHS Trust, Southampton, United Kingdom; 4 Research Development and Support<br />
Unit, University of Southampton, Southampton, United Kingdom; 5 MRC Epidemiology<br />
Resource Centre, University of Southampton, Southampton, United Kingdom;<br />
6<br />
Musculoskeletal Biomedical Research Unit, University of Ox<strong>for</strong>d, Ox<strong>for</strong>d, United Kingdom<br />
Poster No. 334<br />
Poster No. 335<br />
Poster No. 336<br />
FATIGUE IS CORRELATED WITH SLEEP DISTURBANCE IN PATIENTS WITH RHEUMATOID<br />
ARTHRITIS (RA)<br />
Penny Storrs, Cai Brockley, Frank McKenna;<br />
Rheumatic Diseases Unit, Traf<strong>for</strong>d NHS Healthcare Trust, Manchester, United Kingdom<br />
CLINICAL AND LABORATORY CHARACTERISTICS OF RHEUMATOID ARTHRITIS IN PATIENTS<br />
WITH AND WITHOUT ANTI-CYCLIC CITRULLINATED PROTEIN ANTIBODIES<br />
Oleg B. Iaremenko 1 , Anna M. Mikitenko 2 ;<br />
1<br />
<strong>Rheumatology</strong>, National medical university, Kiev, Ukraine; 2 <strong>Rheumatology</strong>, National medical<br />
university, Kiev, Ukraine<br />
PREDICTORS OF SYNOVITIS AND JOINT DAMAGE AT PRESENTATION TO AN EARLY<br />
ARTHRITIS CLINIC<br />
Jenny A. Watkins 1 , Louise Gartner 2 , Denis Remedios 2 , Jacqueline Andrews 1 ;<br />
1<br />
<strong>Rheumatology</strong>, Northwick Park Hospital, London, United Kingdom; 2 Radiology, Northwick<br />
Park Hospital, London, United Kingdom<br />
95
Poster No. 337<br />
IMPACT OF ADJUSTING CARDIOVASCULAR RISK SCORES TO KNOWN RISK RATIOS IN<br />
RHEUMATOID ARTHRITIS<br />
Kimberley A. Bailey 2 , Namita Kumar 1 ;<br />
1<br />
Dept of <strong>Rheumatology</strong>, University Hospital of North Durham, Durham, United Kingdom;<br />
2<br />
Medical School, University of Newcastle, Newcastle-upon-Tyne, United Kingdom<br />
Poster No. 338<br />
ASSESSMENT OF SUBCLINICAL CAROTID ATHEROSCLEROSIS IN RHEUMATOID ARTHRITIS<br />
PATIENTS AND ITS CORRELATION WITH INSULIN RESISTANCE<br />
Nevine M. Fouda 1 , Hanan Abdelaziz 2 , Enas Fouda 3 ;<br />
1<br />
<strong>Rheumatology</strong>, lecturer in ain shams university, Cairo, Egypt; 2 hanan abdelaziz, ass.prof in<br />
ain shams university, Cairo, Egypt; 3internal medicine, ass.prof in ain shams university,<br />
Cairo, Egypt<br />
Poster No. 339<br />
THE LARGEST ARMA STANDARD OF CARE SURVEY IN INFLAMMATORY ARTHRITIS<br />
Ernest Wong 1 , Elizabeth Price 2 , Lynn Williamson 2 , David Collins 2 ;<br />
1<br />
<strong>Rheumatology</strong>, Buckinghamshire Hospital NHS Trust, High Wycombe, United Kingdom;<br />
2<br />
<strong>Rheumatology</strong>, Swindon & Marlborough NHS Trust, Swindon, United Kingdom<br />
Poster No. 340<br />
Poster No. 341<br />
THE USE OF MUSCULOSKELETAL ULTRASOUND TO ASSESS DISEASE ACTIVITY IN<br />
RHEUMATOID ARTHRITIS: A FEASIBILITY EXERCISE<br />
James Dale, Monica Gupta, Duncan Porter;<br />
<strong>Rheumatology</strong>, Gartnavel General Hospital, Glasgow, United Kingdom<br />
FATIGUE IS AN INDEPENDENT DRIVER OF DISABILITY IN RHEUMATOID ARTHRITIS (RA)<br />
Louise C. Pollard 1 , David L. Scott 1 , Nora Donaldson 2 , Ernest Choy 1 ;<br />
1<br />
Academic Department of <strong>Rheumatology</strong>, King’s College London, London, United Kingdom;<br />
2<br />
Oral Health Services Research, King’s College London, London, United Kingdom<br />
Poster No. 342<br />
Poster No. 343<br />
HAQ AND GENDER PREDICT REMISSION IN EARLY RA: EXPERIENCE IN THE EARLY<br />
RHEUMATOID ARTHRITIS NETWORK (ERAN)<br />
Margaret H. Ma 1 , David L. Scott 1 , Patrick Kiely 2 , Richard Williams 3 , David Walsh 4 , Adam Young 5 ;<br />
1<br />
<strong>Rheumatology</strong>, King’s College Hospital, London, United Kingdom; 2 <strong>Rheumatology</strong>,<br />
St George’s Hospital, London, United Kingdom; 3 <strong>Rheumatology</strong>, Here<strong>for</strong>d Hospital, Here<strong>for</strong>d,<br />
United Kingdom; 4 Academic <strong>Rheumatology</strong>, University of Nottingham, Nottingham, United<br />
Kingdom; 5 <strong>Rheumatology</strong>, City Hospital, St Albans, United Kingdom<br />
INVESTIGATION OF THE NATURAL HISTORY OF FOREFOOT BURSITIS DETECTED BY<br />
MUSCULOSKELETAL ULTRASOUND AND PREDICTORS OF ITS CHANGE AFTER ONE YEAR<br />
Catherine J. Bowen 1 , David Culli<strong>for</strong>d 2 , Keith Dewbury 3 , Madeleine Sampson 3 , Jane H. Burridge 1 ,<br />
Christopher J. Edwards 4,5 , Nigel K. Arden 6,7 ;<br />
1<br />
School of Health Sciences, University of Southampton, Southampton, United Kingdom;<br />
2<br />
Research Development and Support Unit, University of Southampton, Southampton, United<br />
Kingdom; 3 Radiology, Southampton University Hospitals Trust, Southampton, United Kingdom;<br />
4<br />
<strong>Rheumatology</strong>, Southampton University Hospitals Trust, Southampton, United Kingdom;<br />
5<br />
Wellcome Trust Clinical Research Facility, Southampton University Hospitals Trust,<br />
Southampton, United Kingdom; 6 MRC Epidemiology Resource Centre, University of<br />
Southampton, Southampton, United Kingdom; 7 Musculoskeletal Biomedical Research Unit,<br />
University of Ox<strong>for</strong>d, Ox<strong>for</strong>d, United Kingdom<br />
96
Poster No. 344<br />
Poster No. 345<br />
Poster No. 346<br />
CARDIOVASCULAR RISK IN PATIENTS WITH RHEUMATOID ARTHRITIS: WHAT DO OUR<br />
GENERAL PRACTITIONERS THINK?<br />
Eranga Hayes 1 , Jayne Little 1 , Vijay Iyer 2 , Amrit Takhar 3 , Sandeep Dahiya 1 ;<br />
1<br />
Department of <strong>Rheumatology</strong>, Peterborough and Stam<strong>for</strong>d Hospitals NHS Foundation Trust,<br />
Peterborough, United Kingdom; 2 <strong>The</strong> Surgery, Hodgson Centre, Werrington, Peterborough,<br />
United Kingdom; 3 Wans<strong>for</strong>d Surgery, Wans<strong>for</strong>d and King’s Cliffe Practice, Peterborough,<br />
United Kingdom<br />
SMOKING ASSOCIATED WITH INCREASED DISEASE ACTIVITY AT PRESENTATION WITH<br />
EARLY INFLAMMATORY POLYARTHRITIS<br />
Sarang Chitale 1,2 , Jenny Humphreys 1 , Cristina Estrach 1 , Robert Thompson 1 ,<br />
Nicola Goodson 1,2 ;<br />
1<br />
<strong>Rheumatology</strong>, Aintree University Hospital, Liverpool, United Kingdom; 2 Academic<br />
<strong>Rheumatology</strong> Department, Liverpool University, Liverpool, United Kingdom<br />
BNP LEVELS CORRELATE WITH DISEASE ACTIVITY IN RHEUMATOID ARTHRITIS PATIENTS<br />
WITHOUT HEART DISEASE<br />
David J. Armstrong 1 , Philip V. Gardiner 1 , Maurice J. O’Kane 2 ;<br />
1<br />
Department of <strong>Rheumatology</strong>, Altnagelvin Hospital, Londonderry, United Kingdom;<br />
Poster Viewing Three | Friday 01 May 2009<br />
2<br />
Department of Biochemistry, Altnagelvin Hospital, Londonderry, United Kingdom<br />
Poster No. 347<br />
CHANGES IN BODY WEIGHT DURING ANTI-TNF THERAPY FOR RHEUMATOID ARTHRITIS<br />
Richard A. Lowdon 1 , Paul Silcocks 2 , Sayka Butt 1 , Greg Summers 1 ;<br />
1<br />
Department of <strong>Rheumatology</strong>, Derbyshire Royal Infirmary, Derby, United Kingdom; 2 Trent<br />
RDSU, Nottingham, United Kingdom.<br />
Poster No. 348<br />
EARLY INFLAMMATORY ARTHRITIS IS BEST MANAGED IN SPECIALISED CLINICS<br />
Cyndi Goh 1 , Jill Bloxham 1 , Varvara Polydoropoulou 2 , Andrew J. Ostör 1 ;<br />
1<br />
<strong>Rheumatology</strong>, Addenbrooke’s Hospital, Cambridge, United Kingdom; 2 Centre <strong>for</strong> Applied<br />
Medical Statistics, University of Cambridge, Cambridge, United Kingdom<br />
Poster No. 349<br />
RHEUMATOID ARTHRITIS (RA): THE ASSESSMENT OF DISEASE ACTIVITY IN<br />
CLINICAL PRACTICE. DOES IT INFLUENCE TREATMENT DECISIONS?<br />
Margaret H. Ma 1,2 , Louise C. Pollard 1 , Gabrielle H. Kingsley 2 , David L. Scott 1 ; 1 <strong>Rheumatology</strong>,<br />
King’s College Hospital, London, United Kingdom; 2 <strong>Rheumatology</strong>, University Hospital<br />
Lewisham, London, United Kingdom<br />
Poster No. 350<br />
CXCR3 AND CXCR4 EXPRESSION ON PERIPHERAL BLOOD T-LYMPHOCYTES FROM<br />
PATIENTS WITH RHEUMATOID ARTHRITIS:RELATION TO DISEASE ACTIVITY<br />
Nevine M. Fouda 1 , Eman Kaddah 1 , Sanaa Zaki 2 , Wafaa Zaki 2 ;<br />
1<br />
<strong>Rheumatology</strong>, lecturer in Ain Shams University, cairo, Egypt; 2 Microbiology and Immunology<br />
Depatments, lecturer in Ain Shams University, Cairo, Egypt<br />
Poster No. 351<br />
DEVELOPMENT AND VALIDATION OF A HEART DISEASE KNOWLEDGE QUESTIONNAIRE<br />
FOR PEOPLE WITH RHEUMATOID ARTHRITIS<br />
Holly John 1 , Gareth J. Treharne 2 , Elizabeth D. Hale 1 , Vasileios Panoulas 1 , Douglas Carroll 3 ,<br />
George Kitas 1 ;<br />
1<br />
Department of <strong>Rheumatology</strong>, Dudley Group of Hospitals NHS Foundation Trust, Dudley,<br />
United Kingdom; 2 Department of Psychology, University of Otago, Dunedin, New Zealand;<br />
3<br />
School of Sport and Exercise Sciences, University of Birmingham, Birmingham,<br />
United Kingdom<br />
97
Poster No. 352<br />
Poster No. 353<br />
ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODY POSITIVITY CORRELATES WELL<br />
WITH LARSEN RADIOGRAPHIC SCORES IN A CROSS-SECTIONAL COHORT OF PATIENTS<br />
WITH RA BUT TITRE DOES NOT<br />
Helena Robinson 1 , Anahita Rezaei 2 , Karen Walker-Bone 3 ;<br />
1<br />
<strong>Rheumatology</strong>, Brighton and Sussex University Hospitals, Brighton, United Kingdom; 2 Clinical<br />
Immunology, Brighton and Sussex University Hospitals, Brighton, United Kingdom; 3 Brighton<br />
and Sussex Medical School, Haywards Heath, United Kingdom<br />
FATIGUE IN RHEUMATOID ARTHRITIS (RA), WHAT ARE WE MEASURING?: A FACTOR<br />
ANALYSIS OF FATIGUE INSTRUMENTS<br />
Louise C. Pollard 1 , David L. Scott 1 , Nora Donaldson 2 , Ernest H. Choy 1 ;<br />
1<br />
Academic Department of <strong>Rheumatology</strong>, King’s College London, London, United Kingdom;<br />
2<br />
Oral Health Services Research, King’s College London, London, United Kingdom<br />
Poster No. 354<br />
THE METABOLIC SYNDROME: A USEFUL CARDIOVASCULAR CONSTRUCT IN EARLY<br />
INFLAMMATORY POLYARTHRITIS?<br />
Hoda Mirjafari 1 , Tracey Farragher 1 , Tarnya Marshall 2 , Diane Bunn 1,2 , Philip Pemberton 3 , Helena<br />
Bodill 4 , Valentine Charlton-Menys 5 , Mark Lunt 1 , Deborah Symmons 1 , Ian Bruce 1 ;<br />
1<br />
ARC Epidemiology Unit, University of Manchester, Manchester, United Kingdom; 2 Norfolk &<br />
Norwich University Hospitals, Norwich, United Kingdom; 3 Clinical Research Department,<br />
Manchester Royal Infirmary, Manchester, United Kingdom; 4 Department of Vascular Surgery,<br />
Manchester Royal Infirmary, Manchester, United Kingdom; 5 Cardiovascular Research Group,<br />
Manchester Royal Infirmary, Manchester, United Kingdom<br />
Poster No. 355<br />
Poster No. 356<br />
COMPARISON OF SUBJECTIVE AND OBJECTIVE MEASURES OF SLEEP IN PATIENTS WITH<br />
FIBROMYALGIA AND RHEUMATOID ARTHRITIS<br />
Penny J. Storrs, Cai Brockley, Frank McKenna;<br />
Rheumatic Diseases Unit, Traf<strong>for</strong>d NHS Healthcare Trust, Manchester, United Kingdom<br />
DISEASE ACTIVITY AND FIVE YEAR OUTCOME OF EARLY RHEUMATOID ARTHRITIS<br />
(RA) IN A BIOLOGIC DRUG FREE INCEPTION COHORT<br />
J. Dixey 1 , K. Jayakumar 1 , G. Koduri 1 , P. Williams 1 , S. Norton 2 , D. James 1 , A. Young 1 ;<br />
1<br />
Early Rheumatoid Arthritis Study (ERAS), c/o St Albans City Hospital, St Albans, United<br />
Kingdom; 2 RDS, University of Hert<strong>for</strong>dshire, Hatfield, United Kingdom<br />
Poster No. 357<br />
Poster No. 358<br />
HOW CAN TNF-BLOCKERS BE STOPPED WITHOUT FLARE? NEEDS EARLY TREATMENT AND<br />
IMMUNOLOGICAL REMISSION<br />
Benazir Saleem, Rekha Parmer, Vincent Goeb, Philip G. Conaghan, Frederique Ponchel,<br />
Paul Emery;<br />
Academic section of musculoskeletal disease, Leeds Institute of Molecular Medicine, Leeds<br />
University, Leeds, United Kingdom<br />
DISCREPANCIES IN CATEGORISING EARLY AND ESTABLISHED RHEUMATOID ARTHRITIS<br />
(RA) PATIENTS BY DAS28(ESR) AND DAS28(CRP): CAN THEY BE REDUCED?<br />
Elizabeth M. Hensor, Paul Emery, Sarah J. Bingham, Philip G. Conaghan, Year Consortium;<br />
Section of Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom<br />
98
Poster No. 359<br />
Poster No. 360<br />
Poster No. 361<br />
THREE_DIMENSIONAL ULTRASOUND IMAGING FOR THE DETECTION AND MONITORING<br />
OF JOINT DAMAGE IN RHEUMATOID ARTHRITIS<br />
Nigel Harris 1 , Jacqueline Shipley 1 , James Thompson 1 , Ashok Bhalla 1 , Graham Robinson 2 ,<br />
David Glew 2 , Francis Duck 2 ;<br />
1<br />
Royal National Hospital <strong>for</strong> Rheumatic Diseases, Bath, United Kingdom; 2 Royal United<br />
Hospital, Bath, United Kingdom<br />
PERSISTENT MODERATE DAS IS NOT A BENIGN STATE: PROGRESSIVE LOSS OF<br />
FUNCTION OCCURS IN EARLY RA DESPITE STEP-UP DMARD THERAPY<br />
Philip G. Conaghan, Elizabeth M. Hensor, Anne-Maree Keenan, Paul Emery,<br />
Year Consortium;<br />
Section of Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom<br />
THE INFLUENCE OF ANTI-TNF THERAPY UPON CANCER INCIDENCE IN PATIENTS WITH<br />
RHEUMATOID ARTHRITIS (RA) WHO HAVE HAD PRIOR MALIGNANCY: RESULTS FROM<br />
THE BSRBR<br />
Will Dixon, Kath Watson, Mark Lunt, .. BSRBR Control Centre Consortium, Kimme Hyrich,<br />
Deborah Symmons, . on behalf of the BSRBR;<br />
arc Epidemiology Unit, University of Manchester, Manchester, United Kingdom<br />
Poster Viewing Three | Friday 01 May 2009<br />
Poster No. 362<br />
Poster No. 363<br />
Poster No. 364<br />
SECULAR CHANGES IN UK ANTI-TNF PRESCRIBING PATTERNS AND TREATMENT<br />
RESPONSE IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS FROM THE BSRBR<br />
Kath Watson, Kimme Hyrich, Mark Lunt, Deborah Symmons, . on behalf of the BSRBR;<br />
arc Epidemiology Unit, <strong>The</strong> University of Manchester, Manchester, United Kingdom<br />
VITAMIN D DEFICIENCY IS ASSOCIATED WITH SIGNIFICANT DISABILITY IN EARLY<br />
INFLAMMATORY POLYARTHRITIS (IP)<br />
John A. Reynolds 1 , Tracey Farragher 1 , Mark Lunt 1 , Sanjeev Patel 2 , Diane Bunn 1 ,<br />
Deborah Symmons 1 , Ian N. Bruce 1 ;<br />
1<br />
arc Epidemiology Unit, University of Manchester, Manchester, United Kingdom; 2 Department<br />
of Medicine & <strong>Rheumatology</strong>, St Helier University Hospital, Carshalton, United Kingdom<br />
ATHEROGENIC BIOMARKER PROFILES AND THE METABOLIC SYNDROME IN<br />
INFLAMMATORY POLYARTHRITIS: RESULTS FROM THE NORFOLK ARTHRITIS<br />
REGISTER (NOAR)<br />
Hoda Mirjafari 1 , Philip Pemberton 2 , Valentine Charlton-Menys 3 , Tracey Farragher 1 ,<br />
Diane Bunn 1,4 , Tarnya Marshall 4 , Deborah Symmons 1 , Ian Bruce 1 ;<br />
1<br />
ARC Epidemiology Unit, University of Manchester, Manchester, United Kingdom;<br />
2<br />
Clinical Research Department, Manchester Royal Infirmary, Manchester, United Kingdom;<br />
3<br />
Cardiovascular Research Group, University of Manchester, Manchester, United Kingdom;<br />
4<br />
Norfolk & Norwich University Hospitals, Norwich, United Kingdom<br />
Poster No. 365<br />
RHEUMATOID ARTHRITIS AND ANTI-TNF THERAPY: DIFFERENT DISEASE ASSESSMENT<br />
NEEDED FOR PATIENTS OF DIFFERENT ETHNIC BACKGROUNDS?<br />
Shabnam Sabah 1 , Sadia Kalsoom 1 , David M. Carruthers 2 , Alison Deeming 2 ;<br />
1<br />
Medical School, University of Birmingham, Birmingham, United Kingdom;<br />
2<br />
<strong>Rheumatology</strong>, City Hospital, Birmingham, United Kingdom<br />
Poster No. 366<br />
SYSTEMATIC REVIEW OF TIGHT CONTROL REGIMES IN RHEUMATOID ARTHRITIS<br />
Margaret H. Ma 1,2 , Gabrielle H. Kingsley 2 , David L. Scott 1 ;<br />
1<br />
<strong>Rheumatology</strong>, King’s College Hospital, London, United Kingdom; 2 <strong>Rheumatology</strong>, University<br />
Hospital Lewisham, London, United Kingdom<br />
99
Poster No. 367<br />
Poster No. 368<br />
CERVICAL SPINE INSTABILITY IN RHEUMATOID ARTHRITIS (RA) IS MORE<br />
COMMON IN PATIENTS UNDERGOING ORTHOPAEDIC SURGERY<br />
B. Ramabhadran, G. Koduri, K. Jayakumar, R. Musa, J. Winfield, P. Williams, A. Young; ERAS,<br />
<strong>Rheumatology</strong>, ERAS, St Albans City Hospital, St Albans, United Kingdom<br />
LOW DISEASE ACTIVITY IN RHEUMATOID ARTHRITIS (RA) RESULTS IN BETTER CLINICAL<br />
OUTCOMES, BUT RADIOLOGICAL DAMAGE IN HANDS AND FEET CAN STILL PROGRESS<br />
K. Jayakumar 1 , A. Young 1 , J. Dixey 1 , C. Sollymosy 1 , P. Williams 1 , S. Norton 2 ;<br />
1<br />
ERAS, Department of <strong>Rheumatology</strong>, St Albans City Hospital, St Albans, United Kingdom;<br />
2<br />
RDS, University of Hert<strong>for</strong>dshire, Hatfield, United Kingdom<br />
Poster No. 369<br />
A HIGH-THROUGHPUT TANSCRIPTOMICS APPROACH TO BIOMARKER DISCOVERY<br />
IN EARLY ARTHRITIS<br />
Arthur G. Pratt 1,2 , Gill Wilson 2 , Daniel C. Swan 3 , David A. Young 1 , Catharien M. Hilkens 1 ,<br />
John D. Isaacs 1,2 ;<br />
1<br />
Musculoskeletal Research Group, Newcastle University, Newcastle upon Tyne, United<br />
Kingdom; 2 Musculoskeletal Unit, Freeman Hospital, Newcastle upon Tyne, United Kingdom;<br />
3<br />
Bioin<strong>for</strong>matics Support Unit, Newcastle University, Newcastle upon Tyne, United Kingdom<br />
Poster No. 370<br />
Poster No. 371<br />
Poster No. 372<br />
Poster No. 373<br />
Poster No. 374<br />
POWER DOPPLER ULTRASOUND PREDICTS DEVELOPMENT OF RA IN CCP NEGATIVE<br />
PATIENTS<br />
Jane E. Freeston, Richard J. Wakefield, Philip G. Conaghan, Elizabeth M. Hensor, Paul Emery;<br />
Academic Section of Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom<br />
HOW TO REDUCE THE MORBIDITY AND MORTALITY FROM LOWER RESPIRATORY TRACT<br />
INFECTIONS IN RHEUMATOID ARTHRITIS<br />
Madeleine Housden, Carol Heycock, Jennifer Hamilton, Vadivelu Saravanan, Clive Kelly;<br />
<strong>Rheumatology</strong>, QEH, Gateshead, United Kingdom<br />
“EXTRA INFORMATION A BIT FURTHER DOWN THE LINE”: RHEUMATOID ARTHRITIS<br />
PATIENTS’ PERCEPTIONS OF DEVELOPING EDUCATIONAL MATERIAL ABOUT THE<br />
CARDIOVASCULAR DISEASE RISK<br />
Holly John 1 , Elizabeth D. Hale 1 , Gareth J. Treharne 2 , Douglas Carroll 3 , George Kitas 1 ;<br />
1<br />
Department of <strong>Rheumatology</strong>, Dudley Group of Hospitals NHS Foundation Trust, Dudley,<br />
United Kingdom; 2 Department of Psychology, University of Otago, Dunedin, New Zealand;<br />
3<br />
School of Sport and Exercise Sciences, University of Birmingham, Birmingham, United<br />
Kingdom.<br />
OUTCOME MEASURES IN RHEUMATOID ARTHRITIS : PATIENT SELF-REPORT JOINT<br />
TENDERNESS IS RELIABLE AND RESPONSIVE TO CHANGE IN DISEASE ACTIVITY<br />
Yasser El Miedany 1 , Deborah Palmer 1 , Maha El Gaafary 2 ;<br />
1<br />
<strong>Rheumatology</strong>, Darent Valley Hospital, Dart<strong>for</strong>d, United Kingdom; 2 Community, Environmental<br />
and Occupational Medicine, Ain Shams University, Cairo, Egypt<br />
PREGNANCY OUTCOMES IN PATIENTS RECEIVING ANTI-TNF THERAPY FOR<br />
RHEUMATIC DISEASES: RESULTS FROM THE BSR BIOLOGICS REGISTER<br />
Yvonne King, Kath Watson, . BSR Control Centre Consortium, Deborah Symmons,<br />
Kimme Hyrich, . on behalf of the BSRBR;<br />
arc Epidemiology Unit, University of Manchester, Manchester, United Kingdom<br />
100
Poster No. 375<br />
Poster No. 376<br />
Poster No. 377<br />
A QUESTIONNAIRE BASED ASSESSMENT IS AS EFFECTIVE AS A NURSE-LED CLINIC<br />
IN IDENTIFYING CARDIOVASCULAR RISK FACTORS IN PATIENTS WITH RHEUMATOID<br />
ARTHRITIS<br />
L. J. Smith, A. M. Meadows, Z. Horne, E. Whalley, N. J. Sheehan;<br />
<strong>Rheumatology</strong> Department, Peterborough & Stam<strong>for</strong>d Hospital NHS Foundation<br />
Trust, Peterborough, United Kingdom<br />
ANTI-CYCLIC CITRULLINATED PEPTIDE (CCP) ANTIBODY TITRE AND DISEASE ACTIVITY IN<br />
RHEUMATOID ARTHRITIS<br />
Sarah J. Evans 1 , Nick Amos 2 , Gill Johnson 1 , Alwyn Lloyd 1 , Margaret M. O’Sullivan 1 ;<br />
1<br />
<strong>Rheumatology</strong>, Wrexham Maelor Hospital, Wrexham, United Kingdom; 2 <strong>Rheumatology</strong>,<br />
University Hospital of Wales, Cardiff, United Kingdom<br />
METHOTREXATE REDUCES THE RISK OF CARDIOVASCULAR DISEASE IN PATIENTS WITH<br />
RHEUMATOID ARTHRITIS (RA) - A SYSTEMATIC LITERATURE REVIEW<br />
Sarah Westlake 1 , Alexandra Colebatch 1 , Janis Baird 2 , Ernest Choy 3 , Patrick Kiely 4 , Andrew<br />
Ostor 5 , Mark Quinn 6 , Christopher Edwards 1 ;<br />
1<br />
Southampton General Hospital, Southampton, United Kingdom; 2 MRC Epidemiology<br />
Resource Centre, University of Southampton, Southampton, United Kingdom; 3 Kings College,<br />
London, United Kingdom; 4 St Georges Healthcare NHS Trust, London, United Kingdom;<br />
5<br />
Cambridge University Hospitals, Cambridge, United Kingdom; 6 York Hospital/ Hull York<br />
Poster Viewing Three | Friday 01 May 2009<br />
Medical School, York, United Kingdom<br />
BHPR audit/service delivery<br />
Poster No. 378<br />
Poster No. 379<br />
Poster No. 380<br />
Poster No. 381<br />
EVALUATION OF A RHEUMATOLOGY VOICEMAIL SERVICE<br />
Leena Das 1 , Patricia Eveson 2 , Vivian Weeks 3 , Madelaine Whitlock 4 , Valerie Maddison 5 ;<br />
1<br />
<strong>Rheumatology</strong>, Southend NHS Foundation Trust, Essex, United Kingdom; 2 <strong>Rheumatology</strong>,<br />
Southend NHS Foundation Trust, Essex, United Kingdom; 3 <strong>Rheumatology</strong>, Southend NHS<br />
Foundation Trust, Essex, United Kingdom; 4 <strong>Rheumatology</strong>, Southend NHS Foundation Trust,<br />
Essex, United Kingdom; 5 <strong>Rheumatology</strong>, Southend NHS Foundation Trust, Essex, United<br />
Kingdom<br />
THE EXPECTATIONS OF RHEUMATOLOGY DOCTORS AND ALLIED HEALTH<br />
PROFESSIONALS REFERRING PATIENTS TO A NURSE LED CHRONIC MUSCULOSKELETAL<br />
PAIN CLINIC<br />
Sarah Ryan, Cath Thwaites;<br />
Staf<strong>for</strong>dshire <strong>Rheumatology</strong> Centre, Haywood Hospital, Burslem, Stoke on Trent,<br />
United Kingdom<br />
EVALUATING THE EDUCATION OF PATIENTS WITH NEWLY DIAGNOSED<br />
RHEUMATOID ARTHRITIS<br />
Martin A. Lee;<br />
<strong>Rheumatology</strong>, Royal Cornwall Hospital, Truro, United Kingdom<br />
DOES A RHEUMATOLOGY ADVICE LINE IMPACT ON PATIENTS TREATMENT?<br />
Eileen A. Taylor 1 , Alan Brooksby 2 ;<br />
1<br />
<strong>Rheumatology</strong> Department, Norfolk & Norwich University Hospital, Norwich, United<br />
Kingdom; 2 Clinical Audit Department, Norfolk & Norwich University Hospital, Norwich, United<br />
Kingdom<br />
101
Poster No. 382<br />
Poster No. 383<br />
Poster No. 384<br />
Poster No. 385<br />
Poster No. 386<br />
Poster No. 387<br />
Poster No. 388<br />
Poster No. 389<br />
Poster No. 390<br />
Poster No. 391<br />
PATIENT OUTCOMES IN RHEUMATOLOGY PRACTITIONER OUTREACH CLINICS IN NORFOLK<br />
Heather F. Hasthorpe, Corrinne Ellis, Karl Gaffney;<br />
<strong>Rheumatology</strong>, Norfolk & Norwich University Hospital NHS Foundation Trust., Norwich,<br />
United Kingdom<br />
THE ROLE OF THE INFECTIOUS DISEASES TEAM, RHEUMATOLOGY AND AUDIT IN<br />
MAINTAINING STANDARDS IN THE ACUTE MANAGEMENT OF HOT JOINTS IN A LARGE<br />
DISTRICT GENERAL HOSPITAL<br />
Samah Alimam 1 , Sam T. Douthwaite 1 , Neil Snowden 2 ;<br />
1<br />
Monsall Unit, Dept of Infectious Diseases & Tropical Medicine, North Manchester General<br />
Hospital, Pennine Acute NHS Trust, U.K, Manchester, United Kingdom; 2 <strong>Rheumatology</strong> Dept,<br />
North Manchester General Hospital, Pennine Acute NHS Trust, U.K, Manchester,<br />
United Kingdom<br />
THE PRACTISE OF SWITCHING ANTI TNF THERAPY. A DISTRICT GENERAL HOSPITAL<br />
EXPERIENCE<br />
Teresa Doherty, Julian Heath, Sathianathan Panthakalam;<br />
<strong>Rheumatology</strong>, Eastbourne District General Hospital, Eastbourne, United Kingdom<br />
A DISTRICT GENERAL HOSPITAL’S EXPERIENCE OF ANTI TNF THERAPY IN<br />
RHEUMATOID ARTHRITIS<br />
Teresa Doherty, Julian Heath, Fatin Sumner, Andrew Ham, Sathianathan Panthakalam;<br />
<strong>Rheumatology</strong>, Eastbourne District General Hospital, Eastbourne, United Kingdom<br />
AUDIT - MANAGEMENT OF INFLAMMATORY ARTHRITIS<br />
Madhura Castelino, Wael Sumaya, Lee-Suan Teh;<br />
<strong>Rheumatology</strong>, Royal Blackburn Hospital, Blackburn, United Kingdom<br />
PATIENT SATISFACTION WITH A NURSE PRESCRIBER LED SUBCUTANEOUS METHOTREXATE<br />
INJECTION SERVICE, FOR PATIENTS WITH INFLAMMATORY ARTHRITIS<br />
Gillian Scott, Janita H. Hayes, Yoke Mei McLoughlin, Frank McKenna;<br />
<strong>Rheumatology</strong>, Traf<strong>for</strong>d NHS Healthcare Trust, Manchester, United Kingdom<br />
THE MANAGEMENT OF OSTEOARTHRITIS IN A HOSPITAL SETTING<br />
Abdelrazig M. Salih;<br />
<strong>Rheumatology</strong> Department, Warrington Hospital (NHS), Warrington, United Kingdom<br />
OSTEOPOROSIS SCREENING FOR PATIENTS WITH RHEUMATOID<br />
ARTHRITIS ATTENDING AN ANNUAL REVIEW CLINIC<br />
Tracey A. O’Rourke, Yvonne Hough, Ann Clayton, Adrian Clewes, Mike Lynch, Julie Dawson,<br />
Rikki Abernethy;<br />
<strong>Rheumatology</strong> Department, St Helens and Knowsley NHS Hospital, St Helens, United Kingdom<br />
COMPLIANCE OF PATIENTS ON DMARDS TO BLOOD MONITORING<br />
Samy Zakout, Mark Pugh, Elaine Healey; Rheumatolgy, St Mary’s Hospital,<br />
Newport, United Kingdom<br />
UTILITY OF SPECIALIST REGISTRAR-RUN URGENT REVIEW CLINICS IN RHEUMATOLOGY<br />
Sangeetha Baskar, Li Koh, Karen Obrenovic, Adrian Pace, Karen Douglas, Nicola Erb,<br />
George D. Kitas, Andrew J. Whallett, Rainer Klocke;<br />
<strong>Rheumatology</strong>, Dudley group of hospitals, Dudley, United Kingdom<br />
102
Poster No. 392<br />
Poster No. 393<br />
Poster No. 394<br />
Poster No. 395<br />
SURVEY TO DETERMINE PATIENT SATISFACTION WITH PRESCRIBED ORTHOSES AND<br />
FOOTWEAR<br />
Yvonne Hough, Elizabeth Macauley, Ann E. Griffiths, Gemma Abbott, Ian Spencer, Adrian<br />
Clewes, Julie K. Dawson, Mike P. Lynch, Rikki E. Abernethy;<br />
<strong>Rheumatology</strong> Department, St Helens Hospital, Merseyside, United Kingdom<br />
PATIENTS’ KNOWLEDGE OF AND PREFERENCES FOR HEALTHY FOOD OPTIONS<br />
Madeline O’Neill, Christina Doyle, Patricia Minnock;<br />
<strong>Rheumatology</strong> Rehabilitation, Our Lady’s Hospice, Dublin, Ireland<br />
COMMUNITY RHEUMATOLOGY? IS THIS THE WAY FORWARD?<br />
Barbara Douglas, Sally Giles, Heather Keating, Tom Sheeran, Tom Price, Venkat Chalam;<br />
<strong>Rheumatology</strong>, Cannock Chase Hospital, Cannock, United Kingdom<br />
AN OVERVIEW OF INFUSION SERVICE FACILITATION - THE CANNOCK EXPERIENCE<br />
Samantha Roskell, Susan Matthews, Lynda Rogers, Tom Price, Tom Sheeran,<br />
Diarmuid Mulherin, Venkat Chalam;<br />
<strong>Rheumatology</strong>, Cannock Chase Hospital, Cannock, United Kingdom<br />
Poster Viewing Three | Friday 01 May 2009<br />
Poster No. 396<br />
Poster No. 397<br />
Poster No. 398<br />
Poster No. 399<br />
RELOCATING PAEDIATRIC SERVICES INTO A PAEDIATRIC SETTING - HOW SUCCESSFUL<br />
HAS THIS BEEN?<br />
Anne Trehane, Patricia Cornell, Paul Thompson;<br />
<strong>Rheumatology</strong>, Poole Hospital NHS Foundation Trust, Poole, United Kingdom<br />
GOUT MANAGEMENT IN SECONDARY CARE: AN AUDIT<br />
Kenneth Baker, Mohammed Bakr, Bara El-Khayat, Malgosia Magliano;<br />
Department of <strong>Rheumatology</strong>, Stoke Mandeville Hospital, Aylesbury, United Kingdom<br />
SUCCESSFUL CONTINUING PROFESSIONAL DEVELOPMENT OF THE MULTIDISCIPLINARY<br />
TEAM - "WORKING TOGETHER, LEARNING TOGETHER"<br />
Lindsey S. Wilcox, John Halsey, Marwan Bukhari;<br />
<strong>Rheumatology</strong>, Royal Lancaster Infirmary, Lancaster, United Kingdom<br />
OUTCOMES FROM A COMBINED RHEUMATOLOGY-OBSTETRIC CLINIC<br />
Viral Amin 1 , David Williams 2 , Ian Giles 1 ;<br />
1<br />
Department of <strong>Rheumatology</strong>, University College London Hospital, London, United Kingdom;<br />
2<br />
Institute of Women’s Health, University College London Hospital, London, United Kingdom<br />
Poster No. 400<br />
AUDIT OF PATIENT AWARENESS OF OSTEOPOROSIS AND ITS RISK FACTORS<br />
Rachael Tan 1 , Madhura Castelino 1 , Robert Wilkinson 2 , Lee-Suan Teh 1 ;<br />
1<br />
Department of <strong>Rheumatology</strong>, Royal Blackburn Hospital, Blackburn, United Kingdom;<br />
2<br />
Department of Endocrinology, Royal Blackburn Hospital, Blackburn, United Kingdom<br />
Poster No. 401<br />
THE ROLE OF A PHYSIOTHERAPY JOINT INJECTION CLINIC WITHIN A RHEUMATOLOGY<br />
DEPARTMENT<br />
Ann Griffiths 1,2 , Michael Lynch 1 , Adrain Clewes 1 , Julie Dawson 1 , Rikki Abernethy 1 ;<br />
1<br />
<strong>Rheumatology</strong> Unit, St Helens & Knowsley Teaching Hospitals NHS Trust, St Helens, United<br />
Kingdom; 2 <strong>The</strong>rapy Service, NHS Knowsley, Knowsley, Liverpool, United Kingdom<br />
103
Poster No. 402<br />
Poster No. 403<br />
Poster No. 404<br />
Poster No. 405<br />
Poster No. 406<br />
Poster No. 407<br />
Poster No. 408<br />
Poster No. 409<br />
Poster No. 410<br />
Poster No. 411<br />
NURSE LED BIOLOGIC CLINICS IN THE CARE OF PATIENTS WITH RHEUMATOID ARTHRITIS<br />
(RA). A DISTRICT GENERAL HOSPITAL (DGH) EXPERIENCE<br />
Teresa Doherty, Julian Heath, Sathianathan Pathakalam;<br />
<strong>Rheumatology</strong>, Eastbourne District General Hospital, Eastbourne, United Kingdom<br />
AN AUDIT OF MANAGEMENT OF ADULTS WITH HOT SWOLLEN JOINTS PRESENTING<br />
TO SALFORD ROYAL ACCIDENT AND EMERGENCY DEPARTMENT(A&E)<br />
Maryam Shahbaz-Samavi;<br />
<strong>Rheumatology</strong>, Sal<strong>for</strong>d Royal NHS Foundation Trust, Manchester, United Kingdom<br />
SLEEP DISTURBANCE IN PATIENTS WITH RHEUMATOID ARTHRITIS<br />
Penny Storrs, Cai Brockley, Frank McKenna;<br />
Rheumatic Diseases Unit, Traf<strong>for</strong>d NHS Healthcare Trust, Manchester, United Kingdom<br />
IN-HOUSE MANTOUX TESTING IS BETTER FOR PATIENTS<br />
Narabda Kara 1 , Veronica H. Love 1 , Jackie Hewlett 2 , Andrew C. Keat 1 ;<br />
1<br />
<strong>Rheumatology</strong>, Northwick Park Hospital, Harrow, United Kingdom; 2 Infectious Diseases,<br />
Northwick Park Hospital, Harrow, United Kingdom<br />
IMPACT OF MUSCULOSKELETAL INTERFACE SERVICES AND ‘CHOOSE & BOOK’ ON<br />
REFERRALS TO A RHEUMATOLOGY DEPARTMENT<br />
Deepak Jadon 1 , Emma Clark 2 , Nicola Minaur 1 ;<br />
1<br />
<strong>Rheumatology</strong> Department, North Bristol NHS Trust, Bristol, United Kingdom; 2 Academic<br />
<strong>Rheumatology</strong> Department, University of Bristol, Bristol, United Kingdom<br />
THE IMPACT OF PODIATRY INPUT INTO A RHEUMATOLOGY CLINIC<br />
Derek A. Robertshaw 1 , David J. Walker 2 ;<br />
1<br />
Podiatry, Freeman Hospital, Newcastle-on-Tyne, United Kingdom; 2 Musculo-Skeletal Unit,<br />
Freeman Hospital, Newcastle-on-Tyne, United Kingdom<br />
A PILOT STUDY OF THE RA-WIS 2 AS A SCREENING TOOL FOR WORK DISABILITY IN THE<br />
RHEUMATOLOGY CLINIC<br />
Claire Sampson 1 , Jillian Frusher 1 , Anne Meadows 2 , Nicholas Sheehan 2 , Sandeep Dahiya 2 ;<br />
1<br />
<strong>The</strong>rapy Services, Peterborough and Stam<strong>for</strong>d Hospitals NHS Foundation Trust, Peterborough,<br />
United Kingdom; 2 <strong>Rheumatology</strong> Department, Peterborough and Stam<strong>for</strong>d Hospitals NHS<br />
Foundation Trust, Peterborough, United Kingdom<br />
TELEPHONE REVIEW FOR PATIENTS WITH RHEUMATOID ARTHRITIS - A VIABLE OPTION?<br />
Lindsey M. Hawley, Brian M. Quilty;<br />
<strong>Rheumatology</strong>, Christchurch Hospital, Christchurch, United Kingdom<br />
PRACTITIONERS CONFIDENCE IN BLOOD TEST REQUESTING IN A MUSCULOSKELETAL<br />
ASSESSMENT SERVICE<br />
Julie Dawson 1,2 , Elaine Hough 2 , Joanne Pates 1 , Treena Chillingworth 2 , Kerry Brookfield 2 ,<br />
Ruth Sephton 2 ;<br />
1<br />
Dept of <strong>Rheumatology</strong>, St Helens and Knowsley Teaching Hospitals, Merseyside,<br />
United Kingdom; 2 MCAS, Knowsley NHS, Merseyside, United Kingdom<br />
THE PERFECT CARPAL TUNNEL CLINIC<br />
Sophia Mavrommatis, Mary Boland, David Holder, Elliot D. Sorene, Vanessa H. Morris;<br />
University College London Hospitals NHS Foundation Trust, London, United Kingdom<br />
104
Poster No. 412<br />
Poster No. 413<br />
Poster No. 414<br />
MANAGEMENT OF SEPTIC ARTHRITIS AT A UK DISTRICT GENERAL HOSPITAL<br />
Ying-Qiao Wong, Gemma Morgan, Laurel Young;<br />
<strong>Rheumatology</strong>, Royal Berkshire Hospital, Reading, United Kingdom<br />
THE POOLE RHEUMATOLOGY NEWSLETTER - THE PATIENTS’ PERSPECTIVE<br />
Sue Benjamin, Patricia Cornell, Sarah Wright, Selwyn Richards, Paul Thompson;<br />
<strong>Rheumatology</strong>, Poole Hospital NHS Foundation Trust, Poole, United Kingdom<br />
A MULTIAGENCY COMPREHENSIVE REHABILITATION PROGRAMME FOR PATIENTS WITH<br />
FIBROMYALGIA<br />
Sophie Taylor 1,2 , Amanda Richards 1 , Abebaw Yohannes 2 ;<br />
1<br />
<strong>The</strong>rapies Directorate, Royal Liverpool and Broadgreen University Hospitals NHS Trust,<br />
Liverpool, United Kingdom; 2 Physiotherapy <strong>Programme</strong>s, Faculty of Health, Psychology &<br />
Social Care, Manchester Metropolitan University, Manchester, United Kingdom<br />
Poster No. 415 TELEPHONE ADVICE LINES FOR CHILDREN WITH MUSCULO SKELETAL COMPLAINTS -<br />
ARE THEY AN EFFICIENT USE OF PRACTITIONER TIME?<br />
Anne Trehane, Tricia Cornell, Paul Thompson;<br />
<strong>Rheumatology</strong>, PooleHospital Foundation Trust, Poole, United Kingdom<br />
Poster Viewing Three | Friday 01 May 2009<br />
BHPR research<br />
Poster No. 416<br />
Poster No. 417<br />
Poster No. 418<br />
Poster No. 419<br />
SLEEP IN RHEUMATOID ARTHITIS: AN INTERVENTION TO IMPROVE SLEEP<br />
QUALITY IN PATIENTS WITH RHEUAMATOID ARTHRITIS<br />
Audrey M. Jolly;<br />
<strong>Rheumatology</strong>, Derri<strong>for</strong>d Hospital, Derri<strong>for</strong>d Road, Plymouth, United Kingdom<br />
THREE DIMENSIONAL MOTION ANALYSIS OF THE RHEUMATOID PROXIMAL<br />
INTERPHALANGEAL JOINT WITH A SILVER RING SPLINT IN SITU: A MATCHED CASE<br />
STUDY<br />
Zoe Gallos, Jo Adams, Cheryl Metcalf;<br />
School of Health Sciences, University of Southampton, Southampton, United Kingdom<br />
ACCEPTABILITY, CONTENT AND FORMAT FOR A GENERIC EXERCISED-BASED<br />
SELF-MANAGEMENT PROGRAMME FOR CHRONIC ILLNESS<br />
Mike Hurley, Patrick White, Kate Doran, Claire Heppenstall;<br />
King’s College London, London, United Kingdom<br />
THE EFFECT OF LUMBAR STABILISING EXERCISES ON CROSS SECTIONAL AREA OF THE<br />
MULTIFIDUS MUSCLE IN CHRONIC LOW BACK PAIN<br />
Rakesh Kumar 1,2 , Jeanette Thom 1 , Jeremy Jones 1,3 ;<br />
1<br />
School of Sport, Health and Exercise Sciences, Bangor University, Bangor, United Kingdom;<br />
2<br />
Dept of Physiotherapy, North West Wales NHS Trust, Bangor, United Kingdom; 3 Dept of<br />
<strong>Rheumatology</strong>, North West Wales NHS Trust, Bangor, United Kingdom<br />
Poster No. 420<br />
TRANSLATING THE EDUCATIONAL NEEDS ASESSMENT TOOL FOR RHEUMATOID<br />
ARTHRITIS PATIENTS INTO 4 EUROPEAN LANGUAGES<br />
Claire Hale, Jackie Hill, Mwidimi Ndosi; Academic and Clinical Unit <strong>for</strong> Musculoskeletal<br />
Nursing, University of Leeds, Leeds, United Kingdom<br />
105
Poster No. 421<br />
Poster No. 422<br />
Poster No. 423<br />
Poster No. 424<br />
Poster No. 425<br />
Poster No. 426<br />
Poster No. 427<br />
Poster No. 428<br />
THE EFFECT OF INDIVIDUAL PHYSIOTHERAPY ON PSYCHOSOCIAL VARIABLES IN SPINAL<br />
PAIN PATIENTS - A PILOT STUDY<br />
Lindsay M. Bearne 1 , Philippa Hartridge 1 , Johan Holte 2 , Emma L. Godfrey 1 ;<br />
1<br />
Division of Applied Biomedical Research, Kings College London, London, United Kingdom;<br />
2<br />
Physiotherapy Department, Kings College Hospital NHS Foundation Trust, London,<br />
United Kingdom<br />
A COMPARISON OF PSYCHOLOGICAL DISTRESS AMONG PEOPLE WITH RHEUMATOID<br />
ARTHRITIS, OSTEOARTHRITIS, MULTIPLE SCLEROSIS AND MYOCARDIAL INFARCTION<br />
Mollie Gilchrist, Andrew P. Turner, Julie H. Barlow, Alison Hipwell;<br />
Applied Research Centre in Health & Lifestyle Interventions, Coventry University, Coventry,<br />
United Kingdom<br />
DELAY IN PRESENTATION TO PRIMARY CARE IN RA PATIENTS OF SOUTH ASIAN ORIGIN<br />
Kanta Kumar 1 , Enid Daley 1 , David M. Carruthers 1 , Deva Situnayake 1 , Caroline Gordon 1 ,<br />
Karl Grindulis 1 , Christopher D. Buckley 2 , Peter Nightingale 3 , Fazal Khattak 1 , Karim Raza 1 ;<br />
1<br />
Department of <strong>Rheumatology</strong>, Sanwell and West Birmingham Hospitals NHS Trust,<br />
Birmingham, United Kingdom; 2 MRC Centre <strong>for</strong> Immune Regulation, University of Birmingham,<br />
Birmingham, United Kingdom; 3 Wellcome Trust Clinical Research Facility, Queen Elizabeth<br />
Hospital, Birmingham, United Kingdom;<br />
MEASURING WELL-BEING IN RHEUMATOID ARTHRITIS (RA): THE DEVELOPMENT<br />
OF FIVE WELL-BEING NUMERICAL RATING SCALES (NRS)<br />
Tessa Sanderson 1 , Marianne Morris 2 , Michael Calnan 3 , Pam Richards 4 , Sarah Hewlett 1 ;<br />
1<br />
Academic <strong>Rheumatology</strong>, University of the West of England, Bristol, United Kingdom; 2 Centre<br />
<strong>for</strong> Appearances Research, University of the West of England, Bristol, United Kingdom; 3 Centre<br />
<strong>for</strong> Health Services Research, University of Kent, Canterbury, United Kingdom; 4 Academic<br />
<strong>Rheumatology</strong>, University of Bristol, Bristol, United Kingdom<br />
HALF OF POSTMENOPAUSAL WOMEN DO NOT FOLLOW RECOMMENDED GUIDELINES ON<br />
DAILY CALCIUM INTAKE<br />
Leigh Morrison, Miranda Cuming, Virginia Gould, Jon Tobias, Emma Clark;<br />
Academic <strong>Rheumatology</strong>, University of Bristol, Bristol, United Kingdom.<br />
PATIENTS EXPERIENCES OF WEARING THERAPEUTIC FOOTWEAR - A QUALITATIVE<br />
INVESTIGATION<br />
Anita E. Williams 1 , Christopher J. Nester 2 , Michael I. Ravey 3 ;<br />
1<br />
Directorate of podiatry, University of Sal<strong>for</strong>d, Sal<strong>for</strong>d, United Kingdom; 2 Centre <strong>for</strong><br />
Rehabilitation and Human Per<strong>for</strong>mance Research, University of Sal<strong>for</strong>d, Sal<strong>for</strong>d, United<br />
Kingdom; 3 School of Nursing, University of Sal<strong>for</strong>d, Sal<strong>for</strong>d, United Kingdom.<br />
DO FOOT ORTHOSES AFFECT STABILITY IN PATIENTS WITH RA?<br />
Victoria Cameron 1 , Derek Santos 1 , Adele Osborne 2 ;<br />
1<br />
Queen Margaret University, Edinburgh, United Kingdom; 2 Fife Rheumatic Diseases Unit, Fife,<br />
United Kingdom<br />
THE CLINICAL EFFECTIVENESS OF OFF-THE-SHELF FOOT ORTHOSES ON THE DYNAMICS<br />
OF GAIT IN PATIENTS WITH RA<br />
Victoria Cameron 1 , Derek Santos 1 , Adele Osborne 2 ;<br />
1<br />
Queen Margaret University, Edinburgh, United Kingdom; 2 Fife Rheumatic Diseases Unit, Fife,<br />
United Kingdom<br />
106
Poster No. 429<br />
Poster No. 430<br />
Poster No. 431<br />
A COMPARISON OF PATIENT-INITIATED VERSUS CONVENTIONAL FOLLOW-UP FOR<br />
RHEUMATOID ARTHRITIS<br />
Annette Sands 1 , Nicola Adams 2 ;<br />
1<br />
Occupational <strong>The</strong>rapy, Wrightington Hospital, Wigan, United Kingdom; 2 Faculty of Medicine<br />
and Health Sciences, University of Nottingham, Nottingham, United Kingdom<br />
QOL SCORES REFLECT DISEASE ACTIVITY BOTH PRE AND POST INITIATION OF<br />
BIOLOGIC THERAPY IN PATIENTS WITH RHEUMATOID AND PSORIATIC ARTHRITIS<br />
Roisin Adams 1 , Chin Teck Ng 2 , Bernadette Lynch 2 , Taj Saber 2 , Eliza Pontiflex 2 , Michael Barry 1 ,<br />
Miriam Molloy 2 , Alexia Grier 2 , Douglas Veale 2 , Barry Bresnihan 2 , Oliver FitzGerald 2 ;<br />
1<br />
National Centre <strong>for</strong> Pharmacoeconomics, St. James Hospital, Dublin, Ireland;<br />
2<br />
<strong>Rheumatology</strong> Unit, St.Vincents University Hospital, Dublin, Ireland<br />
IS NURSE-LED CARE EFFECTIVE? A SYSTEMATIC REVIEW OF PHYSICIAN-NURSE<br />
SPECIALIST COMPARISON STUDIES IN RHEUMATOLOGY<br />
Karen Vinall, Mwidimi Ndosi, Jackie Hill;<br />
Academic and Clinical unit <strong>for</strong> Musculoskeletal Nursing, University of Leeds, Leeds,<br />
United Kingdom<br />
Poster Viewing Three | Friday 01 May 2009<br />
Poster No. 432<br />
PATIENT AND PROFESSIONAL VIEWS OF LONG-TERM MANAGEMENT STRATEGIES FOR<br />
OSTEOARTHRITIS OF THE KNEE: A QUALITATIVE STUDY<br />
Nicola E. Walsh 1 , Kathryn Badlan 1 , Mike V. Hurley 2 ;<br />
1<br />
Faculty of Health and Life Sciences, UWE, Bristol, United Kingdom; 2 Academic<br />
Physiotherapy Department, King’s College, London, United Kingdom<br />
Poster No. 433<br />
CONCURRENT VALIDITY OF HAND-HELD SPHYGMOMANOMETER DYNAMOMETRY FOR<br />
MEASURING THIGH MUSCLE STRENGTHS<br />
Laurence R. Wood, Elaine M. Hay, Julius Sim;<br />
Arthritis Research Campaign National Primary Care Centre, Keele University, Keele,<br />
United Kingdom<br />
Poster No. 434<br />
RCT EXAMINING THE EFFECTS OF EXERCISE FOR PEOPLE WITH RHEUMATOID ARTHRITIS<br />
ON ANTI-TNFα MEDICATION<br />
Angela Reid 1 , Audrey Brady 1 , Tara Cusack 2 , Catherine Blake 2 , Ann-Barbara Mongey 3 ,<br />
Douglas J. Veale 3 , Oliver FitzGerald 3 ;<br />
1<br />
Physiotherapy, Our Lady’s Hospice, Dublin, Ireland; 2 School of Physiotherapy and<br />
Per<strong>for</strong>mance Science, University College Dublin, Dublin, Ireland; 3 <strong>Rheumatology</strong>,<br />
St. Vincent’s University Hospital, Dublin, Ireland<br />
Poster No. 435<br />
EXPERIENCES OF LIVING WITH AND SELF-MANAGING ARTHRITIS: A QUALITATIVE<br />
EXPLORATION FROM PUNJABI SIKH WOMEN’S PERSPECTIVES<br />
Alison Hipwell, Andrew P. Turner, Julie H. Barlow;<br />
Applied Research Centre in Health and Lifestyle Interventions, Coventry University,<br />
Coventry, United Kingdom<br />
Poster No. 436<br />
PARTNERS’ EXPERIENCES OF LIVING WITH RHEUMATOID ARTHRITIS:<br />
"YOUR WHOLE LIFE, YOUR WHOLE WORLD, IT CHANGES"<br />
Lauren E. Matheson, Diana Harcourt, Sarah Hewlett;<br />
Health and Life Sciences, University of the West of England, Bristol, United Kingdom<br />
107
Poster No. 437<br />
“IT’S LIKE TAKING POISON TO KILL POISON BUT I HAVE TO GET BETTER”:<br />
A QUALITATIVE STUDY OF BELIEFS ABOUT MEDICINES IN RA AND SLE PATIENTS<br />
OF SOUTH ASIAN ORIGIN<br />
Kanta Kumar 1 , Caroline Gordon 1 , Robert Barry 1 , Harpal Tiwana 1 , Karen Shaw 5 , Karim Raza 1 ;<br />
1<br />
Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, United Kingdom;<br />
5<br />
University of Birmingham, Birmingham, United Kingdom;<br />
Poster No. 438<br />
DO PERCEPTIONS ABOUT HAND OSTEOARTHRITIS CHANGE OVER AN 18-MONTH PERIOD?<br />
Susan Hill 1 , Elaine Nicholls 1 , Helen Myers 1 , George Peat 1 , Elaine Thomas 1 , Michelle Marshall 1 ,<br />
Danielle van der Windt 1,2 , Krysia Dziedzic 1 ;<br />
1<br />
Arthritis Reseach Campaign National Primary Care Centre, Staf<strong>for</strong>dshire, United Kingdom;<br />
2<br />
EMGO Institute, VU University Medical Center, Amsterdam, Netherlands<br />
Poster No. 439<br />
EDUCATIONAL NEEDS OF PATIENTS WITH 6 RHEUMATIC DISEASES<br />
Mwidimi Ndosi 1 , Jackie Hill 1 , Claire Hale 2 , Bernadette Hardware 3 ;<br />
1<br />
Academic & Clinical Unit <strong>for</strong> Musculoskeletal Nursing, University of Leeds, Leeds, United<br />
Kingdom; 2 School of Healthcare, University of Leeds, Leeds, United Kingdom; 3 Research &<br />
Development, Barnsley Hospital NHS Foundation Trust, Barnsley, United Kingdom<br />
108
Exhibition Floor Plan<br />
Exhibition Floor Plan
Exhibition Floor Plan<br />
Exhibition Floor Plan | 28 April - 01 May ’09<br />
109
Exhibitor Details<br />
Stand Number Company<br />
A10<br />
<strong>Rheumatology</strong>/OUP<br />
A11<br />
Alkaptonuria <strong>Society</strong><br />
A12<br />
Siemens<br />
A40<br />
Healthcare at Home<br />
A42<br />
Up to Date Inc<br />
A44<br />
Smith and Nephew<br />
A46<br />
<strong>The</strong> London Lupus Centre<br />
B50<br />
Know about your DAS<br />
B54<br />
Vertec Scientific<br />
C8<br />
Ehlers-Danlos Support Group<br />
C10<br />
Promedics<br />
C12<br />
Genzyme<br />
C13<br />
Medtronic<br />
C14<br />
RCN RF<br />
C15<br />
PRCA<br />
C16<br />
Lupus UK<br />
C17<br />
NRAS<br />
C20/C21 ARMA<br />
C22<br />
BSSA<br />
C23<br />
Arthritis Care<br />
C24<br />
<strong>The</strong> Scleroderma <strong>Society</strong><br />
C25<br />
PSALV<br />
C26<br />
NASS<br />
C27<br />
Fibromyalgia Association<br />
C30<br />
Wyeth<br />
C40<br />
Abbott<br />
C50<br />
Esaote<br />
C9<br />
arc<br />
E20<br />
UCB<br />
E30<br />
Schering-Plough<br />
E40<br />
Servier<br />
E42/E46 BMS<br />
E44<br />
MSD<br />
F20<br />
Napp<br />
F22<br />
Pfizer<br />
F24/F26 Novartis<br />
F30<br />
Roche (Mabthera)<br />
F40<br />
Roche (Bonviva)<br />
F45 Chugai Roche (IL 6)<br />
G20<br />
Goldshield plc<br />
G30/G35 Actelion<br />
G31/G32 Sonosite<br />
G33<br />
Galen<br />
G34<br />
Altacor<br />
G36<br />
TRB Chemedica<br />
G37<br />
Kennedy Institute of <strong>Rheumatology</strong><br />
G38<br />
BSR Biologics Register<br />
G39<br />
4S In<strong>for</strong>mation Systems Ltd<br />
G40<br />
Proctor & Gamble<br />
G45<br />
Medac<br />
BSR Stand 25th Anniversary exhibition<br />
and BSR/BHPR stand<br />
110<br />
4S In<strong>for</strong>mation Systems Ltd (Stand G39)<br />
Kiss goodbye to the frustration of searching <strong>for</strong> results<br />
and in<strong>for</strong>mation! Kiss goodbye to filling out <strong>for</strong>ms!<br />
Kiss goodbye to the fear of missing an out-of-line<br />
result! Fall in love with DAWN <strong>Rheumatology</strong> Clinic<br />
Software and Embrace improved safety, quality and<br />
productivity.<br />
Abbott (Stand C40)<br />
Abbott is a global, broad-based health care company<br />
devoted to discovering new medicines, new<br />
technologies and new ways to manage health. Abbott<br />
scientists are applying innovative monoclonal antibody<br />
technology to discover and develop novel therapies to<br />
treat diseases of the immune system including<br />
rheumatoid arthritis, psoriatic arthritis, ankylosing<br />
spondylitis, Crohn’s disease and psoriasis.<br />
Actelion (Stand G30/G35)<br />
Actelion Pharmaceuticals Ltd is a biopharmaceutical<br />
company headquartered in Allschwil/Basel, Switzerland,<br />
focusing on the discovery, development and<br />
commercialisation of innovative treatments to serve<br />
high unmet medical needs. Please come and visit at<br />
stand G30 and G35 <strong>for</strong> more in<strong>for</strong>mation on our<br />
products and clinical data.<br />
Alkaptonuria <strong>Society</strong> (Stand A11)<br />
Alkaptonuria <strong>Society</strong> is a charity raising awareness<br />
about the rare genetic disease Alkaptonuria.<br />
Alkaptonuria sufferers are missing an enzyme (HGAO)<br />
and homogentistic acid builds up in the body tissues<br />
where it is toxic. <strong>The</strong> result is ochronosis, a blue-black<br />
discolouration of the connective tissue. Alkaptonuria is<br />
a debilitating and serious disease that damages bone,<br />
cartilage, blood vessels and other parts of the body.<br />
Altacor (Stand G34)<br />
Altacor is an ophthalmology development company.<br />
<strong>The</strong> pipeline comprises development and marketed<br />
therapeutic procducts in ocular surface disease, ocular<br />
anti-infectives and glaucoma. Altacor has four Dry Eye<br />
products marketed in the UK, Clinitas (prescription)<br />
and Clinitas range all commercialized through its own<br />
sales and marketing organization. <strong>The</strong> development<br />
portfolio of prescription products includes novel anti<br />
infectives with broad activity against bacteria,<br />
fungi/yeasts and a low propensity to resistance.
arc (Stand C9)<br />
<strong>The</strong> Arthritis Research Campaign (arc) is the UK’s<br />
fourth largest medical research charity and the only<br />
charity solely committed to funding high-quality<br />
research into the causes and treatment of all types<br />
of arthritis and musculoskeletal conditions. We rely<br />
entirely on public donations to fund our research and<br />
education programmes, spending over £20m a year<br />
supporting research aimed at improving the lives of<br />
people with arthritis.<br />
ARMA (Stand C20/C21)<br />
<strong>The</strong> Arthritis and Musculoskeletal Alliance (ARMA)<br />
brings together over 30 member organisations<br />
including support groups, professional societies and<br />
research organisations. Visit our stand to find out<br />
how you can use the Standards of Care and our local<br />
networks to share good practice and improve services<br />
in your area. Also find out more about our members<br />
and policy developments in the musculoskeletal<br />
community.<br />
Arthritis Care (Stand C23)<br />
Come and visit us at Stand C23 and see how<br />
Arthritis Care can enhance the value of your service.<br />
Influencing health policy and services through<br />
campaigning, Providing self management training<br />
courses to help patients manage their condition.<br />
Offering a free confidential helpline to support your<br />
patients throughout their experience of their condition<br />
and providing award winning in<strong>for</strong>mation enabling<br />
patients to make better use of appointments.<br />
Bristol-Myers Squibb (Stand E42/E46)<br />
Bristol-Myers Squibb is a global pharmaceutical<br />
company whose mission is to extend and enhance<br />
human life. Ranked in the top ten <strong>for</strong> a number of<br />
products in the R&D pipeline, we are looking <strong>for</strong>ward<br />
to an impressive stream of novel treatments. In the<br />
UK, Bristol-Myers Squibb is one of the largest supplier<br />
of medicines to NHS hospitals.<br />
<strong>British</strong> Health Professionals in <strong>Rheumatology</strong><br />
(Exhibition and Seating Area)<br />
<strong>British</strong> Health Professionals in <strong>Rheumatology</strong> (BHPR)<br />
unites and supports members of the multi-disciplinary<br />
team in delivering best quality care which meets the<br />
needs of individuals with musculoskeletal conditions.<br />
We have over 500 members from many professions:<br />
nursing, physiotherapy, occupational therapy, podiatry,<br />
psychology, social work, medicine, pharmacy and<br />
others. Come and visit our stand to learn about<br />
joining our society.<br />
111<br />
<strong>British</strong> <strong>Society</strong> <strong>for</strong> <strong>Rheumatology</strong><br />
(Exhibition and Seating Area)<br />
<strong>British</strong> <strong>Society</strong> <strong>for</strong> <strong>Rheumatology</strong> (BSR) promotes<br />
excellence in the treatment of people with arthritis<br />
and musculoskeletal conditions, and supports those<br />
delivering it. Come and visit our exhibition celebrating<br />
our 25th anniversary; pick up the new draft guidelines<br />
<strong>for</strong> treatment of RA with biologic therapies and hear<br />
our plans <strong>for</strong> the new BSR website.<br />
BSR Biologics Register (Stand G38)<br />
<strong>The</strong> <strong>British</strong> <strong>Society</strong> <strong>for</strong> <strong>Rheumatology</strong> Biologics<br />
Register (BSRBR) is a prospective observational<br />
cohort study of patients receiving biologic therapy<br />
<strong>for</strong> rheumatoid arthritis in the UK. In addition, a<br />
comparison cohort of patients receiving DMARD<br />
therapy is also being collected. Data collection is via<br />
the rheumatology team, the patient and the NHS IC.<br />
<strong>The</strong> primary aim of the study is to monitor the<br />
long-term safety of these therapies in RA.<br />
BSSA (Stand C22)<br />
Sjögren’s Syndrome is an auto immune condition<br />
affecting 3-4% of adults in the UK, Sjögren’s<br />
Syndrome is under diagnosed and may frequently go<br />
untreated. It is a disorder that causes dry eyes and a<br />
dry mouth plus extreme fatigue. <strong>The</strong> <strong>British</strong> Sjögren’s<br />
Syndrome Association supports patients and carers,<br />
educates the public and professionals and raises<br />
funds <strong>for</strong> research into this disabling condition.<br />
Chugai (Stand F45)<br />
Chugai’s mission is to dedicate itself to adding<br />
exceptional value through the creation of innovative<br />
medical products and services <strong>for</strong> the benefit of the<br />
medical community and human health around the<br />
world.<br />
Ehlers-Danlos Support Group (Stand C8)<br />
Ehlers-Danlos Syndrome is the name given to a<br />
group of inherited disorders of connective tissue. It is<br />
characterised by abnormalities of skin, ligaments and<br />
internal organs. Joints are unstable and hypermobile<br />
and chronic joint and limb pain is common. <strong>The</strong><br />
Ehlers-Danlos Support Group aims to provide<br />
in<strong>for</strong>mation, advice and support <strong>for</strong> people with<br />
Ehlers-Danlos Syndrome and their families.<br />
Exhibition Floor Plan | 28 April - 01 May ’09
Esoate (Stand C50)<br />
Visit the Esaote stand to discuss the exciting<br />
opportunities that the latest generation of Ultrasound<br />
scanners can offer your <strong>Rheumatology</strong> practice.<br />
Showcasing will be the revolutionary portable<br />
ultrasound scanner the MyLab25Gold; as well as a<br />
must see <strong>for</strong> <strong>Rheumatology</strong> ‘09 the first showing of<br />
Esaote’s state-of-the-art advanced MyLab70XVG<br />
Virtual Navigator fusion imaging system.<br />
Come and visit us and be innovated!<br />
Fibromyalgia Association (Stand C27)<br />
Fibromyalgia Association UK (FMA UK) is the national<br />
charity supporting those with fibromyalgia, their<br />
families and carers by:<br />
• Providing in<strong>for</strong>mation and support.<br />
• Promoting awareness among health professionals,<br />
the general public, and government.<br />
• Lobbying <strong>for</strong> effective and available treatment.<br />
• Facilitating the networking of those with<br />
fibromyalgia.<br />
• Encouraging self help.<br />
Galen Limited (Stand G33)<br />
Galen Limited is a privately owned pharmaceutical<br />
company that promotes branded and generic<br />
prescription medicines in the UK and Ireland. Galen’s<br />
objective is to improve the healthcare of patients by<br />
providing innovative products and developing<br />
joint-working relationships with healthcare<br />
professionals. Visit the Galen stand <strong>for</strong> more<br />
in<strong>for</strong>mation on the company and its interest in<br />
osteoporosis. We look <strong>for</strong>ward to meeting you!<br />
Genzyme (Stand C12)<br />
4620 Kingsgate<br />
Cascade Way<br />
Ox<strong>for</strong>d Business Park South<br />
OX4 2SU<br />
www.genzyme.com<br />
Goldshield Plc (Stand G20)<br />
NLA Tower, 12th Floor<br />
12-16 Addiscombe Road<br />
Croydon<br />
Surrey<br />
CR0 0XT<br />
www.goldshieldplc.com<br />
Healthcare at Home (Stand A40)<br />
Healthcare at Home are the UK’s leading provider of<br />
high-tech home healthcare and speciality pharmacy<br />
services, covering numerous disease areas. We also<br />
deliver innovative services on-site throughout the NHS<br />
and independent sector.<br />
Our 750 staff include over 400 highly skilled and experienced<br />
nurses. Operating from 24 locations throughout<br />
the UK, our unrivalled infrastructure keeps us close to<br />
over 70,000 patients 24 hours a day, 365 days a year.<br />
Kennedy Institute of <strong>Rheumatology</strong> (Stand G37)<br />
<strong>The</strong> Kennedy Institute of <strong>Rheumatology</strong> is part of<br />
Imperial College London, and supports both clinical and<br />
non-clinical scientists working on the pathogenesis and<br />
treatment of rheumatological disease. Research<br />
projects range from clinical trials to basic matrix<br />
biochemistry and immunology. This integrated<br />
approach allows <strong>for</strong> successful translational research<br />
as well as providing an ideal environment <strong>for</strong> training<br />
and fostering the development of academic clinicians.<br />
Know about your DAS (Stand B50)<br />
<strong>The</strong> stand launches the new National Rheumatoid<br />
Arthritis <strong>Society</strong> (NRAS) booklet, ‘Know About Your<br />
DAS’. <strong>The</strong> DAS booklet is designed to educate and<br />
provide an overview of DAS to patients with rheumatoid<br />
arthritis and to enable patients to track their DAS and<br />
feel better in<strong>for</strong>med about their disease. <strong>The</strong> stand<br />
is sponsored by Roche Products Ltd in collaboration<br />
with NRAS.<br />
<strong>The</strong> stand will be used <strong>for</strong>:<br />
• Distribution of DAS booklets<br />
• BSR attendees to discuss the assessment of<br />
DAS with other healthcare professionals<br />
<strong>The</strong> London Lupus Centre (Stand A46)<br />
(www.thelondonlupuscentre.com)<br />
This International Centre is aimed at the diagnosis and<br />
management of patients with lupus, Hughes Syndrome<br />
and related rheumatic disorders.<br />
<strong>The</strong> Centre comprises nine Consultant Rheumatologists<br />
and is supported by the multi-specialist facilities<br />
available at London Bridge Hospital.<br />
For further in<strong>for</strong>mation:<br />
Tel: +44 (0)20 7234 2155<br />
Fax: +44 (0)20 7234 2462<br />
Email: londonlupuscentre@hcahealthcare.co.uk<br />
112
Lupus UK (Stand C16)<br />
LUPUS UK is the only national charity <strong>for</strong> patients with<br />
lupus offering support through our voluntary network<br />
of over 25 Regional Groups. Our priorities are to<br />
increase lupus awareness amongst the public and the<br />
medical profession, provide support to our members,<br />
and raise funds towards research and Lupus Nurses.<br />
Tel: 01708 731251 (24 hour answerphone)<br />
website www.lupusuk.org.uk<br />
Medac UK (Stand G45)<br />
Metoject® - a fresh new blend of experience and<br />
innovation in the treatment of rheumatoid arthritis.<br />
Our new, improved methotrexate syringe has been<br />
developed as the result of feedback from prescribers<br />
and end users. Come to the Medac stand to learn<br />
more about new improved Metoject.<br />
Medtronic (Stand C13)<br />
Medtronic is the global leader in medical technology -<br />
alleviating pain, restoring health, and extending life<br />
<strong>for</strong> millions of people around the world.<br />
Spinal and Biologics is Medtronic’s second largest<br />
business. Our market leadership is largely a result of<br />
our innovation: we’re developing many of the new<br />
standards of care in spinal and musculoskeletal<br />
therapies. We collaborate with world-renowned<br />
surgeons and researchers to offer state-of-the-art<br />
therapies <strong>for</strong> spinal, neurological and orthopaedic<br />
conditions. www.medtronic.co.uk<br />
MSD (Stand E44)<br />
Merck Sharp and Dohme Limited (MSD) is the<br />
subsidiary of Merck & Co., Inc., of Whitehouse<br />
Station, New Jersey, USA, a leading research-based<br />
pharmaceutical company that discovers, develops,<br />
manufactures and markets a wide range of innovative<br />
pharmaceutical products to improve human health.<br />
Napp Pharmaceuticals (Stand F20)<br />
Napp Pharmaceuticals Limited is renowned as a<br />
leader in pain control with a reputation <strong>for</strong> expertise<br />
in novel <strong>for</strong>mulations and an impressive list of<br />
pioneering products to help individuals fight the<br />
burden of chronic pain.<br />
NASS (Stand C26)<br />
<strong>The</strong> National Ankylosing Spondylitis <strong>Society</strong> (NASS)<br />
was founded over 30 years ago to provide support<br />
and advice <strong>for</strong> patients and their families. NASS works<br />
to raise awareness of AS and provides a website,<br />
publications and in<strong>for</strong>mation as well as running a<br />
branch network of around 95 branches throughout<br />
the UK offering regular supervised exercise sessions.<br />
NASS members also participate in ongoing genetic<br />
research into the disease. www.nass.co.uk<br />
Novartis (Stand F24/F26)<br />
Novartis is a company committed to the discovery and<br />
development of medicines in areas of unmet clinical<br />
need. <strong>The</strong> therapeutic areas that Novartis works in<br />
include cardiovascular and metabolism, neuroscience,<br />
respiratory, arthritis, bone, infectious diseases,<br />
transplantation and immunology and oncology.<br />
Our product pipeline is one of the strongest in the<br />
pharmaceutical industry and in the UK alone we<br />
spend around £1 million per week on research and<br />
development.<br />
NRAS (Stand C17)<br />
NRAS is the only patient-led UK charity focusing on<br />
people with Rheumatoid Arthritis, their families and<br />
carers. We aim to help these groups by:-<br />
• providing in<strong>for</strong>mation and support<br />
• facilitating networking and encouraging self-help<br />
• raising public and government awareness<br />
• campaigning <strong>for</strong> more funding and better use of<br />
existing resources<br />
Pfizer (Stand F22)<br />
Pfizer Inc., founded in 1849, is dedicated to better<br />
health and greater access to health care <strong>for</strong> people<br />
and their valued animals. Every day, colleagues in<br />
more than 150 countries work to discover, develop,<br />
manufacture and deliver quality, safe and effective<br />
prescription medicines to patients.<br />
In the UK, Pfizer has its European R&D headquarters<br />
at Sandwich and its UK business headquarters in<br />
Surrey, and is the major supplier of medicines to the<br />
NHS. Pfizer’s annual UK R&D investment is more<br />
than £550 million – more than £10 million a week.<br />
Exhibition Floor Plan | 28 April - 01 May ’09<br />
PRCA (Stand C15)<br />
<strong>The</strong> PRCA is an independent group working towards<br />
excellence in the care of rheumatic foot disorders<br />
through education and research.<br />
www.prcassoc.org.uk<br />
113
Procter & Gamble Pharmaceuticals (Stand G40)<br />
Procter & Gamble has a rich heritage in health care<br />
that extends back more than 150 years. <strong>The</strong>n and<br />
now, P&G is driven by our mission to improve the lives<br />
of people around the world every day. P&G’s health<br />
care products include prescription medicines,<br />
over-the-counter medications and oral care products.<br />
P&G began developing and marketing prescription products<br />
in the late-1960s.<br />
Promedics (Stand C10)<br />
Promedics are a UK manufacturer and supplier of<br />
an extensive range of splints and supports <strong>for</strong> all<br />
conditions and all areas of the body. We have over 25<br />
years experience of dealing with the health service and<br />
in particular Rhematology. We look <strong>for</strong>ward to<br />
welcoming you to our stand.<br />
PSALV (Stand C25)<br />
PSALV, PSORIASIS SCOTLAND ARTHRITIS LINK<br />
VOLUNTEERS.<br />
<strong>The</strong> only Scottish charity <strong>for</strong> all with skin psoriasis,<br />
and associated inflammatory arthritis- PsA. PSALV is<br />
a national Scottish charity with expert advisers, and a<br />
small grant from the Scottish Government.<br />
We aim to raise awareness of these debilitating<br />
misunderstood diseases. We provide literature <strong>for</strong><br />
enquirers and clinics, hold open info meetings with<br />
specialists, campaign and lobby at Holyrood.<br />
RCN RF (Stand C14)<br />
<strong>The</strong> Royal College of Nursing <strong>Rheumatology</strong> Forum<br />
exists to give support to nurses involved in the care of<br />
rheumatology patients. Currently membership stands<br />
at over 1200 nurses who have voiced an interest in<br />
rheumatology issues. <strong>The</strong> stand will be open during the<br />
break times and staffed by members of the committee,<br />
please drop by and say hello to us.<br />
<strong>Rheumatology</strong>/OUP (Stand A10)<br />
Ox<strong>for</strong>d University Press publishes some of most<br />
respected medical books and journals in the world<br />
including the Ox<strong>for</strong>d Textbook of <strong>Rheumatology</strong> and<br />
<strong>Rheumatology</strong> which is published on behalf of the<br />
<strong>British</strong> <strong>Society</strong> <strong>for</strong> <strong>Rheumatology</strong>. Visit our stand to<br />
discover more about our quality products, and to pick<br />
up a free copy of the journal.<br />
Roche (F30, F40 and F45)<br />
Roche aims to improve people’s health and quality of<br />
life with innovative products and services <strong>for</strong> the early<br />
detection, prevention, diagnosis and treatment of<br />
disease. Part of one of the world’s leading healthcare<br />
groups, Roche in the UK employs nearly 2,000 people<br />
in pharmaceuticals and diagnostics. Globally Roche is<br />
the leader in diagnostics, and a major supplier of<br />
medicines <strong>for</strong> the treatment of cancer, transplantation,<br />
virology, bone and rheumatology, obesity and renal<br />
anaemia.<br />
Schering-Plough (Stand E30)<br />
Schering-Plough is an innovation-driven,<br />
science-centered global health care company. Through<br />
its own biopharmaceutical research and<br />
collaborations with partners, Schering-Plough creates<br />
therapies that help save and improve lives around the<br />
world. <strong>The</strong> company applies its research-anddevelopment<br />
plat<strong>for</strong>m to human prescription and<br />
consumer products as well as to animal health<br />
products.<br />
Servier Laboratories (Stand E40)<br />
Servier Laboratories is the UK subsidiary of <strong>The</strong> Servier<br />
Research Group, the leading independent French<br />
research based pharmaceutical company. <strong>The</strong> key<br />
franchises of the Servier Research Group are rheumatology,<br />
cardiovascular disease, diabetes, Central<br />
Nervous System and oncology. Servier regularly invests<br />
more than 25% of its annual turnover into research,<br />
discovering and delivering therapeutic innovations to<br />
patients through their healthcare professionals.<br />
Siemens (Stand A12)<br />
In line with Siemens reputation <strong>for</strong> innovation we will<br />
be showcasing the new ACUSON X300 PE ultrasound<br />
system. <strong>The</strong> X300 PE is an ultra-compact,<br />
per<strong>for</strong>mance-oriented system designed <strong>for</strong> clinical<br />
efficiency. With an operator-friendly console that helps<br />
to reduce arm and hand movement and its small,<br />
lightweight transducers, the X300 PE system takes<br />
the pain and pressure out of routine scanning.<br />
See us at stand A12 <strong>for</strong> more details.<br />
114
Smith & Nephew (Stand A44)<br />
Smith & Nephew will be presenting advanced<br />
DUROLANE scientific in<strong>for</strong>mation at stand A44<br />
A collection of recently presented pre-clinical studies<br />
show how the DUROLANE NASHA <strong>for</strong>mulation<br />
improves intra-articular residence time, resistance to<br />
degradation and exhibits prolonged anti-nociceptive<br />
behaviour compared with standard HA.<br />
We are pleased to support BSR and look <strong>for</strong>ward to<br />
meeting you in Glasgow.<br />
Sonosite (Stand G31/G32)<br />
SonoSite is the world leader and specialist in<br />
hand-carried ultrasound. All SonoSite systems are<br />
drop-tested to 1 metre and come with a fluid resistant<br />
membrane <strong>for</strong> ease of cleaning along with the<br />
company’s 5-year warranty to deliver the lowest cost<br />
of ownership in point-of-care medicine.<br />
Visit stand G31 and G32 to see the very latest is<br />
hand-carried ultrasound.<br />
<strong>The</strong> Scleroderma <strong>Society</strong> (Stand C24)<br />
A registered charity that has been supporting people<br />
with scleroderma <strong>for</strong> over 25 years.<br />
<strong>The</strong> society aims are to:<br />
• Support people with scleroderma<br />
• Increase awareness of scleroderma<br />
• Fund scientific and medical research in<br />
scleroderma<br />
On this stand you will find our range of in<strong>for</strong>mation<br />
leaflets covering many ways in which people can be<br />
affected by scleroderma.<br />
TRB Chemedica (Stand G36)<br />
Viscoseal enhances post arthroscopy recovery by<br />
replacing lost synovial fluid. Ostenil treats osteoarthritis<br />
in large joints. Ostenil mini treats osteoarthitis in small<br />
joints such as the fingers, toes and shoulder. All TRB<br />
products are non animal derived medical devices.<br />
Samples can be supplied at the stand.<br />
UpToDate (Stand A42)<br />
UpToDate is a dynamic, electronic resource providing<br />
evidence-based, synthesized medical in<strong>for</strong>mation.<br />
It is written and peer-reviewed by leading doctors<br />
worldwide, and is designed to anticipate questions<br />
and support clinical decision-making across thousands<br />
of Topics in 14 clinical specialties. A recent<br />
survey indicated that 98% of UK doctors with access<br />
to UpToDate, during a one-year pilot trial at 18 major<br />
teaching trusts, were satisfied or very satisfied with it<br />
as a clinical resource.<br />
Vertec Scientific (Stand B54)<br />
Vertec Scientific would like to welcome you to the<br />
BSR. We are the UK distributors <strong>for</strong> Hologic Dexa<br />
Scanners, which have been the system of choice in<br />
the diagnosis of Osteoporosis <strong>for</strong> over 20 years.<br />
We will also be showing Ultrasonix, a dedicated<br />
Ultrasound scanner <strong>for</strong> the MSK and <strong>Rheumatology</strong><br />
environment as well as ONI the world’s first dedicated<br />
1.5T High Field MRI <strong>for</strong> extremities.<br />
Wyeth (Stand C30)<br />
Wyeth welcomes all BSR delegates to Glasgow<br />
and invites you to visit us at our stand.<br />
Wyeth is one of the UK’s leading pharmaceutical<br />
companies with a significant commitment to clinical<br />
research. Wyeth is committed to working in<br />
partnership with Government, healthcare<br />
professionals and patient support organisations to<br />
continue to enhance the quality of life <strong>for</strong> as many<br />
people as possible.<br />
Worldwide, the company focuses on finding<br />
groundbreaking medical therapies, and has a broad<br />
portfolio of leading products across a wide range of<br />
therapy areas, including rheumatological disease.<br />
Exhibition Floor Plan | 28 April - 01 May ’09<br />
UCB (Stand E20)<br />
UCB, headquartered in Brussels, Belgium is a<br />
biopharmaceutical company dedicated to the<br />
research, development and commercialisation of<br />
innovative medicines with a focus on the fields of<br />
central nervous system and immunology disorders.<br />
Employing more than 10,000 people in over 40<br />
countries, UCB produced revenue of 3.6 billion<br />
euro in 2008.<br />
115
Abstract Reviewers<br />
<strong>The</strong> BSR Heberden Committee was expanded substantially <strong>for</strong> the purpose of abstract assessment to<br />
ensure that all abstracts were peer reviewed, blind by at least three reviewers. <strong>The</strong> Heberden Committee<br />
is extremely grateful <strong>for</strong> the assistance of everyone that gave up their time to review abstracts, and<br />
acknowledges accordingly:<br />
Prof Hill Gaston Heberden Committee Dr Ross Wilkie Heberden Committee<br />
Dr Richard Watts Heberden Committee Dr Andrew Keat Heberden Committee<br />
Prof Chris Denton Heberden Committee Dr Hector Chinoy Heberden Committee<br />
Dr Elizabeth Price Heberden Committee Dr Clive Ryder Heberden Committee<br />
Prof Alex MacGregor Heberden Committee Prof David Sansom Heberden Committee<br />
Dr Chetan Mukhtyar Heberden Committee<br />
Dr David Abraham<br />
Dr Simon Allard<br />
Prof Nigel Arden<br />
Dr John Ax<strong>for</strong>d<br />
Dr Andrew Bamji<br />
Dr Ashok Bhalla<br />
Dr Fraser Birrell<br />
Prof Fionula Brennan<br />
Prof Matt Brown<br />
Dr Mya Buch<br />
Prof Chris Buckley<br />
Dr Robin Butler<br />
Dr Geraldine Cambridge<br />
Prof Tim Cawston<br />
Prof Kuntal Chakravarty<br />
Prof Yuti Chernajovsky<br />
Dr Ernest Choy<br />
Prof Ian Clark<br />
Dr Gavin Cleary<br />
Dr Andy Cope<br />
Mrs Trish Cornell<br />
Dr Bhaskar Dasgupta<br />
Dr Peter Dawes<br />
Dr Chris Deighton<br />
Dr Karen Douglas<br />
Dr Michael Ehrenstein<br />
Dr Ian Giles<br />
Mr Stewert Glaspole<br />
Dr Nicola Goodson<br />
Dr Alan Hakim<br />
Ms Alison Hammond<br />
Dr Inam Haq<br />
Prof Dorian Haskard<br />
Mrs Lindsey Hawley<br />
Prof Elaine Hay<br />
Dr Ariane Herrick<br />
Dr Rod Hughes<br />
Ms Keri Hutchinson<br />
Dr Charles Hutton<br />
Prof John Isaacs<br />
Dr Ali Jawad<br />
Dr Rachel Jeffery<br />
Dr Adrian Jones<br />
Dr Jeremy Jones<br />
Dr Sharon Jones<br />
Dr Karen Jubb<br />
Dr Lesley Kay<br />
Dr George Kitas<br />
Dr Rainer Klocke<br />
Dr Thomas Lawson<br />
Dr Alison Leak<br />
Dr Raashid Luqmani<br />
Prof Peter Maddison<br />
Dr Janet McDonagh<br />
Prof Dennis McGonagle<br />
Dr Julie McHale<br />
Dr Adrian Pace<br />
Dr Lazlo Pazmany<br />
Prof Frederique Ponchel<br />
Dr Anisur Rahman<br />
Dr Karim Raza<br />
Dr Anthony Redmond<br />
Prof David Reid<br />
Dr Shirley Rigby<br />
Dr Graham Riley<br />
Prof Drew Rowan<br />
Dr Andrew Russel<br />
Ms Sarah Ryan<br />
Dr Ash Samanta<br />
Dr Dagmar Scheel-Toellner<br />
Dr Preeti Shah<br />
Dr Nick Shenker<br />
Dr Paul Thompson<br />
Dr Robert Thompson<br />
Dr Jon Tobias<br />
Dr Gareth Treharne<br />
Prof Patrick Venables<br />
Dr Tonia Vincent<br />
Dr Lyn Williamson<br />
Dr Gerry Wilson<br />
116
Switching to Mab<strong>The</strong>ra can offer your<br />
patients a passport to get away<br />
Dear Doctor,<br />
Following my treatment I am travelling again.<br />
Exploring San Francisco on foot, despite the<br />
hills – I just step onto a tram and whizz<br />
through the streets!<br />
I remember when I came here with my<br />
college friend, many years have passed but it’s<br />
great that I can still enjoy this city.<br />
Thanks<br />
Mary Gibson<br />
Mab<strong>The</strong>ra in combination with methotrexate, provides<br />
sustained efficacy 1 with unprecedented treatment<br />
intervals of 6-12 months in severe active RA patients<br />
with an inadequate response to anti-TNF therapy. 2<br />
B SELECTIVE • B EFFECTIVE<br />
PRESCRIBING INFORMATION MABTHERA ® (rituximab) in<br />
Rheumatoid Arthritis: Please refer to Mab<strong>The</strong>ra SPC <strong>for</strong> full<br />
prescribing in<strong>for</strong>mation. Indication: Mab<strong>The</strong>ra, in combination<br />
with methotrexate, <strong>for</strong> the treatment of adult patients with severe<br />
active rheumatoid arthritis who have had an inadequate response<br />
or intolerance to other DMARDs including one or more TNF inhibitor<br />
therapies. Dosage and Administration: A course of Mab<strong>The</strong>ra<br />
consists of two infusions: 1000mg by iv infusion followed by a<br />
second 1000mg iv infusion two weeks later. Administer through a<br />
dedicated line, with full resuscitation facilities immediately available.<br />
Premedication should be given. Monitor <strong>for</strong> onset of cytokine<br />
release syndrome. Severe reactions e.g. severe dyspnoea,<br />
bronchospasm or hypoxia require immediate interruption of<br />
infusion. First Infusion: Recommended initial infusion rate is<br />
50mg/hr. Second Infusion: Initial rate of 100mg/hr. Dose<br />
adjustments: No dose adjustment is required in elderly patients.<br />
Contraindications: Hypersensitivity to this product or to murine<br />
proteins; active, severe infections; severe heart failure (NYHA Class<br />
IV) or severe, uncontrolled cardiac disease. Precautions: Infusion<br />
reactions: Anaphylactic and other hypersensitivity reactions.<br />
Premedication with iv glucocorticoid is recommended. Treatments<br />
<strong>for</strong> hypersensitivity reactions should be immediately available.<br />
Presence of HACA may be associated with worsening infusion<br />
reactions. Consider carefully patients with cardiac history and<br />
monitor during administration. Hypotension may occur, consider<br />
withholding antihypertensive medications. Infections: Do not give to<br />
patients with an active and/or severe infection, or severely<br />
immunocompromised patients. Exercise caution in patients with<br />
recurring/chronic infections. Treat and evaluate promptly and<br />
appropriately. Use of Mab<strong>The</strong>ra may be associated with an<br />
increased risk of Progressive Multifocal Leukoencephalopathy<br />
(PML). Immunisation: Safety or efficacy of vaccination – consult SPC.<br />
Concomitant/sequential use of other DMARDs: Initial data suggest<br />
that the rate of clinically relevant infection is unchanged.<br />
Malignancy: Limited experience in RA patients cannot exclude a<br />
possible risk <strong>for</strong> the development of solid tumours. Drug<br />
Interactions: Limited data on drug interactions. Co-administration<br />
with methotrexate had no effect on the pharmacokinetics of<br />
Mab<strong>The</strong>ra. Pregnancy and Lactation: Women should not become<br />
pregnant, and should not breastfeed during, and <strong>for</strong> 12 months<br />
following, treatment. Contraception should be used during, and <strong>for</strong><br />
12 months following, treatment. Undesirable effects: Common<br />
adverse reactions: infusion reactions (hypertension, nausea, rash,<br />
pyrexia, pruritis, urticaria, rhinitis, throat irritation, hot flush,<br />
hypotension, chills). Infection (UTI, URTI, any infection). Other:<br />
dyspepsia, hypercholesterolaemia, arthralgia/musculo skeletal pain,<br />
osteoarthritis, parasthesia, migraine. Medically significant events:<br />
Acute infusion reactions, incidence of clinically significant infection,<br />
some of which were fatal, was 0.05 per patient year. Very rare cases<br />
of PML have been reported. Serious cardiac events reported equally<br />
in 2% of Mab<strong>The</strong>ra and placebo treated patients. Other: generalised<br />
oedema, bronchospasm, wheezing, laryngeal oedema, angio -<br />
neurotic oedema, generalized pruritis, anaphylaxis, anaphylactoid<br />
reaction. Prescriber should consult SPC <strong>for</strong> full details of side-effects.<br />
Legal category: POM. Presentations and Basic NHS Costs:<br />
100mg of rituximab in 10ml (10mg/ml) pack of 2 vials: £349.25,<br />
500mg of rituximab in 50ml (10mg/ml) pack of 1 vial: £873.15.<br />
Marketing Authorisation Numbers: EU/1/98/067/001 (100mg),<br />
EU/1/98/067/002 (500mg). Marketing Authorisation Holder:<br />
Roche Registration Limited, 6 Falcon Way, Welwyn Garden City,<br />
Herts AL7 1TW. MABTHERA is a registered trade<br />
mark. MEDI00038 Date of Preparation: January<br />
2009. References: 1. Cohen SB et al. Arthritis<br />
Rheum 2006; 54(9): 2793-2806. 2. Mab<strong>The</strong>ra SmPC.<br />
Adverse events should be reported.<br />
Reporting <strong>for</strong>ms and in<strong>for</strong>mation can be found at<br />
www.yellowcard.gov.uk. Adverse events should also<br />
be reported to Roche Products Ltd. Please contact<br />
Roche Drug Safety Centre on: 01707 367554.<br />
MABR00114f Date of preparation: March 2009.
1<br />
<br />
2,3<br />
4<br />
References:<br />
1. Madhok R, Crilly A, Watson J, Capell HA. Serum interleukin 6 levels in rheumatoid arthritis: correlations with<br />
clinical and laboratory indices of disease activity. Ann Rheum Dis. 1993;52:232-234. 2. Naka T, Nishimoto N,<br />
Kishimoto T. <strong>The</strong> paradigm of IL-6: from basic science to medicine. Arthritis Res. 2002;4(suppl 3):S233-S242.<br />
3. Rose-John S, Scheller J, Elson G, Jones SA. Interleukin-6 biology is coordinated by membrane-bound<br />
and soluble receptors: role in inflammation and cancer. J Leukoc Biol. 2006;80:227-236. 4. Choy E. Inhibiting<br />
interleukin-6 in rheumatoid arthritis. Curr Rheumatol Rep. 2008; 10: 413-417.<br />
Date of preparation: March 2009. ACTE00201a